0001493152-22-022798.txt : 20220815 0001493152-22-022798.hdr.sgml : 20220815 20220815145902 ACCESSION NUMBER: 0001493152-22-022798 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220815 DATE AS OF CHANGE: 20220815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OZOP ENERGY SOLUTIONS, INC. CENTRAL INDEX KEY: 0001679817 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 352540672 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55976 FILM NUMBER: 221165040 BUSINESS ADDRESS: STREET 1: 31 SANDFORT LN. CITY: WARWICK STATE: NY ZIP: 10990 BUSINESS PHONE: (845) 544-5112 MAIL ADDRESS: STREET 1: 31 SANDFORT LN. CITY: WARWICK STATE: NY ZIP: 10990 FORMER COMPANY: FORMER CONFORMED NAME: OZOP SURGICAL CORP. DATE OF NAME CHANGE: 20180521 FORMER COMPANY: FORMER CONFORMED NAME: Newmarkt Corp. DATE OF NAME CHANGE: 20160715 10-Q 1 form10-q.htm
0001679817 false Q2 --12-31 P5Y P5Y P5Y 0001679817 2022-01-01 2022-06-30 0001679817 2022-08-12 0001679817 2022-06-30 0001679817 2021-12-31 0001679817 us-gaap:SeriesDPreferredStockMember 2022-06-30 0001679817 us-gaap:SeriesDPreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesEPreferredStockMember 2022-06-30 0001679817 us-gaap:SeriesEPreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesCPreferredStockMember 2022-06-30 0001679817 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001679817 2022-04-01 2022-06-30 0001679817 2021-04-01 2021-06-30 0001679817 2021-01-01 2021-06-30 0001679817 OZSC:CommonStockToBeIssuedMember 2021-12-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001679817 us-gaap:CommonStockMember 2021-12-31 0001679817 us-gaap:TreasuryStockMember 2021-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001679817 us-gaap:RetainedEarningsMember 2021-12-31 0001679817 us-gaap:NoncontrollingInterestMember 2021-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001679817 us-gaap:CommonStockMember 2022-03-31 0001679817 us-gaap:TreasuryStockMember 2022-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001679817 us-gaap:RetainedEarningsMember 2022-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2022-03-31 0001679817 2022-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2020-12-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001679817 us-gaap:CommonStockMember 2020-12-31 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001679817 us-gaap:RetainedEarningsMember 2020-12-31 0001679817 2020-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2021-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001679817 us-gaap:CommonStockMember 2021-03-31 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001679817 us-gaap:RetainedEarningsMember 2021-03-31 0001679817 2021-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-01-01 2022-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001679817 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001679817 2022-01-01 2022-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-04-01 2022-06-30 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001679817 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001679817 us-gaap:TreasuryStockMember 2022-04-01 2022-06-30 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001679817 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001679817 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001679817 OZSC:CommonStockToBeIssuedMember 2021-01-01 2021-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001679817 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001679817 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001679817 2021-01-01 2021-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2021-04-01 2021-06-30 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001679817 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001679817 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001679817 OZSC:CommonStockToBeIssuedMember 2022-06-30 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001679817 us-gaap:CommonStockMember 2022-06-30 0001679817 us-gaap:TreasuryStockMember 2022-06-30 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001679817 us-gaap:RetainedEarningsMember 2022-06-30 0001679817 us-gaap:NoncontrollingInterestMember 2022-06-30 0001679817 OZSC:CommonStockToBeIssuedMember 2021-06-30 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001679817 us-gaap:CommonStockMember 2021-06-30 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001679817 us-gaap:RetainedEarningsMember 2021-06-30 0001679817 2021-06-30 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:PennsylvaniaCorporationMember 2020-07-01 2020-07-10 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:PennsylvaniaCorporationMember us-gaap:SeriesCPreferredStockMember 2020-07-01 2020-07-10 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:PennsylvaniaCorporationMember us-gaap:SeriesDPreferredStockMember 2020-07-01 2020-07-10 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:PennsylvaniaCorporationMember us-gaap:SeriesEPreferredStockMember 2020-07-01 2020-07-10 0001679817 OZSC:RegistrationStatementMember 2021-10-14 2021-10-14 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember 2022-04-01 2022-04-04 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2022-07-14 2022-07-15 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2022-07-15 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2022-07-31 2022-08-01 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2022-08-01 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2022-08-03 2022-08-04 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2022-08-04 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2022-08-09 2022-08-10 0001679817 OZSC:SecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2022-08-10 0001679817 OZSC:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001679817 OZSC:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:CustomerAMember 2022-06-30 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:CustomerBMember 2022-06-30 0001679817 OZSC:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerCMember 2022-06-30 0001679817 OZSC:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerDMember 2022-06-30 0001679817 OZSC:CustomerEMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerEMember 2022-06-30 0001679817 OZSC:CustomerFMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerFMember 2022-06-30 0001679817 OZSC:CustomerGMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerGMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:CustomerGMember 2022-06-30 0001679817 OZSC:CustomerHMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerHMember 2022-06-30 0001679817 OZSC:CustomerIMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerIMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:CustomerIMember 2022-06-30 0001679817 OZSC:CustomerJMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerJMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:CustomerJMember 2022-06-30 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001679817 OZSC:SuppliersTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001679817 OZSC:SuppliersThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:SuppliersTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:SuppliersThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:SuppliersFourMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:SuppliersTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:SuppliersTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:SuppliersThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:SuppliersThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:TwoVendorMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:DownPaymentMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:ShipmentMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:NoSuppliersMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:DownPaymentMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 srt:MinimumMember OZSC:OfficeFurnitureAndEquipmentMember 2022-01-01 2022-06-30 0001679817 srt:MaximumMember OZSC:OfficeFurnitureAndEquipmentMember 2022-01-01 2022-06-30 0001679817 OZSC:WarehouseEquipmentMember 2022-01-01 2022-06-30 0001679817 OZSC:SourcedAndDistributedProductsMember 2022-04-01 2022-06-30 0001679817 OZSC:SourcedAndDistributedProductsMember 2021-04-01 2021-06-30 0001679817 OZSC:SourcedAndDistributedProductsMember 2022-01-01 2022-06-30 0001679817 OZSC:SourcedAndDistributedProductsMember 2021-01-01 2021-06-30 0001679817 OZSC:ManufacturedProductsMember 2022-04-01 2022-06-30 0001679817 OZSC:ManufacturedProductsMember 2021-04-01 2021-06-30 0001679817 OZSC:ManufacturedProductsMember 2022-01-01 2022-06-30 0001679817 OZSC:ManufacturedProductsMember 2021-01-01 2021-06-30 0001679817 OZSC:OEDInstallationsMember 2022-04-01 2022-06-30 0001679817 OZSC:OEDInstallationsMember 2021-04-01 2021-06-30 0001679817 OZSC:OEDInstallationsMember 2022-01-01 2022-06-30 0001679817 OZSC:OEDInstallationsMember 2021-01-01 2021-06-30 0001679817 us-gaap:FairValueInputsLevel1Member 2022-06-30 0001679817 us-gaap:FairValueInputsLevel2Member 2022-06-30 0001679817 us-gaap:FairValueInputsLevel3Member 2022-06-30 0001679817 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001679817 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001679817 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001679817 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-06-30 0001679817 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-06-30 0001679817 OZSC:UnexercisedCommonStockPurchaseWarrantsMember 2022-01-01 2022-06-30 0001679817 OZSC:UnexercisedCommonStockPurchaseWarrantsMember 2021-01-01 2021-06-30 0001679817 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-06-30 0001679817 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-06-30 0001679817 OZSC:PromissoryNotePayableMember 2022-01-01 2022-06-30 0001679817 OZSC:PromissoryNotePayableMember 2021-01-01 2021-06-30 0001679817 us-gaap:OfficeEquipmentMember 2022-06-30 0001679817 us-gaap:OfficeEquipmentMember 2021-12-31 0001679817 OZSC:FifteenPercentPromissoryNoteMember 2022-06-30 0001679817 OZSC:FifteenPercentPromissoryNoteMember 2021-12-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-06-30 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001679817 us-gaap:MeasurementInputOptionVolatilityMember 2022-06-30 0001679817 us-gaap:MeasurementInputOptionVolatilityMember 2021-12-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2022-06-30 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2022-06-30 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-12-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-12-31 0001679817 us-gaap:MeasurementInputOptionVolatilityMember srt:MinimumMember 2022-06-30 0001679817 us-gaap:MeasurementInputOptionVolatilityMember srt:MaximumMember 2022-06-30 0001679817 us-gaap:MeasurementInputOptionVolatilityMember srt:MinimumMember 2021-12-31 0001679817 us-gaap:MeasurementInputOptionVolatilityMember srt:MaximumMember 2021-12-31 0001679817 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2022-06-30 0001679817 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2022-06-30 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2021-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2021-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2022-01-01 2022-06-30 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2022-01-01 2022-06-30 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2022-06-30 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2022-06-30 0001679817 OZSC:NotePayableMember 2022-06-30 0001679817 OZSC:NotePayableMember 2021-12-31 0001679817 OZSC:NotePayableOneMember 2022-06-30 0001679817 OZSC:NotePayableOneMember 2021-12-31 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2022-06-30 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2021-12-31 0001679817 OZSC:PaycheckProtectionProgramloanMember 2022-06-30 0001679817 OZSC:PaycheckProtectionProgramloanMember 2021-12-31 0001679817 OZSC:NotePayableTwoMember 2022-06-30 0001679817 OZSC:NotePayableTwoMember 2021-12-31 0001679817 OZSC:OtherMember 2022-06-30 0001679817 OZSC:OtherMember 2021-12-31 0001679817 OZSC:NotePayableThreeMember 2022-06-30 0001679817 OZSC:NotePayableThreeMember 2021-12-31 0001679817 OZSC:NotePayableFourMember 2022-06-30 0001679817 OZSC:NotePayableFourMember 2021-12-31 0001679817 OZSC:NotePayableFiveMember 2022-06-30 0001679817 OZSC:NotePayableFiveMember 2021-12-31 0001679817 OZSC:NotePayableSixMember 2022-06-30 0001679817 OZSC:NotePayableSixMember 2021-12-31 0001679817 OZSC:NotePayableSevenMember 2022-06-30 0001679817 OZSC:NotePayableSevenMember 2021-12-31 0001679817 OZSC:NotePayableEightMember 2022-06-30 0001679817 OZSC:NotePayableEightMember 2021-12-31 0001679817 OZSC:NotePayableMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableOneMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableOneMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableTwoMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableTwoMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableThreeMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableThreeMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableFourMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableFourMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableFiveMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableFiveMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableSixMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableSixMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableSevenMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableSevenMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableEightMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableEightMember 2021-01-01 2021-12-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2021-12-07 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2021-12-05 2021-12-07 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2021-12-12 2021-12-13 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2022-01-01 2022-06-30 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2022-06-30 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2021-12-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2021-03-17 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2021-03-16 2021-03-17 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2021-03-22 2021-03-23 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2022-01-01 2022-06-30 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-01-01 2022-06-30 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-06-30 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2022-06-30 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2021-12-31 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember 2021-02-09 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember 2021-02-08 2021-02-09 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember 2021-02-15 2021-02-16 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember 2022-01-01 2022-06-30 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-01-01 2022-06-30 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-06-30 0001679817 OZSC:PromissoryNoteOneMember OZSC:LendersMember 2022-06-30 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember 2021-12-31 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember 2022-06-30 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-11-13 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-11-12 2020-11-13 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-11-17 2020-11-20 0001679817 OZSC:HolderMember 2022-06-30 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2021-12-31 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2022-06-30 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-11-06 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-11-05 2020-11-06 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-07-23 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-07-20 2020-07-23 0001679817 2016-10-26 0001679817 OZSC:PCTIMember 2022-06-30 0001679817 OZSC:PCTIMember 2021-12-31 0001679817 2021-03-15 0001679817 OZSC:PromissoryNoteMember us-gaap:PrimeRateMember 2021-03-15 0001679817 OZSC:PromissoryNoteMember srt:MaximumMember 2021-03-15 0001679817 OZSC:PCTIMember OZSC:PersonalGuaranteeOfChisMember 2021-12-31 0001679817 OZSC:PCTIMember OZSC:PersonalGuaranteeOfChisMember 2020-12-31 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-08-24 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-08-23 2020-08-24 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-08-22 2020-08-25 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember OZSC:NineInstalmentsMember 2021-01-01 2021-12-31 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember OZSC:NineInstalmentsMember 2020-08-23 2020-08-24 0001679817 OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:PromissoryNoteMember 2022-06-30 0001679817 OZSC:PromissoryNoteMember 2021-05-03 0001679817 OZSC:PaycheckProtectionProgramMember 2020-04-20 0001679817 OZSC:PaycheckProtectionProgramMember 2020-04-19 2020-04-20 0001679817 OZSC:PaycheckProtectionProgramMember 2022-06-30 0001679817 OZSC:PaycheckProtectionProgramMember 2021-12-31 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2020-07-11 2020-07-14 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2022-06-30 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2021-12-31 0001679817 OZSC:PCTIMember OZSC:ExchangeAgreementMember 2020-09-02 0001679817 OZSC:PCTIMember OZSC:ExchangeAgreementMember 2020-08-30 2020-09-02 0001679817 OZSC:PCTIMember OZSC:ExchangeAgreementMember 2021-02-25 2021-02-26 0001679817 OZSC:PCTIMember OZSC:ExchangeAgreementMember 2021-06-30 0001679817 OZSC:PCTIMember OZSC:ExchangeAgreementMember 2021-01-01 2021-06-30 0001679817 2020-01-01 2020-12-31 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2020-07-01 2020-07-10 0001679817 OZSC:MrConwayMember OZSC:EmploymentAgreementMember 2021-12-29 2022-01-02 0001679817 OZSC:EmploymentAgreementMember 2021-12-29 2022-01-02 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2022-01-01 2022-01-31 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2022-03-01 2022-03-31 0001679817 us-gaap:SeriesEPreferredStockMember 2021-03-20 2021-03-21 0001679817 OZSC:MrConwayMember 2021-03-20 2021-03-21 0001679817 us-gaap:SeriesEPreferredStockMember 2021-04-16 0001679817 OZSC:MrConwayMember 2021-04-15 2021-04-16 0001679817 OZSC:MrConwayMember 2021-04-01 2021-06-30 0001679817 OZSC:MrConwayMember 2021-01-01 2021-06-30 0001679817 OZSC:DefinitiveAgreementMember us-gaap:SeriesCPreferredStockMember 2021-07-12 2021-07-13 0001679817 OZSC:DefinitiveAgreementMember us-gaap:SeriesDPreferredStockMember 2021-07-12 2021-07-13 0001679817 srt:ChiefExecutiveOfficerMember 2022-04-01 2022-06-30 0001679817 srt:ChiefExecutiveOfficerMember 2021-04-01 2021-06-30 0001679817 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-06-30 0001679817 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-06-30 0001679817 OZSC:ChiefExecutiveOfficerSeriesEPreferredStockMember 2022-04-01 2022-06-30 0001679817 OZSC:ChiefExecutiveOfficerSeriesEPreferredStockMember 2021-04-01 2021-06-30 0001679817 OZSC:ChiefExecutiveOfficerSeriesEPreferredStockMember 2022-01-01 2022-06-30 0001679817 OZSC:ChiefExecutiveOfficerSeriesEPreferredStockMember 2021-01-01 2021-06-30 0001679817 OZSC:PresidentSubsidiaryMember 2022-04-01 2022-06-30 0001679817 OZSC:PresidentSubsidiaryMember 2021-04-01 2021-06-30 0001679817 OZSC:PresidentSubsidiaryMember 2022-01-01 2022-06-30 0001679817 OZSC:PresidentSubsidiaryMember 2021-01-01 2021-06-30 0001679817 OZSC:GarageStorageFacilityMember 2021-01-02 0001679817 OZSC:GarageStorageFacilityMember 2021-01-01 2021-01-02 0001679817 OZSC:RMAAgreementMember 2021-08-28 2021-09-02 0001679817 OZSC:RMAAgreementMember 2021-09-03 2021-09-30 0001679817 OZSC:PJNStrategiesMember 2021-04-12 2021-04-13 0001679817 OZSC:PJNStrategiesMember 2021-08-30 2021-09-01 0001679817 OZSC:PJNStrategiesMember 2022-04-01 2022-06-30 0001679817 OZSC:PJNStrategiesMember 2022-01-01 2022-06-30 0001679817 OZSC:RubensteinPublicRelationsMember 2021-04-15 2021-04-16 0001679817 OZSC:CoDirectorsOfSalesMember 2021-03-29 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-03-29 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001679817 OZSC:CoDirectorsOfSalesMember 2022-01-01 2022-01-14 0001679817 OZSC:CoDirectorsOfSalesMember 2022-01-14 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2021-03-14 2021-03-15 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2021-03-15 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2022-04-01 2022-06-30 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2022-01-01 2022-06-30 0001679817 OZSC:ChristopherRuppelMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001679817 OZSC:ChristopherRuppelMember us-gaap:RestrictedStockMember 2021-12-31 0001679817 OZSC:ChristopherRuppelMember us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001679817 OZSC:ChristopherRuppelMember OZSC:AprilOneTwoThousandAndTwentyOneMember 2022-01-01 2022-06-30 0001679817 OZSC:ChristopherRuppelMember us-gaap:RestrictedStockMember 2021-04-01 2021-06-30 0001679817 us-gaap:RestrictedStockMember 2021-01-21 2021-01-22 0001679817 us-gaap:RestrictedStockMember 2021-01-22 0001679817 us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-14 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-13 2021-01-14 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-04-01 2021-06-30 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-01 2021-06-30 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-14 2021-01-14 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-05 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-01-05 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-04-01 2021-06-30 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2022-04-01 2022-06-30 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember 2019-03-04 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember 2022-06-30 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember 2021-12-31 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2020-09-01 2020-09-02 0001679817 us-gaap:RestrictedStockMember OZSC:LeaseAgreementMember 2022-01-01 2022-06-30 0001679817 us-gaap:RestrictedStockMember OZSC:LeaseAgreementMember 2021-01-01 2021-06-30 0001679817 OZSC:RestructuringAgreementMember 2021-01-01 2021-06-30 0001679817 us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-01 2021-06-30 0001679817 OZSC:RegistrationStatementMember us-gaap:CommonStockMember OZSC:GHSInvestmentsMember 2022-04-01 2022-04-04 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-07 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-06 2020-07-07 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember OZSC:PCTIMember 2020-07-06 2020-07-10 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:ChisMember 2021-07-01 2021-07-13 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember OZSC:PCTIMember 2020-07-06 2020-07-10 0001679817 OZSC:MrConwayMember us-gaap:SeriesDPreferredStockMember 2020-08-27 2020-08-28 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:ChisMember 2021-07-01 2021-07-13 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:SeriesDAmendmentMember 2021-07-27 0001679817 us-gaap:InvestorMember us-gaap:SeriesDPreferredStockMember OZSC:SeriesDSPAMember 2021-07-01 2021-07-28 0001679817 us-gaap:InvestorMember us-gaap:SeriesDPreferredStockMember OZSC:SeriesDSPAMember 2021-07-28 0001679817 us-gaap:WarrantMember 2022-06-30 0001679817 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001679817 OZSC:RemainingWarrantSharesMember 2022-01-01 2022-06-30 0001679817 us-gaap:SeriesEPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-07 0001679817 OZSC:ChisMember us-gaap:SeriesEPreferredStockMember 2020-07-09 2020-07-10 0001679817 OZSC:ConwayMember us-gaap:SeriesEPreferredStockMember OZSC:EmploymentAgreementMember 2020-08-27 2020-08-28 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-03-01 2021-03-02 0001679817 OZSC:ThirdPartyMember us-gaap:SeriesEPreferredStockMember 2021-03-01 2021-03-02 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-03-02 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-06-30 0001679817 us-gaap:SeriesEPreferredStockMember 2021-03-22 2021-03-24 0001679817 us-gaap:SeriesEPreferredStockMember OZSC:MrConvayMember 2021-04-15 2021-04-16 0001679817 us-gaap:SeriesEPreferredStockMember OZSC:MrConvayMember 2021-04-16 0001679817 us-gaap:SeriesEPreferredStockMember OZSC:MrConvayMember 2021-04-01 2021-06-30 0001679817 OZSC:BrianConwayMember 2021-08-19 0001679817 OZSC:PJNStrategiesMember 2021-08-19 0001679817 us-gaap:AccountingStandardsUpdate201602Member 2020-12-31 0001679817 2021-04-14 0001679817 country:CA 2021-04-11 2021-04-14 0001679817 OZSC:ThereafterMember 2021-04-14 0001679817 country:CA 2021-04-14 0001679817 us-gaap:AccountingStandardsUpdate201602Member 2021-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarter ended: June 30, 2022

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition Period from ___________ to____________

 

Commission File Number: 000-55976

 

OZOP ENERGY SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   35-2540672

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

42 N Main St

Florida, NY 10921

(Address of principal executive offices) (zip code)

 

(845) 544-5112

(Registrant’s telephone number, including area code)

 

Not applicable.

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer Accelerated filer
  Non-accelerated filer Smaller reporting company
  (Do not check if a smaller reporting company)   Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

As of August 12, 2022, there were 4,671,592,071 shares outstanding of the registrant’s common stock, $0.001 par value per share.

 

 

 

 

 

 

OZOP ENERGY SOLUTIONS, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Table of Contents

 

  Page
   
Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 (Unaudited) F-1
   
Condensed Consolidated Statements of Operation for the three and six months ended June 30, 2022 and 2021 (Unaudited) F-2
   
Condensed Consolidated Statements of Stockholders’ Deficit for the three and six months ended June 30, 2022 and 2021 (Unaudited) F-3
   
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2022 and 2021 (Unaudited) F-5
   
Notes to Consolidated Financial Statements F-6

 

2

 

 

OZOP ENERGY SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET

(UNAUDITED)

 

   June 30,   December 31, 
   2022   2021 
ASSETS          
Current Assets          
Cash  $1,949,528   $6,767,167 
Prepaid expenses   190,142    151,998 
Accounts receivable   779,682    1,299,334 
Inventory   1,799,095    1,065,982 
Vendor deposits   3,212,660    874,627 
Total Current Assets   7,931,107    10,159,108 
           
Operating lease right-of-use asset, net   606,078    707,686 
Property and equipment, net   147,714    132,889 
Other Assets   548,908    568,249 
TOTAL ASSETS  $9,233,807   $11,567,932 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
Liabilities          
Current Liabilities          
Accounts payable and accrued expenses  $4,601,813   $3,246,342 
Convertible notes payable, net of discounts   25,000    25,000 
Current portion of notes payable, net of discounts   17,211,132    13,011,307 
Customer deposits   568,313    169,849 
Deferred liability   662,185    750,000 
Derivative liabilities   7,589,928    20,966,701 
Operating lease liability, current portion   161,048    194,366 
Current portion of deferred revenues   21,451    21,451 
Total Current Liabilities   30,840,870    38,385,016 
           
Long Term Liabilities          
Note payable, net of discount   389,423    389,423 
Operating lease liability, net of current portion   453,199    517,890 
Deferred revenue, net of current portion   14,301    25,026 
TOTAL LIABILITIES   31,697,793    39,317,355 
           
COMMITMENTS AND CONTINGENCIES   -    - 
           
Stockholders’ Equity (Deficit)          
Preferred stock (10,000,000 shares authorized, par value $0.001) Series C Preferred Stock (50,000 shares authorized and 2,500 and shares issued and outstanding, par value $0.001)   3    3 
Series D Preferred Stock (4,570 shares authorized and 1,334 shares issued and outstanding, par value $0.001)   1    1 
Series E Preferred Stock (3,000 shares authorized, -0- issued and outstanding, par value $0.001)   -    - 
Common stock (4,990,000,000 shares authorized par value $0.001; 4,622,362,977 (2022) and 4,617,362,977 (2021) shares issued and outstanding)   4,622,363    4,617,363 
Common stock to be issued; 637,755 shares as of June 30, 2022, and December 31, 2021   638    638 
Additional paid in capital   196,594,222    196,464,222 
Treasury Stock   (11,249,934)   (11,249,934)
Accumulated Deficit   (211,816,067)   (217,326,611)
Total Ozop Energy Systems, Inc. stockholders’ equity (deficit)   (21,848,774)   (27,494,318)
Noncontrolling interest   (615,212)   (255,105)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)   (22,463,986)   (27,749,423)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)  $9,233,807   $11,567,932 

 

See notes to condensed consolidated financial statements.

 

F-1

 

 

OZOP ENERGY SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(Unaudited)

 

   2022   2021   2022   2021 
   For the Three Months Ended June 30,   For the Six Months Ended June 30, 
   2022   2021   2022   2021 
Revenue  $4,878,636   $1,274,033   $7,960,874   $2,069,587 
Cost of goods sold   4,416,460    1,214,468    7,292,292    1,441,377 
Gross profit   462,177    59,565    668,583    628,210 
                     
Operating expenses:                    
General and administrative, related parties   240,000    1,461,074    630,000    3,576,082 
General and administrative, other   1,274,287    2,898,231    2,862,144    6,572,693 
Total operating expenses   1,514,287    4,359,305    3,492,144    10,148,775 
                     
Loss from operations   (1,052,111)   (4,299,740)   (2,823,562)   (9,520,565)
                     
Other (income) expenses:                    
Interest expense   1,427,554    4,310,335    5,402,775    44,965,085 
(Gain) loss on change in fair value of derivatives   (9,011,570)   (8,866,819)   (13,376,773)   43,331,083 
Loss on extinguishment of debt   -    468,696    -    95,437,587 
Debt restructure expense   -    -    -    16,450,000 
Total Other (Income) Expenses   (7,584,016)   (4,087,788)   (7,973,998)   200,183,755 
                     
Net income (loss) before income taxes   6,531,906    (211,952)   5,150,437    (209,704,320)
Income tax provision   -    -    -    - 
Net income (loss)  $6,531,906   $(211,952)   5,150,437    (209,704,320)
Less: net loss attributable to noncontrolling interest   (172,399)        (360,107)   - 
Net income (loss) attributable to Ozop Energy Solutions, Inc.  $6,704,305   $(211,952)  $5,510,544   $(209,704,320)
                     
Income (loss) per share basic and fully diluted  $0.00   $(0.00)  $0.00    (0.05)
                     
Weighted average shares outstanding                    
Basic and diluted   4,622,362,977    4,554,068,582    4,621,092,259    4,269,239,477 

 

See notes to condensed consolidated financial statements.

 

F-2

 

 

OZOP ENERGY SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

THREE AND SIX MONTHS ENDED JUNE 30, 2022

(Unaudited)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Stock   Capital   Deficit   Interest   (Deficit) 
   Common stock to be issued   Series C Preferred Stock   Series D Preferred Stock   Common Stock   Treasury   Additional Paid-in   Accumulated   Noncontrolling   Total
Stockholders’ Equity
 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Stock   Capital   Deficit   Interest   (Deficit) 
Balances January 1, 2022   637,755   $638    2,500   $3    1,334   $1    4,617,362,977   $4,617,363   $(11,249,934)  $196,464,222   $(217,326,611)  $(255,105)  $(27,749,423)
                                                                  
Common stock issued for services   -    -    -    -    -    -    5,000,000    5,000         130,000    -    -    135,000 
                                                                  
Net loss   -    -    -    -    -    -    -    -    -    -    (1,193,761)   (187,708)   (1,381,469)
Balances March 31, 2022   637,755    638    2,500    3    1,334    1    4,622,362,977    4,622,363    (11,249,934)   196,594,222    (218,520,372)   (442,813)   (28,995,892)
                                                                  
Net income   -    -    -    -    -    -    -    -    -    -    6,704,305    (172,399)   6,531,906 
Balances June 30, 2022   637,755   $638    2,500   $3    1,334   $1    4,622,362,977   $4,622,363   $(11,249,934)  $196,594,222   $(211,816,067)  $(615,212)  $(22,463,986)

 

See notes to condensed consolidated financial statements.

 

F-3

 

 

OZOP ENERGY SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

THREE AND SIX MONTHS ENDED JUNE 30, 2021

(Unaudited)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Loss   Capital   Deficit   (Deficit) 
                                                     Total 
   Common stock to be issued   Series C Preferred Stock   Series D Preferred Stock   Series E Preferred Stock   Common Stock   Accumulated Comprehensive   Additional Paid-in   Accumulated   Stockholders’ Equity 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Loss   Capital   Deficit   (Deficit) 
Balances January 1, 2021   -    -    50,000   $50    20,000   $20    1,000   $1    3,397,958,292   $3,397,958   $(7)  $12,530,933   $(22,278,665)  $(6,349,710)
                                                                       
Shares issued for conversions of note and interest payable   -    -    -    -    -    -    -    -    428,747,654    428,748    -    97,110,282    -    97,539,030 
                                                                       
Shares issued upon cashless exercise of warrants   -    -    -    -    -    -    -    -    330,797,987    330,798    -    38,714,266    -    39,045,064 
                                                                       
Issuance of Series E Preferred Stock   -    -    -    -    -    -    2,000    2    -    -    -    1,999,998    -    2,000,000 
                                                                       
Redemption of Series E Preferred Stock   -    -    -    -    -    -    (3,000)   (3)   -    -    -    (2,999,997)   -    (3,000,000)
                                                                       
Shares issued and to be issued for fees and services   5,000,000    5,000    -    -    -    -    -    -    20,000,000    20,000    -    2,877,000    -    2,902,000 
                                                                       
Shares issued for lease agreement   -    -    -    -    -    -    -    -    100,000,000    100,000    -    530,000    -    630,000 
                                                                       
Shares issue for debt restructure   -    -    -    -    -    -    -    -    175,000,000    175,000    -    16,275,000    -    16,450,000 
                                                                       
Net loss   -    -    -    -    -    -    -    -    -    -    7    -    (209,492,368)   (209,492,361)
Balances March 31, 2021   5,000,000   $5,000    50,000   $50    20,000   $20    -   $-    4,452,503,933   $4,452,504   $-   $167,037,482   $(231,771,033)  $(60,275,977)
                                                                       
Shares issued and to be issued for fees and services   (5,000,000)   (5,000)   -    -    -    -    -    -    25,000,000    25,000    -    1,752,000    -    1,772,000 
                                                                       
Shares issued upon cashless exercise of warrants   -    -    -    -    -    -    -    -    75,000,000    75,000    -    8,990,237    -    9,065,237 
                                                                       
Shares issued for conversions of note and interest payable   -    -    -    -    -    -    -    -    54,406,964    54,407    -    4,945,593    -    5,000,000 
                                                                       
Issuance of Series E Preferred Stock   -    -    -    -    -    -    2,000    2    -    -    -    1,999,998    -    2,000,000 
                                                                       
Redemption of Series E Preferred Stock   -    -    -    -    -    -    (2,000)   (2)   -    -    -    (1,999,998)   -    (2,000,000)
                                                                       
Net loss   -    -    -    -    -    -    -    -    -    -    -    -    (211,952)   (211,952)
Balances June 30, 2021   -   $-    50,000   $50    20,000   $20    -   $-   $4,606,910,897   $4,606,911   $-   $182,725,312   $(231,982,985)  $(44,650,692)

 

See notes to condensed consolidated financial statements.

 

F-4

 

 

OZOP ENERGY SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited)

 

   2022   2021 
   For the Six Months Ended June 30, 
   2022   2021 
Cash flows from operating activities:          
Net income (loss) from continuing operations  $5,150,437   $(209,704,320)
Adjustments to reconcile net income (loss) to net cash used in operations          
Non-cash interest expense   4,199,825    44,170,200 
Amortization and depreciation   126,784    65,388 
Debt restructure expense   -    16,450,000 
Loss on fair value change of derivatives   (13,376,773)   43,331,083 
Loss (gain) on extinguishment of debt   -    95,437,587 
Stock compensation expense   136,249    7,965,945 
Changes in operating assets and liabilities:          
Accounts receivable   519,652    (701,545)
Inventory   (733,113)   (1,247,913)
Prepaid expenses   (20,053)   (1,290,348)
Vendor deposits   (2,338,033)   (64,789)
Accounts payable and accrued expenses   1,267,656    682,845 
Deferred revenue   (10,725)   (7,150)
Operating lease liabilities   (98,009)   (46,054)
Customer deposits   398,464    117,641 
Net cash used in operating activities   (4,777,639)   (4,841,428)
           
Cash flows from investing activities:          
Purchase of office and computer equipment   (40,000)   (94,679)
Net cash used in investing activities   (40,000)   (94,679)
           
Cash flows from financing activities:          
Proceeds from issuances of notes payable   -    12,000,000 
Payments to shareholders   -    (26,367)
Payments of principal of convertible note payable and notes payable   -    (383,722)
Redemption of Series E Preferred Stock   -    (5,000,000)
Net cash provided by financing activities   -    6,589,911 
           
Net (decrease) increase in cash   (4,817,639)   1,653,804 
           
Cash, Beginning of period   6,767,167    1,808,476 
           
Cash, End of period  $1,949,528   $3,462,280 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $28,302   $545,138 
Cash paid for income taxes  $-   $- 
           
Schedule of non-cash Investing or Financing Activity:          
Original issue discount included in notes payable  $-   $1,310,000 
Issuance of common stock upon convertible note and accrued interest conversion  $-   $743,555 
Operating lease right-of-use assets and liabilities  $-   $702,888 
Issuance of common stock and preferred stock for consulting fees and compensation  $136,249   $7,965,945 
Issuance of common stock for lease agreement  $-   $630,000 
Issuance of common stock for debt restructuring  $-   $16,450,000 

 

See notes to condensed consolidated financial statements.

 

F-5

 

 

OZOP ENERGY SOLUTIONS, INC.

Notes to Condensed Consolidated Financial Statements

June 30, 2022

(Unaudited)

 

NOTE 1 - ORGANIZATION

 

Business

 

Ozop Energy Solutions, Inc. (the” Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.

 

On July 10, 2020, the Company entered into a Stock Purchase Agreement (the “SPA”) with Power Conversion Technologies, Inc., a Pennsylvania corporation (“PCTI”), and Catherine Chis (“Chis”), PCTI’s Chief Executive Officer (“CEO”) and its sole shareholder. Under the terms of the SPA, the Company acquired one thousand (1,000) shares of PCTI, which represents all of the outstanding shares of PCTI, from Chis in exchange for the issuance of 47,500 shares of the Company’s Series C Preferred Stock, 18,667 shares of the Company’s Series D Preferred Stock, and 500 shares of the Company’s Series E Preferred Stock to Chis.

 

PCTI designs, develops, manufactures and distributes standard and custom power electronic solutions.

 

On October 29, 2020, the Company formed a new wholly owned subsidiary, Ozop Surgical Name Change Subsidiary, Inc., a Nevada corporation (“Merger Sub”). The Merger Sub was formed under the Nevada Revised Statutes for the sole purpose and effect of changing the Company’s name to “Ozop Energy Solutions, Inc.” That same day the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with the Merger Sub and filed Articles of Merger (the “Articles of Merger”) with the Nevada Secretary of State, merging the Merger Sub into the Company, which were stamped effective as of November 3, 2020. As permitted by the Section 92.A.180 of the Nevada Revised Statutes, the sole purpose and effect of the filing of Articles of Merger was to change the name of the Company from Ozop Surgical Corp to “Ozop Energy Solutions, Inc.”

 

On December 11, 2020, the Company formed Ozop Energy Systems, Inc. (“OES”), a Nevada corporation and a wholly owned subsidiary of the Company. OES was formed to be a manufacturer and distributor of renewable energy products.

 

On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation. The Company is the majority shareholder of Ozop Capital with PJN Holdings LLC (“PJN”), a New York limited liability company, being the minority shareholder. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital.

 

On October 29, 2021, EV Insurance Company, Inc. (“EVCO”) was formed as a captive insurance company in the State of Delaware. EVCO is a wholly owned subsidiary of Ozop Capital. On January 7, 2022, EVCO filed with New Castle County, Delaware DBA OZOP Plus.

 

On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners are able to offer the resources needed for lighting, solar and electrical design projects. OED will provide customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs. We work with architects, engineers, facility managers, electrical contractors and engineers.

 

NOTE 2 – GOING CONCERN AND MANAGEMENT’S PLANS

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2022, the Company had an accumulated deficit of $211,816,067 and a working capital deficit of $22,909,763 (including derivative liabilities of $7,589,928). As of June 30, 2022, the Company was in default of $15,369,247 plus accrued interest on debt instruments due to non-payment upon maturity dates. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date of the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

In December 2019, a novel strain of coronavirus (COVID-19) emerged. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but it may have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

 

F-6

 

 

Management’s Plans

 

As a public company, Management believes it will be able to access the public equities market for fund raising for product development, sales and marketing and inventory requirements as we expand our distribution in the U.S. market.

 

The Company is in negotiations with its’ lenders related to the debt instruments that are currently in default, to extend the maturity dates.

 

On October 14, 2021, the Company received a Notice of effectiveness related to the Company’s Form S-3 Registration Statement (the “Registration Statement”). Pursuant to the Registration Statement the Company may offer and sell from time to time in one or more offerings of up to thirty million dollars ($30,000,000) in aggregate offering price. We may offer these securities in amounts, at prices and on terms determined at the time of offering.

 

On April 4, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (200,000,000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement. As of the date of this Report the Company has sold the following securities pursuant to this Registration Statement:

 

On July 15, 2022, the Company sold 15,353,952 shares to GHS at $0.010285 and received net proceeds of $152,732, after deducting transaction and broker fees of $5,183.

 

On August 1, 2022, the Company sold 7,675,221 shares to GHS at $0.010965 and received net proceeds of $81,451, after deducting transaction and broker fees of $2,708.

 

On August 4, 2022, the Company sold 8,136,272 shares to GHS at $0.010965 and received net proceeds of $86,405, after deducting transaction and broker fees of $2,809.

 

On August 10, 2022, the Company sold 18,063,649 shares to GHS at $0.01088 and received net proceeds of $191,577, after deducting transaction and broker fees of $4,956.

 

OES is actively engaged in the renewable, electric vehicle (“EV”), energy storage and energy resiliency sectors. We are engaged in multiple business lines that include project development as well as equipment distribution. Our solar and energy storage projects involve large-scale battery and solar photovoltaics (PV) installations. Our utility-scale storage business model is based on an arbitrage business model in which we install multiple 1+ megawatt batteries, charge them with off-peak grid electricity under contract with the utility, then sell the power back during peak load hours at a premium, as dictated by prevailing electricity tariffs.

 

Ozop Plus plans on marketing vehicle service contracts (“VSC’s”) for electric vehicles (EV’s) that will offer to consumers to be able to purchase additional months and or miles above the manufacturer’s warranty and to also bring added value to EV owners by utilizing our partnerships and strengths in the energy market to offer unique and innovative services. Among EV owners’ concerns are the EV battery repair and replacement costs, range anxiety, environmental responsibilities, roadside assistance, and the accelerated wear on additional components that EV vehicles experience. Management believes that the Ozop Plus marketed VSC’s will give “peace of mind” to the EV buyer.

 

  In May 2022, the Company entered into an agreement with GS Administrators, Inc., a member of Houston-based GSFSGroup. Under the agreement, the Company will market GSFSGroup’s EV VSC’s in all states (except, California, Florida, Massachusetts and Washington) to Ozop’s network of new and used franchised dealerships and other eligible entities. In addition to acting as an agent for the marketing, Ozop also has the right to white label the product under its’ Ozop Plus brand. Ozop’s role won’t be limited to marketing the product. GSFSGroup plans to tap into Ozop’s experience relative to battery collection and disposal and has agreed to insurance risk sharing in connection with the insurance policies that back the VSC’s. GSFSGroup is working on getting the approvals needed for the above four (4) states.
     
  On June 22, 2022, the Company entered into an Agent Agreement with Royal Administration Services, Inc. (“Royal”). Under the agreement, the Company will market Royal’s EV VSC’s and has the right to white label it under Ozop Plus. Royal has agreed to allow Ozop Plus on all VSC’s, marketed by Royal and the Company, to assume all of the risk related to the electric battery at an agreed upon premium. The battery premium is dependent on the consumer’s selection of the duration of the VSC, the miles selected for coverage and the type of vehicle that the consumer has purchased, with a key component being the kWh size of the battery. These VSC’s have a maximum of 10 years and 150,000 miles and cover new and used cars from model year 2017 and newer. During August 2022, Royal will begin the filing process in all 50 states, 30 plus of which are effective upon filing, and the others have various waiting times or approvals needed.

 

F-7

 

 

During the quarter ended June 30, 2022, OED began operations and generated $16,500 of revenues and currently has six employees in sales, marketing installation and services. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support.

 

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2022, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 10-K/A filed on April 26, 2022.

 

The unaudited condensed consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries OED, PCTI, Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”) and the Company’s majority owned subsidiary Ozop Capital Partners, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has no cash equivalents at June 30, 2022, and December 31, 2021.

 

Sales Concentration and credit risk

 

Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three and six months ended June 30, 2022, and 2021, and their accounts receivable balance as of June 30, 2022:

 

   Sales % Three
Months
Ended June
30, 2022
   Sales % Six
Months
Ended June
30, 2022
   Sales % Three
Months
Ended June
30, 2021
   Sales % Six
Months
Ended
June 30, 2021
   Accounts
receivable
balance
June 30,
2022
 
Customer A   43.5%   26.7%    N/A     N/A   $43,920 
Customer B   10.0%   11.4%   18.3%   11.3%   524,759 
Customer C   N/A    10.3%   13.5%   N/A    - 
Customer D   N/A    N/A    13.5%   N/A    - 
Customer E   N/A    N/A    14.9%   N/A    3,835 
Customer F   N/A    N/A    10.5%   N/A    - 
Customer G   N/A    N/A    18.3%   11.3%   - 
Customer H   N/A    N/A    13.5%   N/A    - 
Customer I   N/A    N/A    14.9%   65.6%   - 
Customer J   N/A    N/A    10.5%   13.4%   - 

 

F-8

 

 

Customers A-F are customers of Ozop Energy Systems Inc. and Customers G- J are customers of PCTI. PCTI, historically does not have year to year many recurring clients as the Company produces customized capital equipment for its’ customers.

 

Accounts Receivable

 

The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.

 

Inventory

 

Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs include finished goods, material, labor and manufacturing overhead. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues.

 

The components of inventories at June 30, 2022, and December 31, 2021, are as follows:

 

   June 30,
2022
   December 31,
2021
 
         
Raw materials  $236,134   $234,168 
Work in process   -    43,704 
Finished goods   1,562,961    788,110 
Inventory net  $1,799,095   $1,065,982 

 

Purchase concentration

 

OES purchases finished renewable energy products from its’ suppliers. For the three months ended June 30, 2022, there were three suppliers that accounted for 41.3%, 23.3% and 19.7%, respectively, and for the six months ended June 30, 2022, there were four suppliers that accounted for 38.0%, 15.9%, 15.6% and 11.2%, respectively. For the three and six months ended June 30, 2021, there were three suppliers that accounted for 29.6%, 21.8% and 12.7%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a 20% down payment with the 30% balances due on shipment and 50% due prior to delivery, while other vendors terms are due in full immediately prior to delivery. We also buy product from other distributors, if we are not able to purchase direct from the manufacturer. While management believes all of its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business

 

The principal purchases by PCTI are comprised of parts and raw materials that PCTI assembles and manufactures and sells to its customers. There were no suppliers who accounted for more than ten percent (10%) of PCTI’s purchases for the three and six months ended June 30, 2022, and 2021.

 

Property, plant and equipment

 

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.

 

The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:

 

  Office furniture and equipment 3-5 years
  Warehouse equipment 7 years

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.

 

F-9

 

 

For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Advance payments are typically required for commercial customers and are recorded as current liability until revenue is recognized. Advance payments are not required for government customers. The majority of contracts typically require payment within 30 to 60 days after transfer of ownership to the customer.

 

For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges.

 

The following table disaggregates our revenue by major source for the three and six months ended June 30, 2022 and 2021:

 

   2022   2021   2022   2021 
   Three months ended
June 30,
   Six months ended
June 30,
 
   2022   2021   2022   2021 
Sourced and distributed products  $4,749,377   $1,254,982   $7,668,699   $1,254,982 
Manufactured products   112,759    19,051    275,675    814,605 
OED Installations   16,500    -    16,500    - 
Total  $4,878,636   $1,274,033   $7,960,874   $2,069,587 

 

Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company brings the finished goods into our California warehouse to fill orders as well as to build inventory for future sales orders. From time to time for some of our larger orders we may have our suppliers ship directly to our customers to avoid extra shipping charges. For manufactured products, there is usually a bidding process by branches of the military or other large firms that need mostly battery charging and storage systems for large industrial projects. We would then purchase the raw materials and parts needed to build out the project in our Pennsylvania warehouse.

 

Advertising and Marketing Expenses

 

The Company expenses advertising and marketing costs as incurred. For the three and six months ended June 30, 2022, the Company recorded advertising and marketing expenses of $2,710 and $5,973, respectively, and for the three and six months ended June 30, 2021, the Company recorded advertising and marketing expenses of $5,944 and $28,544, respectively.

 

Research and Development

 

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the three and six months ended June 30, 2022, and 2021, the Company did not record any research and development expenses.

 

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

 

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

 

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

 

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

 

F-10

 

 

Distinguishing Liabilities from Equity

 

The Company relies on the guidance provided by ASC Topic 480, Distinguishing Liabilities from Equity, to classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.

 

Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.

 

Our CEO and Chairman holds sufficient shares of the Company’s voting preferred stock that give sufficient voting rights under the articles of incorporation and bylaws of the Company such that the CEO and Chairman can at any time unilaterally vote to increase the number of authorized shares of common stock of the Company, without the need to call a general meeting of common shareholders of the Company.

 

Initial Measurement

 

The Company records its financial instruments classified as liability, temporary equity or permanent equity at issuance at the fair value, or cash received.

 

Subsequent Measurement – Financial Instruments Classified as Liabilities

 

The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in fair value of its financial instruments classified as liabilities are recorded as other income (expenses).

 

Fair Value of Financial Instruments

 

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
  Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
  Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to the conversion features within the instrument and that the company has insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.

 

F-11

 

 

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of June 30, 2022, and December 31, 2021, for each fair value hierarchy level:

 

June 30, 2022  Derivative
Liabilities
   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $7,589,928   $7,589,928 

 

December 31, 2021   Derivative
Liabilities
    Total  
Level I   $ -     $ -  
Level II   $ -     $ -  
Level III   $ 20,966,701     $ 20,966,701  

 

Leases

 

The Company accounts for leases under ASU 2016-02 (see Note 14), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

 

Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of 7.5%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the condensed consolidated statements of operations.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.

 

Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.

 

Segment Policy

 

The Company has no reportable segments as it operates in one segment; renewable energy.

 

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of June 30, 2022, and 2021, the Company’s dilutive securities are convertible into approximately 7,689,380,800 and 14,418,538,825, respectively, shares of common stock. The following table represents the classes of dilutive securities as of June 30, 2022, and 2021:

 

   June 30, 2022   June 30, 2021 
Convertible preferred stock (1)   6,933,544,466    13,820,732,691 
Unexercised common stock purchase warrants (1)   672,024,518    597,024,518 
Convertible notes payable   2,520,720    781,816 
Promissory note payable (1)   81,291,096    - 
TOTAL   7,689,380,800    14,418,538,825 

 

(1) The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise.

 

F-12

 

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows.

 

Other than the above, there have no recent accounting pronouncements or changes in accounting pronouncements during the period ended March 31, 2022, that are of significance or potential significance to the Company.

 

NOTE 4 – PROPERTY AND EQUIPMENT

 

The following table summarizes the Company’s property and equipment:

 

   June 30, 2022   December 31, 2021 
Office equipment  $300,083   $260,083 
Less: Accumulated Depreciation   (152,369)   (127,194)
Property and Equipment, Net  $147,714   $132,889 

 

Depreciation expense was $25,175 and $18,681 for the six months ended June 30, 2022, and 2021, respectively.

 

NOTE 5 - CONVERTIBLE NOTES PAYABLE

 

On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a past-due 15% convertible note issued by the Company on September 13, 2017. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $25,000.

 

NOTE 6 – DERIVATIVE LIABILITIES

 

The Company determined the conversion feature of the convertible notes, which all contain variable conversion rates, represented an embedded derivative since the notes were convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability.

 

At any given time, certain of the Company’s embedded conversion features on debt and outstanding warrants may be treated as derivative liabilities for accounting purposes under ASC 815-40 due to insufficient authorized shares to settle these outstanding contracts. Pursuant to SEC staff guidance that permits a sequencing approach based on the use of ASC 815-15-25 which provides guidance for contracts that permit partial net share settlement. The sequencing approach may be applied in one of two ways: contracts may be evaluated based on (1) earliest issuance date or (2) latest maturity date. Pursuant to the sequencing approach, the Company evaluates its contracts based upon the latest maturity date.

 

The Company valued the derivative liabilities at June 30, 2022, and December 31, 2021, at $7,589,928 and $20,966,701, respectively. For the derivative liability associated with convertible notes, the Company used the Monte Carlo simulation valuation model with the following assumptions as of June 30, 2022, and December 31, 2021, risk free interest rates at 2.51% and 0.19%, respectively, and volatility of 69% and 92%, respectively. The following assumptions were utilized in the Black-Scholes valuation of outstanding warrants at June 30, 2022, and December 31, 2021, risk free interest rate of 2.08% to 2.93%, and .48% to .99%, respectively, volatility of 183% to 331%, and 344% to 366%, respectively, and exercise prices of $0.006 to $0.15.

 

F-13

 

 

A summary of the activity related to derivative liabilities for the six months ended June 30, 2022, is as follows:

 

   Derivative liabilities associated with warrants   Derivative liabilities associated with convertible notes   Total derivative liabilities 
Balance December 31, 2021  $20,938,755   $27,946   $20,966,701 
Change in fair value   (13,376,695)   (78)   (13,376,773)
Balance June 30, 2022  $7,562,060   $27,868   $7,589,928 

 

NOTE 7 – NOTES PAYABLE

 

The Company has the following note payables outstanding:

 

   June 30, 2022   December 31, 2021 
         
  $134,681   $134,681 
Note payable bank, interest at 7.75%, matured December 5, 2021, currently in default  $134,681   $134,681 
Note payable bank, interest at 6.5%, matured December 26, 2021, in default   344,166    344,166 
Economic Injury Disaster Loan   10,000    10,000 
Paycheck Protection Program loan   100,400    100,400 
Notes payable, interest at 8%, matured January 5, 2020, in default   45,000    45,000 
Other, due on demand, interest at 6%, currently in default   50,000    50,000 
Note payable $750,000 face value, interest at 12%, matured August 24, 2021, in default   375,000    375,000 
Note payable $389,423 face value, interest at 18%, matures November 6, 2023   389,423    389,423 
Note payable $1,000,000 face value, interest at 12%, matured November 13, 2021, in default   1,000,000    1,000,000 
Note payable $2,200,000 face value, interest at 12%, matured February 9, 2022, net of discount of $243,833 (2021), in default   2,200,000    1,956,167 
Note payable $11,110,000 face value, interest at 12%, matured March 17, 2022, net of discount of $2,314,583 (2021), in default   11,110,000    8,795,417 
Note payable $3,300,000 face value, interest at 12%, matures December 7, 2022, net of discount of $1,458,115 (2022) and $3,099,524 (2021)   1,841,885    200,476 
Sub- total notes payable   17,600,555    13,400,730 
Less long-term portion   389,423    389,423 
Current portion of notes payable, net of discount  $17,211,132   $13,011,307 

 

On December 7, 2021, the Company entered into a 12%, $3,300,000 face value promissory note with a third- party lender with a maturity date of December 7, 2022. In exchange for the issuance of the $3,300,000 note, inclusive of an original issue discount of $300,000, the Company received proceeds of $3,000,000 on December 13, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 75,000,000 shares of common stock at $0.039 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the six months ended June 30, 2022, amortization of the costs of $150,000 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $2,982,815 has been recorded as an initial debt and an initial derivative liability of $2,982,815. For the six months ended June 30, 2022, amortization of the warrant discount of $1,491,407 was charged to interest expense. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $3,300,000 with a carrying value of $1,84,855 and $200,476, respectively, net of unamortized discounts of $1,481,115 and $3,099,524, respectively.

 

On March 17, 2021, the Company entered into a 12%, $11,110,000 face value promissory note with a third- party lender with a maturity date of March 17, 2022. This note is now in default. In exchange for the issuance of the $11,110,000 note, inclusive of an original issue discount of $1,000,000 and lender costs of $110,000 the Company received proceeds of $10,000,000 on March 23, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 250,000,000 shares of common stock at $0.13 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the six months ended June 30, 2022, amortization of the costs of $231,250 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $33,248,433 has been recorded as an initial debt discount of $10,000,000, interest expense of $23,248,433 and initial derivative liability of $32,248,433. For the six months ended June 30, 2022, amortization of the warrant discount of $2,083,333 was charged to interest expense. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $11,110,000 with a carrying value of $11,100,000 and $8,795,417, respectively, net of unamortized discounts of $2,314,583 as of December 31, 2021. As of June 30, 2022, and December 31, 2021, the accrued interest is $1,691,155 and $1,033,687, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

F-14

 

 

On February 9, 2021, the Company entered into a 12%, $2,200,000 face value promissory note with a third- party lender with a maturity date of February 9, 2022. This note is now in default. In exchange for the issuance of the $2,200,000 note, inclusive of an original issue discount of $200,000 the Company received proceeds of $2,000,000 on February 16, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 50,000,000 shares of common stock at $0.15 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the six months ended June 30, 2022, amortization of the costs of $22,167 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $17,659,506 has been recorded as an initial debt discount of $2,000,000, interest expense of $15,659,506 and initial derivative liability of $17,659,506. For the six months ended June 30, 2022, amortization of the warrant discount of $221,667 was charged to interest expense. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $2,200,000 with a carrying value as of December 31, 2021, of $1,956,167, net of unamortized discounts of $243,833. As of June 30, 2022, and December 31, 2021, the accrued interest is $360,921 and $230,729, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

On November 13, 2020, the Company entered into a 12%, $1,000,000 face value promissory note with a third-party due November 13, 2021. Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date. The Company received proceeds of $890,000 on November 20, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $110,000. In conjunction with this note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 125,000,000 shares of common stock at an exercise price of $0.008, subject to adjustments and expires on the five-year anniversary of the issue date. As of June 30, 2022 and December 31, 2021, the outstanding principal balance of this note was $1,000,000. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of June 30, 2022, and December 31, 2021, the accrued interest is $253,808 and $135,452, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

On November 6, 2020, the Company entered into a Settlement Agreement with the holder of $120,000 of convertible notes with accrued and unpaid interest of $8,716 and a $210,000 Promissory Noted dated June 23, 2020 with accrued and unpaid interest of $15,707. The Company issued a new 12% Promissory Note with a face value of $389,423 and a maturity date of November 6, 2023. In conjunction with this settlement, the Company issued a warrant to purchase 60,000,000 shares of common stock at an exercise price of $0.0075, subject to adjustments and expires on the five-year anniversary of the issue date. The Company analyzed the transaction and concluded that this was a modification to the existing debt. The investor exercised the warrant on January 14, 2021.

 

On October 26, 2016, PCTI entered into a $210,000 note payable with a bank. On March 15, 2021, due to defaults with the terms of the note, the note was amended with the outstanding balance due December 5, 2021, and the interest rate changed to 7.75%. Borrowings are collateralized by substantially all of the assets of PCTI and the personal guarantee of PCTI’s former President. As of June 30, 2022, and December 31, 2021, $134,681 and $151,469, respectively, was outstanding on the note payable. This note is in default. On April 19, 2022, PCTI received a Notice of Default, Demand and Reservation of Rights (the “Notice”) from the bank’s legal counsel. The Notice is also addressed to Catherine Chis (former President of PCTI and a guarantor on the note). On May 16, 2022, and June 24, 2022, the bank filed Confessions of Judgment (the “COJ”) that were signed in conjunction with the extension dated March 15, 2021, against Chis and PCTI, respectively. The Company has engaged legal counsel to assist the Company in this matter.

 

On March 15, 2021, PCTI renewed their $350,000 promissory note with a bank that provides for borrowings of up to $350,000. Interest is due monthly and the principal is due on December 26, 2021, interest rate changed to the prime rate plus 3.25% (6.5% at March 15, 2021). Borrowings are collateralized by substantially all of the assets of PCTI and the personal guarantee of PCTI’s former President. As of December 31, 2021, and December 31, 2020, $344,166 and $345,211, respectively, was outstanding on the promissory note. This note is in default. On April 19, 2022, PCTI received a Notice of Default, Demand and Reservation of Rights (the “Notice”) from the bank’s legal counsel. The Notice is also addressed to Catherine Chis (former President of PCTI and a guarantor on the note). ). On May 16, 2022, and June 24, 2022, the bank filed Confessions of Judgment (the “COJ”) that were signed in conjunction with the extension dated March 15, 2021, against Chis and PCTI, respectively. The Company has engaged legal counsel to assist the Company in this matter.

 

On August 24, 2020 (the “Issue Date”), the Company entered into a 12%, $750,000 face value promissory note with a third-party (the “Holder”) due August 24, 2021 (the “Maturity Date”). Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date. The Company received proceeds of $663,000 on August 25, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $87,000. For the year ended December 31, 2021, amortization of the costs of $56,188 was charged to interest expense. In conjunction with this Note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 122,950,819 shares of common stock at an exercise price of $0.0061, subject to adjustments and expires on the five-year anniversary of the Issue Date. The warrants issued resulted in a debt discount of $750,000. During the year ended December 31, 2021, the Company paid $375,000 to the Holder. On May 3, 2021, the Company issued 75,000,000 shares of common stock to the Holder, upon the cashless exercise of a portion of the warrants. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $375,000. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of June 30, 2022, and December 31, 2021, the accrued interest is $135,247 and $90,247, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

F-15

 

 

On April 20, 2020, PCTI was granted a loan from Huntington Bank in the amount of $100,400, pursuant to the Paycheck Protection Program (“PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The loan matures on April 20, 2022 and bears interest at a rate of 1.0% per annum, payable monthly beginning on November 20, 2020. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Payments are deferred until the SBA determines the amount to be forgiven. The Company utilized the proceeds of the PPP loan in a manner which will enable qualification as a forgivable loan. On December 2, 2021, PCTI received a notice from Huntington Bank that the SBA has denied PCTI’s application for loan forgiveness, due to inaccurate statements in the loan application as submitted by the former CEO of PCTI. The balance on this PPP loan was $100,400 as of June 30, 2022, and December 31, 2021, and has been classified in notes payable.

 

On July 14, 2020, PCTI received $10,000 grant under the Economic Injury Disaster Loan (“EIDL”) program. Up to $10,000 of the EIDL can be forgiven as long as such funds were utilized to provide working capital. The first payment due is deferred one year. The loan balance of June 30, 2022, and December 31, 2021 was $10,000 and has been classified in notes payable.

 

NOTE 8 – DEFERRED LIABILITY

 

On September 2, 2020, PCTI entered into an agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $750,000, PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. Payments are due ninety (90) days after each calendar quarter, with the first payment due on or before March 31, 2021, for revenues for the quarter ending December 31, 2020. For the three and six months ended June 30, 2022, the Company reduced this deferred liability by $87,815 and that amount is included in accounts payable and accrued expenses. The deferred liability as of June 30, 2022, and December 31, 2021, on the condensed consolidated balance sheet is $662,185 and $750,000, respectively. No payments have been made and the Company is in default of the agreement with the total amount of $358,446 included in accounts payable and accrued expenses as of June 30, 2022. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the note was amended, whereby in exchange for 175,000,000 shares of common stock, the royalty percentage was amended to 1.8%. The Company valued the shares at $0.094 per share (the market value of the common stock on the date of the agreement) and recorded $16,450,000 as debt restructure expense on the condensed consolidated statement of operations for the six months ended June 30, 2021.

 

NOTE 9 – DEFERRED REVENUE

 

During the year ended December 31, 2020, the Company received $64,353 form a customer for a payment of a three- year extended warranty. The extended warranty period is from, March 2021 through February 2024, and accordingly the Company will recognize the revenue over such period. For the three and six months ended June 30, 2022, and 2021, the Company recognized $5,363 and $10,725, respectively, of revenue. Of the remaining deferred revenue of $35,752, $21,451 is recognized as the current portion of deferred revenue and $14,301 is classified as a long- term liability on the condensed consolidated financial statements. As of December 31, 2021, $21,451 is classified as the current portion and $25,026 is classified as a long- term liability on the condensed consolidated financial statements.

 

NOTE 10 – RELATED PARTY TRANSACTIONS

 

Employment Agreement

 

On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Mr. Conway’s compensation as adjusted was $20,000 per month, and effective September 1, 2021, Mr. Conway receives $10,000 per month from Ozop Capital.

 

Effective January 1, 2022, the Company entered into a new employment agreement with Mr. Conway. Pursuant to the agreement, Mr. Conway received a $250,000 contract renewal bonus and will receive an annual compensation of $240,000 from the Company and will also be eligible to receive bonuses and equity grants at the discretion of the BOD. The Company also agreed to compensate Mr. Conway for services provided directly to any of the Company’s subsidiaries. Ozop Capital increased Mr. Conway’s compensation to $20,000 per month in January 2022, OES began compensating Mr. Conway $20,000 in March 2022, and OED began compensation Mr. Conway $20,000 per month beginning in April 2022.

 

F-16

 

 

Series E Preferred Stock

 

On March 21, 2021, the Company issued 2,000 shares of Series E Preferred Stock (see Note 12), 1,800 of the shares were issued to Mr. Conway. On April 16, 2021, the Board of Directors of the Company authorized the issuance 2,000 shares of Series E Preferred stock, of which 1,050 were issued to Mr. Conway. During the three and six months ended June 30, 2021, the Company redeemed 1,050 and 2,850 shares issued to Mr. Conway, and pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $1,000 per share, recorded stock compensation expense to Mr. Conway of $1,050,000 and $2,850,000 for the three and six months ended June 30, 2021.

 

Management Fees and related party payables

 

For the three and six months ended June 30, 2022, and 2021, the Company recorded expenses to its officers in the following amounts:

 

   2022   2021   2022   2021 
   Three months ended
June 30,
   Six months ended
June 30,
 
   2022   2021   2022   2021 
CEO, parent  $240,000   $360,000   $630,000   $639,999 
CEO, parent- Series E Preferred Stock   -    1,050,000    -    2,850,000 
President, subsidiary (resigned July 2021)   -    51,074    -    86,083 
Total  $240,000   $1,461,074   $630,000   $3,576,082 

 

Redemption of Series C and Series D Preferred Stock

 

On July 13, 2021, the Company entered into a Definitive Agreement (the “Agreement”) with Chis to purchase the 47,500 shares of the Company’s Series C Preferred Stock held by Chis and the 18,667 shares of the Company’s Series D Preferred Stock held by Chis for the total purchase price of $11,250,000. In conjunction with the Agreement, Chis resigned from any and all positions held in the Company’s wholly owned subsidiary, PCTI. Further, Chis agreed that upon her resignation and for a period of five years thereafter (the “Restriction Period”), she shall not, directly or indirectly, solicit the employment of, assist in the soliciting of the employment of, or hire any employee or officer of the Company, including those of any of its present or future subsidiaries, or induce any person who is an employee, officer, agent, consultant or contractor of the Company to terminate such relationship with the Company. Additionally, Chis agreed that during the Restriction Period, she shall not compete with the Company or PCTI anywhere worldwide or be employed by any competitor of the Company.

 

NOTE 11 – COMMITMENTS AND CONTINGENCIES

 

Leases

 

On January 2, 2021, the Company entered into a ten (10) year lease for a 6-bay garage storage facility of approximately 2,500 square feet from the property owner. Pursuant to the lease the Company agreed to issue 100,000,000 shares of restricted common stock. The shares were certificated on March 8, 2021, with an effective date of January 2, 2021. The Company valued the shares $0.0063, (the market value of the common stock on the date of the agreement) and has recorded $630,000 as a prepaid expense. The Company never took occupancy of the space, and the property owner has agreed to purchase a different property and will assign the title of such property to the Company in consideration of the 100,000,000 shares he received in January 2021.

 

Agreements

 

On September 1, 2021, Ozop Capital entered into an advisory agreement (the “RMA Agreement”) with Risk Management Advisors, Inc. (“RMA”). Pursuant to the terms of the RMA Agreement, RMA will assist Ozop Capital in analyzing, structuring, and coordinating Ozop Capital’s participation in a captive insurance company. RMA will coordinate legal, accounting, tax, actuarial and other services necessary to implement the Company’s participation in a captive insurance company, including, but not limited to, the preparation of an actuarial feasibility study, filing of all required regulatory applications, domicile selection, structural selection, and coordination of the preparation of legal documentation. In connection with the services listed above, Ozop Capital agreed to pay $50,000 and to issue $50,000 of shares of restricted common stock. One-half of the cash and stock were due upon the signing of the RMA Agreement. Accordingly, RMA received $25,000 and 452,080 shares of restricted common stock of the Company in September 2021. The balance of the cash and stock became due on October 29, 2021, upon the issuance of the captive insurance company’s certificate of authority from the state of Delaware. The Company has paid the $25,000 balance and recorded 637,755 shares of common stock to be issued.

 

On April 13, 2021, the Company agreed to engage PJN Strategies, LLC (“PJN”) as a consultant. Pursuant to the agreement, the Company agreed to compensate PJN $20,000 per month. Effective September 1, 2021, a new agreement was entered into between PJN and Ozop Capital. Pursuant to the terms of the new one- year agreement Ozop Capital agreed to compensate PJN $84,000 per month. For the three and six months ended June 30, 2022, the Company recorded $252,000 and $504,000, respectively, of consulting expenses.

 

F-17

 

 

On April 16, 2021, the Company signed a letter of agreement with Rubenstein Public Relations, Inc. (“RPR”). Pursuant to the letter of agreement, the Company agreed to engage RPR, effective May 1, 2021, on a month-to-month basis for $17,000 per month.. The Company terminated the agreement in October 2021.

 

On March 30, 2021, OES hired 2 individuals as Co-Directors of Sales. Pursuant to their respective offers of employment, the Company agreed to an annual salary of $130,000 with a signing bonus of $20,000 for each and to issue each 2,500,000 shares of restricted common stock upon the execution of the agreements and every 90 days thereafter for the first year as long as the employee is still employed. The Company valued the initial shares at $0.092 per share (the market price of the common stock on the date of the agreement), and $460,000 is included in stock-based compensation expense for the six months ended June 30, 2021. On January 14, 2022, the Company issued each of the Co-Directors their final 2,500,000 shares due. The shares were valued at $0.027 per share (the market price of the common stock on the date of the issuance), and $135,000 is included in stock-based compensation expense for the six months ended June 30, 2022. One of the individuals resigned on January 24, 2022.

 

On March 15, 2021, the Company entered into a consulting agreement with Aurora Enterprises (“Aurora”). Mr. Steven Martello is a principal of Aurora. Pursuant to the agreement Mr. Martello will provide strategic analysis regarding existing markets and revenue streams as well as the development of new lines of revenue. The Company agreed to a monthly retainer fee of $10,000 and to issue to Aurora or their designee 5,000,000 shares of restricted common stock. The shares were issued in April 2021. Aurora designated the shares to be issued to Pegasus Partners, Inc. The Company valued the shares at $0.1392 per share (the market price of the common stock on the date of the agreement), and $696,000 is included in stock-based compensation expense for the six months ended June 30, 2021. For the three and six months ended June 30, 2022, the Company has recorded $30,000 and $60,000, respectively, of consulting expenses, and for the three and six months ended June 30, 2021, the Company recorded consulting expenses of $xxx and $xxx, respectively.

 

On February 24, 2021, the Company entered into a consulting agreement with Christopher Ruppel. Pursuant to the agreement Mr. Ruppel was to join the Ozop Advisory Board. During the year ended December 31, 2021, the Company issued 10,000,000 shares of restricted common stock to Mr. Ruppel and agreed to a monthly fee of $2,500. The Company valued the shares at $0.2386 per share (the market price of the common stock on the date of the agreement), and $2,386,000 is included in stock-based compensation expense for the six months ended June 30, 2021. Effective April 1, 2021, the agreement was amended to $10,000 per month. Effective May 1, 2021, the Company was no longer using the services of Mr. Ruppel. For the three and six months ended June 30, 2021, the Company recorded $10,000 and $12,500 of consulting expenses, respectively.

 

On January 22, 2021, the Company issued 10,000,000 shares of restricted common stock for legal services performed in 2020 and approved by the BOD of the Company on December 1, 2020. The Company valued the shares at $0.0056 per share (the market price of the common stock on the date of the agreement), and $56,000 is included in stock-based compensation expense for the six months ended June 30, 2021.

 

On January 14, 2021, the Company entered into a Consulting Agreement with Mr. Allen Sosis. Pursuant to the agreement, Mr. Sosis will provide services as the Director of Business Development for the Company’s wholly owned subsidiary. Pursuant to the agreement, as amended, the Company will pay Mr. Sosis a monthly fee of $15,000 and an additional $1,000 in benefits. The Company also agreed to issue Mr. Sosis 5,000,000 shares of restricted common stock. The shares were issued in April 2021. The Company valued the shares at $0.20 per share (the market price of the common stock on the date of the agreement), and $1,000,000 was recorded as deferred stock compensation, to be amortized over the one-year term of the agreement. The Company terminated Mr. Sosis’s employment in October 2021. For the three and six months ended June 30, 2021, the Company recorded $30,000 and $75,500 of consulting expenses and effective June 1, 2021, Mr. Sosis became an employee of the Company through his termination with a $15,000 per month salary.

 

On January 6, 2021, the Company entered into a consulting agreement with Ezra Green to begin on February 8, 2021. The Company agreed to issue 10,000,000 shares of restricted common stock to Mr. Green and to a monthly fee of $2,500. The Company valued the shares at $0.0076 per share (the market price of the common stock on the date of the agreement), and $76,000 was recorded as deferred stock-based compensation, to be amortized over the one-year term of the agreement. For the six months ended June 30, 2022, and 2021, the Company recorded $1,249 and $36,348 as stock-based compensation expense, respectively. Effective April 1, 2021, the agreement was amended to $10,000 per month. For the three and six months ended June 30, 2022, the Company recorded $30,000 and $60,000, respectively, of consulting expenses and for the three and six months ended June 30, 2021, the Company recorded $30,000 and $34,500 of consulting expenses, respectively. Effective June 30, 2022, Mr. Green was no longer providing consulting services to the Company.

 

On March 4, 2019, the Company entered into a Separation Agreement (the “Separation Agreement”) with Salman J. Chaudhry, pursuant to which the Company agreed to pay Mr. Chaudry $227,200 (the “Outstanding Fees”) in certain increments as set forth in the Separation Agreement. As of June 30, 2022 and December 31, 2021, the balance owed Mr. Chaudhry is $162,085.

 

On September 2, 2020, PCTI entered into an Agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $750,000, PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the agreement was amended, whereby in exchange for 175,000,000 shares of common stock, the royalty percentage was amended to 1.8% (see Note 8). The Company valued the shares at $0.094 per share (the market value of the common stock on the date of the agreement) and recorded $16,450,000 as debt restructure expense on the condensed consolidated statement of operations for the six months ended June 30, 2021.

 

F-18

 

 

Legal matters

 

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

 

NOTE 12– STOCKHOLDERS’ EQUITY

 

Common stock

 

During the six months ended June 30, 2022, the Company issued 5,000,000 shares of restricted common stock in the aggregate for services.

 

During the period from January 1, 2021, to June 30, 2021, holders of an aggregate of $760,550 in principal and $201,905 of accrued interest and fees of convertible and promissory notes, converted their debt into 483,154,618 shares of our common stock at an average conversion price of $0.002 per share.

 

During the six months ended June 30 2021, the Company also issued the following shares of restricted common stock:

 

  100,000,000 shares of restricted common stock pursuant to a lease agreement (see Note 10).
  175,000000 shares of restricted common stock pursuant to restructuring agreement related to a deferred liability (see Note 9).
  45,000,000 shares of restricted common stock in the aggregate for services and consulting agreements.

 

During the six months ended June 30, 2021, the Company also issued 405,797,987 shares of common stock upon the cashless exercise of common stock purchase warrants.

 

As of June 30, 2022, the Company has 4,990,000,000 shares of $0.001 par value common stock authorized and there are 4,622,362,977 shares of common stock issued and outstanding.

 

On April 4th, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (200,000,000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement.

 

Preferred stock

 

As of June 30, 2022, and December 31, 2021, 10,000,000 shares have been authorized as preferred stock, par value $0.001 (the “Preferred Stock”), which such Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time.

 

Series C Preferred Stock

 

On July 7, 2020, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company’s Series C Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series C Preferred Stock, 50,000 shares of the Company’s preferred remain designated as Series C Preferred Stock. The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 47,500 shares of Series C preferred Stock to Chis. On July 13, 2021, the Company purchased 47,500 shares of the Company’s Series C Preferred Stock held by Chis (see Note 11). As of June 30, 2022, and December 31, 2021, there were 2,500 shares of Series C Preferred Stock issued and outstanding and the shares are held by Mr. Conway.

 

F-19

 

 

Series D Preferred Stock

 

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series D Preferred Stock. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 18,667 shares of Series D preferred Stock to Chis, and on August 28, 2020, pursuant to Mr. Conway’s employment agreement, the Company issued 1,333 shares of Series D Preferred Stock to Mr. Conway. On July 13, 2021, the Company purchased 18,667 shares of the Company’s Series D Preferred Stock held by Chis (see Note 10).

 

On July 27, 2021, the Company filed with the Secretary of State of the State of Nevada an Amended and Restated Certificate of Designation of Series D Preferred Stock (the “Series D Amendment”). Under the terms of the Series D Amendment, 4,570 shares of the Company’s preferred stock will be designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. Any holder may, at any time convert any number of shares of Series D Convertible Preferred Stock held by such holder into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by 1.5 and dividing that number by the number of authorized shares of Series D Convertible Preferred Stock and multiply that result by the number of shares of Series D Convertible Preferred Stock being converted. Except as provided in the Series D Amendment or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 28, 2021, the Company closed on a Stock and Warrant Purchase Agreement (the “Series D SPA”). Pursuant to the terms of Series D SPA, an investor in exchange for $13,200,000 purchased one share of Series D Preferred Stock, and a warrant to acquire 3,236 shares of Series D Preferred Stock. As of June 30, 2022, and December 31, 2021, there were 1,334 shares, respectively, of Series D Preferred Stock issued and outstanding and a warrant to purchase 3,236 shares of Series D Preferred Stock are outstanding as of June 30, 2022, and December 31, 2021.

 

The warrant has a 15- year term and Partial Warrant Lock Up and Leak-Out Period. The Holder may only exercise the Warrant and purchase Warrant Shares as follows:

 

  i. Up to 162 (one hundred and sixty-two) Warrant Shares, at any time or times on or after five (5) business days from the closing of the Series D SPA (“the Initial Exercise Date”) subject to up to a maximum number of Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company and no later than on or before the 15th year anniversary of the Initial Exercise Date (“the Termination Date”); and
     
  ii. The Remainder of the Warrant representing up to 3,074 (three thousand and seventy-four) Warrant Shares (“Remaining Warrant Shares”) shall be locked up for a period of 36 (thirty-six) months from the Initial Exercise Date (“Lock Up Period”) and shall become exercisable at any time or times from the date that is the 36 (thirty-six) month anniversary of the Initial Exercise Date (“Lock Up Period Termination Date”) and no later than on or before the Termination Date, as follows:

 

  a. During every 1 (one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034 and until the Termination Date.

 

Series E Preferred Stock

 

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series E Preferred Stock. Under the terms of the Certificate of Designation of Series E Preferred Stock, 3,000 shares of the Company’s preferred stock have been designated as Series E Preferred Stock. The holders of the Series E Convertible Preferred Stock shall not be entitled to receive dividends. No holder of the Series E Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, except as may be otherwise expressly required by law. At any time, the Corporation may redeem for cash out of funds legally available therefor, any or all of the outstanding Preferred Stock (“Optional Redemption”) at $1,000 (one thousand dollars) per share. The shares of Series E Preferred Stock have not been registered under the Securities Act of 1933 or the laws of any state of the United States and may not be transferred without such registration or an exemption from registration. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 500 shares of Series E preferred Stock to Chis, and on August 28, 2020. Pursuant to Mr. Conway’s employment agreement, the Company issued 500 shares of Series E Preferred Stock to Mr. Conway. On March 2, 2021, the BOD authorized the issuance of 1,800 shares of Series E Preferred Stock to Mr. Conway and 200 shares of Series E Preferred Stock to a third-party service provider. The issuances were for services performed. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $1,000 per share, the Company recorded $2,000,000 as stock-based compensation expense for expense for the six months ended June 30, 2021. On March 24, 2021, the Company redeemed the 3,000 shares of Series E Preferred Stock outstanding on that date. On April 16, 2021, the BOD authorized the issuance of 2,000 shares of Series E Preferred stock, of which 1,050 were granted to Mr. Conway. The issuances were for services performed. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $1,000 per share, the Company recorded $2,000,000 as stock-based compensation expense for the three and six months ended June 30, 2021. As of June 30, 2022, and December 31, 2021, there were -0- shares of Series E Preferred Stock issued and outstanding, respectively.

 

F-20

 

 

NOTE 13 – NONCONTROLLING INTEREST

 

On August 19, 2021, the Company formed Ozop Capital. The Company owns 51% with PJN owning 49%. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital. The Company presents interest held by noncontrolling interest holders within noncontrolling interest in the condensed consolidated financial statements. During the six months ended June 30, 2022, there was no change in the ownership percentages. For the three and six months ended June 30, 2022, Ozop Capital incurred losses of $351,835 and $734,912, respectively, of which $172,399 and $360,107, respectively, is the loss attributed to the noncontrolling interest for the three- and six- months ending June 30, 2022. As of June 30, 2022, the accumulative noncontrolling interest is $615,212.

 

NOTE 14 - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES

 

On October 25, 2019, PCTI executed a non-cancellable lease for office and industrial space which began December 1, 2019 and expires on November 30, 2022. Operating lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 7.5%, as the interest rate implicit in most of our leases is not readily determinable. Prior to July 10, 2020, PCTI recorded monthly lease expense pursuant to the lease agreement and effective July 10, 2020, pursuant to the PCTI transaction, operating lease expense is recognized pursuant to ASC Topic 842. Leases (Topic 842) over the lease term. During the years ended December 31, 2020, the Company recorded $84,278 for rent expense. During the year ended December 31, 2020, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $185,139 for this lease.

 

On April 14, 2021, the Company entered into a five-year lease which began on June 1, 2021, for approximately 8,100 square feet of office and warehouse space in Carlsbad, California, expiring May 31, 2026. Initial lease payments of $13,148 began on June 1, 2021, and increase by approximately 2.4% annually thereafter. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 7.5%, as the interest rate implicit in most of our leases is not readily determinable. During the year ended December 31, 2021, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $702,888 for this lease.

 

In adopting Topic 842, the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less.

 

Right-of- use assets are summarized below:

 SCHEDULE OF RIGHT-OF-USE ASSETS

   June 30, 2022 
Office and warehouse lease  $888,026 
Less: Accumulated Amortization   (281,498)
Right-of-use asset, net  $606,078 

SCHEDULE OF OPERATING LEASE LIABILITIES

   June 30, 2022 
Lease liability  $614,247 
Less current portion   (161,048)
Long term portion  $453,199 

 

Maturity of lease liabilities are as follows:

SCHEDULE OF MATURITY OF LEASE LIABILITIES

   Amount 
For the year ended December 31, 2022  $117,788 
For the year ended December 31, 2023   167,858 
For the year ended December 31, 2024   171,840 
For the year ended December 31, 2025   175,942 
For the year ended December 31, 2026   74,030 
Total  $707,458 
Less present value discount   (93,211)
Lease liability  $614,247 

 

NOTE 15 – SUBSEQUENT EVENTS

 

On July 15, 2022, the Company sold 15,353,952 shares to GHS at $0.010285 and received net proceeds of $152,732, after deducting transaction and broker fees of $5,183.

 

On August 1, 2022, the Company sold 7,675,221 shares to GHS at $0.010965 and received net proceeds of $81,451, after deducting transaction and broker fees of $2,708.

 

On August 4, 2022, the Company sold 8,136,272 shares to GHS at $0.010965 and received net proceeds of $86,405, after deducting transaction and broker fees of $2,809.

 

On August 10, 2022, the Company sold 18,063,649 shares to GHS at $0.01088 and received net proceeds of $191,577, after deducting transaction and broker fees of $4,956.

 

The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements, except as stated herein.

 

F-21

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying condensed consolidated financial statements, as well as information relating to the plans of our current management. This report includes forward-looking statements. Generally, the words “believes,” “anticipates,” “may,” “will,” “should,” “expect,” “intend,” “estimate,” “continue,” and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this report or other reports or documents we file with the Securities and Exchange Commission from time to time, which could cause actual results or outcomes to differ materially from those projected. Undue reliance should not be placed on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.

 

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments, and assumptions. We believe that the estimates, judgments, and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments, and assumptions are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates.

 

The following discussion should be read in conjunction with our unaudited financial statements and the related notes that appear elsewhere in this Quarterly Report on Form 10-Q.

 

THE COMPANY

 

Ozop Energy Solutions, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.

 

On December 11, 2020, the Company formed Ozop Energy Systems, Inc. (“OES”), a Nevada corporation and a wholly owned subsidiary of the Company. OES was formed to be a manufacturer and distributor of renewable energy products.

 

On October 29, 2020, the Company formed a new wholly owned subsidiary, Ozop Surgical Name Change Subsidiary, Inc., a Nevada corporation (“Merger Sub”). The Merger Sub was formed under the Nevada Revised Statutes for the sole purpose and effect of changing the Company’s name to “Ozop Energy Solutions, Inc.” That same day the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with the Merger Sub and filed Articles of Merger (the “Articles of Merger”) with the Nevada Secretary of State, merging the Merger Sub into the Company, which were stamped effective as of November 3, 2020. As permitted by the Section 92.A.180 of the Nevada Revised Statutes, the sole purpose and effect of the filing of Articles of Merger was to change the name of the Company from Ozop Surgical Corp. to “Ozop Energy Solutions, Inc.”

 

3

 

 

On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation. The Company is the majority shareholder of Ozop Capital with PJN Holdings LLC, a New York limited liability company, being the minority shareholder. Ozop Capital was formed as a holding company to seek to develop a captive insurance company. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital.

 

On October 29, 2021, EV Insurance Company, Inc. (“EVCO”) was formed as a captive insurer that reinsures in the State of Delaware. EVCO is a wholly owned subsidiary of Ozop Capital. On January 7, 2022, EVCO filed with New Castle County, Delaware DBA OZOP Plus.

 

OES is actively engaged in the renewable, electric vehicle (“EV”), energy storage and energy resiliency sectors. We are engaged in multiple business lines that include project development as well as equipment distribution. Our solar and energy storage projects involve large-scale battery and solar photovoltaics (PV) installations. Our utility-scale storage business model is based on an arbitrage business model in which we install multiple 1+ megawatt batteries, charge them with off-peak grid electricity under contract with the utility, then sell the power back during peak load hours at a premium, as dictated by prevailing electricity tariffs.

 

Equipment Distributor: OES has entered the component supply/distribution side of the renewable, resiliency and energy storage industries distributing the core components associated with residential and commercial solar PV systems as well as onsite battery storage and power generation. In April 2021, the Company signed a five- year lease (beginning June 1, 2021) of approximately 8,100 SF in California, for office and warehouse space to support the sales and distribution of our west coast operations. The components we are distributing include PV panels, solar inverters, solar mounting systems, stationary batteries, onsite generators and other associated electrical equipment and components that are all manufactured by multiple companies, both domestic and international. These core products are sourced from management-developed relationships and are distributed through our existing network and our in-house sales team.

 

Solar PV: Our PV business model involves the design and construction of electrical generating PV systems that can sell power to the utilities or be used for off grid use as part of our developing Neo-Grids solution. The Neo-Grids proprietary program, patent pending, was developed for the off-grid distribution of electricity to remove or reduce the dependency on utilities that currently burdens the EV Charging sectors. It will also reduce or eliminate the lengthy permitting processes and streamline the installations of those EV chargers.

 

Modular Energy Distribution System: The Neo-Grids, patent pending, is comprised of the design engineering, installation, and operational methodologies as well as the financial arbitrage of how we produce, capture and distribute electrical energy for the EV markets. OES has acquired the license rights to a proprietary system, the Neo-GridsTM System (patent pending), for the capture and distribution of electrical energy for the EV market. The Neo-GridsTM System will serve both the private auto and the commercial sectors. The exponential growth of the EV industry has been accelerated by the recent major commitments of most of the major car manufacturers. Our Neo-GridsTM System leverages this accelerated growth by offering (1) charging locations that can be installed with reduced delays, restricted areas or load limits and (2) EV charger electricity that is produced from renewable sources claiming little to no carbon footprint.

 

OES has developed a business plan for the Neo Grids distribution, a solution to the stress forthcoming to the existing grid infrastructure. The Company has completed its’ Neo Grid research and development as well as the first set of engineered technical drawings. This first stage of engineered technical drawings allows us to move forward with stage two, as well as to begin to construct the first prototype or proof of concept, (“PoC”). Our PoC design is partially reliant on auto manufacturers establishing standardizations of the actual charging/discharging protocols of the batteries such as on-board inverters as well as bi-directional capabilities in electric vehicles, which have only recently been established. As the market growth rate of EV’s continues to rise, the stress on the existing grid-tied infrastructure shows the need for the continued development of our Neo-Grid solution.

 

OES management has decades of experience in the renewable, storage and resilient energy businesses and associated markets, which include but are not limited to project finance, project development, equipment finance, construction, utility protocol, regulatory policy and technology assessment.

 

Ozop Plus plans on marketing vehicle service contracts (“VSC’s”) for electric vehicles (EV’s) that will offer to consumers to be able to purchase additional months and or miles above the manufacturer’s warranty and to also bring added value to EV owners by utilizing our partnerships and strengths in the energy market to offer unique and innovative services. Among EV owners’ concerns are the EV battery repair and replacement costs, range anxiety, environmental responsibilities, roadside assistance, and the accelerated wear on additional components that EV vehicles experience. Management believes that the Ozop Plus marketed VSC’s will give “peace of mind” to the EV buyer.

 

4

 

 

  In May 2022, the Company entered into an agreement with GS Administrators, Inc., a member of Houston-based GSFSGroup. Under the agreement, the Company will market GSFSGroup’s EV VSC’s in all states (except, California, Florida, Massachusetts and Washington) to Ozop’s network of new and used franchised dealerships and other eligible entities. In addition to acting as an agent for the marketing, Ozop also has the right to white label the product under its’ Ozop Plus brand. Ozop’s role won’t be limited to marketing the product. GSFSGroup plans to tap into Ozop’s experience relative to battery collection and disposal and has agreed to insurance risk sharing in connection with the insurance policies that back the VSC’s. GSFSGroup is working on getting the approvals needed for the above four (4) states.
     
  On June 22, 2022, the Company entered into an Agent Agreement with Royal Administration Services, Inc. (“Royal”). Under the agreement, the Company will market Royal’s EV VSC’s and has the right to white label it under Ozop Plus. Royal has agreed to allow Ozop Plus on all VSC’s, marketed by Royal and the Company, to assume all of the risk related to the electric battery at an agreed upon premium. The battery premium is dependent on the consumer’s selection of the duration of the VSC, the miles selected for coverage and the type of vehicle that the consumer has purchased, with a key component being the kWh size of the battery. These VSC’s have a maximum of 10 years and 150,000 miles and cover new and used cars from model year 2017 and newer. During August 2022, Royal will begin the filing process in all 50 states, 30 plus of which are effective upon filing, and the others have various waiting times or approvals needed.

 

On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners are able to offer the resources needed for lighting, solar and electrical design projects. OED will provide its’ customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs by working with architects, engineers, facility managers, electrical contractors and engineers.

 

Stock Purchase Agreement

 

On July 10, 2020, the Company entered into a Stock Purchase Agreement (the “SPA”) with Power Conversion Technologies, Inc., a Pennsylvania corporation (“PCTI”), and Catherine Chis (“Chis”), PCTI’s Chief Executive Officer (“CEO”) and its sole shareholder. Under the terms of the SPA, the Company acquired one thousand (1,000) shares of PCTI, which represents all of the outstanding shares of PCTI, from Chis in exchange for the issuance of 47,500 shares of the Company’s Series C Preferred Stock, 18,667 shares of the Company’s Series D Preferred Stock, and 500 shares of the Company’s Series E Preferred Stock to Chis. The Acquisition is being accounted for as a business combination and was treated as a reverse acquisition for accounting purposes with PCTI as the accounting acquirer in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”). In accordance with the accounting treatment for a reverse acquisition, the Company’s historical financial statements prior to the reverse merger were and will be replaced with the historical financial statements of PCTI prior to the reverse merger, in all future filings with the U.S. Securities and Exchange Commission (the “SEC”). The consolidated financial statements after completion of the reverse merger have and will include the assets, liabilities and results of operations of the combined company from and after the closing date of the reverse merger.

PCTI designs, develops, manufactures and distributes standard and custom power electronic solutions. All of its products are manufactured in the United States.

 

The results of operations below include PCTI activity for the three and six months ended June 30, 2022, and 2021. Due to supply chain issues and other factors, management is currently reviewing the current business model of PCTI, in determining the best course of action going forward.

 

Stock Redemption Agreement

 

On July 13, 2021, the Company entered into a Definitive Agreement (the “Agreement”) with Chis to purchase the 47,500 shares of the Company’s Series C Preferred Stock held by Chis and the 18,667 shares of the Company’s Series D Preferred Stock held by Chis for the total purchase price of $11,250,000.The Agreement was closed on July 27, 2021.

 

Results of Operations for the three and six months ended June 30, 2022 and 2021:

 

Revenue

 

For the three and six months ended June 30, 2022, the Company generated revenue of $4,878,636 and $7,960,874, respectively, compared to $1,274,033 and $2,069,587 for the three and six months ended June 30, 2021, respectively. The increase in revenues is from Ozop Energy Systems, Inc. (“OES”) and are classified as sourced and distributed products. PCTI sales classified as manufactured products had an increase for the three months ended June 30, 2022 compared to the three months ended June 30, 2021, and decreased for the six month ended June 30, 2022, compared to the six months ended June 30, 2021. Ozop Engineering and design (“OED”) operations began in the quarter ended June 30, 2022, and are classified as design and installation. Sales are summarized as follows:

 

   Three months ended
June 30,
   Six months ended
June 30,
 
   2022   2021   2022   2021 
Sourced and distributed products  $4,749,377   $1,254,982   $7,668,699   $1,254,982 
Manufactured products   112,759    19,051    275,675    814,065 
Design and installation   16,500    -    16,500    - 
Total  $4,878,636   $1,274,033   $7,960,874   $2,069,587 

 

5

 

 

As it did for most of the industry; OES’s importing of solar panels issues that began in the 4th quarter of 2021, continued 2022. Covid issues continued to be disruptive to a continual source of product from foreign manufacturers as well as ocean freight backlogs and covid issues that plagued the port of arrivals related to the unloading of containers and the eventual customs clearance of the imported goods. An announcement by the U.S. Department in March 2022 stated it would investigate allegations that solar panel manufacturers in Southeast Asia are using Chinese-made parts and evading U.S. tariffs has raised alarms concerning both trade and environmental policy The department announced March 28 that it would investigate claims by California-based solar panel manufacturer that solar energy equipment manufacturers in Cambodia, Malaysia, Thailand and Vietnam have close business ties to companies in China that produce the raw materials and some components of solar panel assemblies. On June 6, 2022, President Biden waived tariffs on solar panels from there four Southeast Asian nations for two years and invoked the Defense Production Act to spur domestic solar panel manufacturing at home. The tariff exemption will serve as a “bridge” while U.S. manufacturing ramps up.

 

Based on the situation prior to the June 6, 2022 announcement, the Company placed approximately $10,932,000 of purchase orders for solar panels and as of the date of the filing of this report has fully paid and received approximately $1,262,000 of this product. Additionally, the Company has made approximately $1.9 million of down payments to vendors on the remaining $9,670,000 of open purchase orders to vendors, to assure product delivery of approximately $4.7 million with a forecasted delivery in August and September 2022 and $5 million with a forecasted delivery in November and December 2022. Based on the above and the Company’s current on-hand inventory, management anticipates similar sales results for the third quarter as the second quarter, and the potential for a significant increase in fourth quarter sales.

 

Due to supply chain issues and other factors, management is currently reviewing the current business model of PCTI, in determining the best course of action going forward.

 

Cost of sales

 

For the three and six months ended June 30, 2022, the Company recognized $4,416,400 and $7.292.292, respectively of cost of sales, compared to $1,214,468 and $1,441,377 for the three and six months ended June 30, 2021, respectively..

 

   Three months ended
June 30,
   Six months ended
June 30,
 
   2022   2021   2022   2021 
Sourced and distributed products  $4,286,687   $1,204,877   $7,036,036   $1,204,877 
Manufactured products   129,774    9,591    256,256    236,500 
Total  $4.416.461   $1,214,468   $7,292,292   $1,441,377 

 

Based on the above cost of sales, gross margin was 9.5% and 8.4% for the three and six months ended June 30, 2022, compared to 4.7% and 30.4% for the three and six months ended June 30, 2021, respectively. The decrease of gross margin for the six months is a result of the manufactured orders shipped in 2021 were at a higher margin than the manufactured orders were in 2022. While PCTI’s margin and gross profit decreased in the current year, the Company realized an additional $632,663 of gross profit dollars recognized on OES’s sourced and distributed products. Due to product availability, increased buy prices and delivery issues that the solar industry experienced at the end of the 4th quarter 2021, and into the first quarter of 2022, the Company experienced lower margins on sourced products at the beginning of 2022. However, margins of sourced products were approximately 9.7% in the three months ended June 30, 2022 and the Company expects slightly higher margins and the third and fourth quarters of 2022. While the overall margin will be reduced, the higher gross profit dollars generated from the higher sourced and distributed products revenues will benefit the Company.

 

6

 

 

Operating expenses

 

Total operating expenses for the three months ended March 31, 2022, and 2021, were $1,977,857 and $5,789,470, respectively. The operating expenses were comprised of:

 

   Three Months Ended June 30, 2022   Three Months Ended June 30, 2021   Six Months Ended June 30, 2022   Six
Months Ended
June 30, 2021
 
Wages and management fees, related parties, including stock-based compensation  $240,000   $1,461,074   $630,000   $3,576,082 
Stock-based compensation, other   -    2,013,945    136,249    5,115,945 
Salaries, taxes and benefits   365,655    286,918    730,900    473,493 
Professional and consulting fees   599,619    362,782    1,234,616    566,207 
Advertising and marketing   2,710    5,954    5,973    28,544 
Rent and office expense   75,977    48,837    166,550    90,231 
Insurance   58,729    45,439    152,884    57,514 
General and administrative   171,597    134,356    434,971    240,759 
Total operating expenses  $1,514,287   $4,359,305   $3,492,144   $10,148,775 

 

Wages and management fees- related parties, include amounts paid to our CEO and to the President (resigned July 2021) of PCTI. On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Mr. Conway’s compensation as adjusted was $20,000 per month, and effective September 1, 2021, Mr. Conway began to receive $10,000 per month from Ozop Capital. Effective January 1, 2022, the Company entered into a new employment agreement with Mr. Conway. Pursuant to the agreement, Mr. Conway received a $250,000 contract renewal bonus and will receive an annual compensation of $240,000 from the Company and will also be eligible to receive bonuses and equity grants at the discretion of the BOD. The Company also agreed to compensate Mr. Conway for services provided directly to any of the Company’s subsidiaries. Ozop Capital increased Mr. Conway’s compensation to $20,000 per month in January 2022 and OES began compensating Mr. Conway $20,000 in March 2022. Below is a summary of wages and management fees:

 

   Three months ended
June 30,
   Six months ended
June 30,
 
   2022   2021   2022   2021 
CEO, parent  $240,000   $360,000   $630,000   $639,999 
Stock-based compensation   -    1,050,000    -    2,850,000 
President subsidiary (resigned July 2021)   -    51,074    -    86,083 
Total other (income) expense  $240,000   $1,461,074   $630,000   $3,576,082 

 

Stock based compensation for the six months ended June 30, 2022, of $136,429 is comprised of the following:

 

  5,000,000 shares of common stock issued in the aggregate to two employees pursuant to their offers of employment dated March 31, 2021. The shares were valued at $0.027 per share. During the six months ended June 30, 2022, the Company included $135,000 in stock compensation expense.
  $1,249 of amortization of stock compensation for shares issued in April 2021.

 

Stock based compensation, other for the three and six months ended June 30, 2021, of $2,013,945 and $5,115,945 is comprised of the following stock issuances:

 

  5,000,000 shares issued in April 2021 pursuant to a one-year consulting agreement. The Company valued the shares at $0.20 per share (the market price of the common stock on the date of the agreement), and $1,000,000 was recorded as deferred stock compensation, to be amortized over the one-year term of the agreement. For the six months ended June 30, 2021, $331,507 is included in stock-based compensation expense.
     
  10,000,000 shares issued in April 2021 pursuant to a one-year consulting agreement. The Company valued the shares at $0.0076 per share (the market price of the common stock on the date of the agreement), and $76,000 was recorded as deferred stock-based compensation, to be amortized over the one-year term of the agreement. For the six months ended June 30, 2021, the Company recorded $36,348 as stock-based compensation expense.
     
  5,000,000 shares issued in April 2021 for services. The Company valued the shares at $0.1392 per share (the market price of the common stock on the date of the agreement), and $696,000 is included in stock-based compensation expense for the six months ended June 30, 2021.
     
  10,000,000 shares issued for services. The shares were valued at $0.0056 per share, the date the Company agreed to issue the shares. During the six months ended June 30, 2021, the Company included $56,000 in stock compensation expense.

 

7

 

 

   10,000,000 shares issued pursuant to a consulting agreement dated February 24, 2021 (see Note 11). The shares were valued at $0.2386 per share. During the six months ended June 30, 2021, the Company included $2,386,000 in stock compensation expense.
     
  5,000,000 shares of common stock issued in the aggregate to two new employees pursuant to their offers of employment dated March 31, 2021. The shares were valued at $0.23 per share. During the six months ended June 30, 2021, the Company included $460,000 in stock compensation expense for the 5,000,000 shares of common stock.
     
  Issuance of 200 shares and 950 shares of Series E Preferred Stock, with a redemption value of $1,000 per share, resulting in stock compensation expense of $950,000 and $1,150,000 for the three and six months ended June 30, 2021, respectively.

 

Salaries, taxes and benefits increased for the three and six months ended June 30, 2022, compared to the same periods in 2021. The increase was a result of the current periods including $252,913 and $499,348, respectively, compared to $125,575 and $167,515 for the three and six months ended June 30, 2021, respectively, of expenses related to OES and $55,562 for the three and six months ended June 30, 2022, respectively, for OED. These additional costs were offset by reductions in PCTI’s expenses of $104,164 and $129,999, respectively, for the three and six months ended June 30, 2022, compared to the three and six months ended June 30, 2021. OES now has annual gross payroll of approximately $512,000 and an additional $351,000 on an annual basis of personnel focused on the Company’s battery storage vertical. OED currently has five employees with an aggregate annual compensation of $457,000.

 

Professional and consulting fees increased for the three and six months ended June 30, 2022, compared to June 30, 2021. The increases are due to increases in accounting expenses of Ozop and its’ subsidiaries in the current three- and six-month periods and consultants engaged in the second quarter of 2021 by Ozop Capital Partners that have been engaged for the entire six months ended June 30, 2022, as Ozop Plus initiates its business plan regarding vehicle service contracts on electric vehicles.

 

Advertising and marketing expenses decreased for the three and six months ended June 30, 2022, compared to June 30, 2021. The decreases were related to marketing programs during 2021, including brand awareness programs for both PCTI and Ozop.

 

Rent and office expense (including supplies, utilities and internet costs) increased for the three and six months ended June 30, 2022, compared to the three and six months ended June 30, 2021. The increases are the result of including in the current period, rent and office expense of approximately $52,412 and $98,146, respectively, for the three and six months ended June 30, 2022, compared to $18,421 for the three and six months ended June 30, 2021, for OES. The Company estimates that the monthly OES rent and office expense for the California operation to be approximately $18,000 per month.

 

Insurance expense increased for the three and six months ended June 30, 2022, compared to the three and six months ended June 30, 2021. The increase was the result of including in the current three- and six-month periods, insurance expense of approximately $52,114 and $132,948, respectively, for the three and six months ended June 30, 2022, compared to $26,648 for the three and six months ended June 30, 2021, for OES. The Company estimates that the monthly OES insurance expense for the California operation to be approximately $24,000 per month.

 

Other Income (Expenses)

 

Other income, net was $7,584,016 and $7,973,998 for the three an six months ended June 30, 2022, respectively, compared to other income, net of $4,087,788 for the three months ended June 30, 2021, and other expenses of $200,183,755 for the six months ended June 30, 2021, and were comprised of as follows:

 

   Three months ended
June 30,
   Six months ended
June 30,
 
   2022   2021   2022   2021 
Interest expense  $1,427,554   $4,310,355   $5,402,775   $44,695,085 
(Gain) loss on change in fair value of derivatives   (9,011,570)   (8,866,819)   (13,376,773)   43,331,083 
Loss on extinguishment of debt   -    468,696    -    95,437,587 
Debt restructure expense   -    -    -    16,450,000 
Total other (income) expense  $(7,584,016)  $(4,087,788)  $(7,973,998)  $200,183,755 

 

The increase in other income, net, for the three months ended June 30, 2022, compared to the three months ended June 30, 2021, is primarily a result of reduced interest expense of $2,899,796 related to the amortization of debt discounts associated with the maturity dates of certain of the company’s promissory notes. Other expenses for the six months ended June 30, 2021, includes the loss on extinguishment of debt related to the market value of shares of common stock issued in excess of the debt and accrued interest extinguished. The Company also issued 175,000,000 shares of restricted common stock related to the restructure of the deferred liability. The shares were valued at $0.094 per share and the Company recognized $16,450,000 of restructuring costs. Also included in interest expense for the six months ended June 30, 2021, is the initial $38,907,939 of fair value related to the issuance of 300,000,000 warrants. In addition, the amortization of debt discounts of $5,137,956 and losses on changes in fair values of derivatives, related to convertible notes and warrants.

 

8

 

 

Net income (loss)

 

Net income for the three months ended June 30, 2022, was $6,704,305 compared to a net loss of $211.952 for the three months ended June 30, 2021. The change was primarily a result of an increase in gross profit, a decrease in operating expenses and the increase in other income as discussed above. For the six months ended June 30, 2022, the Company has net income $5,510,544 compares to a net loss of $209,704,320 for the six months ended June 30, 2021. The loss for the six months ended June 30, 2021, was primarily a result of the other expenses descried above as well as $7,965,945 of stock- based compensation expenses included in the operating expenses for the six months ended June 30, 2021.

 

Liquidity and Capital Resources

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2022, the Company had an accumulated deficit of $211,816,067 and a working capital deficit of $22,909,763 (including derivative liabilities of $7,589,928). As of June 30, 2022, the Company was in default of $15,369,247 plus accrued interest on debt instruments due to non-payment upon maturity dates. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date of the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

Currently, our current capital and our other existing resources will be sufficient to provide the working capital needed for our current business, however, additional capital will be required to meet our debt obligations, and to further expand our business. We may be unable to obtain the additional capital required. If we are unable to generate capital or raise additional funds when required it will have a negative impact on our business development and financial results. These conditions raise substantial doubt about our ability to continue as a going concern as well as our recurring losses from operations, deficit in equity, and the need to raise additional capital to fund operations. This “going concern” could impair our ability to finance our operations through the sale of debt or equity securities. Management’s plans in regard to these factors are discussed below and also in Note 2 to the condensed consolidated financial statements filed herein.

 

As of June 30, 2022, we had cash of $1,949,528 as compared to $6,767,167 at December 31, 2021. As of June 30, 2022, we had current liabilities of $30,840,870 (including $7,589,928 of non-cash derivative liabilities), compared to current assets of $7,031,107, which resulted in a working capital deficit of $22,909,763. The current liabilities are comprised of accounts payable, accrued expenses, convertible debt, derivative liabilities, customer deposits, lease obligations and notes payable.

 

In December 2019, a novel strain of coronavirus (COVID-19) emerged. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but it may have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

 

Operating Activities

 

For the six months ended June 30, 2022, net cash used in operating activities was $4,777,639 compared to $4,841,428 for the six months ended June 30, 2021. For the six months ended June 30, 2022, our net cash used in operating activities was primarily attributable to the net income of $5,150,437, adjusted by non- cash interest expense of $4,199,825, stock-based compensation of $136,249 and the non-cash expenses of interest and amortization and depreciation of $126,784. This was offset by the gain on the fair value changes in derivatives related to warrants and convertible notes of $13,376,773. Net changes of $1,014,161 in operating assets and liabilities increased the cash used in operating activities.

 

For the six months ended June 30, 2021, our net cash used in operating activities was primarily attributable to the net loss of $209,704,320, adjusted by loss on debt extinguishment of $95,437,589, non- cash interest expense of $44,170,200 (including $38,907,939 for the initial fair value of the 300,000,000 warrants issued), losses on the fair value changes in derivatives related to warrants and convertible notes of $43,331,083, debt restructuring costs of $16,450,000, stock-based compensation of $7,965,945 and the non-cash expenses of interest and amortization and depreciation of $65,388. Net changes of $2,557,313 in operating assets and liabilities increased the cash used in operating activities, primarily as a result of the start-up of the Company’s California operations in the support of inventory and accounts receivable.

 

9

 

 

Investing Activities

 

For the six months ended June 30, 2022, the net cash used in investing activities was $40,000, compared to $94,679 for the six months ended June 30, 2021. The amounts for both periods were a result of the Company purchasing office furniture and equipment.

 

Financing Activities

 

For the six months ended June 30, 2022, there were no financing activities. During the six months ended June 30, 2021, net cash provided by financing activities was $6,589,911. We received $12,000,000 of proceeds from the issuances of $13,30,000 face value of promissory notes. During the six months ended June 30, 2021, the Company redeemed 5,000 shares of the Series E Preferred Stock for $5,000,000 and repaid $383,772 of notes payable and $26,367 to shareholders.

 

OFF BALANCE SHEET ARRANGEMENTS

 

We have no off-balance sheet arrangements including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support or other benefits.

 

Critical Accounting Policies

 

Our significant accounting policies are described in more details in the notes to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

Not Applicable.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of June 30, 2022. Based on the evaluation of these disclosure controls and procedures, and in light of the material weaknesses found in our internal controls over financial reporting, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective for the reasons discussed below.

 

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting as of June 30, 2022, the Company determined that there were control deficiencies that constituted material weaknesses, as described below.

 

  1. We do not have an Audit Committee – While not being legally obligated to have an audit committee, it is the management’s view that such a committee, including a financial expert member, is an utmost important entity level control over the Company’s financial statement. Currently the Board of Directors acts in the capacity of the Audit Committee, and does not include a member that is considered to be independent of management to provide the necessary oversight over management’s activities.
     
  2. We did not maintain appropriate cash controls – As of June 30, 2022, the Company has not maintained sufficient internal controls over financial reporting for cash, including failure to segregate cash handling and accounting functions, and did not require dual signatures on the Company’s bank accounts.

 

10

 

 

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.

 

Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

Changes in Internal Controls over Financial Reporting

 

There has been no change in our internal control over financial reporting occurred during the three months ended June 30, 2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1. LEGAL PROCEEDINGS

 

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

 

Item 1A. RISK FACTORS

 

Not applicable for smaller reporting companies.

 

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

There were no shares issued during the quarter ended June 30, 2022:

 

Item 3. DEFAULTS UPON SENIOR SECURITIES

 

None

 

Item 4. MINE SAFETY DISCLOSURE

 

Not applicable.

 

Item 5. OTHER INFORMATION

 

  (a) None.
  (b) During the quarter ended June 30, 2022, there have not been any material changes to the procedures by which security holders may recommend nominees to the Board of Directors.

 

11

 

 

Item 6. EXHIBITS

 

The following documents are filed as part of this report:

 

Exhibit

No.

  Description
     
2.1   Share Exchange Agreement dated April 5, 2018 by and among Newmarkt Corp., the shareholders of Ozop Surgical, Inc., Ozop Surgical, Inc. and Denis Razvodovskij (Incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed on April 19, 2018).
     
2.2   Stock Purchase Agreement dated June 26, 2020, by and among Ozop Surgical Corp., Power Conversion Technologies, Inc. and Catherine Chis (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on June 29, 2020).
     
2.3   Merger Agreement and Plan of Merger between Ozop Surgical Corp. and Ozop Surgical Name Change Subsidiary, Inc. (Incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed on November 13, 2020).
     
3.1   Articles of Incorporation (Incorporated by reference to our General Form for Registration of Securities on Form S-1 filed on August 1, 2016)
     
3.2   Bylaws (Incorporated by reference to our General Form for Registration of Securities on Form S-1 filed on August 1, 2016)
     
3.3   Certificate of Amendment of Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on May 8, 2018 (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on May 14, 2018).
     
3.4   Certificate of Designations for Series B Preferred Stock. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on April 2, 2019).
     
3.5   Amended and Restated Bylaws of Ozop Surgical Corp. adopted on May 22, 2019. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on May 22, 2019).
     
3.6   Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on July 25, 2019. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on July 30, 2019).
     
3.7   Certificate of Designation of Series C Preferred Stock. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on September 24, 2019).
     
3.8   Certificate of Withdrawal of Series B Preferred Stock. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on September 24, 2019).
     
3.9   Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on October 29, 2019. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on October 31, 2019).
     
3.10   Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on December 30, 2020, (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on December 31, 2019).
     
3.11   Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on January 21, 2020. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on February 7, 2020).
     
3.12   Amended and Restated Certificate of Designation of Series C Preferred Stock. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on February 5, 2020).
     
3.13   Amendment to Certificate of Designation of Series C Preferred Stock dated July 7, 2020 (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on July 10, 2020).
     
3.14   Certificate of Designation of Series D Preferred Stock dated July 7, 2020 (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on July 10, 2020).
     
3.15   Certificate of Designation of Series E Preferred Stock dated July 7, 2020 (Incorporated by reference to Exhibit 3.3 of the Current Report on Form 8-K filed on July 10, 2020).

 

12

 

 

3.16   Articles of Incorporation of Ozop Surgical Name Change Subsidiary, Inc. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on November 13, 2020).
     
3.17   Articles of Merger between Ozop Surgical Corp. and Ozop Surgical Name Change Subsidiary, Inc. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on November 13, 2020).
     
3.18   Amended and Restated Certificate of Designation Series D Preferred Stock dated July 27, 2021 (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on August 2, 2021).
     
3.19   Advisory agreement between Ozop Capital and RMA dated September 1, 2021 (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on September 2, 2021).
     
10.1   Binding Letter of Intent dated February 28, 2020, by and between Ozop Surgical Corp. and Power Conversion Technologies, Inc, and Catherine Chis, (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on February 28, 2020).
     
10.2+   Employment Agreement dated February 28, 2020, by and between Ozop Surgical Corp. and Brian Conway, (Incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed on February 28, 2020).
     
31.1*   Certification of Chief Executive Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Chief Financial Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1*   Certification of Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63
     
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

+ Management contract or compensatory plan or arrangement.

 

13

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: August 15, 2022

 

/s/ Brian P Conway  
Brian P. Conway  
Chief Executive Officer  
(principal executive officer)  
(principal financial and accounting officer)  

 

14

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION

 

I, Brian P. Conway, Chief Executive Officer of OZOP ENERGY SOLUTIONS, INC. (the “registrant”), certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended June 30, 2022;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 15, 2022

 

/s/ Brian P. Conway  
Brian P Conway  
Chief Executive Officer  
(principal executive officer)  

 

 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION

 

I, Brian P. Conway, Interim Chief Financial Officer of OZOP ENERGY SOLUTIONS, INC. (the “registrant”), certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended June 30, 2022;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 15, 2022

 

/s/ Brian P Conway  
Brian P Conway  
Interim Chief Financial Officer  
(principal financial and accounting officer)  

 

 

 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Each of the undersigned hereby certifies, in his capacity as an officer of OZOP ENERGY SOLUTIONS, INC. (the “Company”), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

 

(1) The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: August 15, 2022

 

/s/ Brian P Conway  
Brian P. Conway  
Chief Executive Officer  
(principal executive officer)  
(principal financial and accounting officer)  

 

 

 

EX-101.SCH 5 ozsc-20220630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statement of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - GOING CONCERN AND MANAGEMENT’S PLANS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - DEFERRED LIABILITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - DEFERRED REVENUE link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - NONCONTROLLING INTEREST link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - DERIVATIVE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - ORGANIZATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SCHEDULE OF INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - DISAGGREGATION OF REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - DEFERRED LIABILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - DEFERRED REVENUE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - NONCONTROLLING INTEREST (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 ozsc-20220630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 ozsc-20220630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 ozsc-20220630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series D Preferred Stock [Member] Series E Preferred Stock [Member] Series C Preferred Stock [Member] Equity Components [Axis] Common Stock To Be Issued [Member] Preferred Stock [Member] Common Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Noncontrolling Interest [Member] AOCI Attributable to Parent [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Securities Purchase Agreement [Member] Business Acquisition [Axis] Pennsylvania Corporation [Member] Registration Statement [Member] Award Type [Axis] GHS Investments LLC [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Customer [Axis] Customer A [Member] Concentration Risk Benchmark [Axis] Accounts Receivable [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer B [Member] Customer C [Member] Customer D [Member] Customer E [Member] Customer F [Member] Customer G [Member] Customer H [Member] Customer I [Member] Customer J [Member] Suppliers One [Member] Accounts Payable [Member] Supplier Concentration Risk [Member] Suppliers Two [Member] Suppliers Three [Member] Suppliers Four [Member] Two Vendor [Member] Down Payment [Member] Shipment [Member] No Suppliers [Member] Statistical Measurement [Axis] Minimum [Member] Long-Lived Tangible Asset [Axis] Office Furniture And Equipment [Member] Maximum [Member] Warehouse Equipment [Member] Product and Service [Axis] Sourced and Distributed Products [Member] Manufactured Products [Member] OED Installations [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Antidilutive Securities [Axis] Convertible Preferred Stock [Member] Unexercised Common Stock Purchase Warrants [Member] Convertible Notes Payable [Member] Promissory Note Payable [Member] Office Equipment [Member] Debt Instrument [Axis] 15% Promissory Note [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Option Volatility [Member] Measurement Input, Exercise Price [Member] Financial Instrument [Axis] Derivative Liabilities Associated With Warrants [Member] Derivative Liabilities Associated With Convertible Notes [Member] Short-Term Debt, Type [Axis] Note Payable [Member] Note Payable One [Member] Economic Injury Disaster Loan [Member] Paycheck Protection Programloan [Member] Note Payable Two [Member] Other [Member] Note Payable Three [Member] Note Payable Four [Member] Note Payable Five [Member] Note Payable Six [Member] Note Payable Seven [Member] Note Payable Eight [Member] Promissory Note [Member] Title of Individual [Axis] Lender [Member] December Seven Two Thousand Twenty Two [Member] Valuation Approach and Technique [Axis] Valuation Technique, Option Pricing Model [Member] Promissory Note One [Member] Lenders [Member] Holder [Member] Legal Entity [Axis] PCTI [Member] Variable Rate [Axis] Prime Rate [Member] Personal Guarantee Of Chis [Member] Nine Instalments [Member] Paycheck Protection Program [Member] Exchange Agreement [Member] Award Date [Axis] Per Month [Member] Related Party [Axis] Mr Conway [Member] Employment Agreement [Member] Definitive Agreement [Member] Chief Executive Officer [Member] Chief Executive Officer Series E Preferred Stock [Member] President Subsidiary [Member] Garage Storage Facility [Member] RMA Agreement [Member] PJN Strategies [Member] Rubenstein Public Relations, Inc. [Member] Co-Directors of Sales [Member] Restricted Stock [Member] Mr Steven Martello [Member] Consulting Agreement [Member] Aurora Enterprises [Member] Christopher Ruppel [Member] April 1, 2021 [Member] Mr Allen Sosis [Member] Ezra Green [Member] Salman J. Chaudhry [Member] Seperation Agreement [Member] Lease Agreement [Member] Restructuring Agreement [Member] GHS Investments [Member] Certificates of Designation [Member] Chis [Member] Series D Amendment [Member] Investor [Member] Series DSPA [Member] Warrant [Member] Remaining Warrant Shares [Member] Conway [Member] Mr. Convay [Member] Third-Party [Member] Ownership [Axis] Brian Conway [Member] Accounting Standards Update [Axis] Accounting Standards Update 2016-02 [Member] Geographical [Axis] CANADA Thereafter [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current Assets Cash Prepaid expenses Accounts receivable Inventory Vendor deposits Total Current Assets Operating lease right-of-use asset, net Property and equipment, net Other Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Liabilities Current Liabilities Accounts payable and accrued expenses Convertible notes payable, net of discounts Current portion of notes payable, net of discounts Customer deposits Deferred liability Derivative liabilities Operating lease liability, current portion Current portion of deferred revenues Total Current Liabilities Long Term Liabilities Note payable, net of discount Operating lease liability, net of current portion Deferred revenue, net of current portion TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES Stockholders’ Equity (Deficit) Preferred stock , value Common stock (4,990,000,000 shares authorized par value $0.001; 4,622,362,977 (2022) and 4,617,362,977 (2021) shares issued and outstanding) Common stock to be issued; 637,755 shares as of June 30, 2022, and December 31, 2021 Additional paid in capital Treasury Stock Accumulated Deficit Total Ozop Energy Systems, Inc. stockholders’ equity (deficit) Noncontrolling interest TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, par value Common stock, shares issued Common stock, shares outstanding Common stock to be issued Income Statement [Abstract] Revenue Cost of goods sold Gross profit Operating expenses: General and administrative, related parties General and administrative, other Total operating expenses Loss from operations Other (income) expenses: Interest expense (Gain) loss on change in fair value of derivatives Loss on extinguishment of debt Debt restructure expense Total Other (Income) Expenses Net income (loss) before income taxes Income tax provision Net income (loss) Less: net loss attributable to noncontrolling interest Net income (loss) attributable to Ozop Energy Solutions, Inc. Income (loss) per share basic and fully diluted Weighted average shares outstanding Basic and diluted Beginning balance, value Balance, shares Shares issued and to be issued for fees and services Shares issued and to be issued for fees and services, shares Net Income (loss) Shares issued for conversions of note and interest payable Shares issued for conversions of note and interest payable, shares Shares issued upon cashless exercise of warrants Shares issued upon cashless exercise of warrants, shares Issuance of Series E Preferred Stock Issuance of Series E Preferred Stock, shares Redemption of Series E Preferred Stock Redemption of Series E Preferred Stock, shares Shares issued for lease agreement Shares issued for lease agreement, shares Shares issue for debt restructure Shares issued for debt restructure, shares Ending balance, value Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net income (loss) from continuing operations Adjustments to reconcile net income (loss) to net cash used in operations Non-cash interest expense Amortization and depreciation Loss on fair value change of derivatives Loss (gain) on extinguishment of debt Stock compensation expense Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses Vendor deposits Accounts payable and accrued expenses Deferred revenue Operating lease liabilities Customer deposits Net cash used in operating activities Cash flows from investing activities: Purchase of office and computer equipment Net cash used in investing activities Cash flows from financing activities: Proceeds from issuances of notes payable Payments to shareholders Payments of principal of convertible note payable and notes payable Redemption of Series E Preferred Stock Net cash provided by financing activities Net (decrease) increase in cash Cash, Beginning of period Cash, End of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income taxes Schedule of non-cash Investing or Financing Activity: Original issue discount included in notes payable Issuance of common stock upon convertible note and accrued interest conversion Operating lease right-of-use assets and liabilities Issuance of common stock and preferred stock for consulting fees and compensation Issuance of common stock for lease agreement Issuance of common stock for debt restructuring Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION GOING CONCERN AND MANAGEMENT’S PLANS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Debt Disclosure [Abstract] CONVERTIBLE NOTES PAYABLE Derivative Liabilities DERIVATIVE LIABILITIES Notes Payable NOTES PAYABLE Deferred Liability DEFERRED LIABILITY Revenue from Contract with Customer [Abstract] DEFERRED REVENUE Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] STOCKHOLDERS’ EQUITY NONCONTROLLING INTEREST Operating Lease Right-of-use Assets And Operating Lease Liabilities OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Use of Estimates Cash and Cash Equivalents Sales Concentration and credit risk Accounts Receivable Inventory Purchase concentration Property, plant and equipment Revenue Recognition Advertising and Marketing Expenses Research and Development Convertible Instruments Distinguishing Liabilities from Equity Fair Value of Financial Instruments Leases Income Taxes Segment Policy Earnings (Loss) Per Share Recent Accounting Pronouncements SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR SCHEDULE OF INVENTORY SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS DISAGGREGATION OF REVENUE SCHEDULE OF DERIVATIVE INSTRUMENTS SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE PROPERTY AND EQUIPMENT SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE SCHEDULE OF NOTES PAYABLE SCHEDULE OF EXPENSES TO OFFICERS SCHEDULE OF RIGHT-OF-USE ASSETS SCHEDULE OF OPERATING LEASE LIABILITIES SCHEDULE OF MATURITY OF LEASE LIABILITIES Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Number of shares acquired Stock Issued During Period, Shares, Acquisitions Retained earnings accumulated deficit Working capital deficit Derivative liabilities current Debt instrument default amount Stock issued during the period, shares Common stock maturity period Agreement description Price per share Stock issued during the period Brokerage fees Schedule of Product Information [Table] Product Information [Line Items] Concentration Risk, Percentage Concentration Risk, Percentage Raw materials Work in process Finished goods Inventory net Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Useful Life Total Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Derivative Liabilities Total Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] TOTAL Outstanding shares, percentage Concentration of credit risk Marketing and Advertising Expense Unrecognized tax benefits Dilutive securities common stock, shares Office equipment Less: Accumulated Depreciation Property and Equipment, Net Depreciation Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Long term debt, gross Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] Derivative liability Change in fair value Change in fair value Derivative liability Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Derivative liabilities Derivative liability measurement input Sub- total notes payable Less long-term portion Current portion of notes payable, net of discount Debt Instrument, interest rate, stated percentage Debt Instrument, maturity date Debt Instrument, face amount Debt Instrument, unamortized discount Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Face Amount Debt Instrument, Maturity Date Debt Instrument, Unamortized Discount Proceeds from Notes Payable Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Amortization of Debt Discount (Premium) Interest Expense Derivative Liabilities Amortization of Warrant Discount Long-Term Debt, Gross Lender Costs Adjustment of Warrants Interest Payable Debt Instrument, Description Legal Fees Warrants and Rights Outstanding, Term Notes payable Debt Instrument, Increase, Accrued Interest Notes Payable ToBank Short-Term Bank Loans and Notes Payable Adjustments to Additional Paid in Capital, Warrant Issued Common Stock, Shares, Issued Loans Payable to Bank Accounts Payable, Interest-Bearing, Interest Rate Debt Instrument, Decrease, Forgiveness Deferred Liability Current Product Liability Contingency, Third-Party Recovery, Percentage Accounts Payable and Accrued Liabilities Deferred Compensation Arrangement with Individual, Shares Issued Royalty Percentage Price Per Share Payments of Debt Restructuring Costs DueToRelatedParties Warranty Description Liability revenue recognized Deferred revenue Deferred revenue, current Deferred revenue, non-current Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Total Compensation value Officers compensation received Amount of initial annual compensation Preferred stock redemption price per share Preferred Stock, Shares Authorized Number of redeemed shares issued ShareBased Compensation Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award Stock purchase, value Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Lease term Land subject to ground leases Number of restricted shares issued Shares issued, price per share Prepaid expense Professional fees Number of restricted stock issued, value Payments of stock issuance costs Cash payments Issuance of common stock Consulting expense Annual salary Accrued bonus Number of shares issued, shares Share Based Compensation Expense Legal fees Stock Issued During Period, Shares, New Issues Professional fees Due to officers or stockholders Accrued employee benefits, current Deferred compensation equity Salary Due to officers or stockholders, current Collaborative arrangement, rights and obligations Number of common stock exchanged Royalty percentage Payments of debt restructuring costs Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Debt instrument principal Debt instrument, accrued interest Debt conversion, converted instrument, shares issued Debt instrument, convertible, conversion price Deferred compensation shares issued Purchase of warrants Common stock shares authorized Common stock par value Common Stock, Shares outstanding Preferred stock Par value Preferred stock, voting rights Number of purchased shares Preferred stock shares outstanding Preferred Stock, Convertible, Conversion Price Proceeds from Issuance of Preferred Stock and Preference Stock Preferred stock shares issued Warrants term Warrant exercise Warrant exercise, description Preferred stock, redemption amount Preferred stock redemption price per share Stock based compensation Number of stock redeemed Shares granted Noncontrolling interest percentage Noncontrolling interest loss Noncontrolling interest Accumulative noncontrolling interest Schedule Of Right-of-use Assets Office and warehouse lease Less: Accumulated Amortization Right-of-use asset, net Schedule Of Operating Lease Liabilities Lease liability Less current portion Long term portion For the year ended December 31, 2022 For the year ended December 31, 2023 For the year ended December 31, 2024 For the year ended December 31, 2025 For the year ended December 31, 2026 Total Less present value discount Lease expiration date Operating lease disount rate Operating lease rent expense Operating lease liability RIght of use of asset Operating lease term Area of land Operating lease payments Lease payments increase percentage Subsequent Event [Table] Subsequent Event [Line Items] Convertible notes payable net. Customer deposits. Deferred liability current. Common stock to be issued. Common stock yet to be issued. General and administrative related parties Interest expenses. Debt restructure expense Common Stock To Be Issued [Member] Shares issued upon cashless exercise of warrants. Issuance of Series E Preferred Stock. Redemption of Series E Preferred Stock. Stock issued during period value new issues for lease agreement Shares Issued Upon Cashless Exercise Of Warrants Shares Issuance of series e preferred stock shares Redemption of series e preferred stock shares Stock issued during period shares new issues for lease agreement Gain Loss On Fair Value Change Of Derivatives. Loss on extinguishment of debt. Increase decrease in vendor deposits Payments to shareholders Proceeds redemption of series e preferred stock Original issue discount included in notes payable Issuance of common stock upon convertible note and accrued interest conversion Issuance of common stock and preferred stock for consulting fees and compensation Issuance of common stock for lease agreement Issuance of common stock for debt restructuring Operating lease right of use assets and liabilities. Business Acquisition Number Of Shares Acquired. Securities Purchase Agreement [Member] Pennsylvania Corporation [Member] Working capital deficit. Registration Statement [Member] GHS Investments LLC [Member] Customer A [Member] Customer B [Member] Customer E [Member] Customer C [Member] Customer D [Member] Customer G [Member] Customer H [Member] Customer I [Member] Customer J [Member] Customer F [Member] Purchase Concentration [Policy Text Block] Suppliers One [Member] Suppliers Two [Member] Suppliers Three [Member] Suppliers Four [Member] Schedule Of Useful Life Of Property And Equipment Assets [Table Text Block] Office Furniture And Equipment [Member] Warehouse Equipment [Member] Sourced and Distributed Products [Member] Manufactured Products [Member] OED Installations [Member] Convertible Instruments [Policy Text Block] Distinguishing Liabilities from Equity [PolicyTextBlock] Unexercised Common Stock Purchase Warrants [Member] Promissory Note Payable [Member] 15% Promissory Note [Member] Derivative Liabilities Associated With Warrants [Member] Derivative Liabilities Associated With Convertible Notes [Member] Notes Payable [Text Block] Schedule Of Notes Payable [Table Text Block] Note Payable [Member] Note Payable One [Member] Note Payable Two [Member] Other [Member] Note Payable Three [Member] Note Payable Four [Member] Note Payable Five [Member] Note Payable Six [Member] Note Payable Seven [Member] Note Payable Eight [Member] Economic Injury Disaster Loan [Member] Paycheck Protection Programloan [Member] Promissory Note [Member] Lender [Member] December Seven Two Thousand Twenty Two [Member] Amortization of warrant discount. Lender Costs Promissory Note One [Member] Two Vendor [Member] Down Payment [Member] Shipment [Member] No Suppliers [Member] Lenders [Member] Holder [Member] PCTI [Member] Personal Guarantee Of Chis [Member] Nine Instalments [Member] Paycheck Protection Program [Member] Deferred Liability [Text Block] Exchange Agreement [Member] Royalty percentage Per Month [Member] Mr Conway [Member] Officers compensation received. Employment Agreement [Member] Definitive Agreement [Member] Stock issued during period value purchased. Garage Storage Facility [Member] RMA Agreement [Member] Consulting Expense. PJN Strategies [Member] Rubenstein Public Relations, Inc. [Member] Co-Directors of Sales [Member] Bonus amount. Mr Steven Martello [Member] Consulting Agreement [Member] Aurora Enterprises [Member] Christopher Ruppel [Member] April 1, 2021 [Member] Mr Allen Sosis [Member] Salary. Ezra Green [Member] Salman J. Chaudhry [Member] Seperation Agreement [Member] Lease Agreement [Member] Restructuring Agreement [Member] Certificates of Designation [Member] Chis [Member] Series D Amendment [Member] Series DSPA [Member] Remaining Warrant Shares [Member] Conway [Member] Mr. Convay [Member]. Third-Party [Member] Brian Conway [Member] Accumulative noncontrolling interest. Operating lease payements increase percentage. Thereafter [Member] Schedule of Right of Use Assets [Table Text Block] Office and warehouse lease. Accumulated amortization. Schedule of Operating Lease Liabilities [Table Text Block] GHS Investments [Member] Stock redeemed or called during period share. Redemption of Series E Preferred Stock Assets, Current Assets Liabilities, Current Liabilities [Default Label] Treasury Stock, Value Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Gain (Loss) on Extinguishment of Debt Nonoperating Income (Expense) Net Income (Loss) Attributable to Parent Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Increase (Decrease) in Deposits Outstanding Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities PaymentsToShareholders Repayments of Notes Payable Redemption of Series E Preferred Stock [Default Label] Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Commitments and Contingencies Disclosure [Text Block] Inventory, Policy [Policy Text Block] Property, Plant and Equipment [Table Text Block] Accounts Receivable, after Allowance for Credit Loss Derivative Assets (Liabilities), at Fair Value, Net Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Derivative Liability Deferred Revenue Salary and Wage, Excluding Cost of Good and Service Sold Professional Fees Less: Accumulated amortization Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount EX-101.PRE 9 ozsc-20220630_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
6 Months Ended
Jun. 30, 2022
Aug. 12, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2022  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 000-55976  
Entity Registrant Name OZOP ENERGY SOLUTIONS, INC.  
Entity Central Index Key 0001679817  
Entity Tax Identification Number 35-2540672  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 42 N Main St  
Entity Address, City or Town Florida  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10921  
City Area Code (845)  
Local Phone Number 544-5112  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   4,671,592,071
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheet (Unaudited) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Current Assets    
Cash $ 1,949,528 $ 6,767,167
Prepaid expenses 190,142 151,998
Accounts receivable 779,682 1,299,334
Inventory 1,799,095 1,065,982
Vendor deposits 3,212,660 874,627
Total Current Assets 7,931,107 10,159,108
Operating lease right-of-use asset, net 606,078 707,686
Property and equipment, net 147,714 132,889
Other Assets 548,908 568,249
TOTAL ASSETS 9,233,807 11,567,932
Current Liabilities    
Accounts payable and accrued expenses 4,601,813 3,246,342
Convertible notes payable, net of discounts 25,000 25,000
Current portion of notes payable, net of discounts 17,211,132 13,011,307
Customer deposits 568,313 169,849
Deferred liability 662,185 750,000
Derivative liabilities 7,589,928 20,966,701
Operating lease liability, current portion 161,048 194,366
Current portion of deferred revenues 21,451 21,451
Total Current Liabilities 30,840,870 38,385,016
Long Term Liabilities    
Note payable, net of discount 389,423 389,423
Operating lease liability, net of current portion 453,199 517,890
Deferred revenue, net of current portion 14,301 25,026
TOTAL LIABILITIES 31,697,793 39,317,355
COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity (Deficit)    
Preferred stock , value 3 3
Common stock (4,990,000,000 shares authorized par value $0.001; 4,622,362,977 (2022) and 4,617,362,977 (2021) shares issued and outstanding) 4,622,363 4,617,363
Common stock to be issued; 637,755 shares as of June 30, 2022, and December 31, 2021 638 638
Additional paid in capital 196,594,222 196,464,222
Treasury Stock (11,249,934) (11,249,934)
Accumulated Deficit (211,816,067) (217,326,611)
Total Ozop Energy Systems, Inc. stockholders’ equity (deficit) (21,848,774) (27,494,318)
Noncontrolling interest (615,212) (255,105)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) (22,463,986) (27,749,423)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) 9,233,807 11,567,932
Series D Preferred Stock [Member]    
Stockholders’ Equity (Deficit)    
Preferred stock , value 1 1
Series E Preferred Stock [Member]    
Stockholders’ Equity (Deficit)    
Preferred stock , value
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 4,990,000,000 4,990,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares issued 4,622,362,977 4,617,362,977
Common stock, shares outstanding 4,622,362,977 4,617,362,977
Common stock to be issued 637,755 637,755
Series C Preferred Stock [Member]    
Preferred stock, shares authorized 50,000 50,000
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares issued 2,500 2,500
Preferred stock, shares outstanding 2,500 2,500
Series D Preferred Stock [Member]    
Preferred stock, shares authorized 4,570 4,570
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares issued 1,334 1,334
Preferred stock, shares outstanding 1,334 1,334
Series E Preferred Stock [Member]    
Preferred stock, shares authorized 3,000 3,000
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]        
Revenue $ 4,878,636 $ 1,274,033 $ 7,960,874 $ 2,069,587
Cost of goods sold 4,416,460 1,214,468 7,292,292 1,441,377
Gross profit 462,177 59,565 668,583 628,210
Operating expenses:        
General and administrative, related parties 240,000 1,461,074 630,000 3,576,082
General and administrative, other 1,274,287 2,898,231 2,862,144 6,572,693
Total operating expenses 1,514,287 4,359,305 3,492,144 10,148,775
Loss from operations (1,052,111) (4,299,740) (2,823,562) (9,520,565)
Other (income) expenses:        
Interest expense 1,427,554 4,310,335 5,402,775 44,965,085
(Gain) loss on change in fair value of derivatives (9,011,570) (8,866,819) (13,376,773) 43,331,083
Loss on extinguishment of debt 468,696 95,437,587
Debt restructure expense 16,450,000
Total Other (Income) Expenses (7,584,016) (4,087,788) (7,973,998) 200,183,755
Net income (loss) before income taxes 6,531,906 (211,952) 5,150,437 (209,704,320)
Income tax provision
Net income (loss) 6,531,906 (211,952) 5,150,437 (209,704,320)
Less: net loss attributable to noncontrolling interest (172,399)   (360,107)
Net income (loss) attributable to Ozop Energy Solutions, Inc. $ 6,704,305 $ (211,952) $ 5,510,544 $ (209,704,320)
Income (loss) per share basic and fully diluted $ 0.00 $ (0.00) $ 0.00 $ (0.05)
Weighted average shares outstanding        
Basic and diluted 4,622,362,977 4,554,068,582 4,621,092,259 4,269,239,477
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock To Be Issued [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Preferred Stock [Member]
Series E Preferred Stock [Member]
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
AOCI Attributable to Parent [Member]
Beginning balance, value at Dec. 31, 2020 $ 50 $ 20 $ 1 $ 3,397,958   $ 12,530,933 $ (22,278,665)   $ (6,349,710) $ (7)
Balance, shares at Dec. 31, 2020 50,000 20,000 1,000 3,397,958,292            
Shares issued and to be issued for fees and services $ 5,000 $ 20,000   2,877,000   2,902,000
Shares issued and to be issued for fees and services, shares 5,000,000       20,000,000            
Net Income (loss)   (209,492,368)   (209,492,361) 7
Shares issued for conversions of note and interest payable $ 428,748   97,110,282   97,539,030
Shares issued for conversions of note and interest payable, shares         428,747,654            
Shares issued upon cashless exercise of warrants $ 330,798   38,714,266   39,045,064
Shares issued upon cashless exercise of warrants, shares         330,797,987            
Issuance of Series E Preferred Stock $ 2   1,999,998   2,000,000
Issuance of Series E Preferred Stock, shares       2,000              
Redemption of Series E Preferred Stock $ (3)   (2,999,997)   (3,000,000)
Redemption of Series E Preferred Stock, shares       (3,000)              
Shares issued for lease agreement $ 100,000   530,000   630,000
Shares issued for lease agreement, shares         100,000,000            
Shares issue for debt restructure $ 175,000   16,275,000   16,450,000
Shares issued for debt restructure, shares         175,000,000            
Ending balance, value at Mar. 31, 2021 $ 5,000 $ 50 $ 20 $ 4,452,504   167,037,482 (231,771,033)   (60,275,977)
Balance, shares at Mar. 31, 2021 5,000,000 50,000 20,000 4,452,503,933            
Beginning balance, value at Dec. 31, 2020 $ 50 $ 20 $ 1 $ 3,397,958   12,530,933 (22,278,665)   (6,349,710) (7)
Balance, shares at Dec. 31, 2020 50,000 20,000 1,000 3,397,958,292            
Net Income (loss)                   (209,704,320)  
Ending balance, value at Jun. 30, 2021 $ 50 $ 20 $ 4,606,911   182,725,312 (231,982,985)   (44,650,692)
Balance, shares at Jun. 30, 2021 50,000 20,000 4,606,910,897            
Beginning balance, value at Mar. 31, 2021 $ 5,000 $ 50 $ 20 $ 4,452,504   167,037,482 (231,771,033)   (60,275,977)
Balance, shares at Mar. 31, 2021 5,000,000 50,000 20,000 4,452,503,933            
Shares issued and to be issued for fees and services $ (5,000) $ 25,000   1,752,000   1,772,000
Shares issued and to be issued for fees and services, shares (5,000,000)       25,000,000            
Net Income (loss)   (211,952)   (211,952)
Shares issued for conversions of note and interest payable $ 54,407   4,945,593   5,000,000
Shares issued for conversions of note and interest payable, shares         54,406,964            
Shares issued upon cashless exercise of warrants $ 75,000   8,990,237   9,065,237
Shares issued upon cashless exercise of warrants, shares         75,000,000            
Issuance of Series E Preferred Stock $ 2   1,999,998   2,000,000
Issuance of Series E Preferred Stock, shares       2,000              
Redemption of Series E Preferred Stock $ (2)   (1,999,998)   (2,000,000)
Redemption of Series E Preferred Stock, shares       (2,000)              
Ending balance, value at Jun. 30, 2021 $ 50 $ 20 $ 4,606,911   182,725,312 (231,982,985)   (44,650,692)
Balance, shares at Jun. 30, 2021 50,000 20,000 4,606,910,897            
Beginning balance, value at Dec. 31, 2021 $ 638 $ 3 $ 1   $ 4,617,363 $ (11,249,934) 196,464,222 (217,326,611) $ (255,105) (27,749,423)  
Balance, shares at Dec. 31, 2021 637,755 2,500 1,334   4,617,362,977            
Shares issued and to be issued for fees and services   $ 5,000   130,000 135,000  
Shares issued and to be issued for fees and services, shares         5,000,000            
Net Income (loss)   (1,193,761) (187,708) (1,381,469)  
Ending balance, value at Mar. 31, 2022 $ 638 $ 3 $ 1   $ 4,622,363 (11,249,934) 196,594,222 (218,520,372) (442,813) (28,995,892)  
Balance, shares at Mar. 31, 2022 637,755 2,500 1,334   4,622,362,977            
Beginning balance, value at Dec. 31, 2021 $ 638 $ 3 $ 1   $ 4,617,363 (11,249,934) 196,464,222 (217,326,611) (255,105) (27,749,423)  
Balance, shares at Dec. 31, 2021 637,755 2,500 1,334   4,617,362,977            
Net Income (loss)                   5,150,437  
Ending balance, value at Jun. 30, 2022 $ 638 $ 3 $ 1   $ 4,622,363 (11,249,934) 196,594,222 (211,816,067) (615,212) (22,463,986)  
Balance, shares at Jun. 30, 2022 637,755 2,500     4,622,362,977            
Beginning balance, value at Mar. 31, 2022 $ 638 $ 3 $ 1   $ 4,622,363 (11,249,934) 196,594,222 (218,520,372) (442,813) (28,995,892)  
Balance, shares at Mar. 31, 2022 637,755 2,500 1,334   4,622,362,977            
Net Income (loss)   6,704,305 (172,399) 6,531,906  
Ending balance, value at Jun. 30, 2022 $ 638 $ 3 $ 1   $ 4,622,363 $ (11,249,934) $ 196,594,222 $ (211,816,067) $ (615,212) $ (22,463,986)  
Balance, shares at Jun. 30, 2022 637,755 2,500     4,622,362,977            
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net income (loss) from continuing operations $ 5,150,437 $ (209,704,320)
Adjustments to reconcile net income (loss) to net cash used in operations    
Non-cash interest expense 4,199,825 44,170,200
Amortization and depreciation 126,784 65,388
Debt restructure expense 16,450,000
Loss on fair value change of derivatives (13,376,773) 43,331,083
Loss (gain) on extinguishment of debt 95,437,587
Stock compensation expense 136,249 7,965,945
Changes in operating assets and liabilities:    
Accounts receivable 519,652 (701,545)
Inventory (733,113) (1,247,913)
Prepaid expenses (20,053) (1,290,348)
Vendor deposits (2,338,033) (64,789)
Accounts payable and accrued expenses 1,267,656 682,845
Deferred revenue (10,725) (7,150)
Operating lease liabilities (98,009) (46,054)
Customer deposits 398,464 117,641
Net cash used in operating activities (4,777,639) (4,841,428)
Cash flows from investing activities:    
Purchase of office and computer equipment (40,000) (94,679)
Net cash used in investing activities (40,000) (94,679)
Cash flows from financing activities:    
Proceeds from issuances of notes payable 12,000,000
Payments to shareholders (26,367)
Payments of principal of convertible note payable and notes payable (383,722)
Redemption of Series E Preferred Stock (5,000,000)
Net cash provided by financing activities 6,589,911
Net (decrease) increase in cash (4,817,639) 1,653,804
Cash, Beginning of period 6,767,167 1,808,476
Cash, End of period 1,949,528 3,462,280
Supplemental disclosure of cash flow information:    
Cash paid for interest 28,302 545,138
Cash paid for income taxes
Schedule of non-cash Investing or Financing Activity:    
Original issue discount included in notes payable 1,310,000
Issuance of common stock upon convertible note and accrued interest conversion 743,555
Operating lease right-of-use assets and liabilities 702,888
Issuance of common stock and preferred stock for consulting fees and compensation 136,249 7,965,945
Issuance of common stock for lease agreement 630,000
Issuance of common stock for debt restructuring $ 16,450,000
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION

NOTE 1 - ORGANIZATION

 

Business

 

Ozop Energy Solutions, Inc. (the” Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.

 

On July 10, 2020, the Company entered into a Stock Purchase Agreement (the “SPA”) with Power Conversion Technologies, Inc., a Pennsylvania corporation (“PCTI”), and Catherine Chis (“Chis”), PCTI’s Chief Executive Officer (“CEO”) and its sole shareholder. Under the terms of the SPA, the Company acquired one thousand (1,000) shares of PCTI, which represents all of the outstanding shares of PCTI, from Chis in exchange for the issuance of 47,500 shares of the Company’s Series C Preferred Stock, 18,667 shares of the Company’s Series D Preferred Stock, and 500 shares of the Company’s Series E Preferred Stock to Chis.

 

PCTI designs, develops, manufactures and distributes standard and custom power electronic solutions.

 

On October 29, 2020, the Company formed a new wholly owned subsidiary, Ozop Surgical Name Change Subsidiary, Inc., a Nevada corporation (“Merger Sub”). The Merger Sub was formed under the Nevada Revised Statutes for the sole purpose and effect of changing the Company’s name to “Ozop Energy Solutions, Inc.” That same day the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with the Merger Sub and filed Articles of Merger (the “Articles of Merger”) with the Nevada Secretary of State, merging the Merger Sub into the Company, which were stamped effective as of November 3, 2020. As permitted by the Section 92.A.180 of the Nevada Revised Statutes, the sole purpose and effect of the filing of Articles of Merger was to change the name of the Company from Ozop Surgical Corp to “Ozop Energy Solutions, Inc.”

 

On December 11, 2020, the Company formed Ozop Energy Systems, Inc. (“OES”), a Nevada corporation and a wholly owned subsidiary of the Company. OES was formed to be a manufacturer and distributor of renewable energy products.

 

On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation. The Company is the majority shareholder of Ozop Capital with PJN Holdings LLC (“PJN”), a New York limited liability company, being the minority shareholder. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital.

 

On October 29, 2021, EV Insurance Company, Inc. (“EVCO”) was formed as a captive insurance company in the State of Delaware. EVCO is a wholly owned subsidiary of Ozop Capital. On January 7, 2022, EVCO filed with New Castle County, Delaware DBA OZOP Plus.

 

On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners are able to offer the resources needed for lighting, solar and electrical design projects. OED will provide customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs. We work with architects, engineers, facility managers, electrical contractors and engineers.

 

XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
GOING CONCERN AND MANAGEMENT’S PLANS
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN AND MANAGEMENT’S PLANS

NOTE 2 – GOING CONCERN AND MANAGEMENT’S PLANS

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2022, the Company had an accumulated deficit of $211,816,067 and a working capital deficit of $22,909,763 (including derivative liabilities of $7,589,928). As of June 30, 2022, the Company was in default of $15,369,247 plus accrued interest on debt instruments due to non-payment upon maturity dates. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date of the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

In December 2019, a novel strain of coronavirus (COVID-19) emerged. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but it may have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

 

 

Management’s Plans

 

As a public company, Management believes it will be able to access the public equities market for fund raising for product development, sales and marketing and inventory requirements as we expand our distribution in the U.S. market.

 

The Company is in negotiations with its’ lenders related to the debt instruments that are currently in default, to extend the maturity dates.

 

On October 14, 2021, the Company received a Notice of effectiveness related to the Company’s Form S-3 Registration Statement (the “Registration Statement”). Pursuant to the Registration Statement the Company may offer and sell from time to time in one or more offerings of up to thirty million dollars ($30,000,000) in aggregate offering price. We may offer these securities in amounts, at prices and on terms determined at the time of offering.

 

On April 4, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (200,000,000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement. As of the date of this Report the Company has sold the following securities pursuant to this Registration Statement:

 

On July 15, 2022, the Company sold 15,353,952 shares to GHS at $0.010285 and received net proceeds of $152,732, after deducting transaction and broker fees of $5,183.

 

On August 1, 2022, the Company sold 7,675,221 shares to GHS at $0.010965 and received net proceeds of $81,451, after deducting transaction and broker fees of $2,708.

 

On August 4, 2022, the Company sold 8,136,272 shares to GHS at $0.010965 and received net proceeds of $86,405, after deducting transaction and broker fees of $2,809.

 

On August 10, 2022, the Company sold 18,063,649 shares to GHS at $0.01088 and received net proceeds of $191,577, after deducting transaction and broker fees of $4,956.

 

OES is actively engaged in the renewable, electric vehicle (“EV”), energy storage and energy resiliency sectors. We are engaged in multiple business lines that include project development as well as equipment distribution. Our solar and energy storage projects involve large-scale battery and solar photovoltaics (PV) installations. Our utility-scale storage business model is based on an arbitrage business model in which we install multiple 1+ megawatt batteries, charge them with off-peak grid electricity under contract with the utility, then sell the power back during peak load hours at a premium, as dictated by prevailing electricity tariffs.

 

Ozop Plus plans on marketing vehicle service contracts (“VSC’s”) for electric vehicles (EV’s) that will offer to consumers to be able to purchase additional months and or miles above the manufacturer’s warranty and to also bring added value to EV owners by utilizing our partnerships and strengths in the energy market to offer unique and innovative services. Among EV owners’ concerns are the EV battery repair and replacement costs, range anxiety, environmental responsibilities, roadside assistance, and the accelerated wear on additional components that EV vehicles experience. Management believes that the Ozop Plus marketed VSC’s will give “peace of mind” to the EV buyer.

 

  In May 2022, the Company entered into an agreement with GS Administrators, Inc., a member of Houston-based GSFSGroup. Under the agreement, the Company will market GSFSGroup’s EV VSC’s in all states (except, California, Florida, Massachusetts and Washington) to Ozop’s network of new and used franchised dealerships and other eligible entities. In addition to acting as an agent for the marketing, Ozop also has the right to white label the product under its’ Ozop Plus brand. Ozop’s role won’t be limited to marketing the product. GSFSGroup plans to tap into Ozop’s experience relative to battery collection and disposal and has agreed to insurance risk sharing in connection with the insurance policies that back the VSC’s. GSFSGroup is working on getting the approvals needed for the above four (4) states.
     
  On June 22, 2022, the Company entered into an Agent Agreement with Royal Administration Services, Inc. (“Royal”). Under the agreement, the Company will market Royal’s EV VSC’s and has the right to white label it under Ozop Plus. Royal has agreed to allow Ozop Plus on all VSC’s, marketed by Royal and the Company, to assume all of the risk related to the electric battery at an agreed upon premium. The battery premium is dependent on the consumer’s selection of the duration of the VSC, the miles selected for coverage and the type of vehicle that the consumer has purchased, with a key component being the kWh size of the battery. These VSC’s have a maximum of 10 years and 150,000 miles and cover new and used cars from model year 2017 and newer. During August 2022, Royal will begin the filing process in all 50 states, 30 plus of which are effective upon filing, and the others have various waiting times or approvals needed.

 

 

During the quarter ended June 30, 2022, OED began operations and generated $16,500 of revenues and currently has six employees in sales, marketing installation and services. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support.

 

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2022, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 10-K/A filed on April 26, 2022.

 

The unaudited condensed consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries OED, PCTI, Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”) and the Company’s majority owned subsidiary Ozop Capital Partners, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has no cash equivalents at June 30, 2022, and December 31, 2021.

 

Sales Concentration and credit risk

 

Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three and six months ended June 30, 2022, and 2021, and their accounts receivable balance as of June 30, 2022:

 

   Sales % Three
Months
Ended June
30, 2022
   Sales % Six
Months
Ended June
30, 2022
   Sales % Three
Months
Ended June
30, 2021
   Sales % Six
Months
Ended
June 30, 2021
   Accounts
receivable
balance
June 30,
2022
 
Customer A   43.5%   26.7%    N/A     N/A   $43,920 
Customer B   10.0%   11.4%   18.3%   11.3%   524,759 
Customer C   N/A    10.3%   13.5%   N/A    - 
Customer D   N/A    N/A    13.5%   N/A    - 
Customer E   N/A    N/A    14.9%   N/A    3,835 
Customer F   N/A    N/A    10.5%   N/A    - 
Customer G   N/A    N/A    18.3%   11.3%   - 
Customer H   N/A    N/A    13.5%   N/A    - 
Customer I   N/A    N/A    14.9%   65.6%   - 
Customer J   N/A    N/A    10.5%   13.4%   - 

 

 

Customers A-F are customers of Ozop Energy Systems Inc. and Customers G- J are customers of PCTI. PCTI, historically does not have year to year many recurring clients as the Company produces customized capital equipment for its’ customers.

 

Accounts Receivable

 

The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.

 

Inventory

 

Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs include finished goods, material, labor and manufacturing overhead. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues.

 

The components of inventories at June 30, 2022, and December 31, 2021, are as follows:

 

   June 30,
2022
   December 31,
2021
 
         
Raw materials  $236,134   $234,168 
Work in process   -    43,704 
Finished goods   1,562,961    788,110 
Inventory net  $1,799,095   $1,065,982 

 

Purchase concentration

 

OES purchases finished renewable energy products from its’ suppliers. For the three months ended June 30, 2022, there were three suppliers that accounted for 41.3%, 23.3% and 19.7%, respectively, and for the six months ended June 30, 2022, there were four suppliers that accounted for 38.0%, 15.9%, 15.6% and 11.2%, respectively. For the three and six months ended June 30, 2021, there were three suppliers that accounted for 29.6%, 21.8% and 12.7%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a 20% down payment with the 30% balances due on shipment and 50% due prior to delivery, while other vendors terms are due in full immediately prior to delivery. We also buy product from other distributors, if we are not able to purchase direct from the manufacturer. While management believes all of its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business

 

The principal purchases by PCTI are comprised of parts and raw materials that PCTI assembles and manufactures and sells to its customers. There were no suppliers who accounted for more than ten percent (10%) of PCTI’s purchases for the three and six months ended June 30, 2022, and 2021.

 

Property, plant and equipment

 

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.

 

The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:

 

  Office furniture and equipment 3-5 years
  Warehouse equipment 7 years

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.

 

 

For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Advance payments are typically required for commercial customers and are recorded as current liability until revenue is recognized. Advance payments are not required for government customers. The majority of contracts typically require payment within 30 to 60 days after transfer of ownership to the customer.

 

For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges.

 

The following table disaggregates our revenue by major source for the three and six months ended June 30, 2022 and 2021:

 

   2022   2021   2022   2021 
   Three months ended
June 30,
   Six months ended
June 30,
 
   2022   2021   2022   2021 
Sourced and distributed products  $4,749,377   $1,254,982   $7,668,699   $1,254,982 
Manufactured products   112,759    19,051    275,675    814,605 
OED Installations   16,500    -    16,500    - 
Total  $4,878,636   $1,274,033   $7,960,874   $2,069,587 

 

Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company brings the finished goods into our California warehouse to fill orders as well as to build inventory for future sales orders. From time to time for some of our larger orders we may have our suppliers ship directly to our customers to avoid extra shipping charges. For manufactured products, there is usually a bidding process by branches of the military or other large firms that need mostly battery charging and storage systems for large industrial projects. We would then purchase the raw materials and parts needed to build out the project in our Pennsylvania warehouse.

 

Advertising and Marketing Expenses

 

The Company expenses advertising and marketing costs as incurred. For the three and six months ended June 30, 2022, the Company recorded advertising and marketing expenses of $2,710 and $5,973, respectively, and for the three and six months ended June 30, 2021, the Company recorded advertising and marketing expenses of $5,944 and $28,544, respectively.

 

Research and Development

 

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the three and six months ended June 30, 2022, and 2021, the Company did not record any research and development expenses.

 

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

 

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

 

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

 

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

 

 

Distinguishing Liabilities from Equity

 

The Company relies on the guidance provided by ASC Topic 480, Distinguishing Liabilities from Equity, to classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.

 

Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.

 

Our CEO and Chairman holds sufficient shares of the Company’s voting preferred stock that give sufficient voting rights under the articles of incorporation and bylaws of the Company such that the CEO and Chairman can at any time unilaterally vote to increase the number of authorized shares of common stock of the Company, without the need to call a general meeting of common shareholders of the Company.

 

Initial Measurement

 

The Company records its financial instruments classified as liability, temporary equity or permanent equity at issuance at the fair value, or cash received.

 

Subsequent Measurement – Financial Instruments Classified as Liabilities

 

The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in fair value of its financial instruments classified as liabilities are recorded as other income (expenses).

 

Fair Value of Financial Instruments

 

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
  Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
  Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to the conversion features within the instrument and that the company has insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.

 

 

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of June 30, 2022, and December 31, 2021, for each fair value hierarchy level:

 

June 30, 2022  Derivative
Liabilities
   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $7,589,928   $7,589,928 

 

December 31, 2021   Derivative
Liabilities
    Total  
Level I   $ -     $ -  
Level II   $ -     $ -  
Level III   $ 20,966,701     $ 20,966,701  

 

Leases

 

The Company accounts for leases under ASU 2016-02 (see Note 14), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

 

Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of 7.5%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the condensed consolidated statements of operations.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.

 

Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.

 

Segment Policy

 

The Company has no reportable segments as it operates in one segment; renewable energy.

 

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of June 30, 2022, and 2021, the Company’s dilutive securities are convertible into approximately 7,689,380,800 and 14,418,538,825, respectively, shares of common stock. The following table represents the classes of dilutive securities as of June 30, 2022, and 2021:

 

   June 30, 2022   June 30, 2021 
Convertible preferred stock (1)   6,933,544,466    13,820,732,691 
Unexercised common stock purchase warrants (1)   672,024,518    597,024,518 
Convertible notes payable   2,520,720    781,816 
Promissory note payable (1)   81,291,096    - 
TOTAL   7,689,380,800    14,418,538,825 

 

(1) The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise.

 

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows.

 

Other than the above, there have no recent accounting pronouncements or changes in accounting pronouncements during the period ended March 31, 2022, that are of significance or potential significance to the Company.

 

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT
6 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

NOTE 4 – PROPERTY AND EQUIPMENT

 

The following table summarizes the Company’s property and equipment:

 

   June 30, 2022   December 31, 2021 
Office equipment  $300,083   $260,083 
Less: Accumulated Depreciation   (152,369)   (127,194)
Property and Equipment, Net  $147,714   $132,889 

 

Depreciation expense was $25,175 and $18,681 for the six months ended June 30, 2022, and 2021, respectively.

 

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONVERTIBLE NOTES PAYABLE
6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
CONVERTIBLE NOTES PAYABLE

NOTE 5 - CONVERTIBLE NOTES PAYABLE

 

On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a past-due 15% convertible note issued by the Company on September 13, 2017. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $25,000.

 

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
DERIVATIVE LIABILITIES
6 Months Ended
Jun. 30, 2022
Derivative Liabilities  
DERIVATIVE LIABILITIES

NOTE 6 – DERIVATIVE LIABILITIES

 

The Company determined the conversion feature of the convertible notes, which all contain variable conversion rates, represented an embedded derivative since the notes were convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability.

 

At any given time, certain of the Company’s embedded conversion features on debt and outstanding warrants may be treated as derivative liabilities for accounting purposes under ASC 815-40 due to insufficient authorized shares to settle these outstanding contracts. Pursuant to SEC staff guidance that permits a sequencing approach based on the use of ASC 815-15-25 which provides guidance for contracts that permit partial net share settlement. The sequencing approach may be applied in one of two ways: contracts may be evaluated based on (1) earliest issuance date or (2) latest maturity date. Pursuant to the sequencing approach, the Company evaluates its contracts based upon the latest maturity date.

 

The Company valued the derivative liabilities at June 30, 2022, and December 31, 2021, at $7,589,928 and $20,966,701, respectively. For the derivative liability associated with convertible notes, the Company used the Monte Carlo simulation valuation model with the following assumptions as of June 30, 2022, and December 31, 2021, risk free interest rates at 2.51% and 0.19%, respectively, and volatility of 69% and 92%, respectively. The following assumptions were utilized in the Black-Scholes valuation of outstanding warrants at June 30, 2022, and December 31, 2021, risk free interest rate of 2.08% to 2.93%, and .48% to .99%, respectively, volatility of 183% to 331%, and 344% to 366%, respectively, and exercise prices of $0.006 to $0.15.

 

 

A summary of the activity related to derivative liabilities for the six months ended June 30, 2022, is as follows:

 

   Derivative liabilities associated with warrants   Derivative liabilities associated with convertible notes   Total derivative liabilities 
Balance December 31, 2021  $20,938,755   $27,946   $20,966,701 
Change in fair value   (13,376,695)   (78)   (13,376,773)
Balance June 30, 2022  $7,562,060   $27,868   $7,589,928 

 

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
NOTES PAYABLE
6 Months Ended
Jun. 30, 2022
Notes Payable  
NOTES PAYABLE

NOTE 7 – NOTES PAYABLE

 

The Company has the following note payables outstanding:

 

   June 30, 2022   December 31, 2021 
         
  $134,681   $134,681 
Note payable bank, interest at 7.75%, matured December 5, 2021, currently in default  $134,681   $134,681 
Note payable bank, interest at 6.5%, matured December 26, 2021, in default   344,166    344,166 
Economic Injury Disaster Loan   10,000    10,000 
Paycheck Protection Program loan   100,400    100,400 
Notes payable, interest at 8%, matured January 5, 2020, in default   45,000    45,000 
Other, due on demand, interest at 6%, currently in default   50,000    50,000 
Note payable $750,000 face value, interest at 12%, matured August 24, 2021, in default   375,000    375,000 
Note payable $389,423 face value, interest at 18%, matures November 6, 2023   389,423    389,423 
Note payable $1,000,000 face value, interest at 12%, matured November 13, 2021, in default   1,000,000    1,000,000 
Note payable $2,200,000 face value, interest at 12%, matured February 9, 2022, net of discount of $243,833 (2021), in default   2,200,000    1,956,167 
Note payable $11,110,000 face value, interest at 12%, matured March 17, 2022, net of discount of $2,314,583 (2021), in default   11,110,000    8,795,417 
Note payable $3,300,000 face value, interest at 12%, matures December 7, 2022, net of discount of $1,458,115 (2022) and $3,099,524 (2021)   1,841,885    200,476 
Sub- total notes payable   17,600,555    13,400,730 
Less long-term portion   389,423    389,423 
Current portion of notes payable, net of discount  $17,211,132   $13,011,307 

 

On December 7, 2021, the Company entered into a 12%, $3,300,000 face value promissory note with a third- party lender with a maturity date of December 7, 2022. In exchange for the issuance of the $3,300,000 note, inclusive of an original issue discount of $300,000, the Company received proceeds of $3,000,000 on December 13, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 75,000,000 shares of common stock at $0.039 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the six months ended June 30, 2022, amortization of the costs of $150,000 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $2,982,815 has been recorded as an initial debt and an initial derivative liability of $2,982,815. For the six months ended June 30, 2022, amortization of the warrant discount of $1,491,407 was charged to interest expense. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $3,300,000 with a carrying value of $1,84,855 and $200,476, respectively, net of unamortized discounts of $1,481,115 and $3,099,524, respectively.

 

On March 17, 2021, the Company entered into a 12%, $11,110,000 face value promissory note with a third- party lender with a maturity date of March 17, 2022. This note is now in default. In exchange for the issuance of the $11,110,000 note, inclusive of an original issue discount of $1,000,000 and lender costs of $110,000 the Company received proceeds of $10,000,000 on March 23, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 250,000,000 shares of common stock at $0.13 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the six months ended June 30, 2022, amortization of the costs of $231,250 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $33,248,433 has been recorded as an initial debt discount of $10,000,000, interest expense of $23,248,433 and initial derivative liability of $32,248,433. For the six months ended June 30, 2022, amortization of the warrant discount of $2,083,333 was charged to interest expense. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $11,110,000 with a carrying value of $11,100,000 and $8,795,417, respectively, net of unamortized discounts of $2,314,583 as of December 31, 2021. As of June 30, 2022, and December 31, 2021, the accrued interest is $1,691,155 and $1,033,687, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

 

On February 9, 2021, the Company entered into a 12%, $2,200,000 face value promissory note with a third- party lender with a maturity date of February 9, 2022. This note is now in default. In exchange for the issuance of the $2,200,000 note, inclusive of an original issue discount of $200,000 the Company received proceeds of $2,000,000 on February 16, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 50,000,000 shares of common stock at $0.15 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the six months ended June 30, 2022, amortization of the costs of $22,167 was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $17,659,506 has been recorded as an initial debt discount of $2,000,000, interest expense of $15,659,506 and initial derivative liability of $17,659,506. For the six months ended June 30, 2022, amortization of the warrant discount of $221,667 was charged to interest expense. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $2,200,000 with a carrying value as of December 31, 2021, of $1,956,167, net of unamortized discounts of $243,833. As of June 30, 2022, and December 31, 2021, the accrued interest is $360,921 and $230,729, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

On November 13, 2020, the Company entered into a 12%, $1,000,000 face value promissory note with a third-party due November 13, 2021. Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date. The Company received proceeds of $890,000 on November 20, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $110,000. In conjunction with this note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 125,000,000 shares of common stock at an exercise price of $0.008, subject to adjustments and expires on the five-year anniversary of the issue date. As of June 30, 2022 and December 31, 2021, the outstanding principal balance of this note was $1,000,000. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of June 30, 2022, and December 31, 2021, the accrued interest is $253,808 and $135,452, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

On November 6, 2020, the Company entered into a Settlement Agreement with the holder of $120,000 of convertible notes with accrued and unpaid interest of $8,716 and a $210,000 Promissory Noted dated June 23, 2020 with accrued and unpaid interest of $15,707. The Company issued a new 12% Promissory Note with a face value of $389,423 and a maturity date of November 6, 2023. In conjunction with this settlement, the Company issued a warrant to purchase 60,000,000 shares of common stock at an exercise price of $0.0075, subject to adjustments and expires on the five-year anniversary of the issue date. The Company analyzed the transaction and concluded that this was a modification to the existing debt. The investor exercised the warrant on January 14, 2021.

 

On October 26, 2016, PCTI entered into a $210,000 note payable with a bank. On March 15, 2021, due to defaults with the terms of the note, the note was amended with the outstanding balance due December 5, 2021, and the interest rate changed to 7.75%. Borrowings are collateralized by substantially all of the assets of PCTI and the personal guarantee of PCTI’s former President. As of June 30, 2022, and December 31, 2021, $134,681 and $151,469, respectively, was outstanding on the note payable. This note is in default. On April 19, 2022, PCTI received a Notice of Default, Demand and Reservation of Rights (the “Notice”) from the bank’s legal counsel. The Notice is also addressed to Catherine Chis (former President of PCTI and a guarantor on the note). On May 16, 2022, and June 24, 2022, the bank filed Confessions of Judgment (the “COJ”) that were signed in conjunction with the extension dated March 15, 2021, against Chis and PCTI, respectively. The Company has engaged legal counsel to assist the Company in this matter.

 

On March 15, 2021, PCTI renewed their $350,000 promissory note with a bank that provides for borrowings of up to $350,000. Interest is due monthly and the principal is due on December 26, 2021, interest rate changed to the prime rate plus 3.25% (6.5% at March 15, 2021). Borrowings are collateralized by substantially all of the assets of PCTI and the personal guarantee of PCTI’s former President. As of December 31, 2021, and December 31, 2020, $344,166 and $345,211, respectively, was outstanding on the promissory note. This note is in default. On April 19, 2022, PCTI received a Notice of Default, Demand and Reservation of Rights (the “Notice”) from the bank’s legal counsel. The Notice is also addressed to Catherine Chis (former President of PCTI and a guarantor on the note). ). On May 16, 2022, and June 24, 2022, the bank filed Confessions of Judgment (the “COJ”) that were signed in conjunction with the extension dated March 15, 2021, against Chis and PCTI, respectively. The Company has engaged legal counsel to assist the Company in this matter.

 

On August 24, 2020 (the “Issue Date”), the Company entered into a 12%, $750,000 face value promissory note with a third-party (the “Holder”) due August 24, 2021 (the “Maturity Date”). Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date. The Company received proceeds of $663,000 on August 25, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $87,000. For the year ended December 31, 2021, amortization of the costs of $56,188 was charged to interest expense. In conjunction with this Note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 122,950,819 shares of common stock at an exercise price of $0.0061, subject to adjustments and expires on the five-year anniversary of the Issue Date. The warrants issued resulted in a debt discount of $750,000. During the year ended December 31, 2021, the Company paid $375,000 to the Holder. On May 3, 2021, the Company issued 75,000,000 shares of common stock to the Holder, upon the cashless exercise of a portion of the warrants. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $375,000. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of June 30, 2022, and December 31, 2021, the accrued interest is $135,247 and $90,247, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

 

On April 20, 2020, PCTI was granted a loan from Huntington Bank in the amount of $100,400, pursuant to the Paycheck Protection Program (“PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The loan matures on April 20, 2022 and bears interest at a rate of 1.0% per annum, payable monthly beginning on November 20, 2020. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Payments are deferred until the SBA determines the amount to be forgiven. The Company utilized the proceeds of the PPP loan in a manner which will enable qualification as a forgivable loan. On December 2, 2021, PCTI received a notice from Huntington Bank that the SBA has denied PCTI’s application for loan forgiveness, due to inaccurate statements in the loan application as submitted by the former CEO of PCTI. The balance on this PPP loan was $100,400 as of June 30, 2022, and December 31, 2021, and has been classified in notes payable.

 

On July 14, 2020, PCTI received $10,000 grant under the Economic Injury Disaster Loan (“EIDL”) program. Up to $10,000 of the EIDL can be forgiven as long as such funds were utilized to provide working capital. The first payment due is deferred one year. The loan balance of June 30, 2022, and December 31, 2021 was $10,000 and has been classified in notes payable.

 

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEFERRED LIABILITY
6 Months Ended
Jun. 30, 2022
Deferred Liability  
DEFERRED LIABILITY

NOTE 8 – DEFERRED LIABILITY

 

On September 2, 2020, PCTI entered into an agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $750,000, PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. Payments are due ninety (90) days after each calendar quarter, with the first payment due on or before March 31, 2021, for revenues for the quarter ending December 31, 2020. For the three and six months ended June 30, 2022, the Company reduced this deferred liability by $87,815 and that amount is included in accounts payable and accrued expenses. The deferred liability as of June 30, 2022, and December 31, 2021, on the condensed consolidated balance sheet is $662,185 and $750,000, respectively. No payments have been made and the Company is in default of the agreement with the total amount of $358,446 included in accounts payable and accrued expenses as of June 30, 2022. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the note was amended, whereby in exchange for 175,000,000 shares of common stock, the royalty percentage was amended to 1.8%. The Company valued the shares at $0.094 per share (the market value of the common stock on the date of the agreement) and recorded $16,450,000 as debt restructure expense on the condensed consolidated statement of operations for the six months ended June 30, 2021.

 

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEFERRED REVENUE
6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
DEFERRED REVENUE

NOTE 9 – DEFERRED REVENUE

 

During the year ended December 31, 2020, the Company received $64,353 form a customer for a payment of a three- year extended warranty. The extended warranty period is from, March 2021 through February 2024, and accordingly the Company will recognize the revenue over such period. For the three and six months ended June 30, 2022, and 2021, the Company recognized $5,363 and $10,725, respectively, of revenue. Of the remaining deferred revenue of $35,752, $21,451 is recognized as the current portion of deferred revenue and $14,301 is classified as a long- term liability on the condensed consolidated financial statements. As of December 31, 2021, $21,451 is classified as the current portion and $25,026 is classified as a long- term liability on the condensed consolidated financial statements.

 

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 10 – RELATED PARTY TRANSACTIONS

 

Employment Agreement

 

On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Mr. Conway’s compensation as adjusted was $20,000 per month, and effective September 1, 2021, Mr. Conway receives $10,000 per month from Ozop Capital.

 

Effective January 1, 2022, the Company entered into a new employment agreement with Mr. Conway. Pursuant to the agreement, Mr. Conway received a $250,000 contract renewal bonus and will receive an annual compensation of $240,000 from the Company and will also be eligible to receive bonuses and equity grants at the discretion of the BOD. The Company also agreed to compensate Mr. Conway for services provided directly to any of the Company’s subsidiaries. Ozop Capital increased Mr. Conway’s compensation to $20,000 per month in January 2022, OES began compensating Mr. Conway $20,000 in March 2022, and OED began compensation Mr. Conway $20,000 per month beginning in April 2022.

 

 

Series E Preferred Stock

 

On March 21, 2021, the Company issued 2,000 shares of Series E Preferred Stock (see Note 12), 1,800 of the shares were issued to Mr. Conway. On April 16, 2021, the Board of Directors of the Company authorized the issuance 2,000 shares of Series E Preferred stock, of which 1,050 were issued to Mr. Conway. During the three and six months ended June 30, 2021, the Company redeemed 1,050 and 2,850 shares issued to Mr. Conway, and pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $1,000 per share, recorded stock compensation expense to Mr. Conway of $1,050,000 and $2,850,000 for the three and six months ended June 30, 2021.

 

Management Fees and related party payables

 

For the three and six months ended June 30, 2022, and 2021, the Company recorded expenses to its officers in the following amounts:

 

   2022   2021   2022   2021 
   Three months ended
June 30,
   Six months ended
June 30,
 
   2022   2021   2022   2021 
CEO, parent  $240,000   $360,000   $630,000   $639,999 
CEO, parent- Series E Preferred Stock   -    1,050,000    -    2,850,000 
President, subsidiary (resigned July 2021)   -    51,074    -    86,083 
Total  $240,000   $1,461,074   $630,000   $3,576,082 

 

Redemption of Series C and Series D Preferred Stock

 

On July 13, 2021, the Company entered into a Definitive Agreement (the “Agreement”) with Chis to purchase the 47,500 shares of the Company’s Series C Preferred Stock held by Chis and the 18,667 shares of the Company’s Series D Preferred Stock held by Chis for the total purchase price of $11,250,000. In conjunction with the Agreement, Chis resigned from any and all positions held in the Company’s wholly owned subsidiary, PCTI. Further, Chis agreed that upon her resignation and for a period of five years thereafter (the “Restriction Period”), she shall not, directly or indirectly, solicit the employment of, assist in the soliciting of the employment of, or hire any employee or officer of the Company, including those of any of its present or future subsidiaries, or induce any person who is an employee, officer, agent, consultant or contractor of the Company to terminate such relationship with the Company. Additionally, Chis agreed that during the Restriction Period, she shall not compete with the Company or PCTI anywhere worldwide or be employed by any competitor of the Company.

 

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 11 – COMMITMENTS AND CONTINGENCIES

 

Leases

 

On January 2, 2021, the Company entered into a ten (10) year lease for a 6-bay garage storage facility of approximately 2,500 square feet from the property owner. Pursuant to the lease the Company agreed to issue 100,000,000 shares of restricted common stock. The shares were certificated on March 8, 2021, with an effective date of January 2, 2021. The Company valued the shares $0.0063, (the market value of the common stock on the date of the agreement) and has recorded $630,000 as a prepaid expense. The Company never took occupancy of the space, and the property owner has agreed to purchase a different property and will assign the title of such property to the Company in consideration of the 100,000,000 shares he received in January 2021.

 

Agreements

 

On September 1, 2021, Ozop Capital entered into an advisory agreement (the “RMA Agreement”) with Risk Management Advisors, Inc. (“RMA”). Pursuant to the terms of the RMA Agreement, RMA will assist Ozop Capital in analyzing, structuring, and coordinating Ozop Capital’s participation in a captive insurance company. RMA will coordinate legal, accounting, tax, actuarial and other services necessary to implement the Company’s participation in a captive insurance company, including, but not limited to, the preparation of an actuarial feasibility study, filing of all required regulatory applications, domicile selection, structural selection, and coordination of the preparation of legal documentation. In connection with the services listed above, Ozop Capital agreed to pay $50,000 and to issue $50,000 of shares of restricted common stock. One-half of the cash and stock were due upon the signing of the RMA Agreement. Accordingly, RMA received $25,000 and 452,080 shares of restricted common stock of the Company in September 2021. The balance of the cash and stock became due on October 29, 2021, upon the issuance of the captive insurance company’s certificate of authority from the state of Delaware. The Company has paid the $25,000 balance and recorded 637,755 shares of common stock to be issued.

 

On April 13, 2021, the Company agreed to engage PJN Strategies, LLC (“PJN”) as a consultant. Pursuant to the agreement, the Company agreed to compensate PJN $20,000 per month. Effective September 1, 2021, a new agreement was entered into between PJN and Ozop Capital. Pursuant to the terms of the new one- year agreement Ozop Capital agreed to compensate PJN $84,000 per month. For the three and six months ended June 30, 2022, the Company recorded $252,000 and $504,000, respectively, of consulting expenses.

 

 

On April 16, 2021, the Company signed a letter of agreement with Rubenstein Public Relations, Inc. (“RPR”). Pursuant to the letter of agreement, the Company agreed to engage RPR, effective May 1, 2021, on a month-to-month basis for $17,000 per month.. The Company terminated the agreement in October 2021.

 

On March 30, 2021, OES hired 2 individuals as Co-Directors of Sales. Pursuant to their respective offers of employment, the Company agreed to an annual salary of $130,000 with a signing bonus of $20,000 for each and to issue each 2,500,000 shares of restricted common stock upon the execution of the agreements and every 90 days thereafter for the first year as long as the employee is still employed. The Company valued the initial shares at $0.092 per share (the market price of the common stock on the date of the agreement), and $460,000 is included in stock-based compensation expense for the six months ended June 30, 2021. On January 14, 2022, the Company issued each of the Co-Directors their final 2,500,000 shares due. The shares were valued at $0.027 per share (the market price of the common stock on the date of the issuance), and $135,000 is included in stock-based compensation expense for the six months ended June 30, 2022. One of the individuals resigned on January 24, 2022.

 

On March 15, 2021, the Company entered into a consulting agreement with Aurora Enterprises (“Aurora”). Mr. Steven Martello is a principal of Aurora. Pursuant to the agreement Mr. Martello will provide strategic analysis regarding existing markets and revenue streams as well as the development of new lines of revenue. The Company agreed to a monthly retainer fee of $10,000 and to issue to Aurora or their designee 5,000,000 shares of restricted common stock. The shares were issued in April 2021. Aurora designated the shares to be issued to Pegasus Partners, Inc. The Company valued the shares at $0.1392 per share (the market price of the common stock on the date of the agreement), and $696,000 is included in stock-based compensation expense for the six months ended June 30, 2021. For the three and six months ended June 30, 2022, the Company has recorded $30,000 and $60,000, respectively, of consulting expenses, and for the three and six months ended June 30, 2021, the Company recorded consulting expenses of $xxx and $xxx, respectively.

 

On February 24, 2021, the Company entered into a consulting agreement with Christopher Ruppel. Pursuant to the agreement Mr. Ruppel was to join the Ozop Advisory Board. During the year ended December 31, 2021, the Company issued 10,000,000 shares of restricted common stock to Mr. Ruppel and agreed to a monthly fee of $2,500. The Company valued the shares at $0.2386 per share (the market price of the common stock on the date of the agreement), and $2,386,000 is included in stock-based compensation expense for the six months ended June 30, 2021. Effective April 1, 2021, the agreement was amended to $10,000 per month. Effective May 1, 2021, the Company was no longer using the services of Mr. Ruppel. For the three and six months ended June 30, 2021, the Company recorded $10,000 and $12,500 of consulting expenses, respectively.

 

On January 22, 2021, the Company issued 10,000,000 shares of restricted common stock for legal services performed in 2020 and approved by the BOD of the Company on December 1, 2020. The Company valued the shares at $0.0056 per share (the market price of the common stock on the date of the agreement), and $56,000 is included in stock-based compensation expense for the six months ended June 30, 2021.

 

On January 14, 2021, the Company entered into a Consulting Agreement with Mr. Allen Sosis. Pursuant to the agreement, Mr. Sosis will provide services as the Director of Business Development for the Company’s wholly owned subsidiary. Pursuant to the agreement, as amended, the Company will pay Mr. Sosis a monthly fee of $15,000 and an additional $1,000 in benefits. The Company also agreed to issue Mr. Sosis 5,000,000 shares of restricted common stock. The shares were issued in April 2021. The Company valued the shares at $0.20 per share (the market price of the common stock on the date of the agreement), and $1,000,000 was recorded as deferred stock compensation, to be amortized over the one-year term of the agreement. The Company terminated Mr. Sosis’s employment in October 2021. For the three and six months ended June 30, 2021, the Company recorded $30,000 and $75,500 of consulting expenses and effective June 1, 2021, Mr. Sosis became an employee of the Company through his termination with a $15,000 per month salary.

 

On January 6, 2021, the Company entered into a consulting agreement with Ezra Green to begin on February 8, 2021. The Company agreed to issue 10,000,000 shares of restricted common stock to Mr. Green and to a monthly fee of $2,500. The Company valued the shares at $0.0076 per share (the market price of the common stock on the date of the agreement), and $76,000 was recorded as deferred stock-based compensation, to be amortized over the one-year term of the agreement. For the six months ended June 30, 2022, and 2021, the Company recorded $1,249 and $36,348 as stock-based compensation expense, respectively. Effective April 1, 2021, the agreement was amended to $10,000 per month. For the three and six months ended June 30, 2022, the Company recorded $30,000 and $60,000, respectively, of consulting expenses and for the three and six months ended June 30, 2021, the Company recorded $30,000 and $34,500 of consulting expenses, respectively. Effective June 30, 2022, Mr. Green was no longer providing consulting services to the Company.

 

On March 4, 2019, the Company entered into a Separation Agreement (the “Separation Agreement”) with Salman J. Chaudhry, pursuant to which the Company agreed to pay Mr. Chaudry $227,200 (the “Outstanding Fees”) in certain increments as set forth in the Separation Agreement. As of June 30, 2022 and December 31, 2021, the balance owed Mr. Chaudhry is $162,085.

 

On September 2, 2020, PCTI entered into an Agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $750,000, PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the agreement was amended, whereby in exchange for 175,000,000 shares of common stock, the royalty percentage was amended to 1.8% (see Note 8). The Company valued the shares at $0.094 per share (the market value of the common stock on the date of the agreement) and recorded $16,450,000 as debt restructure expense on the condensed consolidated statement of operations for the six months ended June 30, 2021.

 

 

Legal matters

 

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

 

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS’ EQUITY
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 12– STOCKHOLDERS’ EQUITY

 

Common stock

 

During the six months ended June 30, 2022, the Company issued 5,000,000 shares of restricted common stock in the aggregate for services.

 

During the period from January 1, 2021, to June 30, 2021, holders of an aggregate of $760,550 in principal and $201,905 of accrued interest and fees of convertible and promissory notes, converted their debt into 483,154,618 shares of our common stock at an average conversion price of $0.002 per share.

 

During the six months ended June 30 2021, the Company also issued the following shares of restricted common stock:

 

  100,000,000 shares of restricted common stock pursuant to a lease agreement (see Note 10).
  175,000000 shares of restricted common stock pursuant to restructuring agreement related to a deferred liability (see Note 9).
  45,000,000 shares of restricted common stock in the aggregate for services and consulting agreements.

 

During the six months ended June 30, 2021, the Company also issued 405,797,987 shares of common stock upon the cashless exercise of common stock purchase warrants.

 

As of June 30, 2022, the Company has 4,990,000,000 shares of $0.001 par value common stock authorized and there are 4,622,362,977 shares of common stock issued and outstanding.

 

On April 4th, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (200,000,000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement.

 

Preferred stock

 

As of June 30, 2022, and December 31, 2021, 10,000,000 shares have been authorized as preferred stock, par value $0.001 (the “Preferred Stock”), which such Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time.

 

Series C Preferred Stock

 

On July 7, 2020, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company’s Series C Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series C Preferred Stock, 50,000 shares of the Company’s preferred remain designated as Series C Preferred Stock. The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 47,500 shares of Series C preferred Stock to Chis. On July 13, 2021, the Company purchased 47,500 shares of the Company’s Series C Preferred Stock held by Chis (see Note 11). As of June 30, 2022, and December 31, 2021, there were 2,500 shares of Series C Preferred Stock issued and outstanding and the shares are held by Mr. Conway.

 

 

Series D Preferred Stock

 

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series D Preferred Stock. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 18,667 shares of Series D preferred Stock to Chis, and on August 28, 2020, pursuant to Mr. Conway’s employment agreement, the Company issued 1,333 shares of Series D Preferred Stock to Mr. Conway. On July 13, 2021, the Company purchased 18,667 shares of the Company’s Series D Preferred Stock held by Chis (see Note 10).

 

On July 27, 2021, the Company filed with the Secretary of State of the State of Nevada an Amended and Restated Certificate of Designation of Series D Preferred Stock (the “Series D Amendment”). Under the terms of the Series D Amendment, 4,570 shares of the Company’s preferred stock will be designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. Any holder may, at any time convert any number of shares of Series D Convertible Preferred Stock held by such holder into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by 1.5 and dividing that number by the number of authorized shares of Series D Convertible Preferred Stock and multiply that result by the number of shares of Series D Convertible Preferred Stock being converted. Except as provided in the Series D Amendment or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 28, 2021, the Company closed on a Stock and Warrant Purchase Agreement (the “Series D SPA”). Pursuant to the terms of Series D SPA, an investor in exchange for $13,200,000 purchased one share of Series D Preferred Stock, and a warrant to acquire 3,236 shares of Series D Preferred Stock. As of June 30, 2022, and December 31, 2021, there were 1,334 shares, respectively, of Series D Preferred Stock issued and outstanding and a warrant to purchase 3,236 shares of Series D Preferred Stock are outstanding as of June 30, 2022, and December 31, 2021.

 

The warrant has a 15- year term and Partial Warrant Lock Up and Leak-Out Period. The Holder may only exercise the Warrant and purchase Warrant Shares as follows:

 

  i. Up to 162 (one hundred and sixty-two) Warrant Shares, at any time or times on or after five (5) business days from the closing of the Series D SPA (“the Initial Exercise Date”) subject to up to a maximum number of Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company and no later than on or before the 15th year anniversary of the Initial Exercise Date (“the Termination Date”); and
     
  ii. The Remainder of the Warrant representing up to 3,074 (three thousand and seventy-four) Warrant Shares (“Remaining Warrant Shares”) shall be locked up for a period of 36 (thirty-six) months from the Initial Exercise Date (“Lock Up Period”) and shall become exercisable at any time or times from the date that is the 36 (thirty-six) month anniversary of the Initial Exercise Date (“Lock Up Period Termination Date”) and no later than on or before the Termination Date, as follows:

 

  a. During every 1 (one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034 and until the Termination Date.

 

Series E Preferred Stock

 

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series E Preferred Stock. Under the terms of the Certificate of Designation of Series E Preferred Stock, 3,000 shares of the Company’s preferred stock have been designated as Series E Preferred Stock. The holders of the Series E Convertible Preferred Stock shall not be entitled to receive dividends. No holder of the Series E Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, except as may be otherwise expressly required by law. At any time, the Corporation may redeem for cash out of funds legally available therefor, any or all of the outstanding Preferred Stock (“Optional Redemption”) at $1,000 (one thousand dollars) per share. The shares of Series E Preferred Stock have not been registered under the Securities Act of 1933 or the laws of any state of the United States and may not be transferred without such registration or an exemption from registration. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued 500 shares of Series E preferred Stock to Chis, and on August 28, 2020. Pursuant to Mr. Conway’s employment agreement, the Company issued 500 shares of Series E Preferred Stock to Mr. Conway. On March 2, 2021, the BOD authorized the issuance of 1,800 shares of Series E Preferred Stock to Mr. Conway and 200 shares of Series E Preferred Stock to a third-party service provider. The issuances were for services performed. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $1,000 per share, the Company recorded $2,000,000 as stock-based compensation expense for expense for the six months ended June 30, 2021. On March 24, 2021, the Company redeemed the 3,000 shares of Series E Preferred Stock outstanding on that date. On April 16, 2021, the BOD authorized the issuance of 2,000 shares of Series E Preferred stock, of which 1,050 were granted to Mr. Conway. The issuances were for services performed. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $1,000 per share, the Company recorded $2,000,000 as stock-based compensation expense for the three and six months ended June 30, 2021. As of June 30, 2022, and December 31, 2021, there were -0- shares of Series E Preferred Stock issued and outstanding, respectively.

 

 

XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
NONCONTROLLING INTEREST
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
NONCONTROLLING INTEREST

NOTE 13 – NONCONTROLLING INTEREST

 

On August 19, 2021, the Company formed Ozop Capital. The Company owns 51% with PJN owning 49%. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital. The Company presents interest held by noncontrolling interest holders within noncontrolling interest in the condensed consolidated financial statements. During the six months ended June 30, 2022, there was no change in the ownership percentages. For the three and six months ended June 30, 2022, Ozop Capital incurred losses of $351,835 and $734,912, respectively, of which $172,399 and $360,107, respectively, is the loss attributed to the noncontrolling interest for the three- and six- months ending June 30, 2022. As of June 30, 2022, the accumulative noncontrolling interest is $615,212.

 

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES
6 Months Ended
Jun. 30, 2022
Operating Lease Right-of-use Assets And Operating Lease Liabilities  
OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES

NOTE 14 - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES

 

On October 25, 2019, PCTI executed a non-cancellable lease for office and industrial space which began December 1, 2019 and expires on November 30, 2022. Operating lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 7.5%, as the interest rate implicit in most of our leases is not readily determinable. Prior to July 10, 2020, PCTI recorded monthly lease expense pursuant to the lease agreement and effective July 10, 2020, pursuant to the PCTI transaction, operating lease expense is recognized pursuant to ASC Topic 842. Leases (Topic 842) over the lease term. During the years ended December 31, 2020, the Company recorded $84,278 for rent expense. During the year ended December 31, 2020, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $185,139 for this lease.

 

On April 14, 2021, the Company entered into a five-year lease which began on June 1, 2021, for approximately 8,100 square feet of office and warehouse space in Carlsbad, California, expiring May 31, 2026. Initial lease payments of $13,148 began on June 1, 2021, and increase by approximately 2.4% annually thereafter. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 7.5%, as the interest rate implicit in most of our leases is not readily determinable. During the year ended December 31, 2021, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $702,888 for this lease.

 

In adopting Topic 842, the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less.

 

Right-of- use assets are summarized below:

 SCHEDULE OF RIGHT-OF-USE ASSETS

   June 30, 2022 
Office and warehouse lease  $888,026 
Less: Accumulated Amortization   (281,498)
Right-of-use asset, net  $606,078 

SCHEDULE OF OPERATING LEASE LIABILITIES

   June 30, 2022 
Lease liability  $614,247 
Less current portion   (161,048)
Long term portion  $453,199 

 

Maturity of lease liabilities are as follows:

SCHEDULE OF MATURITY OF LEASE LIABILITIES

   Amount 
For the year ended December 31, 2022  $117,788 
For the year ended December 31, 2023   167,858 
For the year ended December 31, 2024   171,840 
For the year ended December 31, 2025   175,942 
For the year ended December 31, 2026   74,030 
Total  $707,458 
Less present value discount   (93,211)
Lease liability  $614,247 

 

XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 15 – SUBSEQUENT EVENTS

 

On July 15, 2022, the Company sold 15,353,952 shares to GHS at $0.010285 and received net proceeds of $152,732, after deducting transaction and broker fees of $5,183.

 

On August 1, 2022, the Company sold 7,675,221 shares to GHS at $0.010965 and received net proceeds of $81,451, after deducting transaction and broker fees of $2,708.

 

On August 4, 2022, the Company sold 8,136,272 shares to GHS at $0.010965 and received net proceeds of $86,405, after deducting transaction and broker fees of $2,809.

 

On August 10, 2022, the Company sold 18,063,649 shares to GHS at $0.01088 and received net proceeds of $191,577, after deducting transaction and broker fees of $4,956.

 

The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements, except as stated herein.

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2022, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 10-K/A filed on April 26, 2022.

 

The unaudited condensed consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries OED, PCTI, Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”) and the Company’s majority owned subsidiary Ozop Capital Partners, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has no cash equivalents at June 30, 2022, and December 31, 2021.

 

Sales Concentration and credit risk

Sales Concentration and credit risk

 

Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three and six months ended June 30, 2022, and 2021, and their accounts receivable balance as of June 30, 2022:

 

   Sales % Three
Months
Ended June
30, 2022
   Sales % Six
Months
Ended June
30, 2022
   Sales % Three
Months
Ended June
30, 2021
   Sales % Six
Months
Ended
June 30, 2021
   Accounts
receivable
balance
June 30,
2022
 
Customer A   43.5%   26.7%    N/A     N/A   $43,920 
Customer B   10.0%   11.4%   18.3%   11.3%   524,759 
Customer C   N/A    10.3%   13.5%   N/A    - 
Customer D   N/A    N/A    13.5%   N/A    - 
Customer E   N/A    N/A    14.9%   N/A    3,835 
Customer F   N/A    N/A    10.5%   N/A    - 
Customer G   N/A    N/A    18.3%   11.3%   - 
Customer H   N/A    N/A    13.5%   N/A    - 
Customer I   N/A    N/A    14.9%   65.6%   - 
Customer J   N/A    N/A    10.5%   13.4%   - 

 

 

Customers A-F are customers of Ozop Energy Systems Inc. and Customers G- J are customers of PCTI. PCTI, historically does not have year to year many recurring clients as the Company produces customized capital equipment for its’ customers.

 

Accounts Receivable

Accounts Receivable

 

The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.

 

Inventory

Inventory

 

Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs include finished goods, material, labor and manufacturing overhead. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues.

 

The components of inventories at June 30, 2022, and December 31, 2021, are as follows:

 

   June 30,
2022
   December 31,
2021
 
         
Raw materials  $236,134   $234,168 
Work in process   -    43,704 
Finished goods   1,562,961    788,110 
Inventory net  $1,799,095   $1,065,982 

 

Purchase concentration

Purchase concentration

 

OES purchases finished renewable energy products from its’ suppliers. For the three months ended June 30, 2022, there were three suppliers that accounted for 41.3%, 23.3% and 19.7%, respectively, and for the six months ended June 30, 2022, there were four suppliers that accounted for 38.0%, 15.9%, 15.6% and 11.2%, respectively. For the three and six months ended June 30, 2021, there were three suppliers that accounted for 29.6%, 21.8% and 12.7%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a 20% down payment with the 30% balances due on shipment and 50% due prior to delivery, while other vendors terms are due in full immediately prior to delivery. We also buy product from other distributors, if we are not able to purchase direct from the manufacturer. While management believes all of its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business

 

The principal purchases by PCTI are comprised of parts and raw materials that PCTI assembles and manufactures and sells to its customers. There were no suppliers who accounted for more than ten percent (10%) of PCTI’s purchases for the three and six months ended June 30, 2022, and 2021.

 

Property, plant and equipment

Property, plant and equipment

 

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.

 

The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:

 

  Office furniture and equipment 3-5 years
  Warehouse equipment 7 years

 

Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.

 

 

For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Advance payments are typically required for commercial customers and are recorded as current liability until revenue is recognized. Advance payments are not required for government customers. The majority of contracts typically require payment within 30 to 60 days after transfer of ownership to the customer.

 

For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges.

 

The following table disaggregates our revenue by major source for the three and six months ended June 30, 2022 and 2021:

 

   2022   2021   2022   2021 
   Three months ended
June 30,
   Six months ended
June 30,
 
   2022   2021   2022   2021 
Sourced and distributed products  $4,749,377   $1,254,982   $7,668,699   $1,254,982 
Manufactured products   112,759    19,051    275,675    814,605 
OED Installations   16,500    -    16,500    - 
Total  $4,878,636   $1,274,033   $7,960,874   $2,069,587 

 

Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company brings the finished goods into our California warehouse to fill orders as well as to build inventory for future sales orders. From time to time for some of our larger orders we may have our suppliers ship directly to our customers to avoid extra shipping charges. For manufactured products, there is usually a bidding process by branches of the military or other large firms that need mostly battery charging and storage systems for large industrial projects. We would then purchase the raw materials and parts needed to build out the project in our Pennsylvania warehouse.

 

Advertising and Marketing Expenses

Advertising and Marketing Expenses

 

The Company expenses advertising and marketing costs as incurred. For the three and six months ended June 30, 2022, the Company recorded advertising and marketing expenses of $2,710 and $5,973, respectively, and for the three and six months ended June 30, 2021, the Company recorded advertising and marketing expenses of $5,944 and $28,544, respectively.

 

Research and Development

Research and Development

 

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the three and six months ended June 30, 2022, and 2021, the Company did not record any research and development expenses.

 

Convertible Instruments

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

 

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

 

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

 

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

 

 

Distinguishing Liabilities from Equity

Distinguishing Liabilities from Equity

 

The Company relies on the guidance provided by ASC Topic 480, Distinguishing Liabilities from Equity, to classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.

 

Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.

 

Our CEO and Chairman holds sufficient shares of the Company’s voting preferred stock that give sufficient voting rights under the articles of incorporation and bylaws of the Company such that the CEO and Chairman can at any time unilaterally vote to increase the number of authorized shares of common stock of the Company, without the need to call a general meeting of common shareholders of the Company.

 

Initial Measurement

 

The Company records its financial instruments classified as liability, temporary equity or permanent equity at issuance at the fair value, or cash received.

 

Subsequent Measurement – Financial Instruments Classified as Liabilities

 

The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in fair value of its financial instruments classified as liabilities are recorded as other income (expenses).

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
  Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
  Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to the conversion features within the instrument and that the company has insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.

 

 

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of June 30, 2022, and December 31, 2021, for each fair value hierarchy level:

 

June 30, 2022  Derivative
Liabilities
   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $7,589,928   $7,589,928 

 

December 31, 2021   Derivative
Liabilities
    Total  
Level I   $ -     $ -  
Level II   $ -     $ -  
Level III   $ 20,966,701     $ 20,966,701  

 

Leases

Leases

 

The Company accounts for leases under ASU 2016-02 (see Note 14), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

 

Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of 7.5%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the condensed consolidated statements of operations.

 

Income Taxes

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.

 

Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.

 

Segment Policy

Segment Policy

 

The Company has no reportable segments as it operates in one segment; renewable energy.

 

Earnings (Loss) Per Share

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of June 30, 2022, and 2021, the Company’s dilutive securities are convertible into approximately 7,689,380,800 and 14,418,538,825, respectively, shares of common stock. The following table represents the classes of dilutive securities as of June 30, 2022, and 2021:

 

   June 30, 2022   June 30, 2021 
Convertible preferred stock (1)   6,933,544,466    13,820,732,691 
Unexercised common stock purchase warrants (1)   672,024,518    597,024,518 
Convertible notes payable   2,520,720    781,816 
Promissory note payable (1)   81,291,096    - 
TOTAL   7,689,380,800    14,418,538,825 

 

(1) The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise.

 

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows.

 

Other than the above, there have no recent accounting pronouncements or changes in accounting pronouncements during the period ended March 31, 2022, that are of significance or potential significance to the Company.

XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR

 

   Sales % Three
Months
Ended June
30, 2022
   Sales % Six
Months
Ended June
30, 2022
   Sales % Three
Months
Ended June
30, 2021
   Sales % Six
Months
Ended
June 30, 2021
   Accounts
receivable
balance
June 30,
2022
 
Customer A   43.5%   26.7%    N/A     N/A   $43,920 
Customer B   10.0%   11.4%   18.3%   11.3%   524,759 
Customer C   N/A    10.3%   13.5%   N/A    - 
Customer D   N/A    N/A    13.5%   N/A    - 
Customer E   N/A    N/A    14.9%   N/A    3,835 
Customer F   N/A    N/A    10.5%   N/A    - 
Customer G   N/A    N/A    18.3%   11.3%   - 
Customer H   N/A    N/A    13.5%   N/A    - 
Customer I   N/A    N/A    14.9%   65.6%   - 
Customer J   N/A    N/A    10.5%   13.4%   - 
SCHEDULE OF INVENTORY

The components of inventories at June 30, 2022, and December 31, 2021, are as follows:

 

   June 30,
2022
   December 31,
2021
 
         
Raw materials  $236,134   $234,168 
Work in process   -    43,704 
Finished goods   1,562,961    788,110 
Inventory net  $1,799,095   $1,065,982 
SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS

 

  Office furniture and equipment 3-5 years
  Warehouse equipment 7 years
DISAGGREGATION OF REVENUE

The following table disaggregates our revenue by major source for the three and six months ended June 30, 2022 and 2021:

 

   2022   2021   2022   2021 
   Three months ended
June 30,
   Six months ended
June 30,
 
   2022   2021   2022   2021 
Sourced and distributed products  $4,749,377   $1,254,982   $7,668,699   $1,254,982 
Manufactured products   112,759    19,051    275,675    814,605 
OED Installations   16,500    -    16,500    - 
Total  $4,878,636   $1,274,033   $7,960,874   $2,069,587 
SCHEDULE OF DERIVATIVE INSTRUMENTS

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of June 30, 2022, and December 31, 2021, for each fair value hierarchy level:

 

June 30, 2022  Derivative
Liabilities
   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $7,589,928   $7,589,928 

 

December 31, 2021   Derivative
Liabilities
    Total  
Level I   $ -     $ -  
Level II   $ -     $ -  
Level III   $ 20,966,701     $ 20,966,701  
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

 

   June 30, 2022   June 30, 2021 
Convertible preferred stock (1)   6,933,544,466    13,820,732,691 
Unexercised common stock purchase warrants (1)   672,024,518    597,024,518 
Convertible notes payable   2,520,720    781,816 
Promissory note payable (1)   81,291,096    - 
TOTAL   7,689,380,800    14,418,538,825 

 

(1) The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise.
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Tables)
6 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

The following table summarizes the Company’s property and equipment:

 

   June 30, 2022   December 31, 2021 
Office equipment  $300,083   $260,083 
Less: Accumulated Depreciation   (152,369)   (127,194)
Property and Equipment, Net  $147,714   $132,889 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
DERIVATIVE LIABILITIES (Tables)
6 Months Ended
Jun. 30, 2022
Derivative Liabilities  
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE

A summary of the activity related to derivative liabilities for the six months ended June 30, 2022, is as follows:

 

   Derivative liabilities associated with warrants   Derivative liabilities associated with convertible notes   Total derivative liabilities 
Balance December 31, 2021  $20,938,755   $27,946   $20,966,701 
Change in fair value   (13,376,695)   (78)   (13,376,773)
Balance June 30, 2022  $7,562,060   $27,868   $7,589,928 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
NOTES PAYABLE (Tables)
6 Months Ended
Jun. 30, 2022
Notes Payable  
SCHEDULE OF NOTES PAYABLE

The Company has the following note payables outstanding:

 

   June 30, 2022   December 31, 2021 
         
  $134,681   $134,681 
Note payable bank, interest at 7.75%, matured December 5, 2021, currently in default  $134,681   $134,681 
Note payable bank, interest at 6.5%, matured December 26, 2021, in default   344,166    344,166 
Economic Injury Disaster Loan   10,000    10,000 
Paycheck Protection Program loan   100,400    100,400 
Notes payable, interest at 8%, matured January 5, 2020, in default   45,000    45,000 
Other, due on demand, interest at 6%, currently in default   50,000    50,000 
Note payable $750,000 face value, interest at 12%, matured August 24, 2021, in default   375,000    375,000 
Note payable $389,423 face value, interest at 18%, matures November 6, 2023   389,423    389,423 
Note payable $1,000,000 face value, interest at 12%, matured November 13, 2021, in default   1,000,000    1,000,000 
Note payable $2,200,000 face value, interest at 12%, matured February 9, 2022, net of discount of $243,833 (2021), in default   2,200,000    1,956,167 
Note payable $11,110,000 face value, interest at 12%, matured March 17, 2022, net of discount of $2,314,583 (2021), in default   11,110,000    8,795,417 
Note payable $3,300,000 face value, interest at 12%, matures December 7, 2022, net of discount of $1,458,115 (2022) and $3,099,524 (2021)   1,841,885    200,476 
Sub- total notes payable   17,600,555    13,400,730 
Less long-term portion   389,423    389,423 
Current portion of notes payable, net of discount  $17,211,132   $13,011,307 
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS (Tables)
6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
SCHEDULE OF EXPENSES TO OFFICERS

For the three and six months ended June 30, 2022, and 2021, the Company recorded expenses to its officers in the following amounts:

 

   2022   2021   2022   2021 
   Three months ended
June 30,
   Six months ended
June 30,
 
   2022   2021   2022   2021 
CEO, parent  $240,000   $360,000   $630,000   $639,999 
CEO, parent- Series E Preferred Stock   -    1,050,000    -    2,850,000 
President, subsidiary (resigned July 2021)   -    51,074    -    86,083 
Total  $240,000   $1,461,074   $630,000   $3,576,082 

 

Redemption of Series C and Series D Preferred Stock

 

On July 13, 2021, the Company entered into a Definitive Agreement (the “Agreement”) with Chis to purchase the 47,500 shares of the Company’s Series C Preferred Stock held by Chis and the 18,667 shares of the Company’s Series D Preferred Stock held by Chis for the total purchase price of $11,250,000. In conjunction with the Agreement, Chis resigned from any and all positions held in the Company’s wholly owned subsidiary, PCTI. Further, Chis agreed that upon her resignation and for a period of five years thereafter (the “Restriction Period”), she shall not, directly or indirectly, solicit the employment of, assist in the soliciting of the employment of, or hire any employee or officer of the Company, including those of any of its present or future subsidiaries, or induce any person who is an employee, officer, agent, consultant or contractor of the Company to terminate such relationship with the Company. Additionally, Chis agreed that during the Restriction Period, she shall not compete with the Company or PCTI anywhere worldwide or be employed by any competitor of the Company.

 

XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables)
6 Months Ended
Jun. 30, 2022
Operating Lease Right-of-use Assets And Operating Lease Liabilities  
SCHEDULE OF RIGHT-OF-USE ASSETS

Right-of- use assets are summarized below:

 SCHEDULE OF RIGHT-OF-USE ASSETS

   June 30, 2022 
Office and warehouse lease  $888,026 
Less: Accumulated Amortization   (281,498)
Right-of-use asset, net  $606,078 
SCHEDULE OF OPERATING LEASE LIABILITIES

SCHEDULE OF OPERATING LEASE LIABILITIES

   June 30, 2022 
Lease liability  $614,247 
Less current portion   (161,048)
Long term portion  $453,199 
SCHEDULE OF MATURITY OF LEASE LIABILITIES

Maturity of lease liabilities are as follows:

SCHEDULE OF MATURITY OF LEASE LIABILITIES

   Amount 
For the year ended December 31, 2022  $117,788 
For the year ended December 31, 2023   167,858 
For the year ended December 31, 2024   171,840 
For the year ended December 31, 2025   175,942 
For the year ended December 31, 2026   74,030 
Total  $707,458 
Less present value discount   (93,211)
Lease liability  $614,247 
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION (Details Narrative) - Securities Purchase Agreement [Member] - Pennsylvania Corporation [Member]
Jul. 10, 2020
shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Number of shares acquired 1,000
Series C Preferred Stock [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Stock Issued During Period, Shares, Acquisitions 47,500
Series D Preferred Stock [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Stock Issued During Period, Shares, Acquisitions 18,667
Series E Preferred Stock [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Stock Issued During Period, Shares, Acquisitions 500
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) - USD ($)
Aug. 10, 2022
Aug. 04, 2022
Aug. 01, 2022
Jul. 15, 2022
Apr. 04, 2022
Oct. 14, 2021
Jun. 30, 2022
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Retained earnings accumulated deficit             $ 211,816,067 $ 217,326,611
Working capital deficit             22,909,763  
Derivative liabilities current             7,589,928 $ 20,966,701
Debt instrument default amount             $ 15,369,247  
Registration Statement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Stock issued during the period, shares           30,000,000    
Securities Purchase Agreement [Member] | GHS Investments LLC [Member] | Common Stock [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Stock issued during the period, shares         200,000,000      
Common stock maturity period         Oct. 04, 2022      
Agreement description         The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement      
Securities Purchase Agreement [Member] | GHS Investments LLC [Member] | Common Stock [Member] | Subsequent Event [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Stock issued during the period, shares 18,063,649 8,136,272 7,675,221 15,353,952        
Price per share $ 0.01088 $ 0.010965 $ 0.010965 $ 0.010285        
Stock issued during the period $ 191,577 $ 86,405 $ 81,451 $ 152,732        
Brokerage fees $ 4,956 $ 2,809 $ 2,708 $ 5,183        
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Customer A [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage $ 43,920   $ 43,920  
Customer A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage 43.50%   26.70%  
Customer B [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage $ 524,759   $ 524,759  
Customer B [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage 10.00% 18.30% 11.40% 11.30%
Customer C [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage    
Customer C [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage   13.50% 10.30%  
Customer D [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage    
Customer D [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage   13.50%    
Customer E [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage 3,835   3,835  
Customer E [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage   14.90%    
Customer F [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage    
Customer F [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage   10.50%    
Customer G [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage    
Customer G [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage   18.30%   11.30%
Customer H [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage    
Customer H [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage   13.50%    
Customer I [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage    
Customer I [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage   14.90%   65.60%
Customer J [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage    
Customer J [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration Risk, Percentage   10.50%   13.40%
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF INVENTORY (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Raw materials $ 236,134 $ 234,168
Work in process 43,704
Finished goods 1,562,961 788,110
Inventory net $ 1,799,095 $ 1,065,982
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details)
6 Months Ended
Jun. 30, 2022
Warehouse Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 7 years
Minimum [Member] | Office Furniture And Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
Maximum [Member] | Office Furniture And Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
DISAGGREGATION OF REVENUE (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Product Information [Line Items]        
Total $ 4,878,636 $ 1,274,033 $ 7,960,874 $ 2,069,587
Sourced and Distributed Products [Member]        
Product Information [Line Items]        
Total 4,749,377 1,254,982 7,668,699 1,254,982
Manufactured Products [Member]        
Product Information [Line Items]        
Total 112,759 19,051 275,675 814,605
OED Installations [Member]        
Product Information [Line Items]        
Total $ 16,500 $ 16,500
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Fair Value, Inputs, Level 1 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Derivative Liabilities
Total
Fair Value, Inputs, Level 2 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Derivative Liabilities
Total
Fair Value, Inputs, Level 3 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Derivative Liabilities 7,589,928 20,966,701
Total $ 7,589,928 $ 20,966,701
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
TOTAL 7,689,380,800 14,418,538,825
Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
TOTAL [1] 6,933,544,466 13,820,732,691
Unexercised Common Stock Purchase Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
TOTAL 672,024,518 597,024,518
Convertible Notes Payable [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
TOTAL 2,520,720 781,816
Promissory Note Payable [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
TOTAL [1] 81,291,096
[1] The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise.
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Outstanding shares, percentage 4.99%
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Product Information [Line Items]        
Marketing and Advertising Expense $ 2,710 $ 5,944 $ 5,973 $ 28,544
Unrecognized tax benefits $ 0   $ 0  
Dilutive securities common stock, shares     7,689,380,800 14,418,538,825
Suppliers One [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk 41.30% 29.60% 38.00% 29.60%
Suppliers Two [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk 23.30% 21.80% 15.90% 21.80%
Suppliers Three [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk 19.70% 12.70% 15.60% 12.70%
Suppliers Four [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk     11.20%  
Two Vendor [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk     20.00%  
Down Payment [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk     30.00% 10.00%
Shipment [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk     50.00%  
No Suppliers [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk     10.00%  
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Less: Accumulated Depreciation $ (152,369) $ (127,194)
Property and Equipment, Net 147,714 132,889
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Office equipment $ 300,083 $ 260,083
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Property, Plant and Equipment [Abstract]    
Depreciation $ 25,175 $ 18,681
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
15% Promissory Note [Member]    
Short-Term Debt [Line Items]    
Long term debt, gross $ 25,000 $ 25,000
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Derivative liability     $ 20,966,701  
Change in fair value $ 9,011,570 $ 8,866,819 13,376,773 $ (43,331,083)
Change in fair value (9,011,570) $ (8,866,819) (13,376,773) $ 43,331,083
Derivative liability 7,589,928   7,589,928  
Derivative Liabilities Associated With Warrants [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Derivative liability     20,938,755  
Change in fair value     (13,376,695)  
Change in fair value     13,376,695  
Derivative liability 7,562,060   7,562,060  
Derivative Liabilities Associated With Convertible Notes [Member]        
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]        
Derivative liability     27,946  
Change in fair value     (78)  
Change in fair value     78  
Derivative liability $ 27,868   $ 27,868  
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
DERIVATIVE LIABILITIES (Details Narrative)
Jun. 30, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liabilities | $ $ 7,589,928 $ 20,966,701
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input 2.51 0.19
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input 2.08 0.48
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input 2.93 0.99
Measurement Input, Option Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input 69 92
Measurement Input, Option Volatility [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input 183 344
Measurement Input, Option Volatility [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input 331 366
Measurement Input, Exercise Price [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input 0.006  
Measurement Input, Exercise Price [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability measurement input 0.15  
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF NOTES PAYABLE (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]    
Sub- total notes payable $ 17,600,555 $ 13,400,730
Less long-term portion 389,423 389,423
Current portion of notes payable, net of discount 17,211,132 13,011,307
Note Payable [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable 134,681 134,681
Note Payable One [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable 344,166 344,166
Economic Injury Disaster Loan [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable 10,000 10,000
Paycheck Protection Programloan [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable 100,400 100,400
Note Payable Two [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable 45,000 45,000
Other [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable 50,000 50,000
Note Payable Three [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable 375,000 375,000
Note Payable Four [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable 389,423 389,423
Note Payable Five [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable 1,000,000 1,000,000
Note Payable Six [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable 2,200,000 1,956,167
Note Payable Seven [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable 11,110,000 8,795,417
Note Payable Eight [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable $ 1,841,885 $ 200,476
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Oct. 26, 2016
Short-Term Debt [Line Items]        
Debt Instrument, interest rate, stated percentage       7.75%
Debt Instrument, face amount     $ 760,550  
Note Payable [Member]        
Short-Term Debt [Line Items]        
Debt Instrument, interest rate, stated percentage 7.75% 7.75%    
Debt Instrument, maturity date Dec. 05, 2021 Dec. 05, 2021    
Note Payable One [Member]        
Short-Term Debt [Line Items]        
Debt Instrument, interest rate, stated percentage 6.50% 6.50%    
Debt Instrument, maturity date Dec. 26, 2021 Dec. 26, 2021    
Note Payable Two [Member]        
Short-Term Debt [Line Items]        
Debt Instrument, interest rate, stated percentage 8.00% 8.00%    
Debt Instrument, maturity date Jan. 05, 2020 Jan. 05, 2020    
Other [Member]        
Short-Term Debt [Line Items]        
Debt Instrument, interest rate, stated percentage 6.00% 6.00%    
Note Payable Three [Member]        
Short-Term Debt [Line Items]        
Debt Instrument, interest rate, stated percentage 12.00% 12.00%    
Debt Instrument, maturity date Aug. 24, 2021 Aug. 24, 2021    
Debt Instrument, face amount $ 750,000 $ 750,000    
Note Payable Four [Member]        
Short-Term Debt [Line Items]        
Debt Instrument, interest rate, stated percentage 18.00% 18.00%    
Debt Instrument, maturity date Nov. 06, 2023 Nov. 06, 2023    
Debt Instrument, face amount $ 389,423 $ 389,423    
Note Payable Five [Member]        
Short-Term Debt [Line Items]        
Debt Instrument, interest rate, stated percentage 12.00% 12.00%    
Debt Instrument, maturity date Nov. 13, 2021 Nov. 13, 2021    
Debt Instrument, face amount $ 1,000,000 $ 1,000,000    
Note Payable Six [Member]        
Short-Term Debt [Line Items]        
Debt Instrument, interest rate, stated percentage 12.00% 12.00%    
Debt Instrument, maturity date Feb. 09, 2022 Feb. 09, 2022    
Debt Instrument, face amount $ 2,200,000 $ 2,200,000    
Debt Instrument, unamortized discount   $ 243,833    
Note Payable Seven [Member]        
Short-Term Debt [Line Items]        
Debt Instrument, interest rate, stated percentage 12.00% 12.00%    
Debt Instrument, maturity date Mar. 17, 2022 Mar. 17, 2022    
Debt Instrument, face amount $ 11,110,000 $ 11,110,000    
Debt Instrument, unamortized discount   $ 2,314,583    
Note Payable Eight [Member]        
Short-Term Debt [Line Items]        
Debt Instrument, interest rate, stated percentage 12.00% 12.00%    
Debt Instrument, maturity date Dec. 07, 2022 Dec. 07, 2022    
Debt Instrument, face amount $ 3,300,000 $ 3,300,000    
Debt Instrument, unamortized discount $ 1,458,115 $ 3,099,524    
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
NOTES PAYABLE (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Dec. 13, 2021
Dec. 07, 2021
Mar. 23, 2021
Mar. 17, 2021
Feb. 16, 2021
Feb. 09, 2021
Nov. 20, 2020
Nov. 13, 2020
Nov. 06, 2020
Aug. 25, 2020
Aug. 24, 2020
Jul. 23, 2020
Jul. 14, 2020
Apr. 20, 2020
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
May 03, 2021
Mar. 15, 2021
Dec. 31, 2020
Oct. 26, 2016
Debt Instrument, Interest Rate, Stated Percentage                                             7.75%
Debt Instrument, Face Amount                               $ 760,550   $ 760,550          
Proceeds from Notes Payable                                 $ 12,000,000          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                               405,797,987   405,797,987          
Amortization of Debt Discount (Premium)                                 4,199,825 $ 44,170,200          
Interest Expense                             $ 1,427,554 $ 4,310,335 5,402,775 44,965,085          
Derivative Liabilities                             7,589,928   7,589,928   $ 20,966,701        
Notes payable                             $ 17,600,555   $ 17,600,555   $ 13,400,730        
Debt Instrument, Increase, Accrued Interest                                   $ 201,905          
Notes Payable ToBank                                         $ 350,000   $ 210,000
Short-Term Bank Loans and Notes Payable                                         $ 350,000    
Common Stock, Shares, Issued                             4,622,362,977   4,622,362,977   4,617,362,977        
Economic Injury Disaster Loan [Member]                                              
Proceeds from Notes Payable                         $ 10,000                    
Debt Instrument, Description                         The first payment due is deferred one year.                    
Notes payable                             $ 10,000   $ 10,000   $ 10,000        
Debt Instrument, Decrease, Forgiveness                         $ 10,000                    
PCTI [Member]                                              
Notes payable                             $ 134,681   $ 134,681   151,469        
PCTI [Member] | Personal Guarantee Of Chis [Member]                                              
Notes payable                                     344,166     $ 345,211  
Holder [Member]                                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                             125,000,000   125,000,000            
Class of Warrant or Right, Exercise Price of Warrants or Rights                             $ 0.008   $ 0.008            
Warrants and Rights Outstanding, Term                             5 years   5 years            
Promissory Note [Member]                                              
Debt Instrument, Face Amount                             $ 375,000   $ 375,000   375,000        
Debt Instrument, Unamortized Discount                                     375,000        
Interest Payable                             135,247   135,247   90,247        
Common Stock, Shares, Issued                                       75,000,000      
Promissory Note [Member] | Maximum [Member]                                              
Debt Instrument, Interest Rate, Stated Percentage                                         6.50%    
Promissory Note [Member] | Prime Rate [Member]                                              
Debt Instrument, Interest Rate, Stated Percentage                                         325.00%    
Promissory Note [Member] | Lender [Member]                                              
Debt Instrument, Interest Rate, Stated Percentage       12.00%                                      
Debt Instrument, Face Amount       $ 11,110,000                     11,110,000   11,110,000   11,110,000        
Debt Instrument, Maturity Date       Mar. 17, 2022                                      
Debt Instrument, Unamortized Discount       $ 1,000,000                             2,314,583        
Proceeds from Notes Payable     $ 10,000,000                                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       250,000,000                                      
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 0.13                                      
Amortization of Debt Discount (Premium)                                 231,250            
Amortization of Warrant Discount                             2,083,333   2,083,333            
Long-Term Debt, Gross                             11,100,000   11,100,000   8,795,417        
Lender Costs       $ 110,000                                      
Interest Payable                             1,691,155   1,691,155   1,033,687        
Promissory Note [Member] | Lender [Member] | Valuation Technique, Option Pricing Model [Member]                                              
Debt Instrument, Unamortized Discount                             10,000,000   10,000,000            
Interest Expense                                 23,248,433            
Derivative Liabilities                             32,248,433   32,248,433            
Adjustment of Warrants                                 33,248,433            
Promissory Note [Member] | Lender [Member] | December Seven Two Thousand Twenty Two [Member]                                              
Debt Instrument, Interest Rate, Stated Percentage   12.00%                                          
Debt Instrument, Face Amount   $ 3,300,000                         3,300,000   3,300,000   3,300,000        
Debt Instrument, Maturity Date   Dec. 07, 2022                                          
Debt Instrument, Unamortized Discount   $ 300,000                         1,481,115   1,481,115   3,099,524        
Proceeds from Notes Payable $ 3,000,000                                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   75,000,000                                          
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 0.039                                          
Amortization of Debt Discount (Premium)                                 150,000            
Interest Expense                                 2,982,815            
Derivative Liabilities                             2,982,815   2,982,815            
Amortization of Warrant Discount                             1,491,407   1,491,407            
Long-Term Debt, Gross                             184,855   184,855   200,476        
Promissory Note [Member] | Holder [Member]                                              
Debt Instrument, Interest Rate, Stated Percentage               12.00% 12.00%   12.00%                        
Debt Instrument, Face Amount               $ 1,000,000 $ 389,423   $ 750,000 $ 210,000     1,000,000   1,000,000   1,000,000        
Debt Instrument, Maturity Date               Nov. 13, 2021 Nov. 06, 2023                            
Proceeds from Notes Payable             $ 890,000     $ 663,000                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                     122,950,819                        
Class of Warrant or Right, Exercise Price of Warrants or Rights                 $ 0.0075   $ 0.0061                        
Interest Payable                             253,808   253,808   135,452        
Debt Instrument, Description               Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date     Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date                        
Legal Fees             $ 110,000     $ 87,000                          
Warrants and Rights Outstanding, Term                 5 years                            
Notes payable                 $ 120,000                            
Debt Instrument, Increase, Accrued Interest                 $ 8,716     $ 15,707                      
Promissory Note [Member] | Holder [Member] | Nine Instalments [Member]                                              
Interest Expense                                     56,188        
Adjustments to Additional Paid in Capital, Warrant Issued                     $ 750,000                        
Promissory Note One [Member] | Lender [Member]                                              
Debt Instrument, Interest Rate, Stated Percentage           12.00%                                  
Debt Instrument, Face Amount           $ 2,200,000                 2,200,000   2,200,000   2,200,000        
Debt Instrument, Maturity Date           Feb. 09, 2022                                  
Debt Instrument, Unamortized Discount           $ 200,000                         243,833        
Proceeds from Notes Payable         $ 2,000,000                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           50,000,000                                  
Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 0.15                                  
Amortization of Debt Discount (Premium)                                 22,167            
Long-Term Debt, Gross                                     1,956,167        
Interest Payable                             360,921   360,921   230,729        
Promissory Note One [Member] | Lender [Member] | Valuation Technique, Option Pricing Model [Member]                                              
Debt Instrument, Unamortized Discount                             2,000,000   2,000,000            
Interest Expense                                 15,659,506            
Derivative Liabilities                             17,659,506   17,659,506            
Adjustment of Warrants                                 17,659,506            
Promissory Note One [Member] | Lenders [Member]                                              
Amortization of Warrant Discount                             221,667   221,667            
Paycheck Protection Program [Member]                                              
Debt Instrument, Maturity Date                           Apr. 20, 2022                  
Notes payable                             $ 100,400   $ 100,400   $ 100,400        
Loans Payable to Bank                           $ 100,400                  
Accounts Payable, Interest-Bearing, Interest Rate                           1.00%                  
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEFERRED LIABILITY (Details Narrative) - USD ($)
6 Months Ended
Feb. 26, 2021
Sep. 02, 2020
Jun. 30, 2021
Jun. 30, 2022
Dec. 31, 2021
Deferred Liability Current       $ 662,185 $ 750,000
Accounts Payable and Accrued Liabilities       $ 87,815 $ 358,446
PCTI [Member] | Exchange Agreement [Member]          
Deferred Liability Current   $ 750,000      
Product Liability Contingency, Third-Party Recovery, Percentage   3.00%      
Deferred Compensation Arrangement with Individual, Shares Issued 175,000,000        
Royalty Percentage 1.80%        
Price Per Share     $ 0.094    
Payments of Debt Restructuring Costs     $ 16,450,000    
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEFERRED REVENUE (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Jun. 30, 2022
Dec. 31, 2020
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]        
DueToRelatedParties     $ 64,353  
Warranty Description     payment of a three- year extended warranty  
Liability revenue recognized $ 5,363 $ 10,725    
Deferred revenue 35,752 35,752    
Deferred revenue, current 21,451 21,451   $ 21,451
Deferred revenue, non-current $ 14,301 $ 14,301   $ 25,026
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF EXPENSES TO OFFICERS (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Related Party Transaction [Line Items]        
Total $ 240,000 $ 1,461,074 $ 630,000 $ 3,576,082
Chief Executive Officer [Member]        
Related Party Transaction [Line Items]        
Total 240,000 360,000 630,000 639,999
Chief Executive Officer Series E Preferred Stock [Member]        
Related Party Transaction [Line Items]        
Total 1,050,000 2,850,000
President Subsidiary [Member]        
Related Party Transaction [Line Items]        
Total $ 51,074 $ 86,083
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 02, 2022
Jul. 13, 2021
Apr. 16, 2021
Mar. 24, 2021
Mar. 21, 2021
Aug. 28, 2020
Jul. 10, 2020
Mar. 31, 2022
Jan. 31, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Related Party Transaction [Line Items]                          
Preferred Stock, Shares Authorized                     10,000,000   10,000,000
ShareBased Compensation Expense                     $ 135,000    
Series E Preferred Stock [Member]                          
Related Party Transaction [Line Items]                          
Preferred stock redemption price per share         2,000                
Preferred Stock, Shares Authorized     2,000               3,000   3,000
Number of redeemed shares issued       3,000                  
Series C Preferred Stock [Member]                          
Related Party Transaction [Line Items]                          
Preferred Stock, Shares Authorized                     50,000   50,000
Series D Preferred Stock [Member]                          
Related Party Transaction [Line Items]                          
Preferred Stock, Shares Authorized                     4,570   4,570
Employment Agreement [Member]                          
Related Party Transaction [Line Items]                          
Amount of initial annual compensation $ 240,000                        
Definitive Agreement [Member] | Series C Preferred Stock [Member]                          
Related Party Transaction [Line Items]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award   47,500                      
Stock purchase, value   $ 11,250,000                      
Definitive Agreement [Member] | Series D Preferred Stock [Member]                          
Related Party Transaction [Line Items]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award   18,667                      
Mr Conway [Member]                          
Related Party Transaction [Line Items]                          
Preferred stock redemption price per share     1,050   1,800         1,050   2,850  
Number of redeemed shares issued                       1,000  
ShareBased Compensation Expense                   $ 1,050,000   $ 2,850,000  
Mr Conway [Member] | Series D Preferred Stock [Member]                          
Related Party Transaction [Line Items]                          
Preferred stock redemption price per share           1,333              
Mr Conway [Member] | Employment Agreement [Member]                          
Related Party Transaction [Line Items]                          
Amount of initial annual compensation $ 250,000                        
Per Month [Member] | Mr Conway [Member]                          
Related Party Transaction [Line Items]                          
Compensation value             $ 20,000   $ 20,000        
Officers compensation received             $ 10,000 $ 20,000          
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Details Narrative)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 14, 2022
$ / shares
shares
Sep. 02, 2021
USD ($)
Sep. 01, 2021
USD ($)
Apr. 16, 2021
USD ($)
Apr. 13, 2021
USD ($)
Mar. 30, 2021
USD ($)
$ / shares
shares
Mar. 15, 2021
USD ($)
$ / shares
shares
Feb. 26, 2021
shares
Jan. 22, 2021
$ / shares
shares
Jan. 14, 2021
USD ($)
$ / shares
Jan. 14, 2021
USD ($)
$ / shares
shares
Jan. 06, 2021
USD ($)
$ / shares
shares
Jan. 02, 2021
USD ($)
ft²
$ / shares
shares
Sep. 02, 2020
USD ($)
Sep. 30, 2021
USD ($)
shares
Jun. 30, 2022
USD ($)
shares
Mar. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
$ / shares
Jun. 30, 2022
USD ($)
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Mar. 04, 2019
USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Cash payments                                 $ 25,000          
Issuance of common stock | shares                               637,755     637,755      
Share Based Compensation Expense                                     $ 135,000      
Notes payable                               $ 17,600,555     17,600,555   $ 13,400,730  
PCTI [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Notes payable                               134,681     134,681   $ 151,469  
Restricted Stock [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Number of restricted shares issued | shares                 10,000,000                          
Shares issued, price per share | $ / shares                 $ 0.0056                          
Share Based Compensation Expense                                       $ 56,000    
PJN Strategies [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Consulting expense     $ 84,000   $ 20,000                     252,000     504,000      
Rubenstein Public Relations, Inc. [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Consulting expense       $ 17,000                                    
Co-Directors of Sales [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Shares issued, price per share | $ / shares $ 0.027                                          
Annual salary           $ 130,000                                
Accrued bonus           $ 20,000                                
Number of shares issued, shares | shares 2,500,000                                          
Co-Directors of Sales [Member] | Restricted Stock [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Shares issued, price per share | $ / shares           $ 0.092                                
Number of shares issued, shares | shares           2,500,000                                
Share Based Compensation Expense                                       460,000    
Christopher Ruppel [Member] | April 1, 2021 [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Professional fees                                     10,000      
Christopher Ruppel [Member] | Restricted Stock [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Number of restricted shares issued | shares                                         10,000,000  
Shares issued, price per share | $ / shares                                         $ 0.2386  
Professional fees                                         $ 2,500  
Share Based Compensation Expense                                       2,386,000    
Professional fees                                   $ 10,000   12,500    
Ezra Green [Member] | Restricted Stock [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Shares issued, price per share | $ / shares                       $ 0.0076                    
Consulting expense                               30,000   30,000 34,500 60,000    
Share Based Compensation Expense                                     1,249 $ 36,348    
Professional fees                       $ 2,500                    
Due to officers or stockholders                       10,000                    
Deferred compensation equity                       $ 76,000                    
Garage Storage Facility [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Lease term                         10 years                  
Land subject to ground leases | ft²                         2,500                  
Number of restricted shares issued | shares                         100,000,000                  
Shares issued, price per share | $ / shares                         $ 0.0063                  
Prepaid expense                         $ 630,000                  
Shares issued for lease agreement, shares | shares                         100,000,000                  
RMA Agreement [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Number of restricted shares issued | shares                             452,080              
Professional fees   $ 50,000                                        
Number of restricted stock issued, value   $ 50,000                                        
Payments of stock issuance costs                             $ 25,000              
Consulting Agreement [Member] | Restricted Stock [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Number of shares issued, shares | shares                                       45,000,000    
Consulting Agreement [Member] | Mr Steven Martello [Member] | Aurora Enterprises [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Number of restricted shares issued | shares             5,000,000                              
Shares issued, price per share | $ / shares             $ 0.1392                              
Consulting expense                               30,000     60,000      
Legal fees             $ 10,000                              
Stock Issued During Period, Shares, New Issues             $ 696,000                              
Consulting Agreement [Member] | Mr Allen Sosis [Member] | Restricted Stock [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Number of restricted shares issued | shares                     5,000,000                      
Shares issued, price per share | $ / shares                   $ 0.20 $ 0.20                      
Consulting expense                                   $ 30,000   $ 75,500    
Due to officers or stockholders                   $ 15,000 $ 15,000                      
Accrued employee benefits, current                   1,000 1,000                      
Deferred compensation equity                   1,000,000 $ 1,000,000                      
Salary                   $ 15,000                        
Consulting Agreement [Member] | Ezra Green [Member] | Restricted Stock [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Number of restricted shares issued | shares                       10,000,000                    
Seperation Agreement [Member] | Salman J. Chaudhry [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Due to officers or stockholders, current                                           $ 227,200
Notes payable                               $ 162,085     $ 162,085   $ 162,085  
Exchange Agreement [Member] | PCTI [Member]                                            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                            
Shares issued, price per share | $ / shares                                   $ 0.094   $ 0.094    
Professional fees                           $ 750,000                
Collaborative arrangement, rights and obligations                           PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement                
Number of common stock exchanged | shares               175,000,000                            
Royalty percentage               1.80%                            
Payments of debt restructuring costs                                       $ 16,450,000    
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 04, 2022
Oct. 14, 2021
Jul. 13, 2021
Apr. 16, 2021
Mar. 24, 2021
Mar. 21, 2021
Mar. 02, 2021
Aug. 28, 2020
Jul. 10, 2020
Jul. 10, 2020
Jul. 07, 2020
Jul. 28, 2021
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Jul. 27, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Debt instrument principal                         $ 760,550   $ 760,550    
Debt instrument, accrued interest                             $ 201,905    
Debt conversion, converted instrument, shares issued                             483,154,618    
Debt instrument, convertible, conversion price                         $ 0.002   $ 0.002    
Purchase of warrants                         405,797,987   405,797,987    
Common stock shares authorized                           4,990,000,000   4,990,000,000  
Common stock par value                           $ 0.001   $ 0.001  
Common Stock, Shares, Issued                           4,622,362,977   4,617,362,977  
Common Stock, Shares outstanding                           4,622,362,977   4,617,362,977  
Preferred stock, shares authorized                           10,000,000   10,000,000  
Preferred stock Par value                           $ 0.001   $ 0.001  
Stock based compensation                           $ 135,000      
Mr Conway [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares       1,050   1,800             1,050   2,850    
Stock based compensation                         $ 1,050,000   $ 2,850,000    
Number of stock redeemed                             1,000    
Series C Preferred Stock [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Preferred stock, shares authorized                           50,000   50,000  
Preferred stock Par value                           $ 0.001   $ 0.001  
Preferred stock shares outstanding                           2,500   2,500  
Preferred stock shares issued                           2,500   2,500  
Series D Preferred Stock [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Preferred stock, shares authorized                           4,570   4,570  
Preferred stock Par value                           $ 0.001   $ 0.001  
Preferred stock shares outstanding                           1,334   1,334  
Preferred stock shares issued                           1,334   1,334  
Series D Preferred Stock [Member] | Mr Conway [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares               1,333                  
Series E Preferred Stock [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares           2,000                      
Preferred stock, shares authorized       2,000                   3,000   3,000  
Preferred stock Par value                           $ 0.001   $ 0.001  
Preferred stock shares outstanding                           0   0  
Preferred stock shares issued                           0   0  
Number of stock redeemed         3,000                        
Series E Preferred Stock [Member] | Mr. Convay [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares       2,000     1,800                    
Preferred stock redemption price per share       $ 1,000     $ 1,000                    
Stock based compensation                         $ 2,000,000   $ 2,000,000    
Shares granted       1,050                          
Series E Preferred Stock [Member] | Third-Party [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares             200                    
Series E Preferred Stock [Member] | Chis [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares                   500              
Chis [Member] | Series C Preferred Stock [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of purchased shares     47,500                            
Chis [Member] | Series D Preferred Stock [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of purchased shares     18,667                            
Restructuring Agreement [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Deferred compensation shares issued                             175,000,000    
Registration Statement [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares   30,000,000                              
Registration Statement [Member] | Common Stock [Member] | GHS Investments [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares 200,000,000                                
Debt Instrument, Maturity Date Oct. 04, 2022                                
Certificates of Designation [Member] | Series C Preferred Stock [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Preferred stock, shares authorized                     50,000            
Preferred stock, voting rights                     The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote            
Certificates of Designation [Member] | Series E Preferred Stock [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Preferred stock, shares authorized                     3,000            
Preferred stock, redemption amount                     $ 1,000            
Securities Purchase Agreement [Member] | PCTI [Member] | Series C Preferred Stock [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares                 47,500                
Securities Purchase Agreement [Member] | PCTI [Member] | Series D Preferred Stock [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares                 18,667                
Series D Amendment [Member] | Series D Preferred Stock [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Preferred stock, shares authorized                                 4,570
Preferred Stock, Convertible, Conversion Price                                 $ 1.5
Series DSPA [Member] | Series D Preferred Stock [Member] | Investor [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Purchase of warrants                       3,236          
Proceeds from Issuance of Preferred Stock and Preference Stock                       $ 13,200,000          
Employment Agreement [Member] | Series E Preferred Stock [Member] | Conway [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares               500                  
Restricted Stock [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Stock based compensation                             $ 56,000    
Restricted Stock [Member] | Lease Agreement [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares                           5,000,000 100,000,000    
Restricted Stock [Member] | Consulting Agreement [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Number of shares issued, shares                             45,000,000    
Warrant [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Warrants term                           15 years      
Warrant exercise                           162      
Warrant exercise, description                           During every 1 (one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034 and until the Termination Date      
Remaining Warrant Shares [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Warrant exercise                           3,074      
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
NONCONTROLLING INTEREST (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2022
Jun. 30, 2021
Aug. 19, 2021
Noncontrolling interest loss $ 351,835 $ 734,912    
Noncontrolling interest 172,399 360,107  
Accumulative noncontrolling interest $ 615,212 $ 615,212    
Brian Conway [Member]        
Noncontrolling interest percentage       51.00%
PJN Strategies [Member]        
Noncontrolling interest percentage       49.00%
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF RIGHT-OF-USE ASSETS (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Operating Lease Right-of-use Assets And Operating Lease Liabilities    
Office and warehouse lease $ 888,026  
Less: Accumulated Amortization (281,498)  
Right-of-use asset, net $ 606,078 $ 707,686
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF OPERATING LEASE LIABILITIES (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Operating Lease Right-of-use Assets And Operating Lease Liabilities    
Lease liability $ 614,247  
Less current portion (161,048) $ (194,366)
Long term portion $ 453,199 $ 517,890
XML 65 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)
Jun. 30, 2022
USD ($)
Operating Lease Right-of-use Assets And Operating Lease Liabilities  
For the year ended December 31, 2022 $ 117,788
For the year ended December 31, 2023 167,858
For the year ended December 31, 2024 171,840
For the year ended December 31, 2025 175,942
For the year ended December 31, 2026 74,030
Total 707,458
Less present value discount (93,211)
Lease liability $ 614,247
XML 66 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative)
6 Months Ended 12 Months Ended
Apr. 14, 2021
USD ($)
ft²
Jun. 30, 2022
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
Lease expiration date   Nov. 30, 2022    
Operating lease disount rate   7.50%    
Operating lease rent expense     $ 84,278  
Operating lease liability   $ 614,247    
RIght of use of asset   $ 606,078   $ 707,686
Operating lease term 5 years      
Area of land | ft² 8,100      
Thereafter [Member]        
Lease payments increase percentage 2.40%      
CANADA        
Lease expiration date May 31, 2026      
Operating lease payments $ 13,148      
Lease payments increase percentage 7.50%      
Accounting Standards Update 2016-02 [Member]        
Operating lease liability     185,139 702,888
RIght of use of asset     $ 185,139 $ 702,888
XML 67 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSEQUENT EVENTS (Details Narrative) - Securities Purchase Agreement [Member] - GHS Investments LLC [Member] - Common Stock [Member] - USD ($)
Aug. 10, 2022
Aug. 04, 2022
Aug. 01, 2022
Jul. 15, 2022
Apr. 04, 2022
Subsequent Event [Line Items]          
Stock issued during the period, shares         200,000,000
Subsequent Event [Member]          
Subsequent Event [Line Items]          
Stock issued during the period, shares 18,063,649 8,136,272 7,675,221 15,353,952  
Price per share $ 0.01088 $ 0.010965 $ 0.010965 $ 0.010285  
Stock issued during the period $ 191,577 $ 86,405 $ 81,451 $ 152,732  
Brokerage fees $ 4,956 $ 2,809 $ 2,708 $ 5,183  
XML 68 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001679817 2022-01-01 2022-06-30 0001679817 2022-08-12 0001679817 2022-06-30 0001679817 2021-12-31 0001679817 us-gaap:SeriesDPreferredStockMember 2022-06-30 0001679817 us-gaap:SeriesDPreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesEPreferredStockMember 2022-06-30 0001679817 us-gaap:SeriesEPreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesCPreferredStockMember 2022-06-30 0001679817 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001679817 2022-04-01 2022-06-30 0001679817 2021-04-01 2021-06-30 0001679817 2021-01-01 2021-06-30 0001679817 OZSC:CommonStockToBeIssuedMember 2021-12-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001679817 us-gaap:CommonStockMember 2021-12-31 0001679817 us-gaap:TreasuryStockMember 2021-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001679817 us-gaap:RetainedEarningsMember 2021-12-31 0001679817 us-gaap:NoncontrollingInterestMember 2021-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001679817 us-gaap:CommonStockMember 2022-03-31 0001679817 us-gaap:TreasuryStockMember 2022-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001679817 us-gaap:RetainedEarningsMember 2022-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2022-03-31 0001679817 2022-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2020-12-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001679817 us-gaap:CommonStockMember 2020-12-31 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001679817 us-gaap:RetainedEarningsMember 2020-12-31 0001679817 2020-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2021-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001679817 us-gaap:CommonStockMember 2021-03-31 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001679817 us-gaap:RetainedEarningsMember 2021-03-31 0001679817 2021-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-01-01 2022-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001679817 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001679817 2022-01-01 2022-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-04-01 2022-06-30 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001679817 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001679817 us-gaap:TreasuryStockMember 2022-04-01 2022-06-30 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001679817 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001679817 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001679817 OZSC:CommonStockToBeIssuedMember 2021-01-01 2021-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001679817 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001679817 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001679817 2021-01-01 2021-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2021-04-01 2021-06-30 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001679817 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001679817 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001679817 OZSC:CommonStockToBeIssuedMember 2022-06-30 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001679817 us-gaap:CommonStockMember 2022-06-30 0001679817 us-gaap:TreasuryStockMember 2022-06-30 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001679817 us-gaap:RetainedEarningsMember 2022-06-30 0001679817 us-gaap:NoncontrollingInterestMember 2022-06-30 0001679817 OZSC:CommonStockToBeIssuedMember 2021-06-30 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001679817 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001679817 us-gaap:CommonStockMember 2021-06-30 0001679817 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001679817 us-gaap:RetainedEarningsMember 2021-06-30 0001679817 2021-06-30 0001679817 OZSC:PennsylvaniaCorporationMember OZSC:SecuritiesPurchaseAgreementMember 2020-07-01 2020-07-10 0001679817 OZSC:PennsylvaniaCorporationMember us-gaap:SeriesCPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember 2020-07-01 2020-07-10 0001679817 OZSC:PennsylvaniaCorporationMember us-gaap:SeriesDPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember 2020-07-01 2020-07-10 0001679817 OZSC:PennsylvaniaCorporationMember us-gaap:SeriesEPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember 2020-07-01 2020-07-10 0001679817 OZSC:RegistrationStatementMember 2021-10-14 2021-10-14 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember OZSC:SecuritiesPurchaseAgreementMember 2022-04-01 2022-04-04 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember OZSC:SecuritiesPurchaseAgreementMember 2022-07-14 2022-07-15 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember OZSC:SecuritiesPurchaseAgreementMember 2022-07-15 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember OZSC:SecuritiesPurchaseAgreementMember 2022-07-31 2022-08-01 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember OZSC:SecuritiesPurchaseAgreementMember 2022-08-01 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember OZSC:SecuritiesPurchaseAgreementMember 2022-08-03 2022-08-04 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember OZSC:SecuritiesPurchaseAgreementMember 2022-08-04 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember OZSC:SecuritiesPurchaseAgreementMember 2022-08-09 2022-08-10 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember OZSC:SecuritiesPurchaseAgreementMember 2022-08-10 0001679817 OZSC:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001679817 OZSC:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:CustomerAMember 2022-06-30 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:CustomerBMember 2022-06-30 0001679817 OZSC:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerCMember 2022-06-30 0001679817 OZSC:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerDMember 2022-06-30 0001679817 OZSC:CustomerEMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerEMember 2022-06-30 0001679817 OZSC:CustomerFMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerFMember 2022-06-30 0001679817 OZSC:CustomerGMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerGMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:CustomerGMember 2022-06-30 0001679817 OZSC:CustomerHMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerHMember 2022-06-30 0001679817 OZSC:CustomerIMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerIMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:CustomerIMember 2022-06-30 0001679817 OZSC:CustomerJMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:CustomerJMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:CustomerJMember 2022-06-30 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001679817 OZSC:SuppliersTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001679817 OZSC:SuppliersThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-04-01 2022-06-30 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:SuppliersTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:SuppliersThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:SuppliersFourMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:SuppliersTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:SuppliersTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:SuppliersThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2021-06-30 0001679817 OZSC:SuppliersThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 OZSC:TwoVendorMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:DownPaymentMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:ShipmentMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:NoSuppliersMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-06-30 0001679817 OZSC:DownPaymentMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-06-30 0001679817 srt:MinimumMember OZSC:OfficeFurnitureAndEquipmentMember 2022-01-01 2022-06-30 0001679817 srt:MaximumMember OZSC:OfficeFurnitureAndEquipmentMember 2022-01-01 2022-06-30 0001679817 OZSC:WarehouseEquipmentMember 2022-01-01 2022-06-30 0001679817 OZSC:SourcedAndDistributedProductsMember 2022-04-01 2022-06-30 0001679817 OZSC:SourcedAndDistributedProductsMember 2021-04-01 2021-06-30 0001679817 OZSC:SourcedAndDistributedProductsMember 2022-01-01 2022-06-30 0001679817 OZSC:SourcedAndDistributedProductsMember 2021-01-01 2021-06-30 0001679817 OZSC:ManufacturedProductsMember 2022-04-01 2022-06-30 0001679817 OZSC:ManufacturedProductsMember 2021-04-01 2021-06-30 0001679817 OZSC:ManufacturedProductsMember 2022-01-01 2022-06-30 0001679817 OZSC:ManufacturedProductsMember 2021-01-01 2021-06-30 0001679817 OZSC:OEDInstallationsMember 2022-04-01 2022-06-30 0001679817 OZSC:OEDInstallationsMember 2021-04-01 2021-06-30 0001679817 OZSC:OEDInstallationsMember 2022-01-01 2022-06-30 0001679817 OZSC:OEDInstallationsMember 2021-01-01 2021-06-30 0001679817 us-gaap:FairValueInputsLevel1Member 2022-06-30 0001679817 us-gaap:FairValueInputsLevel2Member 2022-06-30 0001679817 us-gaap:FairValueInputsLevel3Member 2022-06-30 0001679817 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001679817 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001679817 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001679817 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-06-30 0001679817 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-06-30 0001679817 OZSC:UnexercisedCommonStockPurchaseWarrantsMember 2022-01-01 2022-06-30 0001679817 OZSC:UnexercisedCommonStockPurchaseWarrantsMember 2021-01-01 2021-06-30 0001679817 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-06-30 0001679817 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-06-30 0001679817 OZSC:PromissoryNotePayableMember 2022-01-01 2022-06-30 0001679817 OZSC:PromissoryNotePayableMember 2021-01-01 2021-06-30 0001679817 us-gaap:OfficeEquipmentMember 2022-06-30 0001679817 us-gaap:OfficeEquipmentMember 2021-12-31 0001679817 OZSC:FifteenPercentPromissoryNoteMember 2022-06-30 0001679817 OZSC:FifteenPercentPromissoryNoteMember 2021-12-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-06-30 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001679817 us-gaap:MeasurementInputOptionVolatilityMember 2022-06-30 0001679817 us-gaap:MeasurementInputOptionVolatilityMember 2021-12-31 0001679817 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-06-30 0001679817 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-06-30 0001679817 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001679817 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001679817 srt:MinimumMember us-gaap:MeasurementInputOptionVolatilityMember 2022-06-30 0001679817 srt:MaximumMember us-gaap:MeasurementInputOptionVolatilityMember 2022-06-30 0001679817 srt:MinimumMember us-gaap:MeasurementInputOptionVolatilityMember 2021-12-31 0001679817 srt:MaximumMember us-gaap:MeasurementInputOptionVolatilityMember 2021-12-31 0001679817 srt:MinimumMember us-gaap:MeasurementInputExercisePriceMember 2022-06-30 0001679817 srt:MaximumMember us-gaap:MeasurementInputExercisePriceMember 2022-06-30 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2021-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2021-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2022-01-01 2022-06-30 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2022-01-01 2022-06-30 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2022-06-30 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2022-06-30 0001679817 OZSC:NotePayableMember 2022-06-30 0001679817 OZSC:NotePayableMember 2021-12-31 0001679817 OZSC:NotePayableOneMember 2022-06-30 0001679817 OZSC:NotePayableOneMember 2021-12-31 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2022-06-30 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2021-12-31 0001679817 OZSC:PaycheckProtectionProgramloanMember 2022-06-30 0001679817 OZSC:PaycheckProtectionProgramloanMember 2021-12-31 0001679817 OZSC:NotePayableTwoMember 2022-06-30 0001679817 OZSC:NotePayableTwoMember 2021-12-31 0001679817 OZSC:OtherMember 2022-06-30 0001679817 OZSC:OtherMember 2021-12-31 0001679817 OZSC:NotePayableThreeMember 2022-06-30 0001679817 OZSC:NotePayableThreeMember 2021-12-31 0001679817 OZSC:NotePayableFourMember 2022-06-30 0001679817 OZSC:NotePayableFourMember 2021-12-31 0001679817 OZSC:NotePayableFiveMember 2022-06-30 0001679817 OZSC:NotePayableFiveMember 2021-12-31 0001679817 OZSC:NotePayableSixMember 2022-06-30 0001679817 OZSC:NotePayableSixMember 2021-12-31 0001679817 OZSC:NotePayableSevenMember 2022-06-30 0001679817 OZSC:NotePayableSevenMember 2021-12-31 0001679817 OZSC:NotePayableEightMember 2022-06-30 0001679817 OZSC:NotePayableEightMember 2021-12-31 0001679817 OZSC:NotePayableMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableOneMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableOneMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableTwoMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableTwoMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableThreeMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableThreeMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableFourMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableFourMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableFiveMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableFiveMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableSixMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableSixMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableSevenMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableSevenMember 2021-01-01 2021-12-31 0001679817 OZSC:NotePayableEightMember 2022-01-01 2022-06-30 0001679817 OZSC:NotePayableEightMember 2021-01-01 2021-12-31 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-07 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-05 2021-12-07 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-12 2021-12-13 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2022-01-01 2022-06-30 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2022-06-30 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-03-17 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-03-16 2021-03-17 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-03-22 2021-03-23 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2022-01-01 2022-06-30 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-01-01 2022-06-30 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-06-30 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2022-06-30 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-02-09 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-02-08 2021-02-09 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-02-15 2021-02-16 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2022-01-01 2022-06-30 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-01-01 2022-06-30 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-06-30 0001679817 OZSC:LendersMember OZSC:PromissoryNoteOneMember 2022-06-30 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2022-06-30 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-13 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-12 2020-11-13 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-17 2020-11-20 0001679817 OZSC:HolderMember 2022-06-30 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2022-06-30 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-06 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-05 2020-11-06 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-07-23 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-07-20 2020-07-23 0001679817 2016-10-26 0001679817 OZSC:PCTIMember 2022-06-30 0001679817 OZSC:PCTIMember 2021-12-31 0001679817 2021-03-15 0001679817 OZSC:PromissoryNoteMember us-gaap:PrimeRateMember 2021-03-15 0001679817 srt:MaximumMember OZSC:PromissoryNoteMember 2021-03-15 0001679817 OZSC:PersonalGuaranteeOfChisMember OZSC:PCTIMember 2021-12-31 0001679817 OZSC:PersonalGuaranteeOfChisMember OZSC:PCTIMember 2020-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-08-24 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-08-23 2020-08-24 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-08-22 2020-08-25 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember OZSC:NineInstalmentsMember 2021-01-01 2021-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember OZSC:NineInstalmentsMember 2020-08-23 2020-08-24 0001679817 OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:PromissoryNoteMember 2022-06-30 0001679817 OZSC:PromissoryNoteMember 2021-05-03 0001679817 OZSC:PaycheckProtectionProgramMember 2020-04-20 0001679817 OZSC:PaycheckProtectionProgramMember 2020-04-19 2020-04-20 0001679817 OZSC:PaycheckProtectionProgramMember 2022-06-30 0001679817 OZSC:PaycheckProtectionProgramMember 2021-12-31 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2020-07-11 2020-07-14 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2022-06-30 0001679817 OZSC:EconomicInjuryDisasterLoanMember 2021-12-31 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2020-09-02 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2020-08-30 2020-09-02 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2021-02-25 2021-02-26 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2021-06-30 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2021-01-01 2021-06-30 0001679817 2020-01-01 2020-12-31 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2020-07-01 2020-07-10 0001679817 OZSC:MrConwayMember OZSC:EmploymentAgreementMember 2021-12-29 2022-01-02 0001679817 OZSC:EmploymentAgreementMember 2021-12-29 2022-01-02 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2022-01-01 2022-01-31 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2022-03-01 2022-03-31 0001679817 us-gaap:SeriesEPreferredStockMember 2021-03-20 2021-03-21 0001679817 OZSC:MrConwayMember 2021-03-20 2021-03-21 0001679817 us-gaap:SeriesEPreferredStockMember 2021-04-16 0001679817 OZSC:MrConwayMember 2021-04-15 2021-04-16 0001679817 OZSC:MrConwayMember 2021-04-01 2021-06-30 0001679817 OZSC:MrConwayMember 2021-01-01 2021-06-30 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:DefinitiveAgreementMember 2021-07-12 2021-07-13 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:DefinitiveAgreementMember 2021-07-12 2021-07-13 0001679817 srt:ChiefExecutiveOfficerMember 2022-04-01 2022-06-30 0001679817 srt:ChiefExecutiveOfficerMember 2021-04-01 2021-06-30 0001679817 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-06-30 0001679817 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-06-30 0001679817 OZSC:ChiefExecutiveOfficerSeriesEPreferredStockMember 2022-04-01 2022-06-30 0001679817 OZSC:ChiefExecutiveOfficerSeriesEPreferredStockMember 2021-04-01 2021-06-30 0001679817 OZSC:ChiefExecutiveOfficerSeriesEPreferredStockMember 2022-01-01 2022-06-30 0001679817 OZSC:ChiefExecutiveOfficerSeriesEPreferredStockMember 2021-01-01 2021-06-30 0001679817 OZSC:PresidentSubsidiaryMember 2022-04-01 2022-06-30 0001679817 OZSC:PresidentSubsidiaryMember 2021-04-01 2021-06-30 0001679817 OZSC:PresidentSubsidiaryMember 2022-01-01 2022-06-30 0001679817 OZSC:PresidentSubsidiaryMember 2021-01-01 2021-06-30 0001679817 OZSC:GarageStorageFacilityMember 2021-01-02 0001679817 OZSC:GarageStorageFacilityMember 2021-01-01 2021-01-02 0001679817 OZSC:RMAAgreementMember 2021-08-28 2021-09-02 0001679817 OZSC:RMAAgreementMember 2021-09-03 2021-09-30 0001679817 OZSC:PJNStrategiesMember 2021-04-12 2021-04-13 0001679817 OZSC:PJNStrategiesMember 2021-08-30 2021-09-01 0001679817 OZSC:PJNStrategiesMember 2022-04-01 2022-06-30 0001679817 OZSC:PJNStrategiesMember 2022-01-01 2022-06-30 0001679817 OZSC:RubensteinPublicRelationsMember 2021-04-15 2021-04-16 0001679817 OZSC:CoDirectorsOfSalesMember 2021-03-29 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-03-29 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001679817 OZSC:CoDirectorsOfSalesMember 2022-01-01 2022-01-14 0001679817 OZSC:CoDirectorsOfSalesMember 2022-01-14 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2021-03-14 2021-03-15 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2021-03-15 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2022-04-01 2022-06-30 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2022-01-01 2022-06-30 0001679817 OZSC:ChristopherRuppelMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001679817 OZSC:ChristopherRuppelMember us-gaap:RestrictedStockMember 2021-12-31 0001679817 OZSC:ChristopherRuppelMember us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001679817 OZSC:ChristopherRuppelMember OZSC:AprilOneTwoThousandAndTwentyOneMember 2022-01-01 2022-06-30 0001679817 OZSC:ChristopherRuppelMember us-gaap:RestrictedStockMember 2021-04-01 2021-06-30 0001679817 us-gaap:RestrictedStockMember 2021-01-21 2021-01-22 0001679817 us-gaap:RestrictedStockMember 2021-01-22 0001679817 us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-14 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-13 2021-01-14 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-04-01 2021-06-30 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-01 2021-06-30 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-14 2021-01-14 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-05 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-01-05 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-04-01 2021-06-30 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2022-04-01 2022-06-30 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember 2019-03-04 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember 2022-06-30 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember 2021-12-31 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2020-09-01 2020-09-02 0001679817 us-gaap:RestrictedStockMember OZSC:LeaseAgreementMember 2022-01-01 2022-06-30 0001679817 us-gaap:RestrictedStockMember OZSC:LeaseAgreementMember 2021-01-01 2021-06-30 0001679817 OZSC:RestructuringAgreementMember 2021-01-01 2021-06-30 0001679817 us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-01 2021-06-30 0001679817 us-gaap:CommonStockMember OZSC:RegistrationStatementMember OZSC:GHSInvestmentsMember 2022-04-01 2022-04-04 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-07 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-06 2020-07-07 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember OZSC:PCTIMember 2020-07-06 2020-07-10 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:ChisMember 2021-07-01 2021-07-13 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:SecuritiesPurchaseAgreementMember OZSC:PCTIMember 2020-07-06 2020-07-10 0001679817 OZSC:MrConwayMember us-gaap:SeriesDPreferredStockMember 2020-08-27 2020-08-28 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:ChisMember 2021-07-01 2021-07-13 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:SeriesDAmendmentMember 2021-07-27 0001679817 us-gaap:InvestorMember us-gaap:SeriesDPreferredStockMember OZSC:SeriesDSPAMember 2021-07-01 2021-07-28 0001679817 us-gaap:InvestorMember us-gaap:SeriesDPreferredStockMember OZSC:SeriesDSPAMember 2021-07-28 0001679817 us-gaap:WarrantMember 2022-06-30 0001679817 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001679817 OZSC:RemainingWarrantSharesMember 2022-01-01 2022-06-30 0001679817 us-gaap:SeriesEPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-07 0001679817 OZSC:ChisMember us-gaap:SeriesEPreferredStockMember 2020-07-09 2020-07-10 0001679817 OZSC:ConwayMember us-gaap:SeriesEPreferredStockMember OZSC:EmploymentAgreementMember 2020-08-27 2020-08-28 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-03-01 2021-03-02 0001679817 OZSC:ThirdPartyMember us-gaap:SeriesEPreferredStockMember 2021-03-01 2021-03-02 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-03-02 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-06-30 0001679817 us-gaap:SeriesEPreferredStockMember 2021-03-22 2021-03-24 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-04-15 2021-04-16 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-04-16 0001679817 OZSC:MrConvayMember us-gaap:SeriesEPreferredStockMember 2021-04-01 2021-06-30 0001679817 OZSC:BrianConwayMember 2021-08-19 0001679817 OZSC:PJNStrategiesMember 2021-08-19 0001679817 us-gaap:AccountingStandardsUpdate201602Member 2020-12-31 0001679817 2021-04-14 0001679817 country:CA 2021-04-11 2021-04-14 0001679817 OZSC:ThereafterMember 2021-04-14 0001679817 country:CA 2021-04-14 0001679817 us-gaap:AccountingStandardsUpdate201602Member 2021-12-31 iso4217:USD shares iso4217:USD shares utr:sqft pure 0001679817 false Q2 --12-31 P5Y P5Y P5Y 10-Q true 2022-06-30 2022 false 000-55976 OZOP ENERGY SOLUTIONS, INC. NV 35-2540672 42 N Main St Florida NY 10921 (845) 544-5112 Yes Yes Non-accelerated Filer true false false 4671592071 1949528 6767167 190142 151998 779682 1299334 1799095 1065982 3212660 874627 7931107 10159108 606078 707686 147714 132889 548908 568249 9233807 11567932 4601813 3246342 25000 25000 17211132 13011307 568313 169849 662185 750000 7589928 20966701 161048 194366 21451 21451 30840870 38385016 389423 389423 453199 517890 14301 25026 31697793 39317355 10000000 10000000 0.001 0.001 50000 50000 2500 2500 2500 2500 0.001 0.001 3 3 4570 4570 1334 1334 1334 1334 0.001 0.001 1 1 3000 3000 0 0 0 0 0.001 0.001 3 3 4990000000 4990000000 0.001 0.001 4622362977 4622362977 4617362977 4617362977 4622363 4617363 637755 637755 638 638 196594222 196464222 11249934 11249934 -211816067 -217326611 -21848774 -27494318 -615212 -255105 -22463986 -27749423 9233807 11567932 4878636 1274033 7960874 2069587 4416460 1214468 7292292 1441377 462177 59565 668583 628210 240000 1461074 630000 3576082 1274287 2898231 2862144 6572693 1514287 4359305 3492144 10148775 -1052111 -4299740 -2823562 -9520565 1427554 4310335 5402775 44965085 9011570 8866819 13376773 -43331083 -468696 -95437587 16450000 7584016 4087788 7973998 -200183755 6531906 -211952 5150437 -209704320 6531906 -211952 5150437 -209704320 -172399 -360107 6704305 -211952 5510544 -209704320 0.00 -0.00 0.00 -0.05 4622362977 4554068582 4621092259 4269239477 637755 638 2500 3 1334 1 4617362977 4617363 -11249934 196464222 -217326611 -255105 -27749423 5000000 5000 130000 135000 -1193761 -187708 -1381469 637755 638 2500 3 1334 1 4622362977 4622363 -11249934 196594222 -218520372 -442813 -28995892 6704305 -172399 6531906 637755 638 2500 3 1334 1 4622362977 4622363 -11249934 196594222 -211816067 -615212 -22463986 50000 50 20000 20 1000 1 3397958292 3397958 -7 12530933 -22278665 -6349710 428747654 428748 97110282 97539030 330797987 330798 38714266 39045064 2000 2 1999998 2000000 -3000 -3 -2999997 -3000000 5000000 5000 20000000 20000 2877000 2902000 100000000 100000 530000 630000 175000000 175000 16275000 16450000 7 -209492368 -209492361 5000000 5000 50000 50 20000 20 4452503933 4452504 167037482 -231771033 -60275977 -5000000 -5000 25000000 25000 1752000 1772000 75000000 75000 8990237 9065237 54406964 54407 4945593 5000000 2000 2 1999998 2000000 -2000 -2 -1999998 -2000000 -211952 -211952 -211952 -211952 50000 50 20000 20 4606910897 4606911 182725312 -231982985 -44650692 5150437 -209704320 4199825 44170200 126784 65388 16450000 -13376773 43331083 -95437587 136249 7965945 -519652 701545 733113 1247913 20053 1290348 2338033 64789 1267656 682845 -10725 -7150 -98009 -46054 398464 117641 -4777639 -4841428 40000 94679 -40000 -94679 12000000 26367 383722 5000000 6589911 -4817639 1653804 6767167 1808476 1949528 3462280 28302 545138 1310000 743555 702888 136249 7965945 630000 16450000 <p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zpvmj8ekOyPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_829_zlmabfdTzY8k">ORGANIZATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ozop Energy Solutions, Inc. (the” Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 10, 2020, the Company entered into a Stock Purchase Agreement (the “SPA”) with Power Conversion Technologies, Inc., a Pennsylvania corporation (“PCTI”), and Catherine Chis (“Chis”), PCTI’s Chief Executive Officer (“CEO”) and its sole shareholder. Under the terms of the SPA, the Company acquired one thousand (<span id="xdx_90E_ecustom--BusinessAcquisitionNumberOfSharesAcquired_c20200701__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PennsylvaniaCorporationMember_z3ApsoFp5b4f" title="Number of shares acquired">1,000</span>) shares of PCTI, which represents all of the outstanding shares of PCTI, from Chis in exchange for the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200701__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PennsylvaniaCorporationMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zNq31S7PVxmd" title="Stock Issued During Period, Shares, Acquisitions">47,500</span> shares of the Company’s Series C Preferred Stock, <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200701__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PennsylvaniaCorporationMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zGUuXxzAYyYa" title="Stock Issued During Period, Shares, Acquisitions">18,667</span> shares of the Company’s Series D Preferred Stock, and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200701__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PennsylvaniaCorporationMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zTHLKrJL9cmi" title="Stock Issued During Period, Shares, Acquisitions">500</span> shares of the Company’s Series E Preferred Stock to Chis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCTI designs, develops, manufactures and distributes standard and custom power electronic solutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 29, 2020, the Company formed a new wholly owned subsidiary, Ozop Surgical Name Change Subsidiary, Inc., a Nevada corporation (“Merger Sub”). The Merger Sub was formed under the Nevada Revised Statutes for the sole purpose and effect of changing the Company’s name to “Ozop Energy Solutions, Inc.” That same day the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with the Merger Sub and filed Articles of Merger (the “Articles of Merger”) with the Nevada Secretary of State, merging the Merger Sub into the Company, which were stamped effective as of November 3, 2020. As permitted by the Section 92.A.180 of the Nevada Revised Statutes, the sole purpose and effect of the filing of Articles of Merger was to change the name of the Company from Ozop Surgical Corp to “Ozop Energy Solutions, Inc.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 11, 2020, the Company formed Ozop Energy Systems, Inc. (“OES”), a Nevada corporation and a wholly owned subsidiary of the Company. OES was formed to be a manufacturer and distributor of renewable energy products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation. The Company is the majority shareholder of Ozop Capital with PJN Holdings LLC (“PJN”), a New York limited liability company, being the minority shareholder. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 29, 2021, EV Insurance Company, Inc. (“EVCO”) was formed as a captive insurance company in the State of Delaware. EVCO is a wholly owned subsidiary of Ozop Capital. On January 7, 2022, EVCO filed with New Castle County, Delaware DBA OZOP Plus.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners are able to offer the resources needed for lighting, solar and electrical design projects. OED will provide customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs. We work with architects, engineers, facility managers, electrical contractors and engineers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1000 47500 18667 500 <p id="xdx_809_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zRx3gptdExMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_828_zIRtKURLUkd9">GOING CONCERN AND MANAGEMENT’S PLANS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2022, the Company had an accumulated deficit of $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20220630_zhh3nkHcAtmh" title="Retained earnings accumulated deficit">211,816,067</span> and a working capital deficit of $<span id="xdx_903_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20220630_zFXzWa2ipKd3">22,909,763</span> (including derivative liabilities of $<span id="xdx_90A_eus-gaap--DerivativeLiabilitiesCurrent_iI_pp0p0_c20220630_zvTI1Vfm6wm4" title="Derivative liabilities current">7,589,928</span>). As of June 30, 2022, the Company was in default of $<span id="xdx_904_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20220630_zcmlGIPMlkxd" title="Debt instrument default amount">15,369,247</span> plus accrued interest on debt instruments due to non-payment upon maturity dates. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date of the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, a novel strain of coronavirus (COVID-19) emerged. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but it may have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management’s Plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a public company, Management believes it will be able to access the public equities market for fund raising for product development, sales and marketing and inventory requirements as we expand our distribution in the U.S. market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is in negotiations with its’ lenders related to the debt instruments that are currently in default, to extend the maturity dates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 14, 2021, the Company received a Notice of effectiveness related to the Company’s Form S-3 Registration Statement (the “Registration Statement”). Pursuant to the Registration Statement the Company may offer and sell from time to time in one or more offerings of up to thirty million dollars ($<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20211014__20211014__us-gaap--TypeOfArrangementAxis__custom--RegistrationStatementMember_zfmbSqXKKekk" title="Shares issued, amount">30,000,000</span>) in aggregate offering price. We may offer these securities in amounts, at prices and on terms determined at the time of offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 4, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220401__20220404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4tW3BcTsRf5" title="Stock issued during the period">200,000,000</span>) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220401__20220404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFiUa9Gclg1i" title="Common stock maturity period">October 4, 2022</span>, at our sole discretion, to GHS under the GHS Purchase Agreement. <span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20220401__20220404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY8A0V9VWx9a" title="Agreement description">The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement</span>. As of the date of this Report the Company has sold the following securities pursuant to this Registration Statement:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 15, 2022, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220714__20220715__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znzkllb1JuM9" title="Stock issued during the period, shares">15,353,952</span> shares to GHS at $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220715__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpQbStdxDI9k" title="Price per share">0.010285</span> and received net proceeds of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220714__20220715__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zveMYh67Vvqi" title="Stock issued during the period">152,732</span>, after deducting transaction and broker fees of $<span id="xdx_907_eus-gaap--FloorBrokerage_c20220714__20220715__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9q0TKNT0Li5" title="Brokerage fees">5,183</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 1, 2022, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220731__20220801__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziu2IIPH0iTl" title="Stock issued during the period, shares">7,675,221</span> shares to GHS at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220801__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxKXPh7zGbHf" title="Price per share">0.010965</span> and received net proceeds of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220731__20220801__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2PZ9d6bMVw1" title="Stock issued during the period">81,451</span>, after deducting transaction and broker fees of $<span id="xdx_90C_eus-gaap--FloorBrokerage_c20220731__20220801__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaoEieL4Y1Di" title="Brokerage fees">2,708</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 4, 2022, the Company sold <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220803__20220804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEmsRyOKt1li" title="Stock issued during the period, shares">8,136,272</span> shares to GHS at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAzAtYssHWLb" title="Price per share">0.010965</span> and received net proceeds of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220803__20220804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEiqyt6lisZg" title="Stock issued during the period">86,405</span>, after deducting transaction and broker fees of $<span id="xdx_902_eus-gaap--FloorBrokerage_c20220803__20220804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z44jNbeZzc5h" title="Brokerage fees">2,809</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 10, 2022, the Company sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220809__20220810__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk74iO87whRd" title="Stock issued during the period, shares">18,063,649</span> shares to GHS at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220810__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYKWtLBk7WUf" title="Price per share">0.01088</span> and received net proceeds of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220809__20220810__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za53BssGaHY8" title="Stock issued during the period">191,577</span>, after deducting transaction and broker fees of $<span id="xdx_903_eus-gaap--FloorBrokerage_c20220809__20220810__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7sseOFgb634" title="Brokerage fees">4,956</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OES is actively engaged in the renewable, electric vehicle (“EV”), energy storage and energy resiliency sectors. We are engaged in multiple business lines that include project development as well as equipment distribution. Our solar and energy storage projects involve large-scale battery and solar photovoltaics (PV) installations. Our utility-scale storage business model is based on an arbitrage business model in which we install multiple 1+ megawatt batteries, charge them with off-peak grid electricity under contract with the utility, then sell the power back during peak load hours at a premium, as dictated by prevailing electricity tariffs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ozop Plus plans on marketing vehicle service contracts (“VSC’s”) for electric vehicles (EV’s) that will offer to consumers to be able to purchase additional months and or miles above the manufacturer’s warranty and to also bring added value to EV owners by utilizing our partnerships and strengths in the energy market to offer unique and innovative services. Among EV owners’ concerns are the EV battery repair and replacement costs, range anxiety, environmental responsibilities, roadside assistance, and the accelerated wear on additional components that EV vehicles experience. Management believes that the Ozop Plus marketed VSC’s will give “peace of mind” to the EV buyer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2022, the Company entered into an agreement with GS Administrators, Inc., a member of Houston-based GSFSGroup. Under the agreement, the Company will market GSFSGroup’s EV VSC’s in all states (except, California, Florida, Massachusetts and Washington) to Ozop’s network of new and used franchised dealerships and other eligible entities. In addition to acting as an agent for the marketing, Ozop also has the right to white label the product under its’ Ozop Plus brand. Ozop’s role won’t be limited to marketing the product. GSFSGroup plans to tap into Ozop’s experience relative to battery collection and disposal and has agreed to insurance risk sharing in connection with the insurance policies that back the VSC’s. GSFSGroup is working on getting the approvals needed for the above four (4) states.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 22, 2022, the Company entered into an Agent Agreement with Royal Administration Services, Inc. (“Royal”). Under the agreement, the Company will market Royal’s EV VSC’s and has the right to white label it under Ozop Plus. Royal has agreed to allow Ozop Plus on all VSC’s, marketed by Royal and the Company, to assume all of the risk related to the electric battery at an agreed upon premium. The battery premium is dependent on the consumer’s selection of the duration of the VSC, the miles selected for coverage and the type of vehicle that the consumer has purchased, with a key component being the kWh size of the battery. These VSC’s have a maximum of 10 years and 150,000 miles and cover new and used cars from model year 2017 and newer. During August 2022, Royal will begin the filing process in all 50 states, 30 plus of which are effective upon filing, and the others have various waiting times or approvals needed.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the quarter ended June 30, 2022, OED began operations and generated $16,500 of revenues and currently has six employees in sales, marketing installation and services. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -211816067 22909763 7589928 15369247 30000000 200000000 2022-10-04 The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement 15353952 0.010285 152732 5183 7675221 0.010965 81451 2708 8136272 0.010965 86405 2809 18063649 0.01088 191577 4956 <p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zTBReulHrZw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 – <span id="xdx_82F_zEh9nQDwMCp">SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHI2sPnS8ta8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zvuEsxB8dYBg">Basis of Presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2022, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 10-K/A filed on April 26, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries OED, PCTI, Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”) and the Company’s majority owned subsidiary Ozop Capital Partners, Inc. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--UseOfEstimates_z15k6Oea7Xw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zfyVsP43oHU4">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9fLvVyHKSU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zfe0zjxLtgfc">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has no cash equivalents at June 30, 2022, and December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zJVmoCtCaaag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zjDAqnfvTOWb">Sales Concentration and credit risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three and six months ended June 30, 2022, and 2021, and their accounts receivable balance as of June 30, 2022:</span></p> <p id="xdx_898_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zSHP9T1MF7xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_z3RUGUxldk31" style="display: none">SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three<br/> Months<br/> Ended June<br/> 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Six<br/> Months<br/> Ended June<br/> 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three<br/> Months<br/> Ended June<br/> 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Six <br/> Months<br/> Ended <br/> June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accounts<br/> receivable<br/> balance <br/> June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: justify">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztvNQkJQ49Z" title="Concentration Risk, Percentage">43.5</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zykEO6USazRl" title="Concentration Risk, Percentage">26.7</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> N/A </span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerAMember_zMnRvW2uLHrf" title="Concentration Risk, Percentage">43,920</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zMH8usj6W23b" title="Concentration Risk, Percentage">10.0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEH611VhTo5e" title="Concentration Risk, Percentage">11.4</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmA4e5J1UH69" title="Concentration Risk, Percentage">18.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7W1BIaI5h98" title="Concentration Risk, Percentage">11.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerBMember_z4ngmj3CNhEh" title="Concentration Risk, Percentage">524,759</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zReEfr8MHee1" title="Concentration Risk, Percentage">10.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvroznrPbgcf" title="Concentration Risk, Percentage">13.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerCMember_ziobt9hnHLMg"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhFGC7zYfwF6" title="Concentration Risk, Percentage">13.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerDMember_zeiGvlA994Cj" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer E</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zVa1JTk1geOg" title="Concentration Risk, Percentage">14.9</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerEMember_zC4ZnrhKcMUe" title="Concentration Risk, Percentage">3,835</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer F</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerFMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSvM2h71PtK5">10.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerFMember_zbe3Awb3jlp6" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer G</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerGMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzrtInMLkN3a" title="Concentration Risk, Percentage">18.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerGMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4E6jRHhsdA3" title="Concentration Risk, Percentage">11.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerGMember_zYuCscMQ2GZk" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer H</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerHMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zE4lcCMjSJwb" title="Concentration Risk, Percentage">13.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerHMember_zQ6V3K1JdUJb" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer I</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerIMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoXpAx5kllCk" title="Concentration Risk, Percentage">14.9</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerIMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDTHwC5WgnI3" title="Concentration Risk, Percentage">65.6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerIMember_zUjvvTCquOY4" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer J</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerJMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxFVct97zd29" title="Concentration Risk, Percentage">10.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerJMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zg5C6M0Eg7Mk">13.4</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerJMember_zMQxyCpUfeab" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_zmIARqkrsWGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customers A-F are customers of Ozop Energy Systems Inc. and Customers G- J are customers of PCTI. PCTI, historically does not have year to year many recurring clients as the Company produces customized capital equipment for its’ customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zqFCYRW4W1w2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zljNIriJh3C9">Accounts Receivable</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--InventoryPolicyTextBlock_znLpoJyFuRGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zTM1sDt4OCI5">Inventory</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs include finished goods, material, labor and manufacturing overhead. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zRFsjQBfWa57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of inventories at June 30, 2022, and December 31, 2021, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zyUPnfnSVnNa" style="display: none">SCHEDULE OF INVENTORY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220630_zG0plfQER6b5" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20211231_zcAZMOJreuxl" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterials_iI_maCzAkd_maINzA2c_z2wI5UnhWXCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">236,134</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">234,168</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maCzAkd_maINzA2c_zilEnvS8qyN3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,704</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maCzAkd_maINzA2c_z579GAAM2Bpg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,562,961</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">788,110</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pp0p0_mtINzA2c_zdKT54ms1Ugi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,799,095</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,065,982</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_z2ceFf6pQqIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_ecustom--PurchaseConcentrationPolicyTextBlock_zvA65ZJPpcog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_znyEPeXXDVBb">Purchase concentration</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OES purchases finished renewable energy products from its’ suppliers. For the three months ended June 30, 2022, there were three suppliers that accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zPoYOhuYv5D2" title="Concentration of credit risk">41.3</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zwRhFNPIIs52" title="Concentration of credit risk">23.3</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--SuppliersThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_ziiflkYa1HG5" title="Concentration of credit risk">19.7</span>%, respectively, and for the six months ended June 30, 2022, there were four suppliers that accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z11H6IzEeEtg" title="Concentration of credit risk">38.0</span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zMimKdFP5lMl" title="Concentration of credit risk">15.9</span>%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--SuppliersThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zTBbOo3QtZb4" title="Concentration of credit risk">15.6</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--SuppliersFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zaBXHDYpWxq6" title="Concentration of credit risk">11.2</span>%, respectively. For the three and six months ended June 30, 2021, there were three suppliers that accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zPHyizkDTvPf" title="Concentration of credit risk"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zYe09mr0Esgf" title="Concentration of credit risk">29.6</span></span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zNghMVggBr6f" title="Concentration of credit risk"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_znbC1urePSba" title="Concentration of credit risk">21.8</span></span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--SuppliersThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zA0Wqw0MTFF6" title="Concentration of credit risk"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--SuppliersThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zb82wFEJZBCk" title="Concentration of credit risk">12.7</span></span>%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--TwoVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zzcWImCIP2Qb" title="Concentration of credit risk">20</span>% down payment with the <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--DownPaymentMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z9Mo0SXrwvTc" title="Concentration of credit risk">30</span>% balances due on shipment and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--ShipmentMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zLaPJ7OfP815" title="Concentration of credit risk">50</span>% due prior to delivery, while other vendors terms are due in full immediately prior to delivery. We also buy product from other distributors, if we are not able to purchase direct from the manufacturer. While management believes all of its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The principal purchases by PCTI are comprised of parts and raw materials that PCTI assembles and manufactures and sells to its customers. There were no suppliers who accounted for more than ten percent (<span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--NoSuppliersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zA1tZ20UGAqh" title="Concentration of credit risk"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--DownPaymentMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zht1h1CVEENg" title="Concentration of credit risk">10</span></span>%) of PCTI’s purchases for the three and six months ended June 30, 2022, and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8f7d9MYVgO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zIhQXUjGrzhh">Property, plant and equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:</span></p> <p id="xdx_89A_ecustom--ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock_zBE5ObmdYCu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zUpUVB1L7iVe" style="display: none">SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zmzuruJClLD4" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zuzcHjkvFxz7" title="Property, Plant and Equipment, Useful Life">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warehouse equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_zfTHuQGLBxs1" title="Property, Plant and Equipment, Useful Life">7</span> years</span></td></tr> </table> <p id="xdx_8A6_zaD9LMiFRX2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zMUviWbzDUXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zTGJrRxrBX7b">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Advance payments are typically required for commercial customers and are recorded as current liability until revenue is recognized. Advance payments are not required for government customers. The majority of contracts typically require payment within 30 to 60 days after transfer of ownership to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--DisaggregationOfRevenueTableTextBlock_znQvIkzHri92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates our revenue by major source for the three and six months ended June 30, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none"><span id="xdx_8B8_ztKb9ZtCGDMf" style="display: none">DISAGGREGATION OF REVENUE</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220401__20220630_z5o3Yso2ALGk" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210401__20210630_zZCyihiFt5H8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220630_zCtMKlQCD1G5" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20210630_zYV9eCZyAB6f" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SourcedAndDistributedProductsMember_zsmPHdILsWJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Sourced and distributed products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4,749,377</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,254,982</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">7,668,699</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,254,982</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ManufacturedProductsMember_z1OIhHb5inX6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufactured products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,759</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,051</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">275,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">814,605</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OEDInstallationsMember_zE39HJj25Jt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">OED Installations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zJslrMmzzerh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,878,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,274,033</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,960,874</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,069,587</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_z6QUTKCNCg4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company brings the finished goods into our California warehouse to fill orders as well as to build inventory for future sales orders. From time to time for some of our larger orders we may have our suppliers ship directly to our customers to avoid extra shipping charges. For manufactured products, there is usually a bidding process by branches of the military or other large firms that need mostly battery charging and storage systems for large industrial projects. We would then purchase the raw materials and parts needed to build out the project in our Pennsylvania warehouse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--AdvertisingCostsPolicyTextBlock_zSfnTx9T8Ahj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zA83Ku8Cu5i4">Advertising and Marketing Expenses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses advertising and marketing costs as incurred. For the three and six months ended June 30, 2022, the Company recorded advertising and marketing expenses of $<span id="xdx_900_eus-gaap--MarketingAndAdvertisingExpense_c20220401__20220630_zUVrp1yjmNja" title="Marketing and Advertising Expense">2,710</span> and $<span id="xdx_90D_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20220630_zDTk7B5VR8Vj" title="Marketing and Advertising Expense">5,973</span>, respectively, and for the three and six months ended June 30, 2021, the Company recorded advertising and marketing expenses of $<span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_c20210401__20210630_z2BHxTnod1sj" title="Marketing and Advertising Expense">5,944</span> and $<span id="xdx_901_eus-gaap--MarketingAndAdvertisingExpense_c20210101__20210630_zKTjtUSzhTS8" title="Marketing and Advertising Expense">28,544</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_z1IbId6UQQ36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z98MA3JhSyyj">Research and Development</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the three and six months ended June 30, 2022, and 2021, the Company did not record any research and development expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--ConvertibleInstrumentsPolicyTextBlock_zlUW0Z0L37Bb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zmmqtKDHUhH1">Convertible Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_840_ecustom--DistinguishingLiabilitiesfromEquityPolicyTextBlock_zBdRMujmswJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zPuGcRgOyGqd">Distinguishing Liabilities from Equity</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company relies on the guidance provided by ASC Topic 480, <i>Distinguishing Liabilities from Equity</i>, to classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our CEO and Chairman holds sufficient shares of the Company’s voting preferred stock that give sufficient voting rights under the articles of incorporation and bylaws of the Company such that the CEO and Chairman can at any time unilaterally vote to increase the number of authorized shares of common stock of the Company, without the need to call a general meeting of common shareholders of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Initial Measurement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records its financial instruments classified as liability, temporary equity or permanent equity at issuance at the fair value, or cash received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subsequent Measurement – Financial Instruments Classified as Liabilities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in fair value of its financial instruments classified as liabilities are recorded as other income (expenses).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zJfnARMCtUi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zWaqOsRPIuQe">Fair Value of Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following are the hierarchical levels of inputs to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to the conversion features within the instrument and that the company has insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_zJPiuezxAoLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of June 30, 2022, and December 31, 2021, for each fair value hierarchy level:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zZknXjOep5y2" style="display: none">SCHEDULE OF DERIVATIVE INSTRUMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">June 30, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative <br/> Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zutJ7nmeK5F7" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1034">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfPvy5vZOM06" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1036">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxxMjXtPKdr" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1038">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWSwqPZyx3v" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1040">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zd1GTOc5FRs7" style="width: 16%; text-align: right" title="Derivative Liabilities">7,589,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAlei98qrkxl" style="width: 16%; text-align: right" title="Total">7,589,928</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative <br/> Liabilities</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level I</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zw5J4QEM5OXj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative Liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGYGWIkqNYeh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level II</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFPaCbg9rZ17" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative Liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCMLdAJZoImc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level III</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOVfLnEA0Cf4" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Derivative Liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,966,701</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVZTOuIDz4rf" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,966,701</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AA_zxZtZtRhXg19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zPLtuxIwTBee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zc8r8m01RUL7">Leases</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for leases under ASU 2016-02 (see Note 14), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of 7.5%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zxqPs9YYd5D6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zwEIuc72oGoe">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has <span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20220630_z0EMaV7vO7nf" title="Unrecognized tax benefits">no</span>t recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zlwF46zVje9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zlcDKgqR2Wd">Segment Policy</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no reportable segments as it operates in one segment; renewable energy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z4wTS825U6X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z7OuOhpCfwa6">Earnings (Loss) Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of June 30, 2022, and 2021, the Company’s dilutive securities are convertible into approximately <span id="xdx_907_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_pid_c20220101__20220630_zpYdOpVeJnN4" title="Dilutive securities common stock, shares">7,689,380,800</span> and <span id="xdx_905_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_c20210101__20210630_zoEUikAaqZDi" title="Dilutive securities common stock, shares">14,418,538,825</span>, respectively, shares of common stock. The following table represents the classes of dilutive securities as of June 30, 2022, and 2021:</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDlHZtcgLjU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zvdo79cMzSvh" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20220630_zd7owWv2ugZ2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210101__20210630_zAuH7K0zi8S8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zrt5pqd2QhDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_F4A_zOLSn9sIiYqc" style="width: 60%; text-align: left">Convertible preferred stock (1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">6,933,544,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">13,820,732,691</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_zksdm5063WD9" style="vertical-align: bottom; background-color: White"> <td id="xdx_F47_zvs0gyls86He" style="text-align: left">Unexercised common stock purchase warrants (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">672,024,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597,024,518</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zfjdfZbtFyBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,520,720</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">781,816</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PromissoryNotePayableMember_z3J8EIMdwBVg" style="vertical-align: bottom; background-color: White"> <td id="xdx_F4A_zJNi81gzqLuj" style="text-align: left; padding-bottom: 1.5pt">Promissory note payable (1)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">81,291,096</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zYfg31doQTdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,689,380,800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">14,418,538,825</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zrxWkLWwbNUl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_z1ZzrYe0oId" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVElESUxVVElWRSBTRUNVUklUSUVTIEVYQ0xVREVEIEZST00gQ09NUFVUQVRJT04gT0YgRUFSTklOR1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c20220101__20220630_zU2PZcEd6vkh" title="Outstanding shares, percentage">4.99%</span> of the then outstanding shares of common stock subsequent to any conversion or exercise.</span></td></tr> </table> <p id="xdx_8A3_z7sBMR2HAOmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zsRSEZp1VDv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zpK6zc06BSW1">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other than the above, there have no recent accounting pronouncements or changes in accounting pronouncements during the period ended March 31, 2022, that are of significance or potential significance to the Company.</span></p> <p id="xdx_85E_z5scDOaPdPGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHI2sPnS8ta8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zvuEsxB8dYBg">Basis of Presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2022, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 10-K/A filed on April 26, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries OED, PCTI, Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”) and the Company’s majority owned subsidiary Ozop Capital Partners, Inc. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--UseOfEstimates_z15k6Oea7Xw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zfyVsP43oHU4">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9fLvVyHKSU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zfe0zjxLtgfc">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has no cash equivalents at June 30, 2022, and December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zJVmoCtCaaag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zjDAqnfvTOWb">Sales Concentration and credit risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three and six months ended June 30, 2022, and 2021, and their accounts receivable balance as of June 30, 2022:</span></p> <p id="xdx_898_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zSHP9T1MF7xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_z3RUGUxldk31" style="display: none">SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three<br/> Months<br/> Ended June<br/> 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Six<br/> Months<br/> Ended June<br/> 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three<br/> Months<br/> Ended June<br/> 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Six <br/> Months<br/> Ended <br/> June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accounts<br/> receivable<br/> balance <br/> June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: justify">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztvNQkJQ49Z" title="Concentration Risk, Percentage">43.5</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zykEO6USazRl" title="Concentration Risk, Percentage">26.7</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> N/A </span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerAMember_zMnRvW2uLHrf" title="Concentration Risk, Percentage">43,920</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zMH8usj6W23b" title="Concentration Risk, Percentage">10.0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEH611VhTo5e" title="Concentration Risk, Percentage">11.4</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmA4e5J1UH69" title="Concentration Risk, Percentage">18.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7W1BIaI5h98" title="Concentration Risk, Percentage">11.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerBMember_z4ngmj3CNhEh" title="Concentration Risk, Percentage">524,759</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zReEfr8MHee1" title="Concentration Risk, Percentage">10.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvroznrPbgcf" title="Concentration Risk, Percentage">13.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerCMember_ziobt9hnHLMg"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhFGC7zYfwF6" title="Concentration Risk, Percentage">13.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerDMember_zeiGvlA994Cj" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer E</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zVa1JTk1geOg" title="Concentration Risk, Percentage">14.9</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerEMember_zC4ZnrhKcMUe" title="Concentration Risk, Percentage">3,835</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer F</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerFMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSvM2h71PtK5">10.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerFMember_zbe3Awb3jlp6" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer G</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerGMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzrtInMLkN3a" title="Concentration Risk, Percentage">18.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerGMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4E6jRHhsdA3" title="Concentration Risk, Percentage">11.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerGMember_zYuCscMQ2GZk" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer H</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerHMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zE4lcCMjSJwb" title="Concentration Risk, Percentage">13.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerHMember_zQ6V3K1JdUJb" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer I</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerIMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoXpAx5kllCk" title="Concentration Risk, Percentage">14.9</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerIMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDTHwC5WgnI3" title="Concentration Risk, Percentage">65.6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerIMember_zUjvvTCquOY4" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer J</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerJMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxFVct97zd29" title="Concentration Risk, Percentage">10.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerJMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zg5C6M0Eg7Mk">13.4</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerJMember_zMQxyCpUfeab" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_zmIARqkrsWGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customers A-F are customers of Ozop Energy Systems Inc. and Customers G- J are customers of PCTI. PCTI, historically does not have year to year many recurring clients as the Company produces customized capital equipment for its’ customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zSHP9T1MF7xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_z3RUGUxldk31" style="display: none">SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three<br/> Months<br/> Ended June<br/> 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Six<br/> Months<br/> Ended June<br/> 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three<br/> Months<br/> Ended June<br/> 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Six <br/> Months<br/> Ended <br/> June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accounts<br/> receivable<br/> balance <br/> June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: justify">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztvNQkJQ49Z" title="Concentration Risk, Percentage">43.5</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zykEO6USazRl" title="Concentration Risk, Percentage">26.7</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> N/A </span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span id="xdx_905_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerAMember_zMnRvW2uLHrf" title="Concentration Risk, Percentage">43,920</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zMH8usj6W23b" title="Concentration Risk, Percentage">10.0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEH611VhTo5e" title="Concentration Risk, Percentage">11.4</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmA4e5J1UH69" title="Concentration Risk, Percentage">18.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7W1BIaI5h98" title="Concentration Risk, Percentage">11.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerBMember_z4ngmj3CNhEh" title="Concentration Risk, Percentage">524,759</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zReEfr8MHee1" title="Concentration Risk, Percentage">10.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvroznrPbgcf" title="Concentration Risk, Percentage">13.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerCMember_ziobt9hnHLMg"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhFGC7zYfwF6" title="Concentration Risk, Percentage">13.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerDMember_zeiGvlA994Cj" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer E</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zVa1JTk1geOg" title="Concentration Risk, Percentage">14.9</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerEMember_zC4ZnrhKcMUe" title="Concentration Risk, Percentage">3,835</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer F</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerFMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSvM2h71PtK5">10.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerFMember_zbe3Awb3jlp6" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer G</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerGMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzrtInMLkN3a" title="Concentration Risk, Percentage">18.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerGMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4E6jRHhsdA3" title="Concentration Risk, Percentage">11.3</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerGMember_zYuCscMQ2GZk" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer H</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerHMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zE4lcCMjSJwb" title="Concentration Risk, Percentage">13.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerHMember_zQ6V3K1JdUJb" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer I</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerIMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoXpAx5kllCk" title="Concentration Risk, Percentage">14.9</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerIMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDTHwC5WgnI3" title="Concentration Risk, Percentage">65.6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerIMember_zUjvvTCquOY4" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer J</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--CustomerJMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxFVct97zd29" title="Concentration Risk, Percentage">10.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--CustomerJMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zg5C6M0Eg7Mk">13.4</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--AccountsReceivableNet_iI_c20220630__srt--MajorCustomersAxis__custom--CustomerJMember_zMQxyCpUfeab" title="Concentration Risk, Percentage"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></span></td><td style="text-align: left"> </td></tr> </table> 0.435 0.267 43920 0.100 0.114 0.183 0.113 524759 0.103 0.135 0.135 0.149 3835 0.105 0.183 0.113 0.135 0.149 0.656 0.105 0.134 <p id="xdx_846_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zqFCYRW4W1w2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zljNIriJh3C9">Accounts Receivable</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--InventoryPolicyTextBlock_znLpoJyFuRGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zTM1sDt4OCI5">Inventory</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs include finished goods, material, labor and manufacturing overhead. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zRFsjQBfWa57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of inventories at June 30, 2022, and December 31, 2021, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zyUPnfnSVnNa" style="display: none">SCHEDULE OF INVENTORY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220630_zG0plfQER6b5" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20211231_zcAZMOJreuxl" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterials_iI_maCzAkd_maINzA2c_z2wI5UnhWXCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">236,134</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">234,168</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maCzAkd_maINzA2c_zilEnvS8qyN3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,704</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maCzAkd_maINzA2c_z579GAAM2Bpg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,562,961</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">788,110</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pp0p0_mtINzA2c_zdKT54ms1Ugi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,799,095</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,065,982</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_z2ceFf6pQqIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zRFsjQBfWa57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of inventories at June 30, 2022, and December 31, 2021, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zyUPnfnSVnNa" style="display: none">SCHEDULE OF INVENTORY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220630_zG0plfQER6b5" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20211231_zcAZMOJreuxl" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterials_iI_maCzAkd_maINzA2c_z2wI5UnhWXCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">236,134</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">234,168</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maCzAkd_maINzA2c_zilEnvS8qyN3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,704</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_maCzAkd_maINzA2c_z579GAAM2Bpg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,562,961</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">788,110</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pp0p0_mtINzA2c_zdKT54ms1Ugi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,799,095</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,065,982</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 236134 234168 43704 1562961 788110 1799095 1065982 <p id="xdx_840_ecustom--PurchaseConcentrationPolicyTextBlock_zvA65ZJPpcog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_znyEPeXXDVBb">Purchase concentration</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OES purchases finished renewable energy products from its’ suppliers. For the three months ended June 30, 2022, there were three suppliers that accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zPoYOhuYv5D2" title="Concentration of credit risk">41.3</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zwRhFNPIIs52" title="Concentration of credit risk">23.3</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--SuppliersThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_ziiflkYa1HG5" title="Concentration of credit risk">19.7</span>%, respectively, and for the six months ended June 30, 2022, there were four suppliers that accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z11H6IzEeEtg" title="Concentration of credit risk">38.0</span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zMimKdFP5lMl" title="Concentration of credit risk">15.9</span>%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--SuppliersThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zTBbOo3QtZb4" title="Concentration of credit risk">15.6</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--SuppliersFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zaBXHDYpWxq6" title="Concentration of credit risk">11.2</span>%, respectively. For the three and six months ended June 30, 2021, there were three suppliers that accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zPHyizkDTvPf" title="Concentration of credit risk"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zYe09mr0Esgf" title="Concentration of credit risk">29.6</span></span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zNghMVggBr6f" title="Concentration of credit risk"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_znbC1urePSba" title="Concentration of credit risk">21.8</span></span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--SuppliersThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zA0Wqw0MTFF6" title="Concentration of credit risk"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--SuppliersThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zb82wFEJZBCk" title="Concentration of credit risk">12.7</span></span>%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--TwoVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zzcWImCIP2Qb" title="Concentration of credit risk">20</span>% down payment with the <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--DownPaymentMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z9Mo0SXrwvTc" title="Concentration of credit risk">30</span>% balances due on shipment and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--ShipmentMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zLaPJ7OfP815" title="Concentration of credit risk">50</span>% due prior to delivery, while other vendors terms are due in full immediately prior to delivery. We also buy product from other distributors, if we are not able to purchase direct from the manufacturer. While management believes all of its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The principal purchases by PCTI are comprised of parts and raw materials that PCTI assembles and manufactures and sells to its customers. There were no suppliers who accounted for more than ten percent (<span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--NoSuppliersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zA1tZ20UGAqh" title="Concentration of credit risk"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--DownPaymentMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zht1h1CVEENg" title="Concentration of credit risk">10</span></span>%) of PCTI’s purchases for the three and six months ended June 30, 2022, and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.413 0.233 0.197 0.380 0.159 0.156 0.112 0.296 0.296 0.218 0.218 0.127 0.127 0.20 0.30 0.50 0.10 0.10 <p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8f7d9MYVgO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zIhQXUjGrzhh">Property, plant and equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:</span></p> <p id="xdx_89A_ecustom--ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock_zBE5ObmdYCu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zUpUVB1L7iVe" style="display: none">SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zmzuruJClLD4" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zuzcHjkvFxz7" title="Property, Plant and Equipment, Useful Life">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warehouse equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_zfTHuQGLBxs1" title="Property, Plant and Equipment, Useful Life">7</span> years</span></td></tr> </table> <p id="xdx_8A6_zaD9LMiFRX2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_ecustom--ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock_zBE5ObmdYCu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zUpUVB1L7iVe" style="display: none">SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zmzuruJClLD4" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zuzcHjkvFxz7" title="Property, Plant and Equipment, Useful Life">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warehouse equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_zfTHuQGLBxs1" title="Property, Plant and Equipment, Useful Life">7</span> years</span></td></tr> </table> P3Y P5Y P7Y <p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zMUviWbzDUXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zTGJrRxrBX7b">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Advance payments are typically required for commercial customers and are recorded as current liability until revenue is recognized. Advance payments are not required for government customers. The majority of contracts typically require payment within 30 to 60 days after transfer of ownership to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--DisaggregationOfRevenueTableTextBlock_znQvIkzHri92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates our revenue by major source for the three and six months ended June 30, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none"><span id="xdx_8B8_ztKb9ZtCGDMf" style="display: none">DISAGGREGATION OF REVENUE</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220401__20220630_z5o3Yso2ALGk" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210401__20210630_zZCyihiFt5H8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220630_zCtMKlQCD1G5" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20210630_zYV9eCZyAB6f" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SourcedAndDistributedProductsMember_zsmPHdILsWJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Sourced and distributed products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4,749,377</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,254,982</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">7,668,699</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,254,982</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ManufacturedProductsMember_z1OIhHb5inX6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufactured products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,759</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,051</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">275,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">814,605</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OEDInstallationsMember_zE39HJj25Jt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">OED Installations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zJslrMmzzerh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,878,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,274,033</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,960,874</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,069,587</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_z6QUTKCNCg4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company brings the finished goods into our California warehouse to fill orders as well as to build inventory for future sales orders. From time to time for some of our larger orders we may have our suppliers ship directly to our customers to avoid extra shipping charges. For manufactured products, there is usually a bidding process by branches of the military or other large firms that need mostly battery charging and storage systems for large industrial projects. We would then purchase the raw materials and parts needed to build out the project in our Pennsylvania warehouse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--DisaggregationOfRevenueTableTextBlock_znQvIkzHri92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates our revenue by major source for the three and six months ended June 30, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none"><span id="xdx_8B8_ztKb9ZtCGDMf" style="display: none">DISAGGREGATION OF REVENUE</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220401__20220630_z5o3Yso2ALGk" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210401__20210630_zZCyihiFt5H8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220630_zCtMKlQCD1G5" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20210630_zYV9eCZyAB6f" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SourcedAndDistributedProductsMember_zsmPHdILsWJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Sourced and distributed products</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4,749,377</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,254,982</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">7,668,699</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,254,982</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ManufacturedProductsMember_z1OIhHb5inX6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufactured products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,759</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,051</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">275,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">814,605</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OEDInstallationsMember_zE39HJj25Jt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">OED Installations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zJslrMmzzerh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,878,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,274,033</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,960,874</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,069,587</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4749377 1254982 7668699 1254982 112759 19051 275675 814605 16500 16500 4878636 1274033 7960874 2069587 <p id="xdx_846_eus-gaap--AdvertisingCostsPolicyTextBlock_zSfnTx9T8Ahj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zA83Ku8Cu5i4">Advertising and Marketing Expenses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses advertising and marketing costs as incurred. For the three and six months ended June 30, 2022, the Company recorded advertising and marketing expenses of $<span id="xdx_900_eus-gaap--MarketingAndAdvertisingExpense_c20220401__20220630_zUVrp1yjmNja" title="Marketing and Advertising Expense">2,710</span> and $<span id="xdx_90D_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20220630_zDTk7B5VR8Vj" title="Marketing and Advertising Expense">5,973</span>, respectively, and for the three and six months ended June 30, 2021, the Company recorded advertising and marketing expenses of $<span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_c20210401__20210630_z2BHxTnod1sj" title="Marketing and Advertising Expense">5,944</span> and $<span id="xdx_901_eus-gaap--MarketingAndAdvertisingExpense_c20210101__20210630_zKTjtUSzhTS8" title="Marketing and Advertising Expense">28,544</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2710 5973 5944 28544 <p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_z1IbId6UQQ36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z98MA3JhSyyj">Research and Development</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the three and six months ended June 30, 2022, and 2021, the Company did not record any research and development expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--ConvertibleInstrumentsPolicyTextBlock_zlUW0Z0L37Bb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zmmqtKDHUhH1">Convertible Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_840_ecustom--DistinguishingLiabilitiesfromEquityPolicyTextBlock_zBdRMujmswJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zPuGcRgOyGqd">Distinguishing Liabilities from Equity</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company relies on the guidance provided by ASC Topic 480, <i>Distinguishing Liabilities from Equity</i>, to classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our CEO and Chairman holds sufficient shares of the Company’s voting preferred stock that give sufficient voting rights under the articles of incorporation and bylaws of the Company such that the CEO and Chairman can at any time unilaterally vote to increase the number of authorized shares of common stock of the Company, without the need to call a general meeting of common shareholders of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Initial Measurement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records its financial instruments classified as liability, temporary equity or permanent equity at issuance at the fair value, or cash received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subsequent Measurement – Financial Instruments Classified as Liabilities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in fair value of its financial instruments classified as liabilities are recorded as other income (expenses).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zJfnARMCtUi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zWaqOsRPIuQe">Fair Value of Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following are the hierarchical levels of inputs to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to the conversion features within the instrument and that the company has insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_zJPiuezxAoLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of June 30, 2022, and December 31, 2021, for each fair value hierarchy level:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zZknXjOep5y2" style="display: none">SCHEDULE OF DERIVATIVE INSTRUMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">June 30, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative <br/> Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zutJ7nmeK5F7" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1034">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfPvy5vZOM06" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1036">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxxMjXtPKdr" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1038">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWSwqPZyx3v" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1040">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zd1GTOc5FRs7" style="width: 16%; text-align: right" title="Derivative Liabilities">7,589,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAlei98qrkxl" style="width: 16%; text-align: right" title="Total">7,589,928</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative <br/> Liabilities</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level I</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zw5J4QEM5OXj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative Liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGYGWIkqNYeh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level II</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFPaCbg9rZ17" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative Liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCMLdAJZoImc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level III</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOVfLnEA0Cf4" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Derivative Liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,966,701</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVZTOuIDz4rf" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,966,701</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AA_zxZtZtRhXg19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_zJPiuezxAoLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of June 30, 2022, and December 31, 2021, for each fair value hierarchy level:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zZknXjOep5y2" style="display: none">SCHEDULE OF DERIVATIVE INSTRUMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">June 30, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative <br/> Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zutJ7nmeK5F7" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1034">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfPvy5vZOM06" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1036">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxxMjXtPKdr" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1038">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWSwqPZyx3v" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1040">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zd1GTOc5FRs7" style="width: 16%; text-align: right" title="Derivative Liabilities">7,589,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAlei98qrkxl" style="width: 16%; text-align: right" title="Total">7,589,928</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative <br/> Liabilities</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level I</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zw5J4QEM5OXj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative Liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGYGWIkqNYeh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level II</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFPaCbg9rZ17" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative Liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCMLdAJZoImc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level III</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOVfLnEA0Cf4" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Derivative Liabilities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,966,701</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVZTOuIDz4rf" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,966,701</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 7589928 7589928 20966701 20966701 <p id="xdx_84B_eus-gaap--LesseeLeasesPolicyTextBlock_zPLtuxIwTBee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zc8r8m01RUL7">Leases</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for leases under ASU 2016-02 (see Note 14), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of 7.5%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zxqPs9YYd5D6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zwEIuc72oGoe">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has <span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20220630_z0EMaV7vO7nf" title="Unrecognized tax benefits">no</span>t recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 <p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zlwF46zVje9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zlcDKgqR2Wd">Segment Policy</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no reportable segments as it operates in one segment; renewable energy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z4wTS825U6X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z7OuOhpCfwa6">Earnings (Loss) Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of June 30, 2022, and 2021, the Company’s dilutive securities are convertible into approximately <span id="xdx_907_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_pid_c20220101__20220630_zpYdOpVeJnN4" title="Dilutive securities common stock, shares">7,689,380,800</span> and <span id="xdx_905_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_c20210101__20210630_zoEUikAaqZDi" title="Dilutive securities common stock, shares">14,418,538,825</span>, respectively, shares of common stock. The following table represents the classes of dilutive securities as of June 30, 2022, and 2021:</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDlHZtcgLjU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zvdo79cMzSvh" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20220630_zd7owWv2ugZ2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210101__20210630_zAuH7K0zi8S8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zrt5pqd2QhDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_F4A_zOLSn9sIiYqc" style="width: 60%; text-align: left">Convertible preferred stock (1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">6,933,544,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">13,820,732,691</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_zksdm5063WD9" style="vertical-align: bottom; background-color: White"> <td id="xdx_F47_zvs0gyls86He" style="text-align: left">Unexercised common stock purchase warrants (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">672,024,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597,024,518</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zfjdfZbtFyBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,520,720</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">781,816</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PromissoryNotePayableMember_z3J8EIMdwBVg" style="vertical-align: bottom; background-color: White"> <td id="xdx_F4A_zJNi81gzqLuj" style="text-align: left; padding-bottom: 1.5pt">Promissory note payable (1)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">81,291,096</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zYfg31doQTdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,689,380,800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">14,418,538,825</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zrxWkLWwbNUl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_z1ZzrYe0oId" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVElESUxVVElWRSBTRUNVUklUSUVTIEVYQ0xVREVEIEZST00gQ09NUFVUQVRJT04gT0YgRUFSTklOR1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c20220101__20220630_zU2PZcEd6vkh" title="Outstanding shares, percentage">4.99%</span> of the then outstanding shares of common stock subsequent to any conversion or exercise.</span></td></tr> </table> <p id="xdx_8A3_z7sBMR2HAOmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> 7689380800 14418538825 <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDlHZtcgLjU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zvdo79cMzSvh" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20220630_zd7owWv2ugZ2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210101__20210630_zAuH7K0zi8S8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zrt5pqd2QhDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_F4A_zOLSn9sIiYqc" style="width: 60%; text-align: left">Convertible preferred stock (1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">6,933,544,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">13,820,732,691</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_zksdm5063WD9" style="vertical-align: bottom; background-color: White"> <td id="xdx_F47_zvs0gyls86He" style="text-align: left">Unexercised common stock purchase warrants (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">672,024,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597,024,518</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zfjdfZbtFyBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,520,720</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">781,816</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PromissoryNotePayableMember_z3J8EIMdwBVg" style="vertical-align: bottom; background-color: White"> <td id="xdx_F4A_zJNi81gzqLuj" style="text-align: left; padding-bottom: 1.5pt">Promissory note payable (1)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">81,291,096</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zYfg31doQTdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,689,380,800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">14,418,538,825</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zrxWkLWwbNUl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_z1ZzrYe0oId" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVElESUxVVElWRSBTRUNVUklUSUVTIEVYQ0xVREVEIEZST00gQ09NUFVUQVRJT04gT0YgRUFSTklOR1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_c20220101__20220630_zU2PZcEd6vkh" title="Outstanding shares, percentage">4.99%</span> of the then outstanding shares of common stock subsequent to any conversion or exercise.</span></td></tr> </table> 6933544466 13820732691 672024518 597024518 2520720 781816 81291096 7689380800 14418538825 0.0499 <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zsRSEZp1VDv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zpK6zc06BSW1">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other than the above, there have no recent accounting pronouncements or changes in accounting pronouncements during the period ended March 31, 2022, that are of significance or potential significance to the Company.</span></p> <p id="xdx_80C_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zyhNdiavFNKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_82B_zurMLC5vr8xf">PROPERTY AND EQUIPMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKEfv5uuj5o6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s property and equipment:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zPTtYf73Ks3" style="display: none">PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220630_z0YIZCbKw9Hj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20211231_zw1oz3QfHdhg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zFJQKpSqwI4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">300,083</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">260,083</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zShH5Nvsarzh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(152,369</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(127,194</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iI_zgNw6gxIOLP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and Equipment, Net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">147,714</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">132,889</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zuXzgPslhuL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was $<span id="xdx_900_eus-gaap--Depreciation_c20220101__20220630_zDJeO1MWfgd2" title="Depreciation">25,175</span> and $<span id="xdx_90F_eus-gaap--Depreciation_c20210101__20210630_zMRdJ8JnKPa7" title="Depreciation">18,681</span> for the six months ended June 30, 2022, and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKEfv5uuj5o6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s property and equipment:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zPTtYf73Ks3" style="display: none">PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220630_z0YIZCbKw9Hj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20211231_zw1oz3QfHdhg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zFJQKpSqwI4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">300,083</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">260,083</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zShH5Nvsarzh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(152,369</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(127,194</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iI_zgNw6gxIOLP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and Equipment, Net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">147,714</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">132,889</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 300083 260083 152369 127194 147714 132889 25175 18681 <p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_znbdxmEKwBy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 - <span id="xdx_82B_zz4zqO2Pbmc8">CONVERTIBLE NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a past-due 15% convertible note issued by the Company on September 13, 2017. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $<span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--FifteenPercentPromissoryNoteMember_zTjAdOizeVE7" title="Long term debt, gross"><span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--FifteenPercentPromissoryNoteMember_zu2liFtTpHO2" title="Long term debt, gross">25,000</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 25000 25000 <p id="xdx_80E_eus-gaap--DerivativesAndFairValueTextBlock_zY5fDOPGMvUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_828_zelcMfdwyUei">DERIVATIVE LIABILITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined the conversion feature of the convertible notes, which all contain variable conversion rates, represented an embedded derivative since the notes were convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At any given time, certain of the Company’s embedded conversion features on debt and outstanding warrants may be treated as derivative liabilities for accounting purposes under ASC 815-40 due to insufficient authorized shares to settle these outstanding contracts. Pursuant to SEC staff guidance that permits a sequencing approach based on the use of ASC 815-15-25 which provides guidance for contracts that permit partial net share settlement. The sequencing approach may be applied in one of two ways: contracts may be evaluated based on (1) earliest issuance date or (2) latest maturity date. Pursuant to the sequencing approach, the Company evaluates its contracts based upon the latest maturity date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company valued the derivative liabilities at June 30, 2022, and December 31, 2021, at $<span id="xdx_907_eus-gaap--DerivativeLiabilities_iI_c20220630_zfqzWmAZHuXa" title="Derivative liabilities">7,589,928</span> and $<span id="xdx_90A_eus-gaap--DerivativeLiabilities_iI_c20211231_zArAdX1sSakc" title="Derivative liabilities">20,966,701</span>, respectively. For the derivative liability associated with convertible notes, the Company used the Monte Carlo simulation valuation model with the following assumptions as of June 30, 2022, and December 31, 2021, risk free interest rates at <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zuo5TunlBr5d" title="Derivative liability measurement input">2.51</span>% and <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zChBntQNP2Od" title="Derivative liability measurement input">0.19</span>%, respectively, and volatility of <span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zQF0GYlnSK0d" title="Derivative liability measurement input">69</span>% and <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zjd13sadKU18" title="Derivative liability measurement input">92</span>%, respectively. The following assumptions were utilized in the Black-Scholes valuation of outstanding warrants at June 30, 2022, and December 31, 2021, risk free interest rate of <span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zaaLVRmblUbj" title="Derivative liability measurement input">2.08</span>% to <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zqJOjOLPGUH6" title="Derivative liability measurement input">2.93</span>%, and <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_ziUzwuD6dyYi" title="Derivative liability measurement input">.48</span>% to <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zE1vx9bLKzW9" title="Derivative liability measurement input">.99</span>%, respectively, volatility of <span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zW76aErbbX15" title="Derivative liability measurement input">183</span>% to <span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zCKG1ddrhHc7" title="Derivative liability measurement input">331</span>%, and <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zJThcKwiyA3c" title="Derivative liability measurement input">344</span>% to <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zlcLuOLV6eH" title="Derivative liability measurement input">366</span>%, respectively, and exercise prices of $<span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zJIhACzi0L03" title="Derivative liability measurement input">0.006</span> to $<span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_zUTQhkw9jaN9" title="Derivative liability measurement input">0.15</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zNUsfnNMUzB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the activity related to derivative liabilities for the six months ended June 30, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zMVYxDVgQUjl" style="display: none">SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with convertible notes</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total derivative liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iS_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zdQDYNVzarhh" style="width: 14%; text-align: right" title="Derivative liability">20,938,755</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iS_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zaJOmqmQQ4y9" style="width: 14%; text-align: right" title="Derivative liability">27,946</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iS_c20220101__20220630_zwNojvM8pbXk" style="width: 14%; text-align: right" title="Derivative liability">20,966,701</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zhxsVoeTn7X9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(13,376,695</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zFXCz3amap21" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(78</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20220101__20220630_zzCHJwB1cche" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(13,376,773</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iE_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zxgplpgCTFw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">7,562,060</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iE_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zoa3VT43JUpg" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">27,868</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iE_c20220101__20220630_zKOVdd5aNf13" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">7,589,928</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zEaBKBjoC5la" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 7589928 20966701 2.51 0.19 69 92 2.08 2.93 0.48 0.99 183 331 344 366 0.006 0.15 <p id="xdx_89C_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zNUsfnNMUzB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the activity related to derivative liabilities for the six months ended June 30, 2022, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zMVYxDVgQUjl" style="display: none">SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with convertible notes</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total derivative liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iS_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zdQDYNVzarhh" style="width: 14%; text-align: right" title="Derivative liability">20,938,755</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iS_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zaJOmqmQQ4y9" style="width: 14%; text-align: right" title="Derivative liability">27,946</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iS_c20220101__20220630_zwNojvM8pbXk" style="width: 14%; text-align: right" title="Derivative liability">20,966,701</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zhxsVoeTn7X9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(13,376,695</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeGainLossOnDerivativeNet_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zFXCz3amap21" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(78</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_di_c20220101__20220630_zzCHJwB1cche" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(13,376,773</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iE_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zxgplpgCTFw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">7,562,060</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iE_c20220101__20220630__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zoa3VT43JUpg" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">27,868</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iE_c20220101__20220630_zKOVdd5aNf13" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">7,589,928</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 20938755 27946 20966701 -13376695 -78 13376773 7562060 27868 7589928 <p id="xdx_800_ecustom--NotesPayableTextBlock_z0dlQdzbMfI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_82C_zQ9HL264Ryp7">NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_ecustom--ScheduleOfNotesPayableTableTextBlock_zXBifkDomwSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has the following note payables outstanding:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none"><span id="xdx_8B7_zyhCcJwCrEOb" style="display: none">SCHEDULE OF NOTES PAYABLE</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220630_z8y2pVvfEHil" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20211231_zvNThWkqfR48" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"/><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zRcbG6rSw6Z1" style="text-align: right" title="Sub- total notes payable">134,681</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zp6KSgO3TNrb" style="text-align: right" title="Sub- total notes payable">134,681</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Note payable bank, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zZ6Pf6PPibd2" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zJEUA2QKSo6b" title="Debt Instrument, interest rate, stated percentage">7.75</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zeTNyfhmnvY6" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_z1cx0wyEiwwh" title="Debt Instrument, maturity date">December 5, 2021</span></span>, currently in default</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zlVNKOpGiXQ8" style="width: 16%; text-align: right" title="Sub- total notes payable">134,681</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zdgfCdi9rx7i" style="width: 18%; text-align: right" title="Sub- total notes payable">134,681</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable bank, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zKXKjBMPuUwc" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zw8Z76JUmYGi" title="Debt Instrument, interest rate, stated percentage">6.5</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zJPomkeLV4J8" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zb7ka44RdFSi" title="Debt Instrument, maturity date">December 26, 2021</span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zLvruHlmFRSh" style="text-align: right" title="Sub- total notes payable">344,166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zsnot4nfDI36" style="text-align: right" title="Sub- total notes payable">344,166</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Economic Injury Disaster Loan</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--EconomicInjuryDisasterLoanMember_z3UPpVLmJMU5" style="text-align: right" title="Sub- total notes payable">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--EconomicInjuryDisasterLoanMember_zGlKEL2vltQa" style="text-align: right" title="Sub- total notes payable">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Paycheck Protection Program loan</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--PaycheckProtectionProgramloanMember_zltfJdetOaGj" style="text-align: right" title="Sub- total notes payable">100,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--PaycheckProtectionProgramloanMember_zejl4WTBysXi" style="text-align: right" title="Sub- total notes payable">100,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes payable, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_z0evCKj54vt4" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zuraWVVyk7ni" title="Debt Instrument, interest rate, stated percentage">8</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zNzMaZ2DnqK4" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zvYSt66JRFU5" title="Debt Instrument, maturity date">January 5, 2020</span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zruzEW5Bk1V8" style="text-align: right" title="Sub- total notes payable">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_ziTIvWZXempl" style="text-align: right" title="Sub- total notes payable">45,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other, due on demand, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zpXYwJnRG4Kl" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_z3BjplImWVlc" title="Debt Instrument, interest rate, stated percentage">6</span></span>%, currently in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zAEA7dzoyfla" style="text-align: right" title="Sub- total notes payable">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_z59LThZbmmq9" style="text-align: right" title="Sub- total notes payable">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zWYq1tbXmki4" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_z1tFUDWDu3Hk" title="Debt Instrument, face amount"><span>750,000</span></span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_znckhxTHOPz7" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zULe0xptNjh" title="Debt Instrument, interest rate, stated percentage"><span>12</span></span></span>%, matured <span><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zfg74JXP2EEe" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zjYD2qhZbj5e" title="Debt Instrument, maturity date">August 24, 2021</span></span></span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zl1pzm7TEPsf" style="text-align: right" title="Sub- total notes payable">375,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zSmaYj6G8Yob" style="text-align: right" title="Sub- total notes payable">375,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z7z3mzvYpkb7" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z0ULZgWX0GTj" title="Debt Instrument, face amount"><span>389,423</span></span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zkYuXN7ZsC6" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z3DajQ8ZBIuf" title="Debt Instrument, interest rate, stated percentage"><span>18</span></span></span>%, matures <span><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zsXT7xCQGx4f" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zXhylKxY4VVf" title="Debt Instrument, maturity date">November 6, 2023</span></span></span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zgJyPnd6vuV6" style="text-align: right" title="Sub- total notes payable">389,423</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zaYGqbMETFJh" style="text-align: right" title="Sub- total notes payable">389,423</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zxnSqdPAOEw4" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z2mYfcj1cTFd" title="Debt Instrument, face amount">1,000,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zlrPlfhzziR5" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zv80327PHp9h" title="Debt Instrument, interest rate, stated percentage">12</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zfmnPqLgqGn3" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zQ3N1QbYqBJg" title="Debt Instrument, maturity date">November 13, 2021</span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zf3rxmYam0u5" style="text-align: right" title="Sub- total notes payable">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zDQ1RQX3PJod" style="text-align: right" title="Sub- total notes payable">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zyrkwmxoXQxg" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zJchTWNV7whc" title="Debt Instrument, face amount">2,200,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_znNQhPDrTzP" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zVqPY9UCZnx7" title="Debt Instrument, interest rate, stated percentage">12</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zfs9v3cuUfGc" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zXSogtNQd1E" title="Debt Instrument, maturity date">February 9, 2022</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z4iNb4Wf1K0i" title="Debt Instrument, unamortized discount">243,833</span> (2021), in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z43oPQptNFde" style="text-align: right" title="Sub- total notes payable">2,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zOt2g7B3xudf" style="text-align: right" title="Sub- total notes payable">1,956,167</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zxX8uQMRaQF8" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zsFq7ncpStMi" title="Debt Instrument, face amount">11,110,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zjCZN2vEDgqd" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zc73tGIZkfd1" title="Debt Instrument, interest rate, stated percentage">12</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zjpw1Au25IEd" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zLgwohvtnKPj" title="Debt Instrument, maturity date">March 17, 2022</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_pp0p0"><span>2,314,583</span></span> (2021), in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zxiRqDQ0Fn2e" style="text-align: right" title="Sub- total notes payable">11,110,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zIhOsSpLjrr2" style="text-align: right" title="Sub- total notes payable">8,795,417</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zEYSMnJiK154" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zJcEqPGQGCWk" title="Debt Instrument, face amount">3,300,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zfUacMq2s31j" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zfIHN836GeRi" title="Debt Instrument, interest rate, stated percentage">12</span></span>%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zmIcnBpsUBz8" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zUIBtGQ1Bfqk" title="Debt Instrument, maturity date">December 7, 2022</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zHHYZy34J5Zf" title="Debt Instrument, unamortized discount"><span>1,458,115</span></span> (2022) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zr9Inx4jaqUg" title="Debt Instrument, unamortized discount"><span>3,099,524</span></span> (2021)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zu1VTanVopDf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Sub- total notes payable">1,841,885</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zjDrBGuLZXVc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Sub- total notes payable">200,476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sub- total notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,600,555</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,400,730</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less long-term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,423</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,423</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of notes payable, net of discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,211,132</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,011,307</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zPAbFa3lBcH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 7, 2021, the Company entered into a <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zGsNhJ8laeI9" title="Debt Instrument, Interest Rate, Stated Percentage">12</span>%, $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zw4P9G6T5Ga7" title="Debt Instrument, Face Amount">3,300,000</span> face value promissory note with a third- party lender with a maturity date of <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_c20211205__20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zpeldKMpbWa5" title="Debt Instrument, Maturity Date">December 7, 2022</span>. In exchange for the issuance of the $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zYDN4hX3qbM6" title="Debt Instrument, face amount">3,300,000</span> note, inclusive of an original issue discount of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zsMLTG1PogQ3">300,000</span>, the Company received proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20211212__20211213__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zK7NMweu5Sh3" title="Proceeds From Notes Payable">3,000,000</span> on December 13, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zOBMPBn924h8" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">75,000,000</span> shares of common stock at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zb97EKYPqKai" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.039</span> per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the six months ended June 30, 2022, amortization of the costs of $<span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20220101__20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zBqnEIuocuJc" title="Amortization of debt discount premium">150,000</span> was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $<span id="xdx_909_eus-gaap--InterestExpense_pp0p0_c20220101__20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zGEQgZTYqArc" title="Interest expense">2,982,815</span> has been recorded as an initial debt and an initial derivative liability of $<span id="xdx_908_eus-gaap--DerivativeLiabilities_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zedO7Ai6Y5ka" title="Derivative Liabilities">2,982,815</span>. For the six months ended June 30, 2022, amortization of the warrant discount of $<span id="xdx_908_ecustom--AmortizationOfWarrantDiscount_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_z5XQd2BK83S" title="Amortization of warrant discount">1,491,407 </span>was charged to interest expense. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zMTpl3exy4d9" title="Debt Instrument, face amount"><span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zJSR4JuaoF03" title="Debt Instrument, face amount">3,300,000</span></span> with a carrying value of $<span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zjjKS2LTnTy2" title="Carrying amount">1,84,855</span> and $<span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zebn4xgu2kdj" title="Carrying amount">200,476</span>, respectively, net of unamortized discounts of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zC5DcaoiTl4h" title="Debt Instrument, unamortized discount">1,481,115</span> and $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zOUS1Ox8gdr6" title="Debt Instrument, unamortized discount">3,099,524</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 17, 2021, the Company entered into a <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_z0YEIcpSDpba" title="Debt Instrument, Interest Rate, Stated Percentage">12</span>%, $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_znnaoRiDtnre" title="Debt Instrument, Face Amount">11,110,000</span> face value promissory note with a third- party lender with a maturity date of <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20210316__20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_z3EYK1yXQOn8" title="Debt Instrument, Maturity Date">March 17, 2022</span>. This note is now in default. In exchange for the issuance of the $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zepJyHVPb0aj" title="Debt Instrument, Face Amount">11,110,000</span> note, inclusive of an original issue discount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zTDvUuFj0T0d" title="Debt Instrument, Unamortized Discount">1,000,000</span> and lender costs of $<span id="xdx_900_ecustom--LenderCosts_pp0p0_c20210316__20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zTvi7VgoF9T5" title="Lender Costs">110,000</span> the Company received proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20210322__20210323__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_znKrplDuFdN6" title="Proceeds from Notes Payable">10,000,000</span> on March 23, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zinZMwvxEi6j" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">250,000,000</span> shares of common stock at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_ziEbRroOdVGa" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.13</span> per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the six months ended June 30, 2022, amortization of the costs of $<span id="xdx_901_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20220101__20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zmWPATdjfQC3" title="Amortization of Debt Discount Premium">231,250</span> was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20220101__20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zxxeZ0v8rNe6" title="Fair value of adjustment of warrants">33,248,433</span> has been recorded as an initial debt discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zavLkPAHwkD2" title="Debt Instrument, Unamortized Discount">10,000,000</span>, interest expense of $<span id="xdx_903_eus-gaap--InterestExpense_pp0p0_c20220101__20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zMjjwwvz5Bl8" title="Interest Expense">23,248,433</span> and initial derivative liability of $<span id="xdx_90E_eus-gaap--DerivativeLiabilities_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zOY6YdV75mgb" title="Fair value of adjustment of warrants">32,248,433</span>. For the six months ended June 30, 2022, amortization of the warrant discount of $<span id="xdx_907_ecustom--AmortizationOfWarrantDiscount_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zo9C5OUXyWRb" title="Amortization of Warrant Discount">2,083,333</span> was charged to interest expense. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zhsTRZPQaJR2" title="Debt Instrument, Face Amount"><span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zTfxcQOFg8Tk" title="Debt Instrument, Face Amount">11,110,000</span></span> with a carrying value of $<span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zLY9ixVIY2vg" title="Debt Instrument, carrying Amount">11,100,000</span> and $<span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_z9KbA50riFBg" title="Debt Instrument, carrying Amount">8,795,417</span>, respectively, net of unamortized discounts of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zXbRERGGTfl3" title="Debt instrument unamortized discount">2,314,583</span> as of December 31, 2021. As of June 30, 2022, and December 31, 2021, the accrued interest is $<span id="xdx_903_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zeNloIBJ85I5" title="Interest Payable Current And Noncurrent">1,691,155</span> and $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zb8ysNj0Ba7l" title="Interest Payable Current And Noncurrent">1,033,687</span>, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 9, 2021, the Company entered into a <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zFITG328rJM7" title="Debt Instrument, Interest Rate, Stated Percentage">12</span>%, $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_z6lLQSXd5gWl" title="Debt Instrument, Face Amount">2,200,000</span> face value promissory note with a third- party lender with a maturity date of <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210208__20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zHgmPPtHBiMb" title="Debt Instrument, Maturity Date">February 9, 2022</span>. This note is now in default. In exchange for the issuance of the $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zq4XrfwrnPGg" title="Debt Instrument, Face Amount">2,200,000</span> note, inclusive of an original issue discount of $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zAdJW4El3iy4" title="Debt Instrument, Unamortized Discount">200,000</span> the Company received proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_z3WEdx6x0yOi" title="Proceeds from Notes Payable">2,000,000</span> on February 16, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zQwU4FExxCM2" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">50,000,000</span> shares of common stock at $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zAtLvNBKSnch" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.15</span> per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. For the six months ended June 30, 2022, amortization of the costs of $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20220101__20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zIgVN9VyxVG7" title="Amortization of Debt Discount (Premium)">22,167</span> was charged to interest expense. The fair value of the warrant calculated by the Black- Scholes option pricing method of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20220101__20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zfX3Limzdv9d" title="Adjustment of Warrants">17,659,506</span> has been recorded as an initial debt discount of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_z7GUYkio0EM7" title="Debt Instrument Unamortized Discount">2,000,000</span>, interest expense of $<span id="xdx_90D_eus-gaap--InterestExpense_c20220101__20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zf6xoCejLkwl" title="Interest Expense">15,659,506</span> and initial derivative liability of $<span id="xdx_906_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zX4g0rYl0yR7" title="Derivative Liabilities">17,659,506</span>. For the six months ended June 30, 2022, amortization of the warrant discount of $<span id="xdx_90D_ecustom--AmortizationOfWarrantDiscount_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LendersMember_z2hIq8nxGiea" title="Amortization of Warrant Discount">221,667</span> was charged to interest expense. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_ziyDWtEAGL49" title="Debt Instrument, Face Amount"><span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zlyOA7pUFve8">2,200,000</span></span> with a carrying value as of December 31, 2021, of $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zCP3nStrUdma" title="Long-Term Debt, Gross">1,956,167</span>, net of unamortized discounts of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zwQn4aZzeed7" title="Debt Instrument, Unamortized Discount">243,833</span>. As of June 30, 2022, and December 31, 2021, the accrued interest is $<span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zEGcMYbPPGgb" title="Interest Payable">360,921</span> and $<span id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_ztjdMraBNHW4" title="Interest Payable">230,729</span>, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 13, 2020, the Company entered into a <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201113__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_z29LhVXHIL69" title="Debt Instrument, Interest Rate, Stated Percentage">12</span>%, $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201113__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zJhZeJtO4Uy9" title="Debt Instrument, Face Amount">1,000,000</span> face value promissory note with a third-party due <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20201112__20201113__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zyJzOnGYUSs8" title="Debt Instrument, Maturity Date">November 13, 2021</span>. <span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20201112__20201113__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zaiz8z4RliXl" title="Debt instrument description">Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date</span>. The Company received proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20201117__20201120__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zn8GnLwmVcX4" title="Proceeds from Notes Payable">890,000</span> on November 20, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $<span id="xdx_903_eus-gaap--LegalFees_pp0p0_c20201117__20201120__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zFYYh2CiJCOa" title="Legal Fees">110,000</span>. In conjunction with this note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220630__srt--TitleOfIndividualAxis__custom--HolderMember_zDSzLQfe5YI7" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">125,000,000</span> shares of common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__srt--TitleOfIndividualAxis__custom--HolderMember_znDIuBtFTsVb" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.008</span>, subject to adjustments and expires on the <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20220630__srt--TitleOfIndividualAxis__custom--HolderMember_z1fBE76McN1b" title="Warrants and Rights Outstanding, Term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1477">five</span></span>-year anniversary of the issue date. As of June 30, 2022 and December 31, 2021, the outstanding principal balance of this note was $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_z9xM4jNuHxy" title="Debt Instrument, Face Amount"><span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_z6fHuFSj2gT">1,000,000</span></span>. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of June 30, 2022, and December 31, 2021, the accrued interest is $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zLLn0J828eMf" title="Interest Payable">253,808</span> and $<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zbVS8CyufIzd" title="Interest Payable">135,452</span>, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 6, 2020, the Company entered into a Settlement Agreement with the holder of $<span id="xdx_905_eus-gaap--NotesPayable_iI_pp0p0_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zdYzZHTg0KMb" title="Notes Payable">120,000</span> of convertible notes with accrued and unpaid interest of $<span id="xdx_905_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20201105__20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zAaT2HXSKrX8" title="Debt Instrument, Increase, Accrued Interest">8,716</span> and a $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200723__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zWpbUmUkDXrb" title="Debt Instrument, Face Amount">210,000</span> Promissory Noted dated June 23, 2020 with accrued and unpaid interest of $<span id="xdx_907_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20200720__20200723__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zE99yg3gBtS9" title="Debt Instrument, Increase, Accrued Interest">15,707</span>. The Company issued a new <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_znEKCMmeIjB6" title="Debt Instrument, Interest Rate, Stated Percentage">12</span>% Promissory Note with a face value of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zMhPEvsyRr0a" title="Debt Instrument, Face Amount">389,423</span> and a maturity date of <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20201105__20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zjKiSWLyFqTf" title="Debt Instrument, Maturity Date">November 6, 2023</span>. In conjunction with this settlement, the Company issued a warrant to purchase 60,000,000 shares of common stock at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zkkbxhv9Ky2l" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.0075</span>, subject to adjustments and expires on the <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_z6otegcJJOok" title="Warrants and Rights Outstanding, Term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1502">five</span></span>-year anniversary of the issue date. The Company analyzed the transaction and concluded that this was a modification to the existing debt. The investor exercised the warrant on January 14, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 26, 2016, PCTI entered into a $<span id="xdx_90B_eus-gaap--NotesPayableToBank_iI_pp0p0_c20161026_zkVtWZ3AIW2d" title="Notes Payable ToBank">210,000</span> note payable with a bank. On March 15, 2021, due to defaults with the terms of the note, the note was amended with the outstanding balance due December 5, 2021, and the interest rate changed to <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20161026_zNU1qMfQO9J4">7.75</span>%. Borrowings are collateralized by substantially all of the assets of PCTI and the personal guarantee of PCTI’s former President. As of June 30, 2022, and December 31, 2021, $<span id="xdx_90A_eus-gaap--NotesPayable_iI_pp0p0_c20220630__dei--LegalEntityAxis__custom--PCTIMember_zWUX8OjWqMPj" title="Notes payable">134,681</span> and $<span id="xdx_90A_eus-gaap--NotesPayable_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--PCTIMember_zV8hUPsV5mpk" title="Notes payable">151,469</span>, respectively, was outstanding on the note payable. This note is in default. On April 19, 2022, PCTI received a Notice of Default, Demand and Reservation of Rights (the “Notice”) from the bank’s legal counsel. The Notice is also addressed to Catherine Chis (former President of PCTI and a guarantor on the note). On May 16, 2022, and June 24, 2022, the bank filed Confessions of Judgment (the “COJ”) that were signed in conjunction with the extension dated March 15, 2021, against Chis and PCTI, respectively. The Company has engaged legal counsel to assist the Company in this matter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 15, 2021, PCTI renewed their $<span id="xdx_908_eus-gaap--NotesPayableToBank_iI_pp0p0_c20210315_zMzg1OW2ymk" title="Notes Payable ToBank">350,000</span> promissory note with a bank that provides for borrowings of up to $<span id="xdx_904_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20210315_z73b7vd3Tbrj" title="Short-Term Bank Loans and Notes Payable">350,000</span>. Interest is due monthly and the principal is due on December 26, 2021, interest rate changed to the prime rate plus <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_uPure_c20210315__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zPiZkPS1xw53" title="Debt Instrument, Interest Rate, Stated Percentage">3.25</span>% (<span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210315__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--RangeAxis__srt--MaximumMember_zr6c8EEPyDOd" title="Debt Instrument, Interest Rate, Stated Percentage">6.5</span>% at March 15, 2021). Borrowings are collateralized by substantially all of the assets of PCTI and the personal guarantee of PCTI’s former President. As of December 31, 2021, and December 31, 2020, $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20211231__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--PersonalGuaranteeOfChisMember_z8f2FN5yr0F6" title="Notes Payable">344,166</span> and $<span id="xdx_90D_eus-gaap--NotesPayable_iI_c20201231__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--PersonalGuaranteeOfChisMember_zPPHB8Kr9Pad" title="NotesPayable">345,211</span>, respectively, was outstanding on the promissory note. This note is in default. On April 19, 2022, PCTI received a Notice of Default, Demand and Reservation of Rights (the “Notice”) from the bank’s legal counsel. The Notice is also addressed to Catherine Chis (former President of PCTI and a guarantor on the note). ). On May 16, 2022, and June 24, 2022, the bank filed Confessions of Judgment (the “COJ”) that were signed in conjunction with the extension dated March 15, 2021, against Chis and PCTI, respectively. The Company has engaged legal counsel to assist the Company in this matter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 24, 2020 (the “Issue Date”), the Company entered into a <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zDJKLQUg5Eg2" title="Debt Instrument, Interest Rate, Stated Percentage">12</span>%, $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zxHGpuDnOSxi" title="Debt Instrument, Face Amount">750,000</span> face value promissory note with a third-party (the “Holder”) due August 24, 2021 (the “Maturity Date”). <span id="xdx_90C_eus-gaap--DebtInstrumentDescription_c20200823__20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zx4VryVdmda8" title="Debt Instrument, Description">Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date</span>. The Company received proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20200822__20200825__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zas3a4GrTZzc" title="Proceeds From Notes Payable">663,000</span> on August 25, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $<span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20200822__20200825__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zmvKk2D96n0g" title="Legal Fees">87,000</span>. For the year ended December 31, 2021, amortization of the costs of $<span id="xdx_901_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember__us-gaap--TypeOfArrangementAxis__custom--NineInstalmentsMember_z35fUiZ0atjj" title="Interest Expense">56,188</span> was charged to interest expense. In conjunction with this Note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zsTBnianw6xj" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">122,950,819</span> shares of common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zng6b61eI2J8" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.0061</span>, subject to adjustments and expires on the five-year anniversary of the Issue Date. The warrants issued resulted in a debt discount of $<span id="xdx_90C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20200823__20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember__us-gaap--TypeOfArrangementAxis__custom--NineInstalmentsMember_zp1IgsZY8kTh">750,000</span>. During the year ended December 31, 2021, the Company paid $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_ztDExUO0Osa4" title="Debt Instrument, Face Amount"><span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zNcpL6aqMgq4">375,000</span></span> to the Holder. On May 3, 2021, the Company issued <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20210503__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z3Tj4xQXy8Qj" title="Common Stock, Shares, Issued">75,000,000</span> shares of common stock to the Holder, upon the cashless exercise of a portion of the warrants. As of June 30, 2022, and December 31, 2021, the outstanding principal balance of this note was $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z3TjQQWXXCTf" title="Debt Instrument, Unamortized Discount">375,000</span>. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of June 30, 2022, and December 31, 2021, the accrued interest is $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zvlWnLXVgQf7" title="Interest Payable">135,247</span> and $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zWpxtgDgH0Li" title="Interest Payable">90,247</span>, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 20, 2020, PCTI was granted a loan from Huntington Bank in the amount of $<span id="xdx_90E_eus-gaap--LoansPayableToBank_iI_pp0p0_c20200420__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_ziTaEtqJo5gi" title="Loans Payable to Bank">100,400</span>, pursuant to the Paycheck Protection Program (“PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The loan matures on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20200419__20200420__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_z9QNlNWqZ6D7" title="Debt Instrument, Maturity Date">April 20, 2022</span> and bears interest at a rate of <span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20200420__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_zQuQMg9TlVRa" title="Accounts Payable, Interest-Bearing, Interest Rate">1.0</span>% per annum, payable monthly beginning on November 20, 2020. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Payments are deferred until the SBA determines the amount to be forgiven. The Company utilized the proceeds of the PPP loan in a manner which will enable qualification as a forgivable loan. On December 2, 2021, PCTI received a notice from Huntington Bank that the SBA has denied PCTI’s application for loan forgiveness, due to inaccurate statements in the loan application as submitted by the former CEO of PCTI. The balance on this PPP loan was $<span id="xdx_90A_eus-gaap--NotesPayable_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_z7A5fFjqbZCb" title="Loans Payable to Bank"><span id="xdx_904_eus-gaap--NotesPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_zAbMHMF5ENg2" title="Loans Payable to Bank">100,400</span></span> as of June 30, 2022, and December 31, 2021, and has been classified in notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2020, PCTI received $<span id="xdx_900_eus-gaap--ProceedsFromNotesPayable_c20200711__20200714__us-gaap--TypeOfArrangementAxis__custom--EconomicInjuryDisasterLoanMember_zGhecybfwlO8" title="Proceeds from Notes Payable">10,000</span> grant under the Economic Injury Disaster Loan (“EIDL”) program. Up to $<span id="xdx_902_eus-gaap--DebtInstrumentDecreaseForgiveness_c20200711__20200714__us-gaap--TypeOfArrangementAxis__custom--EconomicInjuryDisasterLoanMember_z8OcMwd9Fk9h" title="Debt Instrument, Decrease, Forgiveness">10,000</span> of the EIDL can be forgiven as long as such funds were utilized to provide working capital. <span id="xdx_90E_eus-gaap--DebtInstrumentDescription_c20200711__20200714__us-gaap--TypeOfArrangementAxis__custom--EconomicInjuryDisasterLoanMember_znT8L8NMjxq6">The first payment due is deferred one year.</span> The loan balance of June 30, 2022, and December 31, 2021 was $<span id="xdx_908_eus-gaap--NotesPayable_iI_c20220630__us-gaap--TypeOfArrangementAxis__custom--EconomicInjuryDisasterLoanMember_zujBtj8tYZI4" title="Notes payable"><span id="xdx_90F_eus-gaap--NotesPayable_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--EconomicInjuryDisasterLoanMember_zWCKaXdn1t71" title="Notes payable">10,000</span></span> and has been classified in notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_ecustom--ScheduleOfNotesPayableTableTextBlock_zXBifkDomwSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has the following note payables outstanding:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none"><span id="xdx_8B7_zyhCcJwCrEOb" style="display: none">SCHEDULE OF NOTES PAYABLE</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220630_z8y2pVvfEHil" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20211231_zvNThWkqfR48" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"/><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zRcbG6rSw6Z1" style="text-align: right" title="Sub- total notes payable">134,681</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zp6KSgO3TNrb" style="text-align: right" title="Sub- total notes payable">134,681</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Note payable bank, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zZ6Pf6PPibd2" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zJEUA2QKSo6b" title="Debt Instrument, interest rate, stated percentage">7.75</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zeTNyfhmnvY6" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_z1cx0wyEiwwh" title="Debt Instrument, maturity date">December 5, 2021</span></span>, currently in default</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zlVNKOpGiXQ8" style="width: 16%; text-align: right" title="Sub- total notes payable">134,681</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zdgfCdi9rx7i" style="width: 18%; text-align: right" title="Sub- total notes payable">134,681</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable bank, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zKXKjBMPuUwc" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zw8Z76JUmYGi" title="Debt Instrument, interest rate, stated percentage">6.5</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zJPomkeLV4J8" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zb7ka44RdFSi" title="Debt Instrument, maturity date">December 26, 2021</span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zLvruHlmFRSh" style="text-align: right" title="Sub- total notes payable">344,166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zsnot4nfDI36" style="text-align: right" title="Sub- total notes payable">344,166</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Economic Injury Disaster Loan</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--EconomicInjuryDisasterLoanMember_z3UPpVLmJMU5" style="text-align: right" title="Sub- total notes payable">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--EconomicInjuryDisasterLoanMember_zGlKEL2vltQa" style="text-align: right" title="Sub- total notes payable">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Paycheck Protection Program loan</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--PaycheckProtectionProgramloanMember_zltfJdetOaGj" style="text-align: right" title="Sub- total notes payable">100,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--PaycheckProtectionProgramloanMember_zejl4WTBysXi" style="text-align: right" title="Sub- total notes payable">100,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes payable, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_z0evCKj54vt4" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zuraWVVyk7ni" title="Debt Instrument, interest rate, stated percentage">8</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zNzMaZ2DnqK4" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zvYSt66JRFU5" title="Debt Instrument, maturity date">January 5, 2020</span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zruzEW5Bk1V8" style="text-align: right" title="Sub- total notes payable">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_ziTIvWZXempl" style="text-align: right" title="Sub- total notes payable">45,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other, due on demand, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zpXYwJnRG4Kl" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_z3BjplImWVlc" title="Debt Instrument, interest rate, stated percentage">6</span></span>%, currently in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zAEA7dzoyfla" style="text-align: right" title="Sub- total notes payable">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_z59LThZbmmq9" style="text-align: right" title="Sub- total notes payable">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zWYq1tbXmki4" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_z1tFUDWDu3Hk" title="Debt Instrument, face amount"><span>750,000</span></span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_znckhxTHOPz7" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zULe0xptNjh" title="Debt Instrument, interest rate, stated percentage"><span>12</span></span></span>%, matured <span><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zfg74JXP2EEe" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zjYD2qhZbj5e" title="Debt Instrument, maturity date">August 24, 2021</span></span></span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zl1pzm7TEPsf" style="text-align: right" title="Sub- total notes payable">375,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zSmaYj6G8Yob" style="text-align: right" title="Sub- total notes payable">375,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z7z3mzvYpkb7" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z0ULZgWX0GTj" title="Debt Instrument, face amount"><span>389,423</span></span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zkYuXN7ZsC6" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z3DajQ8ZBIuf" title="Debt Instrument, interest rate, stated percentage"><span>18</span></span></span>%, matures <span><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zsXT7xCQGx4f" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zXhylKxY4VVf" title="Debt Instrument, maturity date">November 6, 2023</span></span></span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zgJyPnd6vuV6" style="text-align: right" title="Sub- total notes payable">389,423</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zaYGqbMETFJh" style="text-align: right" title="Sub- total notes payable">389,423</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zxnSqdPAOEw4" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z2mYfcj1cTFd" title="Debt Instrument, face amount">1,000,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zlrPlfhzziR5" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zv80327PHp9h" title="Debt Instrument, interest rate, stated percentage">12</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zfmnPqLgqGn3" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zQ3N1QbYqBJg" title="Debt Instrument, maturity date">November 13, 2021</span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zf3rxmYam0u5" style="text-align: right" title="Sub- total notes payable">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zDQ1RQX3PJod" style="text-align: right" title="Sub- total notes payable">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zyrkwmxoXQxg" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zJchTWNV7whc" title="Debt Instrument, face amount">2,200,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_znNQhPDrTzP" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zVqPY9UCZnx7" title="Debt Instrument, interest rate, stated percentage">12</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zfs9v3cuUfGc" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zXSogtNQd1E" title="Debt Instrument, maturity date">February 9, 2022</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z4iNb4Wf1K0i" title="Debt Instrument, unamortized discount">243,833</span> (2021), in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z43oPQptNFde" style="text-align: right" title="Sub- total notes payable">2,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zOt2g7B3xudf" style="text-align: right" title="Sub- total notes payable">1,956,167</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zxX8uQMRaQF8" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zsFq7ncpStMi" title="Debt Instrument, face amount">11,110,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zjCZN2vEDgqd" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zc73tGIZkfd1" title="Debt Instrument, interest rate, stated percentage">12</span></span>%, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zjpw1Au25IEd" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zLgwohvtnKPj" title="Debt Instrument, maturity date">March 17, 2022</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_pp0p0"><span>2,314,583</span></span> (2021), in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zxiRqDQ0Fn2e" style="text-align: right" title="Sub- total notes payable">11,110,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zIhOsSpLjrr2" style="text-align: right" title="Sub- total notes payable">8,795,417</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zEYSMnJiK154" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zJcEqPGQGCWk" title="Debt Instrument, face amount">3,300,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zfUacMq2s31j" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zfIHN836GeRi" title="Debt Instrument, interest rate, stated percentage">12</span></span>%, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zmIcnBpsUBz8" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zUIBtGQ1Bfqk" title="Debt Instrument, maturity date">December 7, 2022</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zHHYZy34J5Zf" title="Debt Instrument, unamortized discount"><span>1,458,115</span></span> (2022) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zr9Inx4jaqUg" title="Debt Instrument, unamortized discount"><span>3,099,524</span></span> (2021)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--NotesPayable_iI_pp0p0_c20220630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zu1VTanVopDf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Sub- total notes payable">1,841,885</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zjDrBGuLZXVc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Sub- total notes payable">200,476</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sub- total notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,600,555</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,400,730</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less long-term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,423</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,423</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of notes payable, net of discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,211,132</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,011,307</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 134681 134681 0.0775 0.0775 2021-12-05 2021-12-05 134681 134681 0.065 0.065 2021-12-26 2021-12-26 344166 344166 10000 10000 100400 100400 0.08 0.08 2020-01-05 2020-01-05 45000 45000 0.06 0.06 50000 50000 750000 750000 0.12 0.12 2021-08-24 2021-08-24 375000 375000 389423 389423 0.18 0.18 2023-11-06 2023-11-06 389423 389423 1000000 1000000 0.12 0.12 2021-11-13 2021-11-13 1000000 1000000 2200000 2200000 0.12 0.12 2022-02-09 2022-02-09 243833 2200000 1956167 11110000 11110000 0.12 0.12 2022-03-17 2022-03-17 2314583 11110000 8795417 3300000 3300000 0.12 0.12 2022-12-07 2022-12-07 1458115 3099524 1841885 200476 17600555 13400730 389423 389423 17211132 13011307 0.12 3300000 2022-12-07 3300000 300000 3000000 75000000 0.039 150000 2982815 2982815 1491407 3300000 3300000 184855 200476 1481115 3099524 0.12 11110000 2022-03-17 11110000 1000000 110000 10000000 250000000 0.13 231250 33248433 10000000 23248433 32248433 2083333 11110000 11110000 11100000 8795417 2314583 1691155 1033687 0.12 2200000 2022-02-09 2200000 200000 2000000 50000000 0.15 22167 17659506 2000000 15659506 17659506 221667 2200000 2200000 1956167 243833 360921 230729 0.12 1000000 2021-11-13 Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date 890000 110000 125000000 0.008 1000000 1000000 253808 135452 120000 8716 210000 15707 0.12 389423 2023-11-06 0.0075 210000 0.0775 134681 151469 350000 350000 3.25 0.065 344166 345211 0.12 750000 Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date 663000 87000 56188 122950819 0.0061 750000 375000 375000 75000000 375000 135247 90247 100400 2022-04-20 0.010 100400 100400 10000 10000 The first payment due is deferred one year. 10000 10000 <p id="xdx_803_ecustom--DeferredLiabilityTextBlock_z7h7eNSePHeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_824_zyaRRTrMIVE8">DEFERRED LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 2, 2020, PCTI entered into an agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $<span id="xdx_901_ecustom--DeferredLiabilityCurrent_iI_pp0p0_c20200902__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_z04dLcBhrKL1" title="Deferred Liability Current">750,000</span>, PCTI agreed to pay the third-party a perpetual three percent (<span id="xdx_90D_eus-gaap--ProductLiabilityContingencyThirdPartyRecoveryPercentage_pid_dp_uPure_c20200830__20200902__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zUCmMWI794uc" title="Product Liability Contingency, Third-Party Recovery, Percentage">3</span>%) payment of revenues, as defined in the agreement. Payments are due ninety (90) days after each calendar quarter, with the first payment due on or before March 31, 2021, for revenues for the quarter ending December 31, 2020. For the three and six months ended June 30, 2022, the Company reduced this deferred liability by $<span id="xdx_90B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_c20220630_zSHOBut0tVwc" title="Deferred Liability Current">87,815</span> and that amount is included in accounts payable and accrued expenses. The deferred liability as of June 30, 2022, and December 31, 2021, on the condensed consolidated balance sheet is $<span id="xdx_90A_ecustom--DeferredLiabilityCurrent_iI_pp0p0_c20220630_z9TI2iVNLJw5" title="Deferred Liability Current">662,185</span> and $<span id="xdx_900_ecustom--DeferredLiabilityCurrent_iI_pp0p0_c20211231_zvQFnxbakfCb" title="Deferred Liability Current">750,000</span>, respectively. No payments have been made and the Company is in default of the agreement with the total amount of $<span id="xdx_90C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_c20211231_zsu1G2S6rUV2" title="Accounts Payable and Accrued Liabilities">358,446</span> included in accounts payable and accrued expenses as of June 30, 2022. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the note was amended, whereby in exchange for <span id="xdx_903_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_pid_c20210225__20210226__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_z9qZRK3aEV9" title="Deferred Compensation Arrangement with Individual, Shares Issued">175,000,000</span> shares of common stock, the royalty percentage was amended to <span id="xdx_904_ecustom--RoyaltyPercentage_pid_dp_uPure_c20210225__20210226__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zIlJAZ6CZ4za" title="Royalty Percentage">1.8</span>%. The Company valued the shares at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210630__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zeKETgwwshsl" title="Price Per Share">0.094</span> per share (the market value of the common stock on the date of the agreement) and recorded $<span id="xdx_909_eus-gaap--PaymentsOfDebtRestructuringCosts_pp0p0_c20210101__20210630__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zV8ohwg4WeHa" title="Payments of Debt Restructuring Costs">16,450,000</span> as debt restructure expense on the condensed consolidated statement of operations for the six months ended June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 750000 0.03 87815 662185 750000 358446 175000000 0.018 0.094 16450000 <p id="xdx_806_eus-gaap--RevenueFromContractWithCustomerTextBlock_znVGqW0X41Wd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_82C_zHX6g0ln3Bn9">DEFERRED REVENUE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company received $<span id="xdx_904_eus-gaap--IncreaseDecreaseInDueToRelatedParties_pp0p0_c20200101__20201231_zxyXGq7X33t5" title="DueToRelatedParties">64,353</span> form a customer for a <span id="xdx_909_eus-gaap--ExtendedProductWarrantyDescription_c20200101__20201231_z7NRrD435f4i" title="Warranty Description">payment of a three- year extended warranty</span>. The extended warranty period is from, March 2021 through February 2024, and accordingly the Company will recognize the revenue over such period. For the three and six months ended June 30, 2022, and 2021, the Company recognized $<span id="xdx_90B_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pp0p0_c20220401__20220630_z6aLQRUytJll" title="Liability revenue recognized">5,363</span> and $<span id="xdx_90A_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pp0p0_c20220101__20220630_zhB0WFYx08h" title="Liability revenue recognized">10,725</span>, respectively, of revenue. Of the remaining deferred revenue of $<span id="xdx_904_eus-gaap--DeferredRevenue_iI_pp0p0_c20220630_z9wgZEI8OmP" title="Deferred revenue">35,752</span>, $<span id="xdx_90D_eus-gaap--DeferredRevenueCurrent_iI_pp0p0_c20220630_z4ei86iF4ZS1" title="Deferred revenue, current">21,451</span> is recognized as the current portion of deferred revenue and $<span id="xdx_90E_eus-gaap--DeferredRevenueNoncurrent_iI_pp0p0_c20220630_zS5xcxyl3aDg" title="Deferred revenue, non-current">14,301</span> is classified as a long- term liability on the condensed consolidated financial statements. As of December 31, 2021, $<span id="xdx_904_eus-gaap--DeferredRevenueCurrent_iI_pp0p0_c20211231_zlWHBxZeNiKj" title="Deferred revenue, current">21,451</span> is classified as the current portion and $<span id="xdx_908_eus-gaap--DeferredRevenueNoncurrent_iI_pp0p0_c20211231_zIz9dnZ2VTG" title="Deferred revenue, non-current">25,026</span> is classified as a long- term liability on the condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 64353 payment of a three- year extended warranty 5363 10725 35752 21451 14301 21451 25026 <p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_ziDAqMOAukV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_82D_zgtKcDDXkcmj">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Mr. Conway’s compensation as adjusted was $<span id="xdx_909_eus-gaap--OfficersCompensation_pp0p0_c20200701__20200710__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_z0OZawlHhVpd" title="Compensation value">20,000</span> per month, and effective September 1, 2021, Mr. Conway receives $<span id="xdx_90F_ecustom--OfficersCompensationReceived_pp0p0_c20200701__20200710__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zdyypzsrw3T6" title="Officers compensation received">10,000</span> per month from Ozop Capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective January 1, 2022, the Company entered into a new employment agreement with Mr. Conway. Pursuant to the agreement, Mr. Conway received a $<span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20211229__20220102__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zw0gZXIhtoY3" title="Amount of initial annual compensation">250,000</span> contract renewal bonus and will receive an annual compensation of $<span id="xdx_90F_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20211229__20220102__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0kEKjda5UBe" title="Amount of initial annual compensation">240,000</span> from the Company and will also be eligible to receive bonuses and equity grants at the discretion of the BOD. The Company also agreed to compensate Mr. Conway for services provided directly to any of the Company’s subsidiaries. Ozop Capital increased Mr. Conway’s compensation to $<span id="xdx_90B_eus-gaap--OfficersCompensation_pp0p0_c20220101__20220131__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zvskmPZrclah" title="Compensation value">20,000</span> per month in January 2022, OES began compensating Mr. Conway $<span id="xdx_90B_ecustom--OfficersCompensationReceived_pp0p0_c20220301__20220331__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zZZ4zRDSF6Z5">20,000</span> in March 2022, and OED began compensation Mr. Conway $<span id="xdx_90B_ecustom--OfficersCompensationReceived_pp0p0_c20220301__20220331__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_z5mX69aa1MK6" title="Officers compensation received">20,000</span> per month beginning in April 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series E Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210320__20210321__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zCRaBhXyk9O7" title="Number of shares issued, shares">2,000</span> shares of Series E Preferred Stock (see Note 12), <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210320__20210321__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_z0IpIkvr9wm5" title="Number of shares issued, shares">1,800</span> of the shares were issued to Mr. Conway. On April 16, 2021, the Board of Directors of the Company authorized the issuance <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210416__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zTMGUMZ8eNv9">2,000</span> shares of Series E Preferred stock, of which <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210415__20210416__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zCqRCvk0OSB1" title="Preferred stock redemption price per share">1,050</span> were issued to Mr. Conway. During the three and six months ended June 30, 2021, the Company redeemed <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zfeUd18X3Gr5" title="Preferred stock redemption price per share">1,050</span> and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zkPGtKSRMwtl" title="Preferred stock redemption price per share">2,850</span> shares issued to Mr. Conway, and pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of <span id="xdx_900_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zZ0iDlDkU1fg" title="Number of redeemed shares issued">$1,000</span> per share, recorded stock compensation expense to Mr. Conway of $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pid_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zrgCfmRqmZ1i" title="ShareBased Compensation Expense">1,050,000</span> and $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pid_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zStDcuCdpJAg" title="ShareBased Compensation Expense">2,850,000</span> for the three and six months ended June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management Fees and related party payables</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zAc9CqujC2C1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and six months ended June 30, 2022, and 2021, the Company recorded expenses to its officers in the following amounts:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zyVR6Ib1yqzd" style="display: none">SCHEDULE OF EXPENSES TO OFFICERS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220401__20220630_zzRgDwNtJFx8" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210401__20210630_zcy0g1TTexQ3" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220630_zv6XRbMgfwWa" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20210630_zTppsSmFMEs5" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zoeo5VAL2F6d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">CEO, parent</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">240,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">360,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">630,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">639,999</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerSeriesEPreferredStockMember_zXTFA6OJ8R0i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CEO, parent- Series E Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1651">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,050,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1653">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,850,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PresidentSubsidiaryMember_zLMnBnQUMjeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">President, subsidiary (resigned July 2021)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1656">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,074</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1658">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">86,083</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SalariesWagesAndOfficersCompensation_zpEeY7U14eU1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">240,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,461,074</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">630,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,576,082</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Redemption of Series C and Series D Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 13, 2021, the Company entered into a Definitive Agreement (the “Agreement”) with Chis to purchase the <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210712__20210713__us-gaap--TypeOfArrangementAxis__custom--DefinitiveAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjtoD0Kd5rj3" title="Number of shares purchased">47,500</span> shares of the Company’s Series C Preferred Stock held by Chis and the <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pid_c20210712__20210713__us-gaap--TypeOfArrangementAxis__custom--DefinitiveAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z1P0mLI49703" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award">18,667</span> shares of the Company’s Series D Preferred Stock held by Chis for the total purchase price of $<span id="xdx_904_ecustom--StockIssuedDuringPeriodValuePurchased_c20210712__20210713__us-gaap--TypeOfArrangementAxis__custom--DefinitiveAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zueq66Mg2zL1" title="Stock purchase, value">11,250,000</span>. In conjunction with the Agreement, Chis resigned from any and all positions held in the Company’s wholly owned subsidiary, PCTI. Further, Chis agreed that upon her resignation and for a period of five years thereafter (the “Restriction Period”), she shall not, directly or indirectly, solicit the employment of, assist in the soliciting of the employment of, or hire any employee or officer of the Company, including those of any of its present or future subsidiaries, or induce any person who is an employee, officer, agent, consultant or contractor of the Company to terminate such relationship with the Company. Additionally, Chis agreed that during the Restriction Period, she shall not compete with the Company or PCTI anywhere worldwide or be employed by any competitor of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 20000 10000 250000 240000 20000 20000 20000 2000 1800 2000 1050 1050 2850 1000 1050000 2850000 <p id="xdx_894_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zAc9CqujC2C1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and six months ended June 30, 2022, and 2021, the Company recorded expenses to its officers in the following amounts:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zyVR6Ib1yqzd" style="display: none">SCHEDULE OF EXPENSES TO OFFICERS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220401__20220630_zzRgDwNtJFx8" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210401__20210630_zcy0g1TTexQ3" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220630_zv6XRbMgfwWa" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20210630_zTppsSmFMEs5" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six months ended <br/> June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zoeo5VAL2F6d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">CEO, parent</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">240,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">360,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">630,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">639,999</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerSeriesEPreferredStockMember_zXTFA6OJ8R0i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CEO, parent- Series E Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1651">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,050,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1653">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,850,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PresidentSubsidiaryMember_zLMnBnQUMjeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">President, subsidiary (resigned July 2021)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1656">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,074</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1658">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">86,083</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SalariesWagesAndOfficersCompensation_zpEeY7U14eU1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">240,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,461,074</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">630,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,576,082</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Redemption of Series C and Series D Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 13, 2021, the Company entered into a Definitive Agreement (the “Agreement”) with Chis to purchase the <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210712__20210713__us-gaap--TypeOfArrangementAxis__custom--DefinitiveAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjtoD0Kd5rj3" title="Number of shares purchased">47,500</span> shares of the Company’s Series C Preferred Stock held by Chis and the <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pid_c20210712__20210713__us-gaap--TypeOfArrangementAxis__custom--DefinitiveAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z1P0mLI49703" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award">18,667</span> shares of the Company’s Series D Preferred Stock held by Chis for the total purchase price of $<span id="xdx_904_ecustom--StockIssuedDuringPeriodValuePurchased_c20210712__20210713__us-gaap--TypeOfArrangementAxis__custom--DefinitiveAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zueq66Mg2zL1" title="Stock purchase, value">11,250,000</span>. In conjunction with the Agreement, Chis resigned from any and all positions held in the Company’s wholly owned subsidiary, PCTI. Further, Chis agreed that upon her resignation and for a period of five years thereafter (the “Restriction Period”), she shall not, directly or indirectly, solicit the employment of, assist in the soliciting of the employment of, or hire any employee or officer of the Company, including those of any of its present or future subsidiaries, or induce any person who is an employee, officer, agent, consultant or contractor of the Company to terminate such relationship with the Company. Additionally, Chis agreed that during the Restriction Period, she shall not compete with the Company or PCTI anywhere worldwide or be employed by any competitor of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 240000 360000 630000 639999 1050000 2850000 51074 86083 240000 1461074 630000 3576082 47500 18667 11250000 <p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkWc8AvzKyV9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 – <span id="xdx_829_zILQIZeptn29">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 2, 2021, the Company entered into a ten (<span id="xdx_90C_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtY_c20210102__us-gaap--TypeOfArrangementAxis__custom--GarageStorageFacilityMember_zt0I5YpSByE" title="Lease term">10</span>) year lease for a 6-bay garage storage facility of approximately <span id="xdx_908_eus-gaap--LandSubjectToGroundLeases_iI_pid_usqft_c20210102__us-gaap--TypeOfArrangementAxis__custom--GarageStorageFacilityMember_z7KmWDyk23il" title="Land subject to ground leases">2,500</span> square feet from the property owner. Pursuant to the lease the Company agreed to issue <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210101__20210102__us-gaap--TypeOfArrangementAxis__custom--GarageStorageFacilityMember_zGkiF6mf0nli" title="Number of restricted shares issued">100,000,000</span> shares of restricted common stock. The shares were certificated on March 8, 2021, with an effective date of January 2, 2021. The Company valued the shares $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210102__us-gaap--TypeOfArrangementAxis__custom--GarageStorageFacilityMember_zDmcHQHHI00k" title="Shares issued, price per share">0.0063</span>, (the market value of the common stock on the date of the agreement) and has recorded $<span id="xdx_906_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_pp0p0_c20210102__us-gaap--TypeOfArrangementAxis__custom--GarageStorageFacilityMember_zpzRaDrIPIc2" title="Prepaid expense">630,000</span> as a prepaid expense. The Company never took occupancy of the space, and the property owner has agreed to purchase a different property and will assign the title of such property to the Company in consideration of the <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssuesForLeaseAgreement_pid_c20210101__20210102__us-gaap--TypeOfArrangementAxis__custom--GarageStorageFacilityMember_z14dLRTGEeGf" title="Shares issued for lease agreement, shares">100,000,000</span> shares he received in January 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2021, Ozop Capital entered into an advisory agreement (the “RMA Agreement”) with Risk Management Advisors, Inc. (“RMA”). Pursuant to the terms of the RMA Agreement, RMA will assist Ozop Capital in analyzing, structuring, and coordinating Ozop Capital’s participation in a captive insurance company. RMA will coordinate legal, accounting, tax, actuarial and other services necessary to implement the Company’s participation in a captive insurance company, including, but not limited to, the preparation of an actuarial feasibility study, filing of all required regulatory applications, domicile selection, structural selection, and coordination of the preparation of legal documentation. In connection with the services listed above, Ozop Capital agreed to pay $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20210828__20210902__us-gaap--TypeOfArrangementAxis__custom--RMAAgreementMember_zzmnSpSznip3" title="Payments of stock issuance costs">50,000</span> and to issue $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pp0p0_c20210828__20210902__us-gaap--TypeOfArrangementAxis__custom--RMAAgreementMember_zFeKou5GK1Rg" title="Number of restricted stock issued, value">50,000</span> of shares of restricted common stock. One-half of the cash and stock were due upon the signing of the RMA Agreement. Accordingly, RMA received $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210903__20210930__us-gaap--TypeOfArrangementAxis__custom--RMAAgreementMember_zkfGlWqimsYc" title="Payments of stock issuance costs">25,000</span> and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210903__20210930__us-gaap--TypeOfArrangementAxis__custom--RMAAgreementMember_zsUuadjTDK95" title="Number of restricted stock issued, shares">452,080</span> shares of restricted common stock of the Company in September 2021. The balance of the cash and stock became due on October 29, 2021, upon the issuance of the captive insurance company’s certificate of authority from the state of Delaware. The Company has paid the $<span id="xdx_90E_eus-gaap--PaymentsForParticipationLiabilities_pp0p0_c20220101__20220331_zw837BxwqBh9" title="Cash payments">25,000</span> balance and recorded <span id="xdx_904_eus-gaap--SharesIssued_iI_pid_c20220630_ztu7haNbWlq4" title="Issuance of common stock">637,755</span> shares of common stock to be issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2021, the Company agreed to engage PJN Strategies, LLC (“PJN”) as a consultant. Pursuant to the agreement, the Company agreed to compensate PJN $<span id="xdx_90B_ecustom--ConsultingExpense_pp0p0_c20210412__20210413__srt--TitleOfIndividualAxis__custom--PJNStrategiesMember_zvhxXoz2aCBg" title="Consulting expense">20,000</span> per month. Effective September 1, 2021, a new agreement was entered into between PJN and Ozop Capital. Pursuant to the terms of the new one- year agreement Ozop Capital agreed to compensate PJN $<span id="xdx_901_ecustom--ConsultingExpense_pp0p0_c20210830__20210901__srt--TitleOfIndividualAxis__custom--PJNStrategiesMember_zmB7DUr0VCS8" title="Consulting expense">84,000</span> per month. For the three and six months ended June 30, 2022, the Company recorded $<span id="xdx_90B_ecustom--ConsultingExpense_pp0p0_c20220401__20220630__srt--TitleOfIndividualAxis__custom--PJNStrategiesMember_zafJTz8O9J47" title="Consulting expense">252,000</span> and $<span id="xdx_903_ecustom--ConsultingExpense_pp0p0_c20220101__20220630__srt--TitleOfIndividualAxis__custom--PJNStrategiesMember_zncfjzeN75lj" title="Consulting expense">504,000</span>, respectively, of consulting expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 16, 2021, the Company signed a letter of agreement with Rubenstein Public Relations, Inc. (“RPR”). Pursuant to the letter of agreement, the Company agreed to engage RPR, effective May 1, 2021, on a month-to-month basis for $<span id="xdx_90A_ecustom--ConsultingExpense_pp0p0_c20210415__20210416__srt--TitleOfIndividualAxis__custom--RubensteinPublicRelationsMember_zQbs7jRuYQ76" title="Consulting expense">17,000</span> per month.. The Company terminated the agreement in October 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 30, 2021, OES hired 2 individuals as Co-Directors of Sales. Pursuant to their respective offers of employment, the Company agreed to an annual salary of $<span id="xdx_907_eus-gaap--OfficersCompensation_pp0p0_c20210329__20210330__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_zYglfhT2qAOk" title="Annual salary">130,000</span> with a signing bonus of $<span id="xdx_904_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_c20210330__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_zzAOBUw9eev6" title="Accrued bonus">20,000</span> for each and to issue each <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210329__20210330__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKb3CCqnDTDf" title="Number of shares issued, shares">2,500,000</span> shares of restricted common stock upon the execution of the agreements and every 90 days thereafter for the first year as long as the employee is still employed. The Company valued the initial shares at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210330__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMJb9fhYaZq4" title="Shares issued, price per share">0.092</span> per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z089WoYZu3ze" title="Share based compensation expenses">460,000</span> is included in stock-based compensation expense for the six months ended June 30, 2021. On January 14, 2022, the Company issued each of the Co-Directors their final <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220114__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_zv8hqXFU6GT2" title="Number of shares issued, shares">2,500,000</span> shares due. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220114__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_zk1ZqkM2qbBa" title="Shares issued, price per share">0.027</span> per share (the market price of the common stock on the date of the issuance), and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630_zc8i0eKqp9Ab" title="Share based compensation expenses">135,000</span> is included in stock-based compensation expense for the six months ended June 30, 2022. One of the individuals resigned on January 24, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 15, 2021, the Company entered into a consulting agreement with Aurora Enterprises (“Aurora”). Mr. Steven Martello is a principal of Aurora. Pursuant to the agreement Mr. Martello will provide strategic analysis regarding existing markets and revenue streams as well as the development of new lines of revenue. The Company agreed to a monthly retainer fee of $<span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20210314__20210315__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_z4AQM1Hwg4wj" title="Legal fees">10,000</span> and to issue to Aurora or their designee <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210314__20210315__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_zAj1VvG8rk3g" title="Number of restricted shares issued">5,000,000</span> shares of restricted common stock. The shares were issued in April 2021. Aurora designated the shares to be issued to Pegasus Partners, Inc. The Company valued the shares at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210315__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_zCimXARMMlnl" title="Shares issued, price per share">0.1392</span> per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210314__20210315__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_z9NijdRqVrH8" title="Stock Issued During Period, Shares, New Issues">696,000</span> is included in stock-based compensation expense for the six months ended June 30, 2021. For the three and six months ended June 30, 2022, the Company has recorded $<span id="xdx_90F_ecustom--ConsultingExpense_pp0p0_c20220401__20220630__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_z2T4tdJkhkAh" title="Consulting expense">30,000</span> and $<span id="xdx_901_ecustom--ConsultingExpense_pp0p0_c20220101__20220630__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_zLFK5yBBjajc" title="Consulting expense">60,000</span>, respectively, of consulting expenses, and for the three and six months ended June 30, 2021, the Company recorded consulting expenses of $xxx and $xxx, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2021, the Company entered into a consulting agreement with Christopher Ruppel. Pursuant to the agreement Mr. Ruppel was to join the Ozop Advisory Board. During the year ended December 31, 2021, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYJpkCAytVAf" title="Number of restricted shares issued">10,000,000</span> shares of restricted common stock to Mr. Ruppel and agreed to a monthly fee of $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zftrYfhAVQU5" title="Professional fees">2,500</span>. The Company valued the shares at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211231__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKrBT8g5xdea">0.2386</span> per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0NXlZsrpSad" title="Share based compensation expenses">2,386,000</span> is included in stock-based compensation expense for the six months ended June 30, 2021. Effective April 1, 2021, the agreement was amended to $<span id="xdx_903_eus-gaap--ProfessionalFees_pp0p0_c20220101__20220630__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardDateAxis__custom--AprilOneTwoThousandAndTwentyOneMember_zc9jxDJkUF4h" title="Professional fees">10,000</span> per month. Effective May 1, 2021, the Company was no longer using the services of Mr. Ruppel. For the three and six months ended June 30, 2021, the Company recorded $<span id="xdx_903_eus-gaap--ProfessionalFees_pp0p0_c20210401__20210630__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEUZrpdUL2C" title="Professional Fees">10,000</span> and $<span id="xdx_909_eus-gaap--ProfessionalFees_pp0p0_c20210101__20210630__srt--TitleOfIndividualAxis__custom--ChristopherRuppelMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkE51VwROpz2" title="ProfessionalFees">12,500</span> of consulting expenses, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 22, 2021, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210121__20210122__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRk1fMqwkGv9" title="Number of restricted shares issued">10,000,000</span> shares of restricted common stock for legal services performed in 2020 and approved by the BOD of the Company on December 1, 2020. The Company valued the shares at $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210122__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zywWfOcEfmE4" title="Shares issued, price per share">0.0056 </span>per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeJVRZ6iqwD8" title="Share based compensation expenses">56,000</span> is included in stock-based compensation expense for the six months ended June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 14, 2021, the Company entered into a Consulting Agreement with Mr. Allen Sosis. Pursuant to the agreement, Mr. Sosis will provide services as the Director of Business Development for the Company’s wholly owned subsidiary. Pursuant to the agreement, as amended, the Company will pay Mr. Sosis a monthly fee of $<span id="xdx_90F_eus-gaap--DueToOfficersOrStockholdersCurrentAndNoncurrent_iI_pp0p0_c20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zIvehCRuVNRk" title="Due to officers or stockholders">15,000</span> and an additional $<span id="xdx_90F_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pp0p0_c20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zpVHyzHtyU3i" title="Accrued employee benefits, current">1,000</span> in benefits. The Company also agreed to issue Mr. Sosis <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210113__20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zXbf5AtMs4Ti" title="Number of restricted shares issued">5,000,000</span> shares of restricted common stock. The shares were issued in April 2021. The Company valued the shares at $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zOymygZ5pph6" title="Shares issued, price per share">0.20</span> per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_90C_eus-gaap--DeferredCompensationEquity_iI_pp0p0_c20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zS22t8gYbAe6" title="Deferred compensation equity">1,000,000</span> was recorded as deferred stock compensation, to be amortized over the one-year term of the agreement. The Company terminated Mr. Sosis’s employment in October 2021. For the three and six months ended June 30, 2021, the Company recorded $<span id="xdx_90E_ecustom--ConsultingExpense_pp0p0_c20210401__20210630__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zgAlNIWPZzG6" title="Consulting expense">30,000</span> and $<span id="xdx_909_ecustom--ConsultingExpense_pp0p0_c20210101__20210630__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zflL15iAjC96" title="Consulting expense">75,500</span> of consulting expenses and effective June 1, 2021, Mr. Sosis became an employee of the Company through his termination with a $<span id="xdx_903_eus-gaap--SalariesAndWages_pp0p0_c20210114__20210114__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuXojfkd0zK1" title="Salary">15,000</span> per month salary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 6, 2021, the Company entered into a consulting agreement with Ezra Green to begin on February 8, 2021. The Company agreed to issue <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210105__20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zb0xM3iqI9Fa" title="Number of restricted shares issued">10,000,000</span> shares of restricted common stock to Mr. Green and to a monthly fee of $<span id="xdx_909_eus-gaap--ProfessionalFees_pp0p0_c20210105__20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVPDsfc6ZvHk" title="Professional fees">2,500</span>. The Company valued the shares at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjQhJudy0Neh" title="Shares issued, price per share">0.0076</span> per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_906_eus-gaap--DeferredCompensationEquity_iI_pp0p0_c20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSljws1fV1yf" title="Deferred compensation equity">76,000</span> was recorded as deferred stock-based compensation, to be amortized over the one-year term of the agreement. For the six months ended June 30, 2022, and 2021, the Company recorded $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pid_c20220101__20220630__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zygpcflY4Qi3" title="Share Based Compensation Expense">1,249</span> and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pid_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zT6cfmBhm988" title="Share Based Compensation Expense">36,348</span> as stock-based compensation expense, respectively. Effective April 1, 2021, the agreement was amended to $<span id="xdx_902_eus-gaap--DueToOfficersOrStockholdersCurrentAndNoncurrent_iI_pp0p0_c20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxwjgPiA1J9" title="Due to officers or stockholders">10,000</span> per month. For the three and six months ended June 30, 2022, the Company recorded $<span id="xdx_903_ecustom--ConsultingExpense_pp0p0_c20210401__20210630__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrOzZMdXJ6h3" title="Consulting expense">30,000</span> and $<span id="xdx_90E_ecustom--ConsultingExpense_pp0p0_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgW55PhA2LL9" title="Consulting expense">60,000</span>, respectively, of consulting expenses and for the three and six months ended June 30, 2021, the Company recorded $<span id="xdx_902_ecustom--ConsultingExpense_pp0p0_c20220401__20220630__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCCw25PyIr8l" title="Consulting expense">30,000</span> and $<span id="xdx_90C_ecustom--ConsultingExpense_pp0p0_c20220101__20220630__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr5fgSPrV2Jd" title="Consulting expense">34,500 </span>of consulting expenses, respectively. Effective June 30, 2022, Mr. Green was no longer providing consulting services to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 4, 2019, the Company entered into a Separation Agreement (the “Separation Agreement”) with Salman J. Chaudhry, pursuant to which the Company agreed to pay Mr. Chaudry $<span id="xdx_90C_eus-gaap--DueToOfficersOrStockholdersCurrent_iI_pp0p0_c20190304__srt--TitleOfIndividualAxis__custom--SalmanJChaudhryMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember_zXXeqrlPKiCa" title="Due to officers or stockholders, current">227,200</span> (the “Outstanding Fees”) in certain increments as set forth in the Separation Agreement. As of June 30, 2022 and December 31, 2021, the balance owed Mr. Chaudhry is $<span id="xdx_909_eus-gaap--NotesPayable_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--SalmanJChaudhryMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember_zQz8PFOBMDnc" title="Notes payable"><span id="xdx_90D_eus-gaap--NotesPayable_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--SalmanJChaudhryMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember_zK3nhJJXf943" title="Notes payable">162,085</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 2, 2020, PCTI entered into an Agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $<span id="xdx_906_eus-gaap--ProfessionalFees_pp0p0_c20200901__20200902__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zD8cOipXlzr7" title="Professional fees">750,000</span>, <span id="xdx_90D_eus-gaap--CollaborativeArrangementRightsAndObligations_c20200901__20200902__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zR5ff4lI9PAb" title="Collaborative arrangement, rights and obligations">PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement</span>. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the agreement was amended, whereby in exchange for <span id="xdx_90C_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_pid_c20210225__20210226__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zzQVFwBqIOyh" title="Number of common stock exchanged">175,000,000</span> shares of common stock, the royalty percentage was amended to <span id="xdx_902_ecustom--RoyaltyPercentage_pid_dp_uPure_c20210225__20210226__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zBVlcuFoM6u" title="Royalty percentage">1.8</span>% (see Note 8). The Company valued the shares at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210630__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zM7u0H2arj12" title="Shares issued, price per share">0.094</span> per share (the market value of the common stock on the date of the agreement) and recorded $<span id="xdx_904_eus-gaap--PaymentsOfDebtRestructuringCosts_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zXNm7Q4QqMci" title="Payments of debt restructuring costs">16,450,000</span> as debt restructure expense on the condensed consolidated statement of operations for the six months ended June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal matters</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P10Y 2500 100000000 0.0063 630000 100000000 50000 50000 25000 452080 25000 637755 20000 84000 252000 504000 17000 130000 20000 2500000 0.092 460000 2500000 0.027 135000 10000 5000000 0.1392 696000 30000 60000 10000000 2500 0.2386 2386000 10000 10000 12500 10000000 0.0056 56000 15000 1000 5000000 0.20 1000000 30000 75500 15000 10000000 2500 0.0076 76000 1249 36348 10000 30000 60000 30000 34500 227200 162085 162085 750000 PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement 175000000 0.018 0.094 16450000 <p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zkaUobkSEH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12–<span id="xdx_823_zuKDfbKv8mFe"> STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2022, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zstLGf9Sl47c" title="Number of shares issued, shares">5,000,000</span> shares of restricted common stock in the aggregate for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the period from January 1, 2021, to June 30, 2021, holders of an aggregate of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210630_zOTPCSh3yoNc" title="Debt instrument principal">760,550</span> in principal and $<span id="xdx_90C_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20210101__20210630_zvm60WBcxoBl" title="Debt instrument, accrued interest">201,905</span> of accrued interest and fees of convertible and promissory notes, converted their debt into <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20210630_zmQogYUzOQ25" title="Debt conversion, converted instrument, shares issued">483,154,618</span> shares of our common stock at an average conversion price of $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210630_zEN8aCDOPWal" title="Debt instrument, convertible, conversion price">0.002</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30 2021, the Company also issued the following shares of restricted common stock:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zgD78DGIBLD3" title="Number of shares issued, shares">100,000,000</span> shares of restricted common stock pursuant to a lease agreement (see Note 10).</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_pid_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--RestructuringAgreementMember_ze3BLMBZGndg" title="Deferred compensation shares issued">175,000000</span> shares of restricted common stock pursuant to restructuring agreement related to a deferred liability (see Note 9).</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zSm95RhgWKw6" title="Number of shares issued, shares">45,000,000</span> shares of restricted common stock in the aggregate for services and consulting agreements.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2021, the Company also issued <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210630_z3VF7IKRKhJ2" title="Purchase of warrants">405,797,987</span> shares of common stock upon the cashless exercise of common stock purchase warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022, the Company has <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20220630_zJJakhj2Mt2l" title="Common stock shares authorized">4,990,000,000</span> shares of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220630_z2DXRoUgP5Ii" title="Common stock par value">0.001</span> par value common stock authorized and there are <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_c20220630_zIxQlVIAA7U" title="Common Stock, Shares, Issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20220630_z0Wf0U823KD" title="Common Stock, Shares outstanding">4,622,362,977</span></span> shares of common stock issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 4th, 2022, the Company and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “GHS Purchase Agreement”) for the sale of up to Two Hundred Million (<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220404__us-gaap--TypeOfArrangementAxis__custom--RegistrationStatementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--GHSInvestmentsMember_zgWt8QGIDQe5" title="Stock Issued During Period, Shares, New Issues">200,000,000</span>) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20220401__20220404__us-gaap--TypeOfArrangementAxis__custom--RegistrationStatementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--GHSInvestmentsMember_zqPxcCfNUOFe" title="Debt Instrument, Maturity Date">October 4, 2022</span>, at our sole discretion, to GHS under the GHS Purchase Agreement. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022, and December 31, 2021, <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20220630_zIYNucUmFKXl" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_zx2QQ0fAhCq7" title="Preferred stock, shares authorized">10,000,000</span></span> shares have been authorized as preferred stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220630_zYFZ0c40mPha" title="Preferred stock Par value"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_zXisrgcBYC5b" title="Preferred stock Par value">0.001</span></span> (the “Preferred Stock”), which such Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series C Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2020, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company’s Series C Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series C Preferred Stock, <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zfuUyqbXnH6g" title="Preferred stock, shares authorized">50,000</span> shares of the Company’s preferred remain designated as Series C Preferred Stock. <span id="xdx_90A_eus-gaap--PreferredStockVotingRights_c20200706__20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zH9z2CKnw6h4" title="Preferred stock, voting rights">The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote</span>. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200706__20200710__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zGpgzU54YJo8" title="Number of shares issued, shares">47,500</span> shares of Series C preferred Stock to Chis. On July 13, 2021, the Company purchased <span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20210701__20210713__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__dei--LegalEntityAxis__custom--ChisMember_zND6s8JCUHol" title="Number of purchased shares">47,500</span> shares of the Company’s Series C Preferred Stock held by Chis (see Note 11). As of June 30, 2022, and December 31, 2021, there were <span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zl1gBHeuFj41" title="Preferred stock shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zHJetm5qbs7b" title="Preferred stock shares outstanding">2,500</span></span> shares of Series C Preferred Stock issued and outstanding and the shares are held by Mr. Conway.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series D Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series D Preferred Stock. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200706__20200710__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zDoZog0lalMc" title="Number of shares issued, shares">18,667</span> shares of Series D preferred Stock to Chis, and on August 28, 2020, pursuant to Mr. Conway’s employment agreement, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200827__20200828__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zqUiuCbH1JQ" title="Number of shares issued, shares">1,333</span> shares of Series D Preferred Stock to Mr. Conway. On July 13, 2021, the Company purchased <span id="xdx_90C_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20210701__20210713__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__dei--LegalEntityAxis__custom--ChisMember_zl8WZBivbQWl" title="Number of purchased shares">18,667</span> shares of the Company’s Series D Preferred Stock held by Chis (see Note 10).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 27, 2021, the Company filed with the Secretary of State of the State of Nevada an Amended and Restated Certificate of Designation of Series D Preferred Stock (the “Series D Amendment”). Under the terms of the Series D Amendment, <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210727__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDAmendmentMember_zmraVm5wn0Ok" title="Preferred stock, shares authorized">4,570</span> shares of the Company’s preferred stock will be designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. Any holder may, at any time convert any number of shares of Series D Convertible Preferred Stock held by such holder into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by <span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20210727__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDAmendmentMember_zDZ3b8zSwXFi" title="Preferred Stock, Convertible, Conversion Price">1.5</span> and dividing that number by the number of authorized shares of Series D Convertible Preferred Stock and multiply that result by the number of shares of Series D Convertible Preferred Stock being converted. Except as provided in the Series D Amendment or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 28, 2021, the Company closed on a Stock and Warrant Purchase Agreement (the “Series D SPA”). Pursuant to the terms of Series D SPA, an investor in exchange for $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pp0p0_c20210701__20210728__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDSPAMember_zbnzK3FMdFq6" title="Proceeds from Issuance of Preferred Stock and Preference Stock">13,200,000</span> purchased one share of Series D Preferred Stock, and a warrant to acquire <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210728__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDSPAMember_zn6DSYSgSBHf" title="Purchase of warrants">3,236</span> shares of Series D Preferred Stock. As of June 30, 2022, and December 31, 2021, there were <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zBhFhZ737U11" title="Preferred stock shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zR4hV8L4Jtfe" title="Preferred stock shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z69qKUCN5W5e" title="Preferred stock shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zNe8aRboLqmj" title="Preferred stock shares outstanding">1,334</span></span></span></span> shares, respectively, of Series D Preferred Stock issued and outstanding and a warrant to purchase 3,236 shares of Series D Preferred Stock are outstanding as of June 30, 2022, and December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrant has a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1ZD4IDCuRQf" title="Warrants term">15</span>- year term and Partial Warrant Lock Up and Leak-Out Period. The Holder may only exercise the Warrant and purchase Warrant Shares as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGJF4qHkODz3" title="Warrant exercise">162</span> (one hundred and sixty-two) Warrant Shares, at any time or times on or after five (5) business days from the closing of the Series D SPA (“the Initial Exercise Date”) subject to up to a maximum number of Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company and no later than on or before the 15<sup>th</sup> year anniversary of the Initial Exercise Date (“the Termination Date”); and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Remainder of the Warrant representing up to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220630__us-gaap--AwardTypeAxis__custom--RemainingWarrantSharesMember_zoDdANU4LDd9" title="Warrant exercise">3,074</span> (three thousand and seventy-four) Warrant Shares (“Remaining Warrant Shares”) shall be locked up for a period of 36 (thirty-six) months from the Initial Exercise Date (“Lock Up Period”) and shall become exercisable at any time or times from the date that is the 36 (thirty-six) month anniversary of the Initial Exercise Date (“Lock Up Period Termination Date”) and no later than on or before the Termination Date, as follows:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z0JF9meIqSb2" title="Warrant exercise, description">During every 1 (one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034 and until the Termination Date</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series E Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series E Preferred Stock. Under the terms of the Certificate of Designation of Series E Preferred Stock, <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zkMypmXZplPd" title="Preferred stock, shares authorized">3,000</span> shares of the Company’s preferred stock have been designated as Series E Preferred Stock. The holders of the Series E Convertible Preferred Stock shall not be entitled to receive dividends. No holder of the Series E Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, except as may be otherwise expressly required by law. At any time, the Corporation may redeem for cash out of funds legally available therefor, any or all of the outstanding Preferred Stock (“Optional Redemption”) at $<span id="xdx_902_eus-gaap--PreferredStockRedemptionAmount_iI_pp0p0_c20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zyZLi3tRjmB7" title="Preferred stock, redemption amount">1,000</span> (one thousand dollars) per share. The shares of Series E Preferred Stock have not been registered under the Securities Act of 1933 or the laws of any state of the United States and may not be transferred without such registration or an exemption from registration. On July 10, 2020, pursuant to the SPA with PCTI, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200709__20200710__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChisMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zH4rQmeraUVe" title="Number of shares issued, shares">500</span> shares of Series E preferred Stock to Chis, and on August 28, 2020. Pursuant to Mr. Conway’s employment agreement, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200827__20200828__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConwayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zoyt2JIfeG88" title="Number of shares issued, shares">500</span> shares of Series E Preferred Stock to Mr. Conway. On March 2, 2021, the BOD authorized the issuance of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210301__20210302__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_ztICbo7fxU5f" title="Number of shares issued, shares">1,800</span> shares of Series E Preferred Stock to Mr. Conway and <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210301__20210302__srt--TitleOfIndividualAxis__custom--ThirdPartyMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zNPFk6SIOKF5" title="Number of shares issued, shares">200</span> shares of Series E Preferred Stock to a third-party service provider. The issuances were for services performed. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $<span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20210302__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zRqLRlnZN541" title="Preferred stock, redemption price per share">1,000</span> per share, the Company recorded $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__srt--TitleOfIndividualAxis__custom--MrConvayMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zMHp1YgK4ZF" title="Share-based payment arrangement, expense">2,000,000</span> as stock-based compensation expense for expense for the six months ended June 30, 2021. On March 24, 2021, the Company redeemed the <span id="xdx_902_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20210322__20210324__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zlH6olCLmjG9" title="Number of stock redeemed">3,000</span> shares of Series E Preferred Stock outstanding on that date. On April 16, 2021, the BOD authorized the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210415__20210416__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrConvayMember_zKLz4eDzrPyh">2,000</span> shares of Series E Preferred stock, of which <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20210415__20210416__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrConvayMember_ziR9isvDDC6i" title="Shares granted">1,050</span> were granted to Mr. Conway. The issuances were for services performed. Pursuant to the terms and conditions of the Certificate of Designation of the Series E Preferred Stock, including the redemption value of $<span id="xdx_90A_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20210416__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrConvayMember_zZru9P3NdAnl" title="Preferred stock redemption price per share">1,000</span> per share, the Company recorded $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pid_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrConvayMember_ztigxvXB6H3j" title="Stock based compensation"><span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pid_c20210401__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrConvayMember_zrFAV2lDhQih">2,000,000</span></span> as stock-based compensation expense for the three and six months ended June 30, 2021. As of June 30, 2022, and December 31, 2021, there were -<span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zD0joXZ71Et3" title="Preferred stock shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zeoddkFr2FN9" title="Preferred stock shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z2k7aWqfExf4" title="Preferred stock shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zc8djLbjR5G8" title="Preferred stock shares outstanding">0</span></span></span></span>- shares of Series E Preferred Stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 5000000 760550 201905 483154618 0.002 100000000 175000000 45000000 405797987 4990000000 0.001 4622362977 4622362977 200000000 2022-10-04 10000000 10000000 0.001 0.001 50000 The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote 47500 47500 2500 2500 18667 1333 18667 4570 1.5 13200000 3236 1334 1334 1334 1334 P15Y 162 3074 During every 1 (one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034 and until the Termination Date 3000 1000 500 500 1800 200 1000 2000000 3000 2000 1050 1000 2000000 2000000 0 0 0 0 <p id="xdx_80C_eus-gaap--OtherComprehensiveIncomeNoncontrollingInterestTextBlock_zxA7AmCUUMKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13 – <span id="xdx_825_zGqMU1rF2n3c">NONCONTROLLING INTEREST</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 19, 2021, the Company formed Ozop Capital. The Company owns <span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20210819__srt--OwnershipAxis__custom--BrianConwayMember_zoBhphnSggWb" title="Noncontrolling interest percentage">51</span>% with PJN owning <span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20210819__srt--OwnershipAxis__custom--PJNStrategiesMember_zmBvhTFWXQdh" title="Noncontrolling interest percentage">49</span>%. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital. The Company presents interest held by noncontrolling interest holders within noncontrolling interest in the condensed consolidated financial statements. During the six months ended June 30, 2022, there was no change in the ownership percentages. For the three and six months ended June 30, 2022, Ozop Capital incurred losses of $<span id="xdx_908_eus-gaap--IncomeLossAttributableToNoncontrollingInterest_pp0p0_c20220401__20220630_z5JvRrwjLDff" title="Noncontrolling interest loss">351,835</span> and $<span id="xdx_906_eus-gaap--IncomeLossAttributableToNoncontrollingInterest_pp0p0_c20220101__20220630_zE7g2tQZftdk" title="Noncontrolling interest loss">734,912</span>, respectively, of which $<span id="xdx_909_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pp0p0_di_c20220401__20220630_z7cY5GDcwlXi" title="Noncontrolling interest">172,399</span> and $<span id="xdx_90A_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pp0p0_di_c20220101__20220630_zNww81g8Qwyg" title="Noncontrolling interest">360,107</span>, respectively, is the loss attributed to the noncontrolling interest for the three- and six- months ending June 30, 2022. As of June 30, 2022, the accumulative noncontrolling interest is $<span id="xdx_90B_ecustom--AccumulativeNoncontrollingInterest_iI_c20220630_zb9crAS46rG3" title="Accumulative noncontrolling interest">615,212</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.51 0.49 351835 734912 -172399 -360107 615212 <p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_znXjUxZnd4Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14 - <span id="xdx_820_z1qd2EXeW5z4">OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 25, 2019, PCTI executed a non-cancellable lease for office and industrial space which began December 1, 2019 and expires on <span id="xdx_906_eus-gaap--LeaseExpirationDate1_dd_c20220101__20220630_z0CMXHAIRaag" title="Lease expiration date">November 30, 2022</span>. Operating lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220630_zIcXvadl0uh8" title="Operating lease disount rate">7.5</span>%, as the interest rate implicit in most of our leases is not readily determinable. Prior to July 10, 2020, PCTI recorded monthly lease expense pursuant to the lease agreement and effective July 10, 2020, pursuant to the PCTI transaction, operating lease expense is recognized pursuant to ASC Topic 842. Leases (Topic 842) over the lease term. During the years ended December 31, 2020, the Company recorded $<span id="xdx_909_eus-gaap--OperatingLeasesRentExpenseNet_pp0p0_c20200101__20201231_zTUzMmS92cM" title="Operating lease rent expense">84,278</span> for rent expense. During the year ended December 31, 2020, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $<span id="xdx_902_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zkwDJj4wX8Ee" title="Operating lease liability"><span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_z290fF6MJtuj" title="RIght of use of asset">185,139</span></span> for this lease.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 14, 2021, the Company entered into a <span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtYxL_c20210414_z1tYwTmpVgGd" title="Operating lease term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1955">five</span></span>-year lease which began on June 1, 2021, for approximately <span id="xdx_90D_eus-gaap--AreaOfLand_iI_usqft_c20210414_zo3kC40xxSv3" title="Area of land">8,100</span> square feet of office and warehouse space in Carlsbad, California, expiring <span id="xdx_90B_eus-gaap--LeaseExpirationDate1_dd_c20210411__20210414__srt--StatementGeographicalAxis__country--CA_zMeTWNQP0S4f" title="Lease expiration date">May 31, 2026</span>. Initial lease payments of $<span id="xdx_908_eus-gaap--OperatingLeasePayments_pp0p0_c20210411__20210414__srt--StatementGeographicalAxis__country--CA_z88vofQYaFPb" title="Operating lease payments">13,148</span> began on June 1, 2021, and increase by approximately <span id="xdx_90A_ecustom--OperatingLeasePayementsIncreasePercentage_iI_pid_dp_uPure_c20210414__us-gaap--AwardTypeAxis__custom--ThereafterMember_zAbXXyfA7b6a" title="Lease payments increase percentage">2.4</span>% annually thereafter. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be <span id="xdx_901_ecustom--OperatingLeasePayementsIncreasePercentage_iI_pid_dp_uPure_c20210414__srt--StatementGeographicalAxis__country--CA_zfZZa4v5K3Od" title="Lease payments increase percentage">7.5</span>%, as the interest rate implicit in most of our leases is not readily determinable. During the year ended December 31, 2021, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $<span id="xdx_906_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_ztn1DzuM49z6" title="RIght of use of asset"><span id="xdx_90D_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20211231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zN85KYuIpDek" title="Operating lease liability">702,888</span></span> for this lease.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In adopting Topic 842, the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfRightofUseAssetsTableTextBlock_zegOzmlu5Qs" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of- use assets are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none"><span id="xdx_8B4_zgFum3qs3A41">SCHEDULE OF RIGHT-OF-USE ASSETS</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220630_zdXLCetZO9c9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_pp0p0_maOLROUzSPd_zP3FUuoQMNB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Office and warehouse lease</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">888,026</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iNI_pp0p0_di_msOLROUzSPd_z86xKx3TZUQ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Accumulated Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(281,498</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_pp0p0_mtOLROUzSPd_zzVja9mQ3Hsg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Right-of-use asset, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">606,078</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zI2VTAjkjDB8" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_ecustom--ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_zXh3AUmnXVre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8BA_zf1rdDPmIVCj">SCHEDULE OF OPERATING LEASE LIABILITIES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220630_zNQeTTiNy7Of" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pp0p0_za3V7a6H9Vdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Lease liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">614,247</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zGPUcbNSVsz5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(161,048</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zLh6NBsrAzT8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">453,199</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_ziPLXC3P2gy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zF8WjLed2Pa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity of lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B4_z5xXi1lAlwWj">SCHEDULE OF MATURITY OF LEASE LIABILITIES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220630_z8i9G2Kla82e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzPVR_zFUXyQaZx2T4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">For the year ended December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">117,788</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzPVR_zwPxkmsQgk8h" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">For the year ended December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">167,858</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzPVR_z7tbAxlIrLDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">For the year ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,840</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzPVR_zqEDmqMtMLad" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">For the year ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,942</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzPVR_zWOOTniy66X4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">For the year ended December 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzPVR_zqT2FJVEDvl6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">707,458</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zUKbr7qTVESb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(93,211</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">614,247</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zucI4ipDiQUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2022-11-30 0.075 84278 185139 185139 8100 2026-05-31 13148 0.024 0.075 702888 702888 <p id="xdx_89B_ecustom--ScheduleOfRightofUseAssetsTableTextBlock_zegOzmlu5Qs" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of- use assets are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none"><span id="xdx_8B4_zgFum3qs3A41">SCHEDULE OF RIGHT-OF-USE ASSETS</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220630_zdXLCetZO9c9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_pp0p0_maOLROUzSPd_zP3FUuoQMNB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Office and warehouse lease</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">888,026</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iNI_pp0p0_di_msOLROUzSPd_z86xKx3TZUQ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Accumulated Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(281,498</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_pp0p0_mtOLROUzSPd_zzVja9mQ3Hsg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Right-of-use asset, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">606,078</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 888026 281498 606078 <p id="xdx_89D_ecustom--ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_zXh3AUmnXVre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8BA_zf1rdDPmIVCj">SCHEDULE OF OPERATING LEASE LIABILITIES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220630_zNQeTTiNy7Of" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pp0p0_za3V7a6H9Vdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Lease liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">614,247</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zGPUcbNSVsz5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(161,048</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zLh6NBsrAzT8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">453,199</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 614247 161048 453199 <p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zF8WjLed2Pa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity of lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B4_z5xXi1lAlwWj">SCHEDULE OF MATURITY OF LEASE LIABILITIES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220630_z8i9G2Kla82e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzPVR_zFUXyQaZx2T4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">For the year ended December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">117,788</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzPVR_zwPxkmsQgk8h" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">For the year ended December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">167,858</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzPVR_z7tbAxlIrLDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">For the year ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,840</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzPVR_zqEDmqMtMLad" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">For the year ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,942</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzPVR_zWOOTniy66X4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">For the year ended December 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzPVR_zqT2FJVEDvl6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">707,458</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zUKbr7qTVESb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(93,211</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">614,247</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 117788 167858 171840 175942 74030 707458 93211 614247 <p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zZ3hiv6zbTnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15 – <span id="xdx_820_zZTs9MyqOWxl">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 15, 2022, the Company sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220714__20220715__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8du1dZPhz2g" title="Stock issued during the period, shares">15,353,952</span> shares to GHS at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220715__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq9xS6aiw1fg" title="Price per share">0.010285</span> and received net proceeds of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220714__20220715__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEnhZ5H9QVBj" title="Stock issued during the period">152,732</span>, after deducting transaction and broker fees of $<span id="xdx_90E_eus-gaap--FloorBrokerage_c20220714__20220715__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNiGUEDuPRZh" title="Brokerage fees">5,183</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 1, 2022, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220731__20220801__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zK3ACq9RBO3d" title="Stock issued during the period, shares">7,675,221</span> shares to GHS at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220801__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWdchyOeSvnf" title="Price per share">0.010965</span> and received net proceeds of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220731__20220801__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z45494eYPudl" title="Stock issued during the period">81,451</span>, after deducting transaction and broker fees of $<span id="xdx_900_eus-gaap--FloorBrokerage_c20220731__20220801__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCRejkSHUfva" title="Brokerage fees">2,708</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 4, 2022, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220803__20220804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7N5ibQtA443" title="Stock issued during the period, shares">8,136,272</span> shares to GHS at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuLUwtHJahl2" title="Price per share">0.010965</span> and received net proceeds of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220803__20220804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz051GCf6G8f" title="Stock issued during the period">86,405</span>, after deducting transaction and broker fees of $<span id="xdx_906_eus-gaap--FloorBrokerage_c20220803__20220804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyMUSNQONkYg" title="Brokerage fees">2,809</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 10, 2022, the Company sold <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220809__20220810__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxZ1nwZOcYfe" title="Stock issued during the period, shares">18,063,649</span> shares to GHS at $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220810__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zirPH1RtFEA" title="Price per share">0.01088</span> and received net proceeds of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220809__20220810__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd7gJ7n8LTgk" title="Stock issued during the period">191,577</span>, after deducting transaction and broker fees of $<span id="xdx_909_eus-gaap--FloorBrokerage_c20220809__20220810__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQctR6rjayYi" title="Brokerage fees">4,956</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements, except as stated herein.</span></p> 15353952 0.010285 152732 5183 7675221 0.010965 81451 2708 8136272 0.010965 86405 2809 18063649 0.01088 191577 4956 The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise. EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 422 294 1 true 126 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://ir.ozopsurgical.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheet (Unaudited) Sheet http://ir.ozopsurgical.com/role/BalanceSheet Condensed Consolidated Balance Sheet (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) Sheet http://ir.ozopsurgical.com/role/BalanceSheetParenthetical Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statement of Operations (Unaudited) Sheet http://ir.ozopsurgical.com/role/StatementOfOperations Condensed Consolidated Statement of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) Sheet http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet http://ir.ozopsurgical.com/role/StatementOfCashFlows Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION Sheet http://ir.ozopsurgical.com/role/Organization ORGANIZATION Notes 7 false false R8.htm 00000008 - Disclosure - GOING CONCERN AND MANAGEMENT???S PLANS Sheet http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans GOING CONCERN AND MANAGEMENT???S PLANS Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Notes 9 false false R10.htm 00000010 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://ir.ozopsurgical.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 10 false false R11.htm 00000011 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://ir.ozopsurgical.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - DERIVATIVE LIABILITIES Sheet http://ir.ozopsurgical.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 12 false false R13.htm 00000013 - Disclosure - NOTES PAYABLE Notes http://ir.ozopsurgical.com/role/NotesPayable NOTES PAYABLE Notes 13 false false R14.htm 00000014 - Disclosure - DEFERRED LIABILITY Sheet http://ir.ozopsurgical.com/role/DeferredLiability DEFERRED LIABILITY Notes 14 false false R15.htm 00000015 - Disclosure - DEFERRED REVENUE Sheet http://ir.ozopsurgical.com/role/DeferredRevenue DEFERRED REVENUE Notes 15 false false R16.htm 00000016 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://ir.ozopsurgical.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://ir.ozopsurgical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 17 false false R18.htm 00000018 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://ir.ozopsurgical.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 18 false false R19.htm 00000019 - Disclosure - NONCONTROLLING INTEREST Sheet http://ir.ozopsurgical.com/role/NoncontrollingInterest NONCONTROLLING INTEREST Notes 19 false false R20.htm 00000020 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES Sheet http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES Notes 20 false false R21.htm 00000021 - Disclosure - SUBSEQUENT EVENTS Sheet http://ir.ozopsurgical.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 21 false false R22.htm 00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) Policies 22 false false R23.htm 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) Tables http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements 23 false false R24.htm 00000024 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://ir.ozopsurgical.com/role/PropertyAndEquipment 24 false false R25.htm 00000025 - Disclosure - DERIVATIVE LIABILITIES (Tables) Sheet http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables DERIVATIVE LIABILITIES (Tables) Tables http://ir.ozopsurgical.com/role/DerivativeLiabilities 25 false false R26.htm 00000026 - Disclosure - NOTES PAYABLE (Tables) Notes http://ir.ozopsurgical.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://ir.ozopsurgical.com/role/NotesPayable 26 false false R27.htm 00000027 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables RELATED PARTY TRANSACTIONS (Tables) Tables http://ir.ozopsurgical.com/role/RelatedPartyTransactions 27 false false R28.htm 00000028 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables) Sheet http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables) Tables http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities 28 false false R29.htm 00000029 - Disclosure - ORGANIZATION (Details Narrative) Sheet http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative ORGANIZATION (Details Narrative) Details http://ir.ozopsurgical.com/role/Organization 29 false false R30.htm 00000030 - Disclosure - GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Details http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans 30 false false R31.htm 00000031 - Disclosure - SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) Sheet http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) Details 31 false false R32.htm 00000032 - Disclosure - SCHEDULE OF INVENTORY (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails SCHEDULE OF INVENTORY (Details) Details 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details) Details 33 false false R34.htm 00000034 - Disclosure - DISAGGREGATION OF REVENUE (Details) Sheet http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails DISAGGREGATION OF REVENUE (Details) Details 34 false false R35.htm 00000035 - Disclosure - SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) Details 35 false false R36.htm 00000036 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Details 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical) Sheet http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical) Details 37 false false R38.htm 00000038 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) Details http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables 38 false false R39.htm 00000039 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables 39 false false R40.htm 00000040 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables 40 false false R41.htm 00000041 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://ir.ozopsurgical.com/role/ConvertibleNotesPayable 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) Details 42 false false R43.htm 00000043 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) Sheet http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative DERIVATIVE LIABILITIES (Details Narrative) Details http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables 43 false false R44.htm 00000044 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) Notes http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails SCHEDULE OF NOTES PAYABLE (Details) Details 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) Notes http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) Details 45 false false R46.htm 00000046 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://ir.ozopsurgical.com/role/NotesPayableTables 46 false false R47.htm 00000047 - Disclosure - DEFERRED LIABILITY (Details Narrative) Sheet http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative DEFERRED LIABILITY (Details Narrative) Details http://ir.ozopsurgical.com/role/DeferredLiability 47 false false R48.htm 00000048 - Disclosure - DEFERRED REVENUE (Details Narrative) Sheet http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative DEFERRED REVENUE (Details Narrative) Details http://ir.ozopsurgical.com/role/DeferredRevenue 48 false false R49.htm 00000049 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails SCHEDULE OF EXPENSES TO OFFICERS (Details) Details 49 false false R50.htm 00000050 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables 50 false false R51.htm 00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://ir.ozopsurgical.com/role/CommitmentsAndContingencies 51 false false R52.htm 00000052 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://ir.ozopsurgical.com/role/StockholdersEquity 52 false false R53.htm 00000053 - Disclosure - NONCONTROLLING INTEREST (Details Narrative) Sheet http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative NONCONTROLLING INTEREST (Details Narrative) Details http://ir.ozopsurgical.com/role/NoncontrollingInterest 53 false false R54.htm 00000054 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails SCHEDULE OF RIGHT-OF-USE ASSETS (Details) Details 54 false false R55.htm 00000055 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITIES (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails SCHEDULE OF OPERATING LEASE LIABILITIES (Details) Details 55 false false R56.htm 00000056 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) Details 56 false false R57.htm 00000057 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative) Sheet http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative) Details http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables 57 false false R58.htm 00000058 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://ir.ozopsurgical.com/role/SubsequentEvents 58 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:WarrantsAndRightsOutstandingTerm - form10-q.htm 191, 192, 197 form10-q.htm ex31-1.htm ex31-2.htm ex32-1.htm ozsc-20220630.xsd ozsc-20220630_cal.xml ozsc-20220630_def.xml ozsc-20220630_lab.xml ozsc-20220630_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 75 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 27, "contextCount": 422, "dts": { "calculationLink": { "local": [ "ozsc-20220630_cal.xml" ] }, "definitionLink": { "local": [ "ozsc-20220630_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "ozsc-20220630_lab.xml" ] }, "presentationLink": { "local": [ "ozsc-20220630_pre.xml" ] }, "schema": { "local": [ "ozsc-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 564, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 118, "http://ir.ozopsurgical.com/20220630": 53, "http://xbrl.sec.gov/dei/2022": 4, "total": 175 }, "keyCustom": 45, "keyStandard": 249, "memberCustom": 89, "memberStandard": 34, "nsprefix": "OZSC", "nsuri": "http://ir.ozopsurgical.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://ir.ozopsurgical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://ir.ozopsurgical.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - CONVERTIBLE NOTES PAYABLE", "role": "http://ir.ozopsurgical.com/role/ConvertibleNotesPayable", "shortName": "CONVERTIBLE NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - DERIVATIVE LIABILITIES", "role": "http://ir.ozopsurgical.com/role/DerivativeLiabilities", "shortName": "DERIVATIVE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - NOTES PAYABLE", "role": "http://ir.ozopsurgical.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:DeferredLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - DEFERRED LIABILITY", "role": "http://ir.ozopsurgical.com/role/DeferredLiability", "shortName": "DEFERRED LIABILITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:DeferredLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - DEFERRED REVENUE", "role": "http://ir.ozopsurgical.com/role/DeferredRevenue", "shortName": "DEFERRED REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://ir.ozopsurgical.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://ir.ozopsurgical.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://ir.ozopsurgical.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - NONCONTROLLING INTEREST", "role": "http://ir.ozopsurgical.com/role/NoncontrollingInterest", "shortName": "NONCONTROLLING INTEREST", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheet (Unaudited)", "role": "http://ir.ozopsurgical.com/role/BalanceSheet", "shortName": "Condensed Consolidated Balance Sheet (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES", "role": "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - SUBSEQUENT EVENTS", "role": "http://ir.ozopsurgical.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - DERIVATIVE LIABILITIES (Tables)", "role": "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables", "shortName": "DERIVATIVE LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:ScheduleOfNotesPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - NOTES PAYABLE (Tables)", "role": "http://ir.ozopsurgical.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:ScheduleOfNotesPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "role": "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables)", "role": "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-07-012020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_PennsylvaniaCorporationMember", "decimals": "INF", "first": true, "lang": null, "name": "OZSC:BusinessAcquisitionNumberOfSharesAcquired", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - ORGANIZATION (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "shortName": "ORGANIZATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-07-012020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_PennsylvaniaCorporationMember", "decimals": "INF", "first": true, "lang": null, "name": "OZSC:BusinessAcquisitionNumberOfSharesAcquired", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)", "role": "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "shortName": "Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "lang": null, "name": "OZSC:CommonStockYetToBeIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "shortName": "GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "lang": null, "name": "OZSC:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_custom_CustomerAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details)", "role": "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "shortName": "SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember", "decimals": "INF", "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SCHEDULE OF INVENTORY (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails", "shortName": "SCHEDULE OF INVENTORY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "OZSC:ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_custom_WarehouseEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails", "shortName": "SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "OZSC:ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_custom_WarehouseEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - DISAGGREGATION OF REVENUE (Details)", "role": "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "shortName": "DISAGGREGATION OF REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30_custom_SourcedAndDistributedProductsMember", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SCHEDULE OF DERIVATIVE INSTRUMENTS (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails", "shortName": "SCHEDULE OF DERIVATIVE INSTRUMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical", "shortName": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MarketingAndAdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MarketingAndAdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "role": "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statement of Operations (Unaudited)", "role": "http://ir.ozopsurgical.com/role/StatementOfOperations", "shortName": "Condensed Consolidated Statement of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_custom_FifteenPercentPromissoryNoteMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "shortName": "CONVERTIBLE NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_custom_FifteenPercentPromissoryNoteMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails", "shortName": "SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_custom_DerivativeLiabilitiesAssociatedWithWarrantsMember", "decimals": "0", "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "shortName": "DERIVATIVE LIABILITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember", "decimals": "INF", "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfNotesPayableTableTextBlock", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "shortName": "SCHEDULE OF NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfNotesPayableTableTextBlock", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_custom_NotePayableMember", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "p", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2016-10-26", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical", "shortName": "SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "OZSC:ScheduleOfNotesPayableTableTextBlock", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30_custom_NotePayableMember", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "p", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2016-10-26", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - NOTES PAYABLE (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-03-15", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayableToBank", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "OZSC:DeferredLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - DEFERRED LIABILITY (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "shortName": "DEFERRED LIABILITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "OZSC:DeferredLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncreaseDecreaseInDueToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - DEFERRED REVENUE (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative", "shortName": "DEFERRED REVENUE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncreaseDecreaseInDueToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesWagesAndOfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails", "shortName": "SCHEDULE OF EXPENSES TO OFFICERS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesWagesAndOfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_SeriesCPreferredStockMember_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited)", "role": "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-03-31_custom_CommonStockToBeIssuedMember", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-12-292022-01-02_custom_EmploymentAgreementMember", "decimals": "0", "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForParticipationLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForParticipationLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - NONCONTROLLING INTEREST (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative", "shortName": "NONCONTROLLING INTEREST (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "OZSC:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails", "shortName": "SCHEDULE OF RIGHT-OF-USE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "OZSC:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITIES (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails", "shortName": "SCHEDULE OF OPERATING LEASE LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)", "role": "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails", "shortName": "SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-04-04_custom_SecuritiesPurchaseAgreementMember_custom_GHSInvestmentsLLCMember_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)", "role": "http://ir.ozopsurgical.com/role/StatementOfCashFlows", "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION", "role": "http://ir.ozopsurgical.com/role/Organization", "shortName": "ORGANIZATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - GOING CONCERN AND MANAGEMENT\u2019S PLANS", "role": "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans", "shortName": "GOING CONCERN AND MANAGEMENT\u2019S PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 126, "tag": { "OZSC_AccumulativeNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulative noncontrolling interest.", "label": "Accumulative noncontrolling interest" } } }, "localname": "AccumulativeNoncontrollingInterest", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_AmortizationOfWarrantDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amortization of warrant discount.", "label": "Amortization of Warrant Discount" } } }, "localname": "AmortizationOfWarrantDiscount", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_AprilOneTwoThousandAndTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "April 1, 2021 [Member]", "label": "April 1, 2021 [Member]" } } }, "localname": "AprilOneTwoThousandAndTwentyOneMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_AuroraEnterprisesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Enterprises [Member]", "label": "Aurora Enterprises [Member]" } } }, "localname": "AuroraEnterprisesMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_BrianConwayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brian Conway [Member]", "label": "Brian Conway [Member]" } } }, "localname": "BrianConwayMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_BusinessAcquisitionNumberOfSharesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisition Number Of Shares Acquired.", "label": "Number of shares acquired" } } }, "localname": "BusinessAcquisitionNumberOfSharesAcquired", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "OZSC_CertificatesOfDesignationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Certificates of Designation [Member]", "label": "Certificates of Designation [Member]" } } }, "localname": "CertificatesOfDesignationMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ChiefExecutiveOfficerSeriesEPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Executive Officer Series E Preferred Stock [Member]" } } }, "localname": "ChiefExecutiveOfficerSeriesEPreferredStockMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "domainItemType" }, "OZSC_ChisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chis [Member]", "label": "Chis [Member]" } } }, "localname": "ChisMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ChristopherRuppelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Christopher Ruppel [Member]", "label": "Christopher Ruppel [Member]" } } }, "localname": "ChristopherRuppelMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_CoDirectorsOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Co-Directors of Sales [Member]", "label": "Co-Directors of Sales [Member]" } } }, "localname": "CoDirectorsOfSalesMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_CommonStockToBeIssued": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock to be issued.", "label": "Common stock to be issued; 637,755 shares as of June 30, 2022, and December 31, 2021" } } }, "localname": "CommonStockToBeIssued", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "OZSC_CommonStockToBeIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock To Be Issued [Member]", "label": "Common Stock To Be Issued [Member]" } } }, "localname": "CommonStockToBeIssuedMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "OZSC_CommonStockYetToBeIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock yet to be issued.", "label": "Common stock to be issued" } } }, "localname": "CommonStockYetToBeIssued", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "OZSC_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting Agreement [Member]", "label": "Consulting Agreement [Member]" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ConsultingExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consulting Expense.", "label": "Consulting expense" } } }, "localname": "ConsultingExpense", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_ConvertibleInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Instruments [Policy Text Block]", "label": "Convertible Instruments" } } }, "localname": "ConvertibleInstrumentsPolicyTextBlock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "OZSC_ConvertibleNotesPayableNet": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible notes payable net.", "label": "Convertible notes payable, net of discounts" } } }, "localname": "ConvertibleNotesPayableNet", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "OZSC_ConwayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conway [Member]", "label": "Conway [Member]" } } }, "localname": "ConwayMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]" } } }, "localname": "CustomerAMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B [Member]", "label": "Customer B [Member]" } } }, "localname": "CustomerBMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer C [Member]", "label": "Customer C [Member]" } } }, "localname": "CustomerCMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer D [Member]", "label": "Customer D [Member]" } } }, "localname": "CustomerDMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerDeposits": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Customer deposits.", "label": "Customer deposits" } } }, "localname": "CustomerDeposits", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "OZSC_CustomerEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer E [Member]", "label": "Customer E [Member]" } } }, "localname": "CustomerEMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerFMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer F [Member]", "label": "Customer F [Member]" } } }, "localname": "CustomerFMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer G [Member]", "label": "Customer G [Member]" } } }, "localname": "CustomerGMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer H [Member]", "label": "Customer H [Member]" } } }, "localname": "CustomerHMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer I [Member]", "label": "Customer I [Member]" } } }, "localname": "CustomerIMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerJMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer J [Member]", "label": "Customer J [Member]" } } }, "localname": "CustomerJMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_DebtRestructureExpense": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt restructure expense", "label": "Debt restructure expense" } } }, "localname": "DebtRestructureExpense", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows", "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "OZSC_DecemberSevenTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December Seven Two Thousand Twenty Two [Member]", "label": "December Seven Two Thousand Twenty Two [Member]" } } }, "localname": "DecemberSevenTwoThousandTwentyTwoMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_DeferredLiabilityCurrent": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred liability current.", "label": "Deferred liability", "verboseLabel": "Deferred Liability Current" } } }, "localname": "DeferredLiabilityCurrent", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_DeferredLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Liability [Text Block]", "label": "DEFERRED LIABILITY" } } }, "localname": "DeferredLiabilityTextBlock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredLiability" ], "xbrltype": "textBlockItemType" }, "OZSC_DefinitiveAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Definitive Agreement [Member]", "label": "Definitive Agreement [Member]" } } }, "localname": "DefinitiveAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_DerivativeLiabilitiesAssociatedWithConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liabilities Associated With Convertible Notes [Member]", "label": "Derivative Liabilities Associated With Convertible Notes [Member]" } } }, "localname": "DerivativeLiabilitiesAssociatedWithConvertibleNotesMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "OZSC_DerivativeLiabilitiesAssociatedWithWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liabilities Associated With Warrants [Member]", "label": "Derivative Liabilities Associated With Warrants [Member]" } } }, "localname": "DerivativeLiabilitiesAssociatedWithWarrantsMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "OZSC_DisclosureDeferredLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Liability" } } }, "localname": "DisclosureDeferredLiabilityAbstract", "nsuri": "http://ir.ozopsurgical.com/20220630", "xbrltype": "stringItemType" }, "OZSC_DisclosureDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities" } } }, "localname": "DisclosureDerivativeLiabilitiesAbstract", "nsuri": "http://ir.ozopsurgical.com/20220630", "xbrltype": "stringItemType" }, "OZSC_DisclosureNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable" } } }, "localname": "DisclosureNotesPayableAbstract", "nsuri": "http://ir.ozopsurgical.com/20220630", "xbrltype": "stringItemType" }, "OZSC_DisclosureOperatingLeaseRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Right-of-use Assets And Operating Lease Liabilities", "terseLabel": "Schedule Of Operating Lease Liabilities", "verboseLabel": "Schedule Of Right-of-use Assets" } } }, "localname": "DisclosureOperatingLeaseRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract", "nsuri": "http://ir.ozopsurgical.com/20220630", "xbrltype": "stringItemType" }, "OZSC_DistinguishingLiabilitiesfromEquityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distinguishing Liabilities from Equity [PolicyTextBlock]", "label": "Distinguishing Liabilities from Equity" } } }, "localname": "DistinguishingLiabilitiesfromEquityPolicyTextBlock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "OZSC_DownPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Down Payment [Member]", "label": "Down Payment [Member]" } } }, "localname": "DownPaymentMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_EconomicInjuryDisasterLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Economic Injury Disaster Loan [Member]", "label": "Economic Injury Disaster Loan [Member]" } } }, "localname": "EconomicInjuryDisasterLoanMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "OZSC_EmploymentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employment Agreement [Member]", "label": "Employment Agreement [Member]" } } }, "localname": "EmploymentAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange Agreement [Member]", "label": "Exchange Agreement [Member]" } } }, "localname": "ExchangeAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_EzraGreenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ezra Green [Member]", "label": "Ezra Green [Member]" } } }, "localname": "EzraGreenMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FifteenPercentPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "15% Promissory Note [Member]", "label": "15% Promissory Note [Member]" } } }, "localname": "FifteenPercentPromissoryNoteMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_GHSInvestmentsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GHS Investments LLC [Member]", "label": "GHS Investments LLC [Member]" } } }, "localname": "GHSInvestmentsLLCMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_GHSInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GHS Investments [Member]", "label": "GHS Investments [Member]" } } }, "localname": "GHSInvestmentsMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_GainLossOnFairValueChangeOfDerivatives": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gain Loss On Fair Value Change Of Derivatives.", "label": "Loss on fair value change of derivatives" } } }, "localname": "GainLossOnFairValueChangeOfDerivatives", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_GarageStorageFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Garage Storage Facility [Member]", "label": "Garage Storage Facility [Member]" } } }, "localname": "GarageStorageFacilityMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_GeneralAndAdministrativeRelatedParties": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "General and administrative related parties", "label": "General and administrative, related parties" } } }, "localname": "GeneralAndAdministrativeRelatedParties", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "OZSC_HolderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Holder [Member]", "label": "Holder [Member]" } } }, "localname": "HolderMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_IssuanceOfCommonStockAndPreferredStockForConsultingFeesAndCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and preferred stock for consulting fees and compensation", "label": "Issuance of common stock and preferred stock for consulting fees and compensation" } } }, "localname": "IssuanceOfCommonStockAndPreferredStockForConsultingFeesAndCompensation", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_IssuanceOfCommonStockForDebtRestructuring": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for debt restructuring", "label": "Issuance of common stock for debt restructuring" } } }, "localname": "IssuanceOfCommonStockForDebtRestructuring", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_IssuanceOfCommonStockForLeaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for lease agreement", "label": "Issuance of common stock for lease agreement" } } }, "localname": "IssuanceOfCommonStockForLeaseAgreement", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_IssuanceOfCommonStockUponConvertibleNoteAndAccruedInterestConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon convertible note and accrued interest conversion", "label": "Issuance of common stock upon convertible note and accrued interest conversion" } } }, "localname": "IssuanceOfCommonStockUponConvertibleNoteAndAccruedInterestConversion", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_IssuanceOfSeriesEPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of Series E Preferred Stock.", "label": "Issuance of Series E Preferred Stock" } } }, "localname": "IssuanceOfSeriesEPreferredStock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "OZSC_IssuanceOfSeriesEPreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of series e preferred stock shares", "label": "Issuance of Series E Preferred Stock, shares" } } }, "localname": "IssuanceOfSeriesEPreferredStockShares", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "OZSC_LeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Agreement [Member]", "label": "Lease Agreement [Member]" } } }, "localname": "LeaseAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_LenderCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lender Costs", "label": "Lender Costs" } } }, "localname": "LenderCosts", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_LenderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lender [Member]", "label": "Lender [Member]" } } }, "localname": "LenderMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_LendersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lenders [Member]", "label": "Lenders [Member]" } } }, "localname": "LendersMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ManufacturedProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufactured Products [Member]", "label": "Manufactured Products [Member]" } } }, "localname": "ManufacturedProductsMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "OZSC_MrAllenSosisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Allen Sosis [Member]", "label": "Mr Allen Sosis [Member]" } } }, "localname": "MrAllenSosisMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MrConvayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr. Convay [Member].", "label": "Mr. Convay [Member]" } } }, "localname": "MrConvayMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MrConwayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Conway [Member]", "label": "Mr Conway [Member]" } } }, "localname": "MrConwayMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MrStevenMartelloMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Steven Martello [Member]", "label": "Mr Steven Martello [Member]" } } }, "localname": "MrStevenMartelloMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_NineInstalmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nine Instalments [Member]", "label": "Nine Instalments [Member]" } } }, "localname": "NineInstalmentsMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_NoSuppliersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No Suppliers [Member]", "label": "No Suppliers [Member]" } } }, "localname": "NoSuppliersMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Eight [Member]", "label": "Note Payable Eight [Member]" } } }, "localname": "NotePayableEightMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Five [Member]", "label": "Note Payable Five [Member]" } } }, "localname": "NotePayableFiveMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Four [Member]", "label": "Note Payable Four [Member]" } } }, "localname": "NotePayableFourMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable [Member]", "label": "Note Payable [Member]" } } }, "localname": "NotePayableMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable One [Member]", "label": "Note Payable One [Member]" } } }, "localname": "NotePayableOneMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Seven [Member]", "label": "Note Payable Seven [Member]" } } }, "localname": "NotePayableSevenMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Six [Member]", "label": "Note Payable Six [Member]" } } }, "localname": "NotePayableSixMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Three [Member]", "label": "Note Payable Three [Member]" } } }, "localname": "NotePayableThreeMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Two [Member]", "label": "Note Payable Two [Member]" } } }, "localname": "NotePayableTwoMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotesPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable [Text Block]", "label": "NOTES PAYABLE" } } }, "localname": "NotesPayableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "OZSC_OEDInstallationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OED Installations [Member]", "label": "OED Installations [Member]" } } }, "localname": "OEDInstallationsMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "OZSC_OfficeFurnitureAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office Furniture And Equipment [Member]", "label": "Office Furniture And Equipment [Member]" } } }, "localname": "OfficeFurnitureAndEquipmentMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "OZSC_OfficersCompensationReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Officers compensation received.", "label": "Officers compensation received" } } }, "localname": "OfficersCompensationReceived", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_OperatingLeasePayementsIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease payements increase percentage.", "label": "Lease payments increase percentage" } } }, "localname": "OperatingLeasePayementsIncreasePercentage", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "OZSC_OperatingLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amortization.", "label": "Less: Accumulated amortization", "negatedLabel": "Less: Accumulated Amortization" } } }, "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Office and warehouse lease.", "label": "Office and warehouse lease" } } }, "localname": "OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_OperatingLeaseRightofuseAssetsAndLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating lease right of use assets and liabilities.", "label": "Operating lease right-of-use assets and liabilities" } } }, "localname": "OperatingLeaseRightofuseAssetsAndLiabilities", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_OriginalIssueDiscountIncludedInNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Original issue discount included in notes payable", "label": "Original issue discount included in notes payable" } } }, "localname": "OriginalIssueDiscountIncludedInNotesPayable", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other [Member]", "label": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_PCTIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PCTI [Member]", "label": "PCTI [Member]" } } }, "localname": "PCTIMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PJNStrategiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PJN Strategies [Member]", "label": "PJN Strategies [Member]" } } }, "localname": "PJNStrategiesMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Program [Member]", "label": "Paycheck Protection Program [Member]" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PaycheckProtectionProgramloanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Programloan [Member]", "label": "Paycheck Protection Programloan [Member]" } } }, "localname": "PaycheckProtectionProgramloanMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "OZSC_PaymentsForRedemptionOfPreferredStock": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redemption of Series E Preferred Stock", "label": "Redemption of Series E Preferred Stock [Default Label]", "negatedLabel": "Redemption of Series E Preferred Stock" } } }, "localname": "PaymentsForRedemptionOfPreferredStock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_PaymentsToShareholders": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to shareholders", "label": "PaymentsToShareholders", "negatedLabel": "Payments to shareholders" } } }, "localname": "PaymentsToShareholders", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_PennsylvaniaCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pennsylvania Corporation [Member]", "label": "Pennsylvania Corporation [Member]" } } }, "localname": "PennsylvaniaCorporationMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PerMonthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per Month [Member]", "label": "Per Month [Member]" } } }, "localname": "PerMonthMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PersonalGuaranteeOfChisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Personal Guarantee Of Chis [Member]", "label": "Personal Guarantee Of Chis [Member]" } } }, "localname": "PersonalGuaranteeOfChisMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PresidentSubsidiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "President Subsidiary [Member]" } } }, "localname": "PresidentSubsidiaryMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "domainItemType" }, "OZSC_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Member]", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PromissoryNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note One [Member]", "label": "Promissory Note One [Member]" } } }, "localname": "PromissoryNoteOneMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PromissoryNotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note Payable [Member]", "label": "Promissory Note Payable [Member]" } } }, "localname": "PromissoryNotePayableMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "OZSC_PurchaseConcentrationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Concentration [Policy Text Block]", "label": "Purchase concentration" } } }, "localname": "PurchaseConcentrationPolicyTextBlock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "OZSC_RMAAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RMA Agreement [Member]", "label": "RMA Agreement [Member]" } } }, "localname": "RMAAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_RedemptionOfSeriesEPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redemption of Series E Preferred Stock.", "label": "Redemption of Series E Preferred Stock" } } }, "localname": "RedemptionOfSeriesEPreferredStock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "OZSC_RedemptionOfSeriesEPreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption of series e preferred stock shares", "label": "Redemption of Series E Preferred Stock, shares" } } }, "localname": "RedemptionOfSeriesEPreferredStockShares", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "OZSC_RegistrationStatementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Registration Statement [Member]", "label": "Registration Statement [Member]" } } }, "localname": "RegistrationStatementMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_RemainingWarrantSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Warrant Shares [Member]", "label": "Remaining Warrant Shares [Member]" } } }, "localname": "RemainingWarrantSharesMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_RestructuringAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring Agreement [Member]", "label": "Restructuring Agreement [Member]" } } }, "localname": "RestructuringAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_RoyaltyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty percentage", "label": "Royalty Percentage", "verboseLabel": "Royalty percentage" } } }, "localname": "RoyaltyPercentage", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "percentItemType" }, "OZSC_RubensteinPublicRelationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rubenstein Public Relations, Inc. [Member]", "label": "Rubenstein Public Relations, Inc. [Member]" } } }, "localname": "RubensteinPublicRelationsMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SalmanJChaudhryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Salman J. Chaudhry [Member]", "label": "Salman J. Chaudhry [Member]" } } }, "localname": "SalmanJChaudhryMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ScheduleOfNotesPayableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Notes Payable [Table Text Block]", "label": "SCHEDULE OF NOTES PAYABLE" } } }, "localname": "ScheduleOfNotesPayableTableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "OZSC_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Operating Lease Liabilities [Table Text Block]", "label": "SCHEDULE OF OPERATING LEASE LIABILITIES" } } }, "localname": "ScheduleOfOperatingLeaseLiabilitiesTableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "OZSC_ScheduleOfRightofUseAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Right of Use Assets [Table Text Block]", "label": "SCHEDULE OF RIGHT-OF-USE ASSETS" } } }, "localname": "ScheduleOfRightofUseAssetsTableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "OZSC_ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Useful Life Of Property And Equipment Assets [Table Text Block]", "label": "SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS" } } }, "localname": "ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "OZSC_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement [Member]", "label": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SeparationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seperation Agreement [Member]", "label": "Seperation Agreement [Member]" } } }, "localname": "SeparationAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SeriesDAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Amendment [Member]", "label": "Series D Amendment [Member]" } } }, "localname": "SeriesDAmendmentMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SeriesDSPAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series DSPA [Member]", "label": "Series DSPA [Member]" } } }, "localname": "SeriesDSPAMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SharesIssuedUponCashlessExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued upon cashless exercise of warrants.", "label": "Shares issued upon cashless exercise of warrants" } } }, "localname": "SharesIssuedUponCashlessExerciseOfWarrants", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "OZSC_SharesIssuedUponCashlessExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Issued Upon Cashless Exercise Of Warrants Shares", "label": "Shares issued upon cashless exercise of warrants, shares" } } }, "localname": "SharesIssuedUponCashlessExerciseOfWarrantsShares", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "OZSC_ShipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shipment [Member]", "label": "Shipment [Member]" } } }, "localname": "ShipmentMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SourcedAndDistributedProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sourced and Distributed Products [Member]", "label": "Sourced and Distributed Products [Member]" } } }, "localname": "SourcedAndDistributedProductsMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "OZSC_StockIssuedDuringPeriodSharesNewIssuesForLeaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares new issues for lease agreement", "label": "Shares issued for lease agreement, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesForLeaseAgreement", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "OZSC_StockIssuedDuringPeriodValueNewIssuesForLeaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value new issues for lease agreement", "label": "Shares issued for lease agreement" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesForLeaseAgreement", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "OZSC_StockIssuedDuringPeriodValuePurchased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value purchased.", "label": "Stock purchase, value" } } }, "localname": "StockIssuedDuringPeriodValuePurchased", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_SuppliersFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suppliers Four [Member]", "label": "Suppliers Four [Member]" } } }, "localname": "SuppliersFourMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SuppliersOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suppliers One [Member]", "label": "Suppliers One [Member]" } } }, "localname": "SuppliersOneMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SuppliersThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suppliers Three [Member]", "label": "Suppliers Three [Member]" } } }, "localname": "SuppliersThreeMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SuppliersTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suppliers Two [Member]", "label": "Suppliers Two [Member]" } } }, "localname": "SuppliersTwoMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ThereafterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thereafter [Member]", "label": "Thereafter [Member]" } } }, "localname": "ThereafterMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ThirdPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third-Party [Member]", "label": "Third-Party [Member]" } } }, "localname": "ThirdPartyMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_TwoVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Vendor [Member]", "label": "Two Vendor [Member]" } } }, "localname": "TwoVendorMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_UnexercisedCommonStockPurchaseWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unexercised Common Stock Purchase Warrants [Member]", "label": "Unexercised Common Stock Purchase Warrants [Member]" } } }, "localname": "UnexercisedCommonStockPurchaseWarrantsMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "OZSC_WarehouseEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warehouse Equipment [Member]", "label": "Warehouse Equipment [Member]" } } }, "localname": "WarehouseEquipmentMember", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "OZSC_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital deficit.", "label": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://ir.ozopsurgical.com/20220630", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r672", "r674", "r675" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r673" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r664" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r667" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r687" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r669" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r666" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r665" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r670" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r183", "r328", "r334", "r623" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r229", "r230", "r231", "r232", "r250", "r289", "r351", "r353", "r536", "r537", "r538", "r539", "r540", "r541", "r560", "r620", "r624", "r659", "r660" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r229", "r230", "r231", "r232", "r250", "r289", "r351", "r353", "r536", "r537", "r538", "r539", "r540", "r541", "r560", "r620", "r624", "r659", "r660" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r183", "r328", "r334", "r623" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r180", "r230", "r231", "r328", "r332", "r563", "r619", "r621" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r180", "r230", "r231", "r328", "r332", "r563", "r619", "r621" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r225", "r229", "r230", "r231", "r232", "r250", "r289", "r336", "r351", "r353", "r380", "r381", "r382", "r536", "r537", "r538", "r539", "r540", "r541", "r560", "r620", "r624", "r659", "r660" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r225", "r229", "r230", "r231", "r232", "r250", "r289", "r336", "r351", "r353", "r380", "r381", "r382", "r536", "r537", "r538", "r539", "r540", "r541", "r560", "r620", "r624", "r659", "r660" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r181", "r182", "r328", "r333", "r622", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r181", "r182", "r328", "r333", "r622", "r643", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r184", "r520" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r587", "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableInterestBearingInterestRate": { "auth_ref": [ "r485", "r486", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.", "label": "Accounts Payable, Interest-Bearing, Interest Rate" } } }, "localname": "AccountsPayableInterestBearingInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r602", "r644" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "verboseLabel": "Concentration Risk, Percentage" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r185", "r186" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued bonus" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued employee benefits, current" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r16", "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r66", "r67", "r475", "r476", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r61", "r62", "r66", "r67", "r68", "r111", "r112", "r113", "r422", "r514", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r27", "r526" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r111", "r112", "r113", "r386", "r387", "r388", "r450" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r114", "r115", "r116", "r117", "r126", "r194", "r195", "r202", "r203", "r204", "r205", "r206", "r207", "r386", "r387", "r388", "r400", "r401", "r402", "r403", "r409", "r410", "r411", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r482", "r483", "r494", "r495", "r496", "r497", "r509", "r510", "r511", "r512", "r513", "r514", "r564", "r565", "r566", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r246", "r302", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash used in operations" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising and Marketing Expenses" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "ShareBased Compensation Expense", "terseLabel": "Stock based compensation", "verboseLabel": "Share Based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r80", "r92", "r270", "r487" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Non-cash interest expense", "verboseLabel": "Amortization of Debt Discount (Premium)" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "TOTAL" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r18", "r107", "r163", "r172", "r178", "r201", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r417", "r423", "r465", "r524", "r526", "r581", "r603" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r40", "r107", "r201", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r417", "r423", "r465", "r524", "r526" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r350", "r352", "r408" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r350", "r352", "r406", "r407", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r14", "r94" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r88", "r94", "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, End of period", "periodStartLabel": "Cash, Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r88", "r474" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of non-cash Investing or Financing Activity:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r24", "r25", "r26", "r104", "r107", "r128", "r129", "r132", "r134", "r136", "r143", "r144", "r145", "r201", "r235", "r239", "r240", "r241", "r244", "r245", "r286", "r287", "r291", "r295", "r302", "r465", "r677" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Purchase of warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of reason for issuing warrant or right.", "label": "Warrant exercise, description" } } }, "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementRightsAndObligations": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Description of rights and obligations under the collaborative arrangements.", "label": "Collaborative arrangement, rights and obligations" } } }, "localname": "CollaborativeArrangementRightsAndObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r51", "r590", "r609" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r226", "r227", "r228", "r233", "r646" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r111", "r112", "r450" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r302" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Common Stock, Shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26", "r526" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock (4,990,000,000 shares authorized par value $0.001; 4,622,362,977 (2022) and 4,617,362,977 (2021) shares issued and outstanding)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r153", "r154", "r183", "r462", "r463", "r645" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r153", "r154", "r183", "r462", "r463", "r637", "r645" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r153", "r154", "r183", "r462", "r463", "r637", "r645" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r148", "r598" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Sales Concentration and credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r153", "r154", "r183", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "verboseLabel": "Concentration of credit risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r153", "r154", "r183", "r462", "r463", "r645" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r309", "r310", "r329" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Vendor deposits" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Liability revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r20", "r582", "r600", "r639" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r286", "r287", "r291" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r76", "r563" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r152", "r183" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r97", "r98" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt conversion, converted instrument, shares issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDefaultLongtermDebtAmount": { "auth_ref": [ "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "Debt instrument default amount" } } }, "localname": "DebtDefaultLongtermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r103", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r264", "r271", "r272", "r274", "r283" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "CONVERTIBLE NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r20", "r21", "r22", "r106", "r109", "r247", "r248", "r249", "r250", "r251", "r252", "r254", "r260", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r277", "r278", "r279", "r280", "r490", "r582", "r583", "r600" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r22", "r275", "r583", "r600" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long term debt, gross", "verboseLabel": "Long-Term Debt, Gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r249", "r276" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt instrument, convertible, conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt Instrument, Decrease, Forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r20", "r22", "r303", "r582", "r583", "r597", "r600" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Agreement description", "verboseLabel": "Debt Instrument, Description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r247", "r277", "r278", "r488", "r490", "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, face amount", "terseLabel": "Debt instrument principal", "verboseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest", "verboseLabel": "Debt instrument, accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r48", "r248" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, interest rate, stated percentage", "verboseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r49", "r250", "r457" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Common stock maturity period", "terseLabel": "Debt Instrument, Maturity Date", "verboseLabel": "Debt Instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r50", "r106", "r109", "r247", "r248", "r249", "r250", "r251", "r252", "r254", "r260", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r277", "r278", "r279", "r280", "r490" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r260", "r487", "r491" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, unamortized discount", "verboseLabel": "Debt Instrument, Unamortized Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]" } } }, "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]" } } }, "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Shares Issued", "terseLabel": "Deferred compensation shares issued", "verboseLabel": "Number of common stock exchanged" } } }, "localname": "DeferredCompensationArrangementWithIndividualSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredCompensationEquity": { "auth_ref": [ "r56", "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.", "label": "Deferred compensation equity" } } }, "localname": "DeferredCompensationEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Current portion of deferred revenues", "verboseLabel": "Deferred revenue, current" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred revenue, net of current portion", "verboseLabel": "Deferred revenue, non-current" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r92", "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "auth_ref": [ "r92" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization and depreciation" } } }, "localname": "DepreciationAmortizationAndAccretionNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r429" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "verboseLabel": "Derivative Liabilities" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r461" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Total" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r435" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Change in fair value", "negatedLabel": "(Gain) loss on change in fair value of derivatives", "negatedTerseLabel": "Change in fair value" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails", "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r58", "r59", "r60", "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "periodEndLabel": "Derivative liability", "periodStartLabel": "Derivative liability", "terseLabel": "Derivative Liabilities", "verboseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liabilities", "verboseLabel": "Derivative liabilities current" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative liability measurement input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativesAndFairValueTextBlock": { "auth_ref": [ "r454", "r459" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.", "label": "DERIVATIVE LIABILITIES" } } }, "localname": "DerivativesAndFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "DISAGGREGATION OF REVENUE" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToOfficersOrStockholdersCurrent": { "auth_ref": [ "r19", "r518", "r601", "r638" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to officers or stockholders, current" } } }, "localname": "DueToOfficersOrStockholdersCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent": { "auth_ref": [ "r518", "r588", "r614", "r640" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.", "label": "Due to officers or stockholders" } } }, "localname": "DueToOfficersOrStockholdersCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r72", "r118", "r119", "r120", "r121", "r122", "r127", "r128", "r134", "r135", "r136", "r139", "r140", "r451", "r452", "r593", "r616" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Income (loss) per share basic and fully diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r137", "r138" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Amount of initial annual compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r66", "r67", "r68", "r111", "r112", "r113", "r115", "r123", "r125", "r142", "r205", "r302", "r305", "r386", "r387", "r388", "r402", "r403", "r450", "r475", "r476", "r477", "r478", "r479", "r480", "r514", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ExtendedProductWarrantyDescription": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of the extended product warranties, which generally require additional fees to be paid by the buyer, and other guarantee contracts excluded from the initial recognition and initial measurement requirements. Does not include disclosures for standard product warranties, which typically have substantially shorter periods of time or provide less coverage, or both.", "label": "Warranty Description" } } }, "localname": "ExtendedProductWarrantyDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r92", "r284" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Adjustment of Warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r262", "r277", "r278", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r349", "r455", "r533", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r262", "r337", "r338", "r343", "r349", "r455", "r533" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r262", "r277", "r278", "r337", "r338", "r343", "r349", "r455", "r534" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r262", "r277", "r278", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r349", "r455", "r535" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r262", "r277", "r278", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r349", "r533", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r458", "r460" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r273", "r300", "r440", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r677", "r678", "r679", "r680", "r681", "r682", "r683" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FloorBrokerage": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Broker-dealers often use other brokers to execute trades on their behalf. The trading broker-dealer becomes a customer of the executing broker-dealer and pays a floor brokerage fee. Such fees are paid periodically either directly to the executing broker-dealer or through a clearing house.", "label": "Brokerage fees" } } }, "localname": "FloorBrokerage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r92", "r281", "r282" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "negatedTerseLabel": "Loss (gain) on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows", "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r74", "r107", "r163", "r171", "r174", "r177", "r179", "r201", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r465" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r68", "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Noncontrolling interest loss" } } }, "localname": "IncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r70", "r163", "r171", "r174", "r177", "r179", "r580", "r591", "r595", "r617" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Net income (loss) from continuing operations", "totalLabel": "Net income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows", "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r108", "r124", "r125", "r162", "r394", "r404", "r405", "r618" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r65", "r392", "r393", "r396", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r91" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r91" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r91", "r561" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Customer deposits" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r91" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositsOutstanding": { "auth_ref": [ "r91" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in monies given as security or collateral for items acquired or borrowed on a temporary basis. Deposits may also be paid as initial payment of the cost of acquisition or for the right to enter into a contract or agreement.", "label": "Increase (Decrease) in Deposits Outstanding", "negatedLabel": "Vendor deposits" } } }, "localname": "IncreaseDecreaseInDepositsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "DueToRelatedParties" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredRevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r91" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r91", "r503" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r91" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r130", "r131", "r136" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Dilutive securities common stock, shares" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r69", "r161", "r484", "r489", "r594" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense", "verboseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r86", "r89", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r589", "r611" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r32" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r9", "r38", "r526" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory", "totalLabel": "Inventory net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r12", "r36", "r101", "r141", "r217", "r218", "r219", "r562" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r34" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r33" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LandSubjectToGroundLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land subject to a ground lease.", "label": "Land subject to ground leases" } } }, "localname": "LandSubjectToGroundLeases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "verboseLabel": "Legal fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF MATURITY OF LEASE LIABILITIES" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r505" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r505" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ended December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r505" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ended December 31, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r505" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ended December 31, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r505" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ended December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r505" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "For the year ended December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r505" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease term" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r45", "r107", "r173", "r201", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r418", "r423", "r424", "r465", "r524", "r525" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities [Default Label]", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r107", "r201", "r465", "r526", "r585", "r607" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r11", "r47", "r107", "r201", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r418", "r423", "r424", "r465", "r524", "r525", "r526" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableToBank": { "auth_ref": [ "r22", "r583", "r599" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the normal operating cycle if longer.", "label": "Loans Payable to Bank" } } }, "localname": "LoansPayableToBank", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r50" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Note payable, net of discount", "verboseLabel": "Less long-term portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Marketing and Advertising Expense" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputOptionVolatilityMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.", "label": "Measurement Input, Option Volatility [Member]" } } }, "localname": "MeasurementInputOptionVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r57", "r107", "r201", "r235", "r239", "r240", "r241", "r244", "r245", "r465", "r584", "r606" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling interest percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r88" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r88" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r88", "r90", "r93" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r63", "r64", "r68", "r71", "r93", "r107", "r114", "r118", "r119", "r120", "r121", "r124", "r125", "r133", "r163", "r171", "r174", "r177", "r179", "r201", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r452", "r465", "r592", "r615" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income (loss) attributable to Ozop Energy Solutions, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r63", "r64", "r68", "r124", "r125", "r420", "r426" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Less: net loss attributable to noncontrolling interest", "negatedLabel": "Noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r111", "r112", "r113", "r305", "r414" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total Other (Income) Expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (income) expenses:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r22", "r583", "r604" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Sub- total notes payable", "verboseLabel": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Current portion of notes payable, net of discounts", "verboseLabel": "Current portion of notes payable, net of discount" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBank": { "auth_ref": [ "r22", "r583", "r604" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, the carrying value as of the balance sheet date of notes payable to banks, excluding mortgage notes, initially due beyond one year or beyond the operating cycle if longer.", "label": "Notes Payable ToBank" } } }, "localname": "NotesPayableToBank", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Compensation value", "verboseLabel": "Annual salary" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r163", "r171", "r174", "r177", "r179" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r499" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Lease liability", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails", "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r499" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability, current portion", "negatedLabel": "Less current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r499" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability, net of current portion", "verboseLabel": "Long term portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r500", "r503" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r498" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use asset, net", "totalLabel": "Right-of-use asset, net", "verboseLabel": "RIght of use of asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r504", "r506" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating lease disount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating lease rent expense" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r7", "r428" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r17" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for tabular information relating to Other Comprehensive Income (OCI) as is applicable to noncontrolling interests. This text block may also include OCI relative to the filing entity, the aforementioned noncontrolling interest OCI, as well as OCI on a consolidated basis.", "label": "NONCONTROLLING INTEREST" } } }, "localname": "OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterest" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r78" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "General and administrative, other" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForParticipationLiabilities": { "auth_ref": [ "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments related to participation costs.", "label": "Cash payments" } } }, "localname": "PaymentsForParticipationLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtRestructuringCosts": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.", "label": "Payments of Debt Restructuring Costs", "verboseLabel": "Payments of debt restructuring costs" } } }, "localname": "PaymentsOfDebtRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Professional fees" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r81" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of office and computer equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred Stock, Convertible, Conversion Price" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r25", "r286" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Preferred stock Par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionAmount": { "auth_ref": [ "r52", "r285" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Preferred stock, redemption amount" } } }, "localname": "PreferredStockRedemptionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r285", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Preferred stock redemption price per share" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r25", "r286" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding", "verboseLabel": "Preferred stock shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r25", "r526" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock , value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r25", "r303" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred stock, voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "auth_ref": [ "r39", "r586", "r610" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.", "label": "Prepaid expense" } } }, "localname": "PrepaidExpenseCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Payments of stock issuance costs" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r83" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from issuances of notes payable", "verboseLabel": "Proceeds from Notes Payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the estimated recovery from third parties recorded in the period pertaining to product liability damages from specified products.", "label": "Product Liability Contingency, Third-Party Recovery, Percentage" } } }, "localname": "ProductLiabilityContingencyThirdPartyRecoveryPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r641", "r642" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees", "verboseLabel": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r63", "r64", "r68", "r87", "r107", "r114", "r124", "r125", "r163", "r171", "r174", "r177", "r179", "r201", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r416", "r419", "r421", "r426", "r427", "r452", "r465", "r595" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r224", "r647", "r648", "r649" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r15", "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Office equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r223", "r526", "r596", "r608" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "verboseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r223", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r344", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r344", "r517", "r521", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r515", "r516", "r518", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r84" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Payments of principal of convertible note payable and notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r28", "r305", "r526", "r605", "r631", "r636" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit", "negatedLabel": "Retained earnings accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r111", "r112", "r113", "r115", "r123", "r125", "r205", "r386", "r387", "r388", "r402", "r403", "r450", "r627", "r629" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r159", "r160", "r170", "r175", "r176", "r180", "r181", "r183", "r327", "r328", "r563" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue", "verboseLabel": "Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r102", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r335" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r331", "r335" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "DEFERRED REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesWagesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, Excluding Cost of Good and Service Sold", "verboseLabel": "Total" } } }, "localname": "SalariesWagesAndOfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r345", "r346", "r347", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r430", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "SCHEDULE OF DERIVATIVE INSTRUMENTS" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r35", "r36", "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "SCHEDULE OF INVENTORY" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r519", "r521" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "SCHEDULE OF EXPENSES TO OFFICERS" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r354", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r151", "r153", "r154", "r155", "r462", "r464" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r164", "r165", "r166", "r167", "r168", "r169", "r181" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Policy" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r24", "r25", "r302" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [ "r24", "r25", "r302" ], "lang": { "en-us": { "role": { "documentation": "Series D preferred stock.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesEPreferredStockMember": { "auth_ref": [ "r24", "r25", "r302" ], "lang": { "en-us": { "role": { "documentation": "Series E preferred stock.", "label": "Series E Preferred Stock [Member]" } } }, "localname": "SeriesEPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r91" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Warrant exercise" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Outstanding shares, percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Issuance of common stock" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Price per share", "terseLabel": "Shares issued, price per share", "verboseLabel": "Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBankLoansAndNotesPayable": { "auth_ref": [ "r41", "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.", "label": "Short-Term Bank Loans and Notes Payable" } } }, "localname": "ShortTermBankLoansAndNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r100", "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r24", "r25", "r26", "r104", "r107", "r128", "r129", "r132", "r134", "r136", "r143", "r144", "r145", "r201", "r235", "r239", "r240", "r241", "r244", "r245", "r286", "r287", "r291", "r295", "r302", "r465", "r677" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r55", "r66", "r67", "r68", "r111", "r112", "r113", "r115", "r123", "r125", "r142", "r205", "r302", "r305", "r386", "r387", "r388", "r402", "r403", "r450", "r475", "r476", "r477", "r478", "r479", "r480", "r514", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r111", "r112", "r113", "r142", "r563" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/BalanceSheetParenthetical", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r25", "r26", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r54", "r265", "r302", "r303", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Shares issued for conversions of note and interest payable, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Shares issued and to be issued for fees and services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r25", "r26", "r302", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock issued during the period, shares", "terseLabel": "Number of shares issued, shares", "verboseLabel": "Preferred stock redemption price per share" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Shares issued for debt restructure, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r302", "r305" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Number of restricted shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r55", "r302", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Shares issued for conversions of note and interest payable" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Shares issued and to be issued for fees and services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r25", "r26", "r302", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock issued during the period", "verboseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Shares issue for debt restructure" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r25", "r26", "r302", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Number of restricted stock issued, value" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Number of redeemed shares issued", "verboseLabel": "Number of stock redeemed" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r25", "r26", "r302", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Number of purchased shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r29", "r30", "r107", "r192", "r201", "r465", "r526" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Ozop Energy Systems, Inc. stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r67", "r107", "r111", "r112", "r113", "r115", "r123", "r201", "r205", "r305", "r386", "r387", "r388", "r402", "r403", "r414", "r415", "r425", "r450", "r465", "r475", "r476", "r480", "r514", "r628", "r629" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet", "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r105", "r287", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r305", "r308", "r441" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r481", "r528" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r481", "r528" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r481", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r481", "r528" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r527", "r529" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN AND MANAGEMENT\u2019S PLANS" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r187", "r188", "r189", "r190", "r191", "r193" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r273", "r300", "r440", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r677", "r678", "r679", "r680", "r681", "r682", "r683" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r53", "r306" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r53", "r306", "r307" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury Stock" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r114", "r115", "r116", "r117", "r126", "r194", "r195", "r202", "r203", "r204", "r205", "r206", "r207", "r386", "r387", "r388", "r400", "r401", "r402", "r403", "r409", "r410", "r411", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r482", "r483", "r494", "r495", "r496", "r497", "r509", "r510", "r511", "r512", "r513", "r514", "r564", "r565", "r566", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards." } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OrganizationDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r391", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r146", "r147", "r149", "r150", "r156", "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique." } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueOptionPricingModelMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating price of option.", "label": "Valuation Technique, Option Pricing Model [Member]" } } }, "localname": "ValuationTechniqueOptionPricingModelMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "verboseLabel": "Warrants term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r127", "r136" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r428": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r454": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r459": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "https://asc.fasb.org/topic&trid=2155941" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=29642582&loc=d3e27862-108397" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=29642582&loc=d3e27881-108397" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r507": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r523": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r529": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=6473203&loc=d3e55336-107963" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(17))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.12(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r661": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r662": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r663": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r664": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r665": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r666": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r667": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r668": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r669": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r670": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r671": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r672": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r673": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r674": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r675": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r676": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r677": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r678": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r679": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r680": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r681": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r682": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r683": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r684": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r685": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r686": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r687": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" } }, "version": "2.1" } ZIP 76 0001493152-22-022798-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-022798-xbrl.zip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